

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72751 A1

(51) International Patent Classification⁷: C07D 487/04, A61K 31/505, A61P 35/00

(21) International Application Number: PCT/US00/08593

(22) International Filing Date: 29 March 2000 (29.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): BASF AKTIENGESELLSCHAFT [DE/DE]; 67056 Ludwigshafen, D-Rheinland-Pfalz (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HIRST, Gavin, C. [GB/US]; 112 Robert Road, Marlborough, MA 01752 (US). CALDERWOOD, David [GB/US]; 4 McCarthy Circle, Framingham, MA 01702 (US). MUNSCHAUER, Rainer [DE/DE]; Zeppelinstrasse 5, D-67435 Neustadt (DE). ARNOLD, Lee, D. [CA/US]; 216 Ruggles Street, Westborough, MA 01581 (US). JOHNSTON, David, N. [GB/GB]; R5 Pennyfoot Street, Nottingham, NG1 1GF (GB). RAFFERTY, Paul [GB/GB]; R5 Pennyfoot Street, Nottingham, NG1 1GF (GB).

(74) Agents: ELMORE, Carolyn, S. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS



(I)

(57) Abstract: Chemical compounds having structural formula (I), and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and inflammatory disorders.



WO 01/72751 A1

PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS

BACKGROUND OF THE INVENTION

There are at least 400 enzymes identified as protein kinases. These enzymes
5 catalyze the phosphorylation of target protein substrates. The phosphorylation is
usually a transfer reaction of a phosphate group from ATP to the protein substrate.
The specific structure in the target substrate to which the phosphate is transferred is
a tyrosine, serine or threonine residue. Since these amino acid residues are the target
structures for the phosphoryl transfer, these protein kinase enzymes are commonly
10 referred to as tyrosine kinases or serine/threonine kinases.

The phosphorylation reactions, and counteracting phosphatase reactions, at
the tyrosine, serine and threonine residues are involved in countless cellular
processes that underlie responses to diverse intracellular signals (typically mediated
through cellular receptors), regulation of cellular functions, and activation or
15 deactivation of cellular processes. A cascade of protein kinases often participate in
intracellular signal transduction and are necessary for the realization of these cellular
processes. Because of their ubiquity in these processes, the protein kinases can be
found as an integral part of the plasma membrane or as cytoplasmic enzymes or
localized in the nucleus, often as components of enzyme complexes. In many
20 instances, these protein kinases are an essential element of enzyme and structural
protein complexes that determine where and when a cellular process occurs within a
cell.

Protein Tyrosine Kinases. Protein tyrosine kinases (PTKs) are enzymes
which catalyze the phosphorylation of specific tyrosine residues in cellular proteins.
25 This post-translational modification of these substrate proteins, often enzymes
themselves, acts as a molecular switch regulating cell proliferation, activation or
differentiation (for review, see Schlessinger and Ullrich, 1992, *Neuron* 9:383-391).
Aberrant or excessive PTK activity has been observed in many disease states
including benign and malignant proliferative disorders as well as diseases resulting
30 from inappropriate activation of the immune system (e.g., autoimmune disorders),

-2-

allograft rejection, and graft vs. host disease. In addition, endothelial-cell specific receptor PTKs such as KDR and Tie-2 mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal
5 neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, infantile hemangiomas).

Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular).

10 *Receptor Tyrosine Kinases (RTKs)*. The RTKs comprise a large family of transmembrane receptors with diverse biological activities. At present, at least nineteen (19) distinct RTK subfamilies have been identified. The receptor tyrosine kinase (RTK) family includes receptors that are crucial for the growth and differentiation of a variety of cell types (Yarden and Ullrich, *Ann. Rev. Biochem.*
15 57:433-478, 1988; Ullrich and Schlessinger, *Cell* 61:243-254, 1990). The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses (Ullrich & Schlessinger, 1990, *Cell* 61:203-212). Thus, receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction
20 with a specific growth factor (ligand), typically followed by receptor dimerization, stimulation of the intrinsic protein tyrosine kinase activity and receptor trans-phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response.
25 (e.g., cell division, differentiation, metabolic effects, changes in the extracellular microenvironment) see Schlessinger and Ullrich, 1992, *Neuron* 9:1-20.

Proteins with SH2 (src homology -2) or phosphotyrosine binding (PTB) domains bind activated tyrosine kinase receptors and their substrates with high affinity to propagate signals into cell. Both of the domains recognize
30 phosphotyrosine. (Fantl *et al.*, 1992, *Cell* 69:413-423; Songyang *et al.*, 1994, *Mol.*

Cell Biol. 14:2777-2785; Songyang *et al.*, 1993, *Cell* 72:767-778; and Koch *et al.*, 1991, *Science* 252:668-678; Shoelson, *Curr. Opin. Chem. Biol.* (1997), 1(2), 227-234; Cowburn, *Curr. Opin. Struct. Biol.* (1997), 7(6), 835-838). Several intracellular substrate proteins that associate with receptor tyrosine kinases (RTKs) have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such a domain but serve as adapters and associate with catalytically active molecules (Songyang *et al.*, 1993, *Cell* 72:767-778). The specificity of the interactions between receptors or proteins and SH2 or PTB domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. For example, differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors correlate with the observed differences in their substrate phosphorylation profiles (Songyang *et al.*, 1993, *Cell* 72:767-778). Observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor as well as the timing and duration of those stimuli. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

Several receptor tyrosine kinases such as FGFR-1, PDGFR, TIE-2 and c-Met, and growth factors that bind thereto, have been suggested to play a role in angiogenesis, although some may promote angiogenesis indirectly (Mustonen and Alitalo, *J. Cell Biol.* 129:895-898, 1995). One such receptor tyrosine kinase, known as "fetal liver kinase 1" (FLK-1), is a member of the type III subclass of RTKs. An alternative designation for human FLK-1 is "kinase insert domain-containing receptor" (KDR) (Terman *et al.*, *Oncogene* 6:1677-83, 1991). Another alternative designation for FLK-1/KDR is "vascular endothelial cell growth factor receptor 2" (VEGFR-2) since it binds VEGF with high affinity. The murine version of FLK-1/VEGFR-2 has also been called NYK (Oelrichs *et al.*, *Oncogene* 8(1):11-15, 1993).

DNAs encoding mouse, rat and human FLK-1 have been isolated, and the nucleotide and encoded amino acid sequences reported (Matthews *et al.*, *Proc. Natl. Acad. Sci. USA*, 88:9026-30, 1991; Terman *et al.*, 1991, *supra*; Terman *et al.*, *Biochem. Biophys. Res. Comm.* 187:1579-86, 1992; Sarzani *et al.*, *supra*; and
5 Millauer *et al.*, *Cell* 72:835-846, 1993). Numerous studies such as those reported in Millauer *et al.*, *supra*, suggest that VEGF and FLK-1/KDR/VEGFR-2 are a ligand-receptor pair that play an important role in the proliferation of vascular endothelial cells, and formation and sprouting of blood vessels, termed vasculogenesis and angiogenesis, respectively.

10 Another type III subclass RTK designated "fms-like tyrosine kinase-1" (Flt-1) is related to FLK-1/KDR (DeVries *et al.* *Science* 255:989-991, 1992; Shibuya *et al.*, *Oncogene* 5:519-524, 1990). An alternative designation for Flt-1 is "vascular endothelial cell growth factor receptor 1" (VEGFR-1). To date, members of the FLK-1/ KDR/VEGFR-2 and Flt-1/ VEGFR-1 subfamilies have been found
15 expressed primarily on endothelial cells. These subclass members are specifically stimulated by members of the vascular endothelial cell growth factor (VEGF) family of ligands (Klagsburn and D'Amore, *Cytokine & Growth Factor Reviews* 7: 259-270, 1996). Vascular endothelial cell growth factor (VEGF) binds to Flt-1 with higher affinity than to FLK-1/KDR and is mitogenic toward vascular endothelial
20 cells (Terman *et al.*, 1992, *supra*; Mustonen *et al.* *supra*; DeVries *et al.*, *supra*). Flt-1 is believed to be essential for endothelial organization during vascular development. Flt-1 expression is associated with early vascular development in mouse embryos, and with neovascularization during wound healing (Mustonen and Alitalo, *supra*). Expression of Flt-1 in monocytes, osteoclasts, and osteoblasts, as
25 well as in adult tissues such as kidney glomeruli suggests an additional function for this receptor that is not related to cell growth (Mustonen and Alitalo, *supra*).

As previously stated, recent evidence suggests that VEGF plays a role in the stimulation of both normal and pathological angiogenesis (Jakeman *et al.*, *Endocrinology* 133: 848-859, 1993; Kolch *et al.*, *Breast Cancer Research and Treatment* 36: 139-155, 1995; Ferrara *et al.*, *Endocrine Reviews* 18(1); 4-25, 1997;
30

Ferrara et al., Regulation of Angiogenesis (ed. L. D. Goldberg and E.M. Rosen), 209-232, 1997). In addition, VEGF has been implicated in the control and enhancement of vascular permeability (Connolly, *et al.*, *J. Biol. Chem.* 264: 20017-20024, 1989; Brown *et al.*, *Regulation of Angiogenesis* (ed. L.D. Goldberg and E.M. Rosen), 233-269, 1997). Different forms of VEGF arising from alternative splicing of mRNA have been reported, including the four species described by Ferrara *et al.* (*J. Cell. Biochem.* 47:211-218, 1991). Both secreted and predominantly cell-associated species of VEGF have been identified by Ferrara *et al. supra*, and the protein is known to exist in the form of disulfide linked dimers.

Several related homologs of VEGF have recently been identified. However, their roles in normal physiological and disease processes have not yet been elucidated. In addition, the members of the VEGF family are often coexpressed with VEGF in a number of tissues and are, in general, capable of forming heterodimers with VEGF. This property likely alters the receptor specificity and biological effects of the heterodimers and further complicates the elucidation of their specific functions as illustrated below (Korpelainen and Alitalo, *Curr. Opin. Cell Biol.*, 159-164, 1998 and references cited therein).

Placenta growth factor (PlGF) has an amino acid sequence that exhibits significant homology to the VEGF sequence (Park *et al.*, *J. Biol. Chem.* 269:25646-54, 1994; Maglione *et al. Oncogene* 8:925-31, 1993). As with VEGF, different species of PlGF arise from alternative splicing of mRNA, and the protein exists in dimeric form (Park *et al.*, *supra*). PlGF-1 and PlGF-2 bind to Flt-1 with high affinity, and PlGF-2 also avidly binds to neuropilin-1 (Migdal *et al.*, *J. Biol. Chem.* 273 (35): 22272-22278), but neither binds to FLK-1/KDR (Park *et al.*, *supra*). PlGF has been reported to potentiate both the vascular permeability and mitogenic effect of VEGF on endothelial cells when VEGF is present at low concentrations (purportedly due to heterodimer formation) (Park *et al.*, *supra*).

VEGF-B is produced as two isoforms (167 and 185 residues) that also appear to bind Flt-1/VEGFR-1. It may play a role in the regulation of extracellular matrix degradation, cell adhesion, and migration through modulation of the expression and

activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1 (Pepper *et al*, *Proc. Natl. Acad. Sci. U. S. A.* (1998), 95(20): 11709-11714).

VEGF-C was originally cloned as a ligand for VEGFR-3/Flt-4 which is primarily expressed by lymphatic endothelial cells. In its fully processed form,
5 VEGF-C can also bind KDR/VEGFR-2 and stimulate proliferation and migration of endothelial cells *in vitro* and angiogenesis in *in vivo* models (Lymboussaki *et al*, *Am. J. Pathol.* (1998), 153(2): 395-403; Witzenbichler *et al*, *Am. J. Pathol.* (1998), 153(2), 381-394). The transgenic overexpression of VEGF-C causes proliferation and enlargement of only lymphatic vessels, while blood vessels are unaffected.
10 Unlike VEGF, the expression of VEGF-C is not induced by hypoxia (Ristimaki *et al*, *J. Biol. Chem.* (1998), 273(14),8413-8418).

The most recently discovered VEGF-D is structurally very similar to VEGF-C. VEGF-D is reported to bind and activate at least two VEGFRs, VEGFR-3/Flt-4 and KDR/VEGFR-2. It was originally cloned as a c-fos inducible mitogen for
15 fibroblasts and is most prominently expressed in the mesenchymal cells of the lung and skin (Achen *et al*, *Proc. Natl. Acad. Sci. U. S. A.* (1998), 95(2), 548-553 and references therein).

As for VEGF, VEGF-C and VEGF-D have been claimed to induce increases in vascular permeability *in vivo* in a Miles assay when injected into cutaneous tissue
20 (PCT/US97/14696; WO98/07832, Witzenbichler *et al.*, *supra*). The physiological role and significance of these ligands in modulating vascular hyperpermeability and endothelial responses in tissues where they are expressed remains uncertain.

There has been recently reported a virally encoded, novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), which preferentially utilizes
25 KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain (Meyer *et al*, *EMBO J.* (1999), 18(2), 363-374; Ogawa *et al*, *J. Biol. Chem.* (1998), 273(47), 31273-31282.). VEGF-E sequences possess 25% homology to mammalian VEGF and are encoded by the parapoxvirus Orf virus (OV). This parapoxvirus that affects sheep and goats and occasionally, humans, to generate
30 lesions with angiogenesis. VEGF-E is a dimer of about 20 kDa with no basic

domain nor affinity for heparin, but has the characteristic cysteine knot motif present in all mammalian VEGFs, and was surprisingly found to possess potency and bioactivities similar to the heparin-binding VEGF165 isoform of VEGF-A, i.e. both factors stimulate the release of tissue factor (TF), the proliferation, chemotaxis and sprouting of cultured vascular endothelial cells in vitro and angiogenesis in vivo. Like VEGF165, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation and a biphasic rise in free intracellular Ca^{2+} concentrations, while in contrast to VEGF165, VEGF-E did not bind to VEGF receptor-1 (Flt-1).

Based upon emerging discoveries of other homologs of VEGF and VEGFRs and the precedents for ligand and receptor heterodimerization, the actions of such VEGF homologs may involve formation of VEGF ligand heterodimers, and/or heterodimerization of receptors, or binding to a yet undiscovered VEGFR (Witzenbichler *et al.*, *supra*). Also, recent reports suggest neuropilin-1 (Migdal *et al.*, *supra*) or VEGFR-3/Flt-4 (Witzenbichler *et al.*, *supra*), or receptors other than KDR/VEGFR-2 may be involved in the induction of vascular permeability (Stacker, S.A., Vitali, A., Domagala, T., Nice, E., and Wilks, A.F., "Angiogenesis and Cancer" Conference, Amer. Assoc. Cancer Res., Jan. 1998, Orlando, FL; Williams, *Diabetologia* 40: S118-120 (1997)).

Tie-2 (TEK) is a member of a recently discovered family of endothelial cell specific receptor tyrosine kinases which is involved in critical angiogenic processes, such as vessel branching, sprouting, remodeling, maturation and stability. Tie-2 is the first mammalian receptor tyrosine kinase for which both agonist ligand(s) (e.g., Angiopoietin1 ("Ang1")), which stimulates receptor autophosphorylation and signal transduction), and antagonist ligand(s) (e.g., Angiopoietin2 ("Ang2")), have been identified. Knock-out and transgenic manipulation of the expression of Tie-2 and its ligands indicates tight spatial and temporal control of Tie-2 signaling is essential for the proper development of new vasculature. The current model suggests that stimulation of Tie-2 kinase by the Ang1 ligand is directly involved in the branching, sprouting and outgrowth of new vessels, and recruitment and interaction of

periendothelial support cells important in maintaining vessel integrity and inducing quiescence. The absence of Ang1 stimulation of Tie-2 or the inhibition of Tie-2 autophosphorylation by Ang2, which is produced at high levels at sites of vascular regression, may cause a loss in vascular structure and matrix contacts resulting in endothelial cell death, especially in the absence of growth/survival stimuli. The situation is however more complex, since at least two additional Tie-2 ligands (Ang3 and Ang4) have recently been reported, and the capacity for heterooligomerization of the various agonistic and antagonistic angiopoietins, thereby modifying their activity, has been demonstrated. Targeting Tie-2 ligand-receptor interactions as an antiangiogenic therapeutic approach is thus less favored and a kinase inhibitory strategy preferred.

The soluble extracellular domain of Tie-2 ("ExTek") can act to disrupt the establishment of tumor vasculature in a breast tumor xenograft and lung metastasis models and in tumor-cell mediated ocular neovascularization. By adenoviral infection, the *in vivo* production of mg/ml levels ExTek in rodents may be achieved for 7-10 days with no adverse side effects. These results suggest that disruption of Tie-2 signaling pathways in normal healthy animals may be well tolerated. These Tie-2 inhibitory responses to ExTek may be a consequence sequestration of ligand(s) and/or generation of a nonproductive heterodimer with full-length Tie-2.

Recently, significant upregulation of Tie-2 expression has been found within the vascular synovial pannus of arthritic joints of humans, consistent with a role in the inappropriate neovascularization. This finding suggests that Tie-2 plays a role in the progression of rheumatoid arthritis. Point mutations producing constitutively activated forms of Tie-2 have been identified in association with human venous malformation disorders. Tie-2 inhibitors are, therefore, useful in treating such disorders, and in other situations of inappropriate neovascularization.

The Non-Receptor Tyrosine Kinases. The non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences. At present, over twenty-four individual non-receptor tyrosine kinases, comprising eleven (11) subfamilies (Src, Frk, Btk, Csk, Abl,

Zap70, Fes/Fps, Fak, Jak, Ack and LIMK) have been identified. At present, the Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and include Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to oncogenesis and immune responses. A more detailed discussion of non-receptor tyrosine kinases is provided in Bohlen, 5 1993, *Oncogene* 8:2025-2031, which is incorporated herein by reference.

Many of the tyrosine kinases, whether an RTK or non-receptor tyrosine kinase, have been found to be involved in cellular signaling pathways involved in numerous pathogenic conditions, including cancer, psoriasis, and other 10 hyperproliferative disorders or hyper-immune responses.

Development of Compounds to Modulate the PTKs. In view of the surmised importance of PTKs to the control, regulation, and modulation of cell proliferation, the diseases and disorders associated with abnormal cell proliferation, many attempts have been made to identify receptor and non-receptor tyrosine kinase 15 "inhibitors" using a variety of approaches, including the use of mutant ligands (U.S. Application No. 4,966,849), soluble receptors and antibodies (Application No. WO 94/10202; Kendall & Thomas, 1994, *Proc. Natl. Acad. Sci* 90:10705-09; Kim *et al.*, 1993, *Nature* 362:841-844), RNA ligands (Jellinek, *et al.*, *Biochemistry* 33:10450-56; Takano, *et al.*, 1993, *Mol. Bio. Cell* 4:358A; Kinsella, *et al.* 1992, *Exp. Cell Res.* 20 199:56-62; Wright, *et al.*, 1992, *J. Cellular Phys.* 152:448-57) and tyrosine kinase inhibitors (WO 94/03427; WO 92/21660; WO 91/15495; WO 94/14808; U.S. Patent No. 5,330,992; Mariani, *et al.*, 1994, *Proc. Am. Assoc. Cancer Res.* 35:2268).

More recently, attempts have been made to identify small molecules which act as tyrosine kinase inhibitors. For example, bis monocyclic, bicyclic or 25 heterocyclic aryl compounds (PCT WO 92/20642) and vinylene-azaindole derivatives (PCT WO 94/14808) have been described generally as tyrosine kinase inhibitors. Styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1; *Expert Opin. Ther. Pat.* (1998), 8(4): 475-478), 30 selenoindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic

compounds (PCT WO 92/21660) and benzylphosphonic acid compounds (PCT WO 91/15495) have been described as compounds for use as tyrosine kinase inhibitors for use in the treatment of cancer. Anilinoquinolines (PCT WO97/34876) and quinazoline derivative compounds (PCT WO97/22596; PCT WO97/42187) have
5 been described as inhibitors of angiogenesis and vascular permeability.

In addition, attempts have been made to identify small molecules which act as serine/threonine kinase inhibitors. For example, bis(indolylmaleimide) compounds have been described as inhibiting particular PKC serine/threonine kinase isoforms whose signal transducing function is associated with altered vascular
10 permeability in VEGF-related diseases (PCT WO97/40830; PCT WO97/40831).

Plk-1 Kinase Inhibitors

Plk-1 is a serine/threonine kinase which is an important regulator of cell cycle progression. It plays critical roles in the assembly and the dynamic function of the mitotic spindle apparatus. Plk-1 and related kinases have also been shown to be closely involved in the activation and inactivation of other cell cycle regulators, such as cyclin-dependent kinases. High levels of Plk-1 expression are associated with cell proliferation activities. It is often found in malignant tumors of various origins. Inhibitors of Plk-1 are expected to block cancer cell proliferation by disrupting processes involving mitotic spindles and inappropriately activated cyclin-dependent kinases.

Cdc2/Cyclin B Kinase Inhibitors (Cdc2 is also known as cdk1)

Cdc2/cyclin B is another serine/threonine kinase enzyme which belongs to the cyclin-dependent kinase (cdks) family. These enzymes are involved in the critical transition between various phases of cell cycle progression. It is believed that uncontrolled cell proliferation, which is the hallmark of cancer is dependent upon elevated cdk activities in these cells. The inhibition of elevated cdk activities in cancer cells by cdc2/cyclin B kinase inhibitors could suppress proliferation and may restore the normal control of cell cycle progression.

The regulation of CDK activation is complex, but requires the association of the CDK with a member of the cyclin family of regulatory subunits (Draetta, *Trends in Cell Biology*, 3:287-289 (1993)); Murray and Kirschner, *Nature*, 339:275-280 (1989); Solomon *et al.*, *Molecular Biology of the Cell*, 3:13-27 (1992)). A further level of regulation occurs through both activating and inactivating phosphorylations of the CDK subunit (Draetta, *Trends in Cell Biology*, 3:287-289 (1993)); Murray and Kirschner, *Nature*, 339:275-280 (1989); Solomon *et al.*, *Molecular Biology of the Cell*, 3:13-27 (1992); Ducommun *et al.*, *EMBO Journal*, 10:3311-3319 (1991); Gautier *et al.*, *Nature* 339:626-629 (1989); Gould and Nurse, *Nature*, 342:39-45 (1989); Krek and Nigg, *EMBO Journal*, 10:3331-3341 (1991); Solomon *et al.*, *Cell*,

63:1013-1024 (1990)). The coordinate activation and inactivation of different cyclin/CDK complexes is necessary for normal progression through the cell cycle (Pines, *Trends in Biochemical Sciences*, 18:195-197 (1993); Sherr, *Cell*, 73:1059-1065 (1993)). Both the critical G1-S and G 2-M transitions are controlled by the
5 activation of different cyclin/CDK activities. In G1, both cyclin D/CDK4 and cyclin E/CDK2 are thought to mediate the onset of S-phase (Matsushima *et al.*, *Molecular & Cellular Biology*, 14:2066-2076 (1994); Ohtsubo and Roberts, *Science*, 259:1908-1912 (1993); Quelle *et al.*, *Genes & Development*, 7:1559-1571 (1993); Resnitzky *et al.*, *Molecular & Cellular Biology*, 14:1669-1679 (1994)). Progression through S-
10 phase requires the activity of cyclin A/CDK2 (Girard *et al.*, *Cell*, 67:1169-1179 (1991); Pagano *et al.*, *EMBO Journal*, 11:961-971 (1992); Rosenblatt *et al.*, *Proceedings of the National Academy of Science USA*, 89:2824-2828 (1992); Walker and Maller, *Nature*, 354:314-317 (1991); Zindy *et al.*, *Biochemical & Biophysical Research Communications*, 182:1144-1154 (1992)) whereas the
15 activation of cyclin A/cdc2 (CDK1) and cyclin B/cdc2 are required for the onset of metaphase (Draetta, *Trends in Cell Biology*, 3:287-289 (1993)); Murray and Kirschner, *Nature*, 339:275-280 (1989); Solomon *et al.*, *Molecular Biology of the Cell*, 3:13-27 (1992); Girard *et al.*, *Cell*, 67:1169-1179 (1991); Pagano *et al.*, *EMBO Journal*, 11:961-971 (1992); Rosenblatt *et al.*, *Proceedings of the National Academy of Science USA*, 89:2824-2828 (1992); Walker and Maller, *Nature*, 354:314-317
20 (1991); Zindy *et al.*, *Biochemical & Biophysical Research Communications*, 182:1144-1154 (1992)). It is not surprising, therefore, that the loss of control of CDK regulation is a frequent event in hyperproliferative diseases and cancer. (Pines, *Current Opinion in Cell Biology*, 4:144-148 (1992); Lees, *Current Opinion in Cell Biology*, 7:773-780 (1995); Hunter and Pines, *Cell*, 79:573-582 (1994)).
25

Inhibitors of kinases involved in mediating or maintaining disease states represent novel therapies for these disorders. Examples of such kinases include, but are not limited to: (1) inhibition of c-Src (Brickell, *Critical Reviews in Oncogenesis*, 3:401-406 (1992); Courtneidge, *Seminars in Cancer Biology*, 5:236-246 (1994), raf
30 (Powis, *Pharmacology & Therapeutics*, 62:57-95 (1994)) and the cyclin-dependent

kinases (CDKs) 1, 2 and 4 in cancer (Pines, *Current Opinion in Cell Biology*, 4:144-148 (1992); Lees, *Current Opinion in Cell Biology*, 7:773-780 (1995); Hunter and Pines, *Cell*, 79:573-582 (1994)), (2) inhibition of CDK2 or PDGF-R kinase in restenosis (Buchdunger *et al.*, *Proceedings of the National Academy of Science USA*, 92:2258-2262 (1995)), (3) inhibition of CDK5 and GSK3 kinases in Alzheimers (Hosoi *et al.*, *Journal of Biochemistry (Tokyo)*, 117:741-749 (1995); Aplin *et al.*, *Journal of Neurochemistry*, 67:699-707 (1996), (4) inhibition of c-Src kinase in osteoporosis (Tanaka *et al.*, *Nature*, 383:528-531 (1996), (5) inhibition of GSK-3 kinase in type-2 diabetes (Borthwick *et al.*, *Biochemical & Biophysical Research Communications*, 210:738-745 (1995), (6) inhibition of the p38 kinase in inflammation (Badger *et al.*, *The Journal of Pharmacology and Experimental Therapeutics*, 279:1453-1461 (1996)), (7) inhibition of VEGF-R 1-3 and TIE-1 and -2 kinases in diseases which involve angiogenesis (Shawver *et al.*, *Drug Discovery Today*, 2:50-63 (1997)), (8) inhibition of UL97 kinase in viral infections (He *et al.*, *Journal of Virology*, 71:405-411 (1997)), (9) inhibition of CSF-1R kinase in bone and hematopoietic diseases (Myers *et al.*, *Bioorganic & Medicinal Chemistry Letters*, 7:421-424 (1997), and (10) inhibition of Lck kinase in autoimmune diseases and transplant rejection (Myers *et al.*, *Bioorganic & Medicinal Chemistry Letters*, 7:417-420 (1997)).

It is additionally possible that inhibitors of certain kinases may have utility in the treatment of diseases when the kinase is not misregulated, but it nonetheless essential for maintenance of the disease state. In this case, inhibition of the kinase activity would act either as a cure or palliative for these diseases. For example, many viruses, such as human papilloma virus, disrupt the cell cycle and drive cells into the S-phase of the cell cycle (Vousden, *FASEB Journal*, 7:8720879 (1993)). Preventing cells from entering DNA synthesis after viral infection by inhibition of essential S-phase initiating activities such as CDK2, may disrupt the virus life cycle by preventing virus replication. This same principle may be used to protect normal cells of the body from toxicity of cycle-specific chemotherapeutic agents (Stone *et al.*, *Cancer Research*, 56:3199-3202 (1996); Kohn *et al.*, *Journal of Cellular*


Biochemistry, 54:44-452 (1994)). Inhibition of CDKs 2 or 4 will prevent progression into the cycle in normal cells and limit the toxicity of cytotoxics which act in S-phase, G2 or mitosis. Furthermore, CDK2/cyclin E activity has also been shown to regulate NF-kB. Inhibition of CDK2 activity stimulates NF-kB-dependent gene expression, an event mediated through interactions with the p300 coactivator (Perkins *et al.*, *Science*, 275:523-527 (1997)). NF-kB regulates genes involved in inflammatory responses (such as hematopoietic growth factors, chemokines and leukocyte adhesion molecules) (Baeuerle and Henkel, *Annual Review of Immunology*, 12:141-179 (1994)) and may be involved in the suppression of apoptotic signals within the cell (Beg and Baltimore, *Science*, 274:782-784 (1996); Wang *et al.*, *Science*, 274:784-787 (1996); Van Antwerp *et al.*, *Science*, 274:787-789 (1996)). Thus, inhibition of CDK2 may suppress apoptosis induced by cytotoxic drugs via a mechanism which involves NF-kB. This therefore suggests that inhibition of CDK2 activity may also have utility in other cases where regulation of NF-kB plays a role in etiology of disease. A further example may be take from fungal infections: Aspergillosis is a common infection in immune-compromised patients (Armstrong, *Clinical Infectious Diseases*, 16:1-7 (1993)). Inhibition of the Aspergillus kinases Cdc2/CDC28 or Nim A (Osmani *et al.*, *EMBO Journal*, 10:2669-2679 (1991); Osmani *et al.*, *Cell*, 67:283-291 (1991)) may cause arrest or death in the fungi, improving the therapeutic outcome for patients with these infections.

The identification of effective small compounds which specifically inhibit signal transduction and cellular proliferation by modulating the activity of receptor and non-receptor tyrosine and serine/threonine kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism is therefore desirable. In particular, the identification of methods and compounds that specifically inhibit the function of a tyrosine kinase which is essential for angiogenic processes or the formation of vascular hyperpermeability leading to edema, ascites, effusions, exudates, and macromolecular extravasation and matrix deposition as well as associated disorders would be beneficial.

SUMMARY OF THE INVENTION

The present invention provides compounds of Formula I,

5



(I)

and pharmaceutically acceptable salts thereof.

In Formula I, Ring A is a six membered aromatic ring or a five or six
 10 membered heteroaromatic ring. Ring A is optionally substituted such as with one or
 more of the following substituents: a substituted or unsubstituted aliphatic group, a
 halogen, a substituted or unsubstituted aromatic group, substituted or unsubstituted
 heteroaromatic group, substituted or unsubstituted cycloalkyl, substituted or
 unsubstituted heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or
 15 unsubstituted heteroaralkyl, cyano, nitro, $-NR_4R_5$, $-C(O)_2H$, $-OH$, a substituted or
 unsubstituted alkoxycarbonyl, $-C(O)_2$ -haloalkyl, a substituted or unsubstituted
 alkylthio ether, a substituted or unsubstituted alkylsulfoxide, a substituted or
 unsubstituted alkylsulfone, a substituted or unsubstituted arylthio ether, a substituted
 or unsubstituted arylsulfoxide, a substituted or unsubstituted arylsulfone, a
 20 substituted or unsubstituted alkyl carbonyl, $-C(O)$ -haloalkyl, a substituted or
 unsubstituted aliphatic ether, a substituted or unsubstituted aromatic ether,
 carboxamido, tetrazolyl, trifluoromethylsulphonamido,
 trifluoromethylcarbonylamino, a substituted or unsubstituted alkynyl, a substituted


or unsubstituted alkyl amido, a substituted or unsubstituted aryl amido, a substituted or unsubstituted styryl and a substituted or unsubstituted aralkyl amido.

L is one of the following linkers: -O-; -S-; -S(O)-; -S(O)₂-; -N(R)-; -N(C(O)OR)-; -N(C(O)R)-; -N(SO₂R)-; -CH₂O-; -CH₂S-; -CH₂N(R)-; -CH(NR)-; -CH₂N(C(O)R)-; -CH₂N(C(O)OR)-; -CH₂N(SO₂R)-; -CH(NHR)-; -CH(NHC(O)R)-; -CH(NHSO₂R)-; -CH(NHC(O)OR)-; -CH(OC(O)R)-; -CH(OC(O)NHR)-; -CH=CH-; -C(=NOR)-; -C(O)-; -CH(OR)-; -C(O)N(R)-; -N(R)C(O)-; -N(R)S(O)-; -N(R)S(O)₂-; -OC(O)N(R)-; -N(R)C(O)N(R)-; -NRC(O)O-; -S(O)N(R)-; -S(O)₂N(R)-; -N(C(O)R)S(O)-; -N(C(O)R)S(O)₂-; -N(R)S(O)N(R)-; -N(R)S(O)₂N(R)-; -C(O)N(R)C(O)-; -S(O)N(R)C(O)-; -S(O)₂N(R)C(O)-; -OS(O)N(R)-; -OS(O)₂N(R)-; -N(R)S(O)O-; -N(R)S(O)₂O-; -N(R)S(O)C(O)-; -N(R)S(O)₂C(O)-; -SON(C(O)R)-; -SO₂N(C(O)R)-; -N(R)SON(R)-; -N(R)SO₂N(R)-; -C(O)O-; -N(R)P(OR')O-; -N(R)P(OR')-; -N(R)P(O)(OR')O-; -N(R)P(O)(OR')-; -N(C(O)R)P(OR')O-; -N(C(O)R)P(OR')-; -N(C(O)R)P(O)(OR')O-; -N(C(O)R)P(OR')-; -CH(R)S(O)-; -CH(R)S(O)₂-; -CH(R)N(C(O)OR)-; -CH(R)N(C(O)R)-; -CH(R)N(SO₂R)-; -CH(R)O-; -CH(R)S-; -CH(R)N(R)-; -CH(R)N(C(O)R)-; -CH(R)N(C(O)OR)-; -CH(R)N(SO₂R)-; -CH(R)C(=NOR)-; -CH(R)C(O)-; -CH(R)CH(OR)-; -CH(R)C(O)N(R)-; -CH(R)N(R)C(O)-; -CH(R)N(R)S(O)-; -CH(R)N(R)S(O)₂-; -CH(R)OC(O)N(R)-; -CH(R)N(R)C(O)N(R)-; -CH(R)NRC(O)O-; -CH(R)S(O)N(R)-; -CH(R)S(O)₂N(R)-; -CH(R)N(C(O)R)S(O)-; -CH(R)N(C(O)R)S(O)₂-; -CH(R)N(R)S(O)N(R)-; -CH(R)N(R)S(O)₂N(R)-; -CH(R)C(O)N(R)C(O)-; -CH(R)S(O)N(R)C(O)-; -CH(R)S(O)₂N(R)C(O)-; -CH(R)OS(O)N(R)-; -CH(R)OS(O)₂N(R)-; -CH(R)N(R)S(O)O-; -CH(R)N(R)S(O)₂O-; -CH(R)N(R)S(O)C(O)-; -CH(R)N(R)S(O)₂C(O)-; -CH(R)SON(C(O)R)-; -CH(R)SO₂N(C(O)R)-; -CH(R)N(R)SON(R)-; -CH(R)N(R)SO₂N(R)-; -CH(R)C(O)O-; -CH(R)N(R)P(OR')O-; -CH(R)N(R)P(OR')-; -CH(R)N(R)P(O)(OR')O-; -CH(R)N(R)P(O)(OR')-; -CH(R)N(C(O)R)P(OR')O-; -CH(R)N(C(O)R)P(OR')-; -CH(R)N(C(O)R)P(O)(OR')O- or -CH(R)N(C(O)R)P(OR')-. R and R' are each, independently, -H, an acyl group, a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or

unsubstituted cycloalkyl group.

Alternatively, L is $-R_bN(R)S(O)_2-$, $-R_bN(R)P(O)-$, or $-R_bN(R)P(O)O-$. R_b is an alkylene group which when taken together with the sulphonamide, phosphinamide, or phosphonamide group to which it is bound forms a five or six
5 membered ring fused to ring A.

Alternatively, L is represented by one of the following structural formulas:



10 R_{85} taken together with the phosphinamide, or phosphonamide is a 5-, 6-, or 7-membered, aromatic, heteroaromatic or heterocycloalkyl ring system.

In Formula I, R_1 is a substituted aliphatic group, a substituted cycloalkyl, a substituted bicycloalkyl, a substituted cycloalkenyl, an optionally substituted aromatic group, an optionally substituted heteroaromatic group, an optionally
15 substituted heteroaralkyl, an optionally substituted heterocycloalkyl, an optionally substituted heterobicycloalkyl, an optionally substituted alkylamindo, and optionally

substituted arylamido, an optionally substituted $-S(O)_2$ -alkyl or optionally substituted $-S(O)_2$ -cycloalkyl, a $-C(O)$ -alkyl or an optionally substituted $-C(O)$ -alkyl.

R_1 can be substituted with one or more substituents. Preferably, R_1 is substituted with a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aromatic ether, a substituted or unsubstituted aliphatic ether, a substituted or unsubstituted alkoxycarbonyl, a substituted or unsubstituted alkylcarbonyl, a substituted or unsubstituted arylcarbonyl, a substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted aryloxycarbonyl, $-OH$, a substituted or unsubstituted aminocarbonyl, an oxime, a substituted or unsubstituted azabicycloalkyl, heterocycloalkyl, oxo, aldehyde, a substituted or unsubstituted alkyl sulfonamido group, a substituted or unsubstituted aryl sulfonamido group, a substituted or unsubstituted bicycloalkyl, a substituted or unsubstituted heterobicycloalkyl, cyano, $-NH_2$, an alkylamino, ureido, thioureido and $-B-E$.

B is a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aromatic, a substituted or unsubstituted heteroaromatic, an alkylene, an aminoalkyl, an alkylencarbonyl, or an aminoalkylcarbonyl.

E is a substituted or unsubstituted azacycloalkyl, a substituted or unsubstituted azacycloalkylcarbonyl, a substituted or unsubstituted azacycloalkylsulfonyl, a substituted or unsubstituted azacycloalkylalkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroarylcarbonyl, a substituted or unsubstituted heteroarylsulfonyl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted alkyl sulfonamido, a substituted or unsubstituted aryl sulfonamido, a substituted or unsubstituted bicycloalkyl, a substituted or unsubstituted ureido, a substituted or unsubstituted thioureido or a substituted or unsubstituted aryl.

G is a direct bond; $-(CH_2)_j-$, wherein j is 1 to 6; a C_2-C_6 - alkenylene group, a C_3-C_8 -cycloalkylene group or a C_1-C_6 -oxaalkylene group;

However, when R_1 is an aliphatic group or cycloalkyl group, R_1 is not exclusively substituted with one or more substituent selected from the group consisting of hydroxyl and lower alkyl ethers. In addition, a heterocycloalkyl is not 2-phenyl-1,3-dioxan-5-yl, and an aliphatic group is not substituted exclusively with one or more aliphatic groups.

In Formula I, R_2 is $-H$, a substituted or unsubstituted aliphatic group, a substituted or unsubstituted cycloalkyl, a halogen, $-OH$, cyano, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaralkyl, $-NR_4R_5$, or $-C(O)NR_4R_5$.

In Formula I, R_3 is a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocycloalkyl.

In Formula I, R_4 , R_5 and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterobicycloalkyl or a substituted or unsubstituted heteroaromatic.

Alternatively, R_4 and R_5 are each, independently, $-H$, azabicycloalkyl, heterocycloalkyl, a substituted or unsubstituted alkyl group or Y-Z.

Y is selected from the group consisting of $-C(O)-$, $-(CH_2)_p-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_pO-$, $-(CH_2)_pNH-$, $-(CH_2)_pS-$, $-(CH_2)_pS(O)-$, and $-(CH_2)_pS(O)_2-$.

p is an integer from 0 to about 6.

Z is a substituted or unsubstituted alkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl group.

j an integer from 0 to 6.

However, when L is $-CH_2NR-$, $-C(O)NR-$ or $-NRC(O)-$ and R_3 is azacycloalkyl or azaheteroaryl, j is 0. In addition, when L is $-O-$ and R_3 is phenyl, j is 0.

In a preferred subset of the compounds of Formula I, R_1 is B-E, where E is a heterocyclyl group; L is $-\text{CH}_2\text{NHC(O)}-$; $-\text{CH}_2\text{NHC(O)NH}-$; $-\text{CH}_2\text{NHC(O)O}-$; $-\text{CH}_2\text{C(O)NH}-$; $-\text{CH}_2\text{NHS(O)}_2-$; $-\text{NHC(O)}-$; $-\text{NHC(O)NH}-$; $-\text{NHC(O)O}-$; $-\text{C(O)NH}-$; $-\text{NS(O)}_2-$; A is 1,4-phenylene or 1,4-phenylene substituted with one or more methoxy groups or fluorine atoms; R_3 is phenyl or phenyl substituted with one or more substituents selected from the group consisting of chloro, cyano, bromo, fluoro, trifluoromethoxy, methoxy, methylenedioxy, methyl, amino, dimethylamino and nitro; R_2 is hydrogen; and G is a direct bond or $-(\text{CH}_2)_j-$, wherein j is 0 to 4.

In another preferred subset of the compounds of Formula I, ring A is 1,4-phenylene, L is $-\text{O}-$, G is a direct bond and R_3 is phenyl.

The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially in cancer and in the process of angiogenesis. For example, certain of these compounds are inhibitors of such receptor kinases as KDR, Flt-1, FGFR, PDGFR, c-Met, TIE-2 or IGF-1-R. Since certain of these compounds are anti-angiogenic, they are important substances for inhibiting the progression of disease states where angiogenesis is an important component. Certain compounds of the invention are effective as inhibitors of such serine/threonine kinases as PKCs, erk, MAP kinases, MAP kinase kinases, MAP kinase kinase kinases, cdks, Plk-1 or Raf-1. These compounds are useful in the treatment of cancer, and hyperproliferative disorders. In addition, certain compounds are effective inhibitors of non-receptor kinases such as those of the Src (for example, Ick, blk and lyn), Tec, Csk, Jak, Map, Nik and Syk families. These compounds are useful in the treatment of cancer, hyperproliferative disorders and immunologic diseases.

Certain compounds of this invention are selective TIE-2 kinase inhibitors which may be anti-angiogenic (especially in combination with one or more VEGFR inhibitors), or pro-angiogenic, when employed in the presence of, or in conjunction with, a VEGF-related stimulus. In this manner such inhibitors can be used in the promotion of therapeutic angiogenesis to treat, for example, ischemia, infarct or occlusion, or to promote wound healing.

-21-

The present invention provides a method of inhibiting the kinase activity of tyrosine kinases and serine/threonine kinases comprising the administration of a compound represented by formula I to said kinase in sufficient concentration to inhibit the enzyme activity of said kinase.

5 The present invention further includes the use of these compounds in pharmaceutical compositions with a pharmaceutically effective amount of the above-described compounds and a pharmaceutically acceptable carrier or excipient. These pharmaceutical compositions can be administered to individuals to slow or halt the process of angiogenesis in angiogenesis-aided diseases, or to treat edema, effusions,
10 exudates or ascites and other conditions associated with vascular hyperpermeability. Certain pharmaceutical compositions can be administered to individuals to treat cancer and hyperproliferative disorders by inhibiting serine/threonine kinases such as cdk, Plk-1, erk, etc.

15 DETAILED DESCRIPTION OF THE INVENTION

The values of substituents in a first preferred group of compounds of formula I are given below.

Preferably, L is -N(R)C(O)N(R)-, -N(R)S(O)₂-, -S(O)₂N(R)-, -N(R)C(O)-, -C(O)N(R)-, or -O-.

20 Preferably, G is a direct bond; -(CH₂)_j-, wherein j is from 1 or 2; trans -CH=CH-; -cycloC₃H₄-; or -CH₂O-.


Preferably, R₃ is a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted pyridyl, a substituted or unsubstituted thienyl, a substituted or unsubstituted benzotriazole, a substituted or
25 unsubstituted tetrahydropyranyl, a substituted or unsubstituted tetrahydrofuranyl, a substituted or unsubstituted dioxane, a substituted or unsubstituted dioxolane, a substituted or unsubstituted quinoline, a substituted or unsubstituted thiazole, substituted or unsubstituted isoxazole, substituted or unsubstituted cyclopentanyl, a substituted or unsubstituted benzofuran, substituted or unsubstituted
30 benzothiophene, substituted or unsubstituted benzisoxazole, substituted or unsubstituted benzisothiazole, substituted or unsubstituted benzothiazole, substituted

or unsubstituted benzoxazole, substituted or unsubstituted benzimidazole, substituted or unsubstituted benzoxadiazole, substituted or unsubstituted benzothiadiazole, substituted or unsubstituted isoquinoline, substituted or unsubstituted quinoxaline, substituted or unsubstituted indole or substituted or unsubstituted pyrazole. Alternatively, R_3 can be a substituted or unsubstituted aliphatic group or a substituted or unsubstituted alkenyl, provided that

5 L is $-\text{SN}(\text{R})-$, $-\text{S}(\text{O})\text{N}(\text{R})-$, $-\text{S}(\text{O})_2\text{N}(\text{R})-$, $-\text{N}(\text{R})\text{S}-$, $-\text{N}(\text{R})\text{S}(\text{O})-$, $-\text{N}(\text{R})\text{S}(\text{O})_2-$, $-\text{N}(\text{R})\text{C}(\text{O})\text{N}(\text{R})-$, $-\text{N}(\text{R})\text{SN}(\text{R}')-$, $-\text{N}(\text{R})\text{S}(\text{O})\text{N}(\text{R}')-$, or $-\text{N}(\text{R})\text{S}(\text{O})_2\text{N}(\text{R}')-$;

In one embodiment, R_3 is a substituted or unsubstituted phenyl or phenyl fused to a five- or six-membered heterocyclic group. In this embodiment, suitable

10 examples of R_3 include, but are not limited to, the groups shown below.



where R is hydrogen or alkyl.

15 R_3 can be substituted by one or more substituents. Preferable substituents for R_3 are F, Cl, Br, I, CH_3 , NO_2 , OCF_3 , OCH_3 , CN, CO_2CH_3 , CF_3 , t-butyl, pyridyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted benzyl, substituted or unsubstituted benzenesulfonyl, substituted or unsubstituted phenoxy, substituted or unsubstituted phenyl, substituted or unsubstituted amino, carboxyl, substituted or

20 unsubstituted tetrazolyl, styryl, $-\text{S}-(\text{substituted or unsubstituted aryl})$, $-\text{S}-(\text{substituted or unsubstituted heteroaryl})$, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, alkynyl, $-\text{C}(\text{O})\text{NR}_f\text{R}_g$, R_e , CH_2OR_e .

R_f , R_g and the nitrogen atom together form a 3-, 4-, 5-, 6- or 7-membered, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted

25 heterobicycloalkyl or a substituted or unsubstituted heteroaromatic.

Alternatively, R_f and R_g are each, independently, a substituted or unsubstituted aliphatic group or a substituted or unsubstituted aromatic group.

R_c is hydrogen, or substituted or unsubstituted alkyl or substituted or unsubstituted aryl; $-W-(CH_2)_t-NR_dR_e$, $-W-(CH_2)_t-O$ -alkyl, $-W-(CH_2)_t-S$ -alkyl, or $-W-(CH_2)_t-OH$.

t is an integer from 0 to about 6.

W is a bond or $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, or $-NR_k-$.

R_k is $-H$ or alkyl.

R_d , R_e and the nitrogen atom to which they are attached together form a 3, 4, 5, 6 or 7-membered substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterobicyclic group.

Alternatively, R_d and R_e are each, independently, $-H$, alkyl, alkanoyl or $-K-D$.

K is $-S(O)_2-$, $-C(O)-$, $-C(O)NH-$, $-C(O)_2-$, or a direct bond.

D is a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aminoalkyl, a substituted or unsubstituted aminocycloalkyl, $COOR_i$, or substituted or unsubstituted alkyl.

R_i is a substituted or unsubstituted aliphatic group or a substituted or unsubstituted aromatic group.

More preferred substituents for R_3 are F, Cl, Br, I, cyano, nitro, OCF_3 , CH_3 , and CF_3 .

Preferably, ring A is a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted pyridyl, or a substituted or unsubstituted indole. In one embodiment, ring A is a substituted or unsubstituted phenyl. In one embodiment, ring A is a substituted or unsubstituted 1,4-phenylene group which is optionally substituted with one or more methoxy or fluoro groups.


Ring A can be substituted by one or more substituents. Preferable substituents for ring A are F, Cl, Br, I, CH₃, NO₂, OCF₃, OCH₃, CN, CO₂CH₃, CF₃, t-butyl, pyridyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted benzyl, substituted or unsubstituted benzenesulfonyl, substituted or unsubstituted phenoxy, substituted or unsubstituted phenyl, substituted or unsubstituted amino, carboxyl, substituted or unsubstituted tetrazolyl, styryl, -S-(substituted or unsubstituted aryl), -S-(substituted or unsubstituted heteroaryl), substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, alkynyl, -C(O)NR_fR_g, R_e and CH₂OR_c. R_f, R_g and R_c are defined as above.

Ring A is more preferably substituted with F, Cl, and nitro.

R₂ is preferably hydrogen.

In one embodiment, R₁ is of the formula


I(a)



m is an integer from 0 to about 3.

In another embodiment, R₁ is of the formula


I(b)



m, t are defined as above. R₈, R₉ and the nitrogen atom together form a 3-, 4-, 5-, 6- or 7-membered, substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted heteroaromatic or substituted or unsubstituted heterobicyclicalkyl

group. Alternatively, R_8 and R_9 are each, independently, -H, azabicycloalkyl, heterocycloalkyl, alkyl; hydroxyalkyl; dihydroxyalkyl or Y_2-Z_2 . Y_2 is -C(O)-, -
(CH₂)_q-, -S(O)₂-, -C(O)O-, -SO₂NH-, -CONH-, (CH₂)_qO-, -(CH₂)_qNH-, -(CH₂)_qS-, -
(CH₂)_qS(O)-, or -(CH₂)_qS(O)₂-. q is an integer from 0 to 6. Z_2 is a substituted or
5 unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or
unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or
unsubstituted heterocycloalkyl group.

In another embodiment, R_1 is of the formula




10

m , t , R_8 , and R_9 are defined as above. s is an integer from 0 to 6. q is an integer from 0 to about 6. R_{77} is $-OR_{78}$, or $-NR_{79}R_{80}$. R_{78} is $-H$ or a substituted or unsubstituted aliphatic group. R_{79} , R_{80} and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl group, substituted or unsubstituted heteroaryl group, or a substituted heterobicyclicalkyl group. R_{79} and R_{80} are each, independently, $-H$, azabicycloalkyl, heterocycloalkyl or $-Y_3-Z_3$. Y_3 is selected from the group consisting of $-C(O)-$, $-(CH_2)_q-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$ and $-(CH_2)_qS(O)_2-$. Z_3 is $-H$, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl. In one embodiment, m is 2; s is 0; and R_{77} is $-OH$. In one embodiment, R_1 is selected from the groups shown below.


15

20



In another embodiment, R₁ is of the formula


-28-



I(d)

v is an integer from 1 to about 3. R₁₀ is -H, azabicycloalkyl, heterocycloalkyl or Y₂-Z₂. Y₂ and Z₂ are as defined previously.

In another embodiment, R₁ is of the formula



I(e)

m and R₁₀ are as previously defined. R₁₁ represents one or more substituents independently selected from the group consisting of hydrogen, hydroxy, oxo, a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted alkoxycarbonyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted aminocarbonyl, a substituted or unsubstituted alkylcarbonyl, a substituted or unsubstituted arylcarbonyl, a substituted or unsubstituted heteroarylcarbonyl, a substituted or unsubstituted aminoalkyl and a substituted or unsubstituted aralkyl groups, provided that the carbon atoms adjacent to the nitrogen atom are not substituted by a hydroxy group.


-29-

In another embodiment, R_1 is of the formula

5

10

15



I(f)


R_{10} is as previously defined. Preferably, R_{10} is methyl, isopropyl or methoxyethyl

20

In another embodiment, R_1 is of the formula

25


30



I(g)


r is an integer from 1 to about 6. R_8 and R_9 are as previously defined.

In another embodiment, R_1 is of the formula



- 15 R_8 , R_9 and t are as previously defined. w is an integer from 0 to about 4. u is 0 or 1.
 R_{12} is hydrogen or a substituted or unsubstituted alkyl group.

In another embodiment, R_1 is of the formula




w , t , R_{10} , R_{12} are as previously defined.

In yet another embodiment, R_1 is of the formula




wherein m is 0, 1 or 2; R_{81} and R_{82} are each, independently, selected from the group consisting of hydrogen, hydroxyl, cyanomethyl, carboxymethyl, aminocarbonylmethyl, aminocarbonyl; aminomethyl, hydroxymethyl and amino,



provided that no more than one of R_{81} and R_{82} is hydrogen. R_{81} and R_{82} can also
 5 together form oxo; $-O-(CH_2)_i-O$, wherein i is 2 or 3; $-NH-C(O)-NH-C(O)-$; or $-NH-C(O)-NH-CH_2-$. For example, R_1 can be, but is not limited to, one of the groups shown below.


In another subset of the compounds of Formula I, R_1 is of the formula B-E,
 10 wherein B is cyclohexyl and E is substituted or unsubstituted heterocyclyl, heterocyclylalkyl or heterocyclylazaalkyl. For example, E can be a substituted or unsubstituted pyrazolyl, diazepinyl, piperazyl, piperidyl or morpholyl group. Suitable examples of R_1 include, but are not limited to, the groups shown below.

-32-



In another embodiment, when R₁ is I(g) or I(H), R₈, R₉ and the nitrogen atom together form a heterocycloalkyl group of the formula

5




- 10 u is as previously defined. R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, R₁₉ and R₂₀ are each, independently, lower alkyl or hydrogen. Alternatively, at least one pair of substituents R₁₃ and R₁₄; R₁₅ and R₁₆; R₁₇ and R₁₈; or R₁₉ and R₂₀ together are an oxygen atom. Alternatively, at least one of R₁₃ and R₁₅ is cyano, CONHR₂₁, COOR₂₁, CH₂OR₂₁ or CH₂NR₂₁(R₂₂). R₂₁, R₂₂ and the nitrogen atom together form a
- 15 3-, 4-, 5-, 6- or 7-membered, substituted or unsubstituted heterocycloalkyl group, substituted or unsubstituted heteroaryl group, or a substituted heterobicyclicalkyl group. Alternatively, R₂₁ and R₂₂ are each, independently, -H, azabicycloalkyl, heterocycloalkyl or Y₃-Z₃; Y₃ and Z₃ are as previously defined. X is -O-, -S-, -SO-, -SO₂-, -CH₂-, -CH(OR₂₃)- or NR₂₃. R₂₃ is -H, substituted or unsubstituted alkyl, a
- 20 substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, -C(NH)NH₂,

-C(O)R₂₄, or -C(O)OR₂₄. R₂₄ is hydrogen, substituted or unsubstituted alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl.

In another embodiment, R₈, R₉ and the nitrogen atom together form a heterocycloalkyl of the formula

5




10

t, R₂₁ and R₂₂ are as previously defined. R₂₅ and R₂₆ are each, independently, hydrogen or lower alkyl. Alternatively, R₂₅ and R₂₆ together are an oxygen atom. i is an integer from 1 to about 6.

15 In another embodiment, R₈, R₉ and the nitrogen atom together form a heterocycloalkyl group; of the formula


20



25 i is as previously defined. R₂₇ is CH₂OH, C(O)NR₂₄R₂₈ or COOR₂₄. R₂₄ and R₂₈ are as previously defined.


In another embodiment, R₈, R₉ and the nitrogen atom together form a heteroaromatic group of the formula

30



5 R_{29} is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl group, carboxylic acid, cyano, $C(O)OR_{30}$, CH_2OR_{30} , $CH_2NR_{21}R_{22}$ or $C(O)NR_{21}R_{22}$. R_{30} is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heterocycloalkyl or heterocycloaryl group. R_{21} and R_{22} are as previously defined.

10 In another embodiment, at least one of R_8 and R_9 is of the formula Y_3-D , wherein D is of the formula




15

Y_3 is as previously defined. x is 0, 1 or 2. T is $-O-$, $-C(O)-$, $-S-$, $-SO-$, $-SO_2-$, $-CH_2-$, $-CH(OR_{24})-$ or $-N(R_{24})-$. R_{24} is as previously defined.

20 In another embodiment, at least one of R_8 and R_9 is of the formula $Y_3-N(R_{31})R_{32}$, Y_3 is as previously defined. R_{31} and R_{32} are each, independently, substituted or unsubstituted carboxyalkyl, a substituted or unsubstituted alkoxycarbonylalkyl, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted alkylsulfonyl, a substituted or unsubstituted alkylcarbonyl or a substituted or unsubstituted cyanoalkyl. Alternatively, R_{31} and R_{32} , together with the nitrogen atom, form a five- or six-membered heterocycloalkyl group, a substituted or unsubstituted heteroaromatic or a substituted or unsubstituted heterobicycloalkyl.

25 In another embodiment, when R_1 is I(e), Z_2 is of the formula $N(R_{35})R_{36}$. R_{35} and R_{36} are each, independently, hydrogen, alkyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl, aminocarbonyl, cyano, alkylcarbonyl or aralkyl.

30 In another embodiment, when R_1 is I(e), Z_2 is of the formula




Each X_1 is, independently, CH or N. R_{37} is hydrogen, cyano or a substituted or unsubstituted alkyl, a substituted or unsubstituted alkoxyacetyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted aminocarbonyl, a substituted or unsubstituted alkylcarbonyl or a substituted or unsubstituted aralkyl group.

In another embodiment, when R_1 is I(e), Z_2 is of the formula

10


15



g is an integer from 0 to about 3. T is as previously defined. R_{37} is hydrogen, cyano or a substituted or unsubstituted alkyl, a substituted or unsubstituted alkoxyacetyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted aminocarbonyl, a substituted or unsubstituted alkylcarbonyl or a substituted or unsubstituted aralkyl group.


In another embodiment, when R_1 is I(e), Z_2 is of the formula

25



g and R_{37} are as previously defined unsubstituted aralkyl group.

In another embodiment, when R_1 is I(e), Z_2 is of the formula




5

T, g and R₃₇ are as previously defined.

In another embodiment, when R₁ is I(e), Z₂ is of the formula

10




15

R₃₇ is as previously defined. R₃₈ is hydrogen, substituted or unsubstituted alkyl, a substituted or unsubstituted alkoxy carbonyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted aminocarbonyl, perhaloalkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkyl carbonyl or a substituted or unsubstituted aralkyl.

20

In another embodiment, R₁ is of the formula

25




30

u is as previously defined. R₃₉, R₄₀, R₄₁, R₄₂, R₄₃, R₄₄, R₄₅ and R₄₆ are each, independently, methyl or hydrogen. Alternatively, at least one pair of substituents


35

R_{39} and R_{40} ; R_{36} and R_{37} ; R_{38} and R_{39} . Alternatively, R_{40} and R_{41} together are an oxygen atom. R_{47} is H, azabicycloalkyl, heterocycloalkyl or Y_2 - Z_2 . Y_2 and Z_2 are as previously defined. Alternatively, R_{47} is of the formula




15 y is 0 or 1. R_{48} , R_{49} , R_{50} , R_{51} , R_{52} , R_{53} , R_{54} and R_{55} are each, independently, methyl or hydrogen. Alternatively, at least one pair of substituents R_{48} and R_{49} ; R_{50} and R_{51} ; R_{52} and R_{53} ; or R_{54} and R_{55} together are an oxygen atom. R_{56} is -H, azabicycloalkyl, heterocycloalkyl or Y_3 - Z_3 . Y_3 and Z_3 are defined as above.

In another embodiment, R_1 is of the formula



35 e , f , h , u and y are independently 0 or 1. R_{57} , R_{58} , R_{59} , R_{60} , R_{61} , R_{62} , R_{63} , R_{64} , R_{65} and R_{66} are each, independently, methyl or hydrogen. Alternatively, at least one pair of substituents R_{57} and R_{58} ; R_{59} and R_{60} ; R_{61} and R_{62} ; or R_{63} and R_{64} together are an oxygen atom. R_{67} is H, azabicycloalkyl, heterocycloalkyl or Y_2 - Z_2 . Y_2 and Z_2 are defined as above. Alternatively, R_{67} is of the formula



5

d is 0 or 1. R_{68} , R_{69} , R_{70} , R_{71} , R_{72} , R_{73} , R_{74} and R_{75} are each, independently, lower alkyl or hydrogen. Alternatively, at least one pair of substituents R_{68} and R_{69} ; R_{70} and R_{71} ; R_{72} and R_{73} . R_{74} and R_{75} together are an oxygen atom. R_{76} is -H, azabicycloalkyl, heterocycloalkyl or Y_3 - Z_3 . Y_3 and Z_3 are defined as above.

As used herein, aromatic groups include carbocyclic ring systems (e.g. benzyl and cinnamyl) and fused polycyclic aromatic ring systems (e.g. naphthyl and 1,2,3,4-tetrahydronaphthyl). Aromatic groups are also referred to as aryl groups herein.

Heteroaromatic groups, as used herein, include heteroaryl ring systems (e.g., thienyl, pyridyl, isoxazolyl, thiadiazolyl, oxadiazolyl, indazolyl, furanlyls, pyrroles, imidazoles, pyrazoles, triazoles, pyrimidines, pyrazyls, thiazolyls, isoxazolyls, isothiazolyls, tetrazolyls, oxadiazolyls,) and heteroaryl ring systems in which a carbocyclic aromatic ring, carbocyclic non-aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings (e.g., benzo(b)thienyl, benzimidazole, indole, tetrahydroindole, azaindole, indazole, quinoline, imidazopyridine, purine, pyrrolo[2,3-d]pyrimidine, pyrazolo[3,4-d]pyrimidine, 2,1,3-benzoxadiazolyl, 2,1,3-benzothiadiazolyl, benzoxazolyl, 3,4-dihydro-2H-benzoxazolyl, benzothiazolyl, quinazolyl, quinoxalyl, isoquinolyl, indolizyl) and their N-oxides.

An aralkyl group, as used herein, is an aromatic substituent that is linked to a compound by an aliphatic group having from one to about six carbon atoms.

An heteroaralkyl group, as used herein, is a heteroaromatic substituent that is linked to a compound by an aliphatic group having from one to about six carbon atoms.

A heterocycloalkyl group, as used herein, is a non-aromatic ring system that

has 3 to 8 atoms and includes at least one heteroatom, such as nitrogen, oxygen, or sulfur.

An acyl group, as used herein, is an $-C(O)NR_xR_z$, $-C(O)OR_x$, $-C(O)R_x$, in which R_x and R_z are each, independently, -H, a substituted or unsubstituted aliphatic group or a substituted or unsubstituted aromatic group.

As used herein, aliphatic groups include straight chained, branched or cyclic C_1 - C_8 hydrocarbons which are completely saturated or which contain one or more units of unsaturation (e.g. one or more double or triple bonds). The term "alkyl" refers to a saturated hydrocarbyl group; "alkoxy" refers to an alkyl-O- group. A "lower alkyl group" is a saturated aliphatic group having from 1-6 carbon atoms; a "lower alkoxy group" is a lower-alkyl-O- group.

As used herein, the term "oxaalkylene" refers to an alkylene chain which is interrupted at one or more points by an oxygen atom. Examples of oxaalkylene groups include, but are not limited to, $-OCH_2-$, $-CH_2O-$ and $-CH_2OCH_2-$.

For substituted groups described above, substituents can include, but are not to be construed as being limited to, one or more substituents independently selected from halo, hydroxy, oxo, nitro, amino, mono- or di-alkylamino, alkoxy, cyano, perfluoroalkyl (preferably CF_3), perfluoroalkoxy (preferably OCF_3), COOR (where R is H or alkyl), carboxamide, acetyl, cycloalkyl, aryloxy, heteroaryl, heteroaryloxy, heterocycloalkyl, amido, aminocarbonyl, alkylthio ether, alkylsulfonyl, alkylsulfonamido, aliphatic group (optionally substituted with one or more of the following: halo, hydroxy, oxo, nitro, amino, mono- or di-alkylamino, alkoxy, cyano, perfluoroalkyl, perfluoroalkoxy and COOR (where R is H or alkyl)), phenyl (optionally substituted with one or more of the following: halo, hydroxy, nitro, amino, alkylamino, mono- or di-alkylamino, mono- or di-alkylaminoalkyl, alkoxy, cyano, perfluoroalkyl, perfluoroalkoxy and COOR (where R is H or alkyl)).

Compounds of formula I may exist as salts with pharmaceutically acceptable acids. The present invention includes such salts. Examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [eg (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino

acids such as glutamic acid. These salts may be prepared by methods known to those skilled in the art.

Certain compounds of formula I which have acidic substituents may exist as salts with pharmaceutically acceptable bases. The present invention includes such salts. Example of such salts include sodium salts, potassium salts, lysine salts and arginine salts. These salts may be prepared by methods known to those skilled in the art.

Certain compounds of formula I and their salts may exist in more than one crystal form and the present invention includes each crystal form and mixtures thereof.

Certain compounds of formula I and their salts may also exist in the form of solvates, for example hydrates, and the present invention includes each solvate and mixtures thereof.

Certain compounds of formula I may contain one or more chiral centres, and exist in different optically active forms. When compounds of formula I contain one chiral centre, the compounds exist in two enantiomeric forms and the present invention includes both enantiomers and mixtures of enantiomers, such as racemic mixtures. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts which may be separated, for example, by crystallization; formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation.

When a compound of formula I contains more than one chiral center it may exist in diastereoisomeric forms. The diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above. The present invention includes each diastereoisomer of compounds of formula I and mixtures thereof.

Certain compounds of formula I may exist in different tautomeric forms or as different geometric isomers, and the present invention includes each tautomer and/or geometric isomer of compounds of formula I and mixtures thereof.

Certain compounds of formula I may exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers. The present invention includes each conformational isomer of compounds of formula I and mixtures thereof.

Certain compounds of formula I may exist in zwitterionic form and the present invention includes each zwitterionic form of compounds of formula I and mixtures thereof.

A preferred group of compounds of the present invention are:

Cis-5-(4-phenoxyphenyl)-7-(4-pyrrolidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

Trans-5-(4-phenoxyphenyl)-7-(4-pyrrolidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

Cis-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine hydrochloride

Trans-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

- Trans*-7-(4-dimethylaminocyclohexyl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo
[2,3-*d*]pyrimidin-4-ylamine
- 5 *Cis*-7-(4-dimethylaminocyclohexyl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-ylamine
- 5-(4-phenoxyphenyl)-7-(4-piperidyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-ylamine
dihydrochloride
- 10 5-(4-phenoxyphenyl)-7-(3-pyrrolidinyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-ylamine
dihydrochloride
- Cis*-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine
- 15 *Trans*-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-
pyrrolo[2,3-*d*]pyrimidin-4-amine
- Cis*-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-
pyrrolo[2,3-*d*]pyrimidin-4-amine
- 20 *Trans*-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-
pyrrolo[2,3-*d*]pyrimidin-4-amine
- Cis*-7-[4-(4-ethylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]
25 *d*]pyrimidin-4-amine
- trans*-7-[4-(4-ethylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]
d]pyrimidin-4-amine
- 30 *Cis*-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-

d]pyrimidin-4-amine tris maleate

Trans-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-
pyrrolo[2,3-*d*]pyrimidin-4-amine tris maleate

5

Cis-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-
pyrrolo[2,3-*d*]pyrimidin-4-amine tris maleate

Trans-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-
pyrrolo[2,3-*d*]pyrimidin-4-amine tris maleate

10

Cis-7-(4-{[3-(1*H*-1-imidazolyl)propyl]amino}cyclohexyl)-5-(4-phenoxyphenyl)-7*H*-
pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt

Trans-7-(4-{[3-(1*H*-1-imidazolyl)propyl]amino}cyclohexyl)-5-(4-phenoxyphenyl)-
7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine dimaleate salt

15

Cis-7-[4-(dimethylamino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-
d]pyrimidin-4-amine dimaleate salt

20

Trans-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohexyl)-7*H*-pyrrolo[2,3-
d]pyrimidin-4-amine dimaleate salt

Trans-5-(4-phenoxyphenyl)-7-(4-tetrahydro-1*H*-1-pyrrolylcyclohexyl)-7*H*-
pyrrolo[2,3-*d*]pyrimidin-4-amine dimaleate salt

25

Cis-5-(4-phenoxyphenyl)-7-(4-piperazinocyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-
4-amine trimaleate salt

Trans-5-(4-phenoxyphenyl)-7-(4-piperazinocyclohexyl)-7*H*-pyrrolo[2,3-
d]pyrimidin-4-amine trimaleate salt

30

7-[3-(4-methylpiperazino)cyclopentyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-maleate

5 *Trans*-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

Trans-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-maleate

10

trans-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-hydrochloride

15 *cis*-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-maleate salt

cis-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-hydrochloride

20 *Trans*-5-(2-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate

Cis- benzyl N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}2-methoxyphenyl)carbamate tri-maleate

25

Trans- benzyl N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)carbamate tri-maleate

30 *Trans*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)benzamide

- Trans*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-methoxyphenyl)benzamide tri-maleate
- 5 *Cis*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-methoxyphenyl)-3-phenylpropanamide
- Trans*- N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-methoxyphenyl)-3-phenylpropanamide
- 10 *cis*- N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide trimaleate salt
- trans*-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide tri-maleate
- 15 *cis*-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-ylphenoxy)-6-[(3-methoxypropyl)amino]benzonitrile tri-maleate
- trans*-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-ylphenoxy)-6-[(3-methoxypropyl)amino]benzonitrile tri-maleate
- 20 *cis*-2-amino-6-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-ylphenoxy)benzonitrile tri-maleate
- 25 *trans*-2-amino-6-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-ylphenoxy)benzonitrile tri-maleate
- cis*-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-ylphenoxy)-6-[(4-methylphenyl)sulfanyl]benzonitrile tri-maleate
- 30 *trans*-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-

d]pyrimidin-5-ylphenoxy)-6-[(4-methylphenyl)sulfanyl]benzonitrile tri-maleate

cis-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-ylphenoxy)-6-(2-pyridylsulfanyl)benzonitrile tri-maleate

5

trans-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-ylphenoxy)-6-(2-pyridylsulfanyl)benzonitrile tri-maleate

cis-5-(2-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-
10 pyrrolo[2,3-*d*]pyrimidin-4-amine tri-maleate

trans-5-(2-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-
pyrrolo[2,3-*d*]pyrimidin-4-amine tri-maleate

15 *cis*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide tri-maleate

trans-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide tri-maleate

20

N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-
fluorophenyl-4-fluoro-1-benzenesulfonamide

N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-
25 fluorophenyl-2,3-dichloro-1-benzenesulfonamide

N1-4-[4-amino-7-(4-piperidyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-fluorophenyl-4-
fluoro-1-benzenesulfonamide

- N1-4-[4-amino-7-(1-formyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide
- 5 N1-[4-(4-amino-7-1-[(1-methyl-1H-4-imidazolyl)sulfonyl]-4-piperidyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide dimaleate
- 10 N1-[4-(4-amino-7-1-[(1,2-dimethyl-1H-4-imidazolyl)sulfonyl]-4-piperidyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide
- N1-[4-(4-amino-7-1-[(1,3-dimethyl-1H-5-pyrazolyl)carbonyl]-4-piperidyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide
- 15 N1-(4-{4-amino-7-[1-(2-pyridylcarbonyl)-4-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide
- N1-4-(4-amino-7-{4-[1-(1-methylpiperid-4-yl)piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl})-2-fluorophenyl-4-fluoro-1-benzenesulfonamide tri-maleate
- trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-(trifluoromethoxy)-1-benzenesulfonamide trimaleate
- trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-5-chloro-2-thiophenesulfonamide benzenesulfonamide trimaleate
- trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-4-fluoro-1-benzenesulfonamide
benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-
5-yl}-2-fluorophenyl)-2-chloro-4-fluoro-1-benzenesulfonamide trimaleate

cis-N-1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-
5-yl-2-fluorophenyl)-2,5-difluoro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-fluorophenyl)-2,6-difluoro-1-benzenesulfonamide trimaleate

trans-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzothiadiazole-4-sulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trifluoro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-
5-yl}-2-fluorophenyl)-2-nitro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-
5-yl}-2-fluorophenyl)-2-fluoro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-
5-yl}-2-fluorophenyl)-2,4,6-trichloro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,6-dichloro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-fluoro-1-benzenesulfonamide dimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-5-chloro-2-thiophenesulfonamide dimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-bromo-2,6-difluoro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-chloro-4-fluoro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-iodo-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-(trifluoromethoxy)-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-

5-yl}-2-fluorophenyl)-2-chloro-6-methyl-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-4-cyano-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trifluoro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3,4-difluoro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-bromo-2-fluoro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-5-bromo-2-thiophenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,4-dichloro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trichloro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-bromo-5-chloro-2-thiophenesulfonamide trimaleate

cis-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzothiadiazole-4-sulfonamide trimaleate

cis-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzoxadiazole-4-sulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,5-dichloro-1-thiophenesulfonamide trimaleate

cis- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(7-chloro-2,1,3-benzoxadiazole)-4-sulfonamide trimaleate

cis- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(7-methyl-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate

cis- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(5-methyl-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate

cis- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(5-chloro-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-chloro-2-methyl-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-bromo-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,5-dibromo-3,6-difluoro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(2-nitrophenyl)methanesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-nitro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-fluoro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,4,6-trichloro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,6-dichloro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-fluoro-1-benzenesulfonamide dimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-bromo-2,5-difluoro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-chloro-4-fluoro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

d]pyrimidin-5-yl}-2-fluorophenyl-2-iodo-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-6-methyl-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-4-cyano-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3,4-difluoro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-bromo-2-fluoro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-5-bromo-2-thiophenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,4-dichloro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trichloro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-bromo-5-chloro-2-thiophenesulfonamide trimaleate

trans-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzoxadiazole-4-sulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,5-dichloro-1-thiophenesulfonamide trimaleate

trans- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(7-chloro-2,1,3-benzoxadiazole)-4-sulfonamide trimaleate

trans- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(7-methyl-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate

trans- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(5-methyl-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate

trans- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(5-chloro-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-chloro-2-methyl-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-bromo-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,5-dibromo-3,6-difluoro-1-benzenesulfonamide trimaleate

trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

d]pyrimidin-5-yl}-2-fluorophenyl)- (2-nitrophenyl)methanesulfonamide trimaleate

The compounds of this invention have antiangiogenic properties. These antiangiogenic properties are due at least in part to the inhibition of protein tyrosine kinases essential for angiogenic processes. For this reason, these compounds can be used as active agents against such disease states as arthritis, atherosclerosis, restenosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, ischemia/reperfusion injury, wound healing, peptic ulcer Helicobacter related diseases, virally-induced angiogenic disorders, fractures, Crow-Fukase syndrome (POEMS), preeclampsia, menometrorrhagia, cat scratch fever, rubeosis, neovascular glaucoma and retinopathies such as those associated with diabetic retinopathy, retinopathy of prematurity, or age-related macular degeneration. In addition, some of these compounds can be used as active agents against solid tumors, malignant ascites, von Hippel Lindau disease, hematopoietic cancers and hyperproliferative disorders such as thyroid hyperplasia (especially Grave's disease), and cysts (such as hypervascularity of ovarian stroma characteristic of polycystic ovarian syndrome (Stein-Leventhal syndrome) and polycystic kidney disease since such diseases require a proliferation of blood vessel cells for growth and/or metastasis.

Further, some of these compounds can be used as active agents against burns, chronic lung disease, stroke, polyps, anaphylaxis, chronic and allergic inflammation, delayed-type hypersensitivity, ovarian hyperstimulation syndrome, brain tumor-associated cerebral edema, high-altitude, trauma or hypoxia induced cerebral or pulmonary edema, ocular and macular edema, ascites, glomerulonephritis and other diseases where vascular hyperpermeability, effusions, exudates, protein extravasation, or edema is a manifestation of the disease. The compounds will also be useful in treating disorders in which protein extravasation leads to the deposition of fibrin and extracellular matrix, promoting stromal proliferation (e.g. keloid, fibrosis, cirrhosis and carpal tunnel syndrome). Increased VEGF production potentiates inflammatory processes such as monocyte recruitment and activation.

The compounds of this invention will also be useful in treating inflammatory disorders such as inflammatory bowel disease (IBD) and Crohn's disease.

VEGF's are unique in that they are the only angiogenic growth factors known to contribute to vascular hyperpermeability and the formation of edema. Indeed, 5 vascular hyperpermeability and edema that is associated with the expression or administration of many other growth factors appears to be mediated via VEGF production. Inflammatory cytokines stimulate VEGF production. Hypoxia results in a marked upregulation of VEGF in numerous tissues, hence situations involving infarct, occlusion, ischemia, anemia, or circulatory impairment typically invoke 10 VEGF/VPF mediated responses. Vascular hyperpermeability, associated edema, altered transendothelial exchange and macromolecular extravasation, which is often accompanied by diapedesis, can result in excessive matrix deposition, aberrant stromal proliferation, fibrosis, etc. Hence, VEGF-mediated hyperpermeability can significantly contribute to disorders with these etiologic features.

15 Because blastocyst implantation, placental development and embryogenesis are angiogenesis dependent, certain compounds of the invention are useful as contraceptive agents and antifertility agents.

It is envisaged that the disorders listed above are mediated to a significant extent by protein tyrosine kinase activity involving the KDR/VEGFR-2 and/or the 20 Flt-1/VEGFR-1 and/or TIE-2 tyrosine kinases. By inhibiting the activity of these tyrosine kinases, the progression of the listed disorders is inhibited because the angiogenic or vascular hyperpermeability component of the disease state is severely curtailed. The action of certain compounds of this invention, by their selectivity for specific tyrosine kinases, result in a minimization of side effects that would occur if 25 less selective tyrosine kinase inhibitors were used. Certain compounds of the invention are also effective inhibitors of FGFR, PDGFR, c-Met and IGF-1-R. These receptor kinases can directly or indirectly potentiate angiogenic and hyperproliferative responses in various disorders, hence their inhibition can impede disease progression.

30 The compounds of this invention have inhibitory activity against protein kinases. That is, these compounds modulate signal transduction by protein kinases.

Compounds of this invention inhibit protein kinases from serine/threonine and tyrosine kinase classes. In particular, these compounds selectively inhibit the activity of the KDR/FLK-1/VEGFR-2 tyrosine kinases. Certain compounds of this invention also inhibit the activity of additional tyrosine kinases such as Flt-
5 1/VEGFR-1, Tie-2, FGFR, PDGFR, IGF-1R, c-Met, Src-subfamily kinases such as Lck, Src, fyn, yes, etc. Additionally, some compounds of this invention significantly inhibit serine/threonine kinases such as PKC, MAP kinases, erk, CDKs, Plk-1, or Raf-1 which play an essential role in cell proliferation and cell-cycle progression. The potency and specificity of the generic compounds of this invention
10 towards a particular protein kinase can often be altered and optimized by variations in the nature, number and arrangement of the substituents (i.e., R₁, R₂, R₃, A and ring 1) and conformational restrictions. In addition the metabolites of certain compounds may also possess significant protein kinase inhibitory activity.

The compounds of this invention, when administered to individuals in need
15 of such compounds, inhibit vascular hyperpermeability and the formation of edema in these individuals. These compounds act, it is believed, by inhibiting the activity of KDR tyrosine kinase which is involved in the process of vascular hyperpermeability and edema formation. The KDR tyrosine kinase may also be referred to as FLK-1 tyrosine kinase, NYK tyrosine kinase or VEGFR-2 tyrosine
20 kinase. KDR tyrosine kinase is activated when vascular endothelial cell growth factor (VEGF) or another activating ligand (such as VEGF-C, VEGF-D, VEGF-E or HIV Tat protein) binds to a KDR tyrosine kinase receptor which lies on the surface of vascular endothelial cells. Following such KDR tyrosine kinase activation, hyperpermeability of the blood vessels occurs and fluid moves from the blood
25 stream past the blood vessel walls into the interstitial spaces, thereby forming an area of edema. Diapedesis also often accompanies this response. Similarly, excessive vascular hyperpermeability can disrupt normal molecular exchange across the endothelium in critical tissues and organs (e.g., lung and kidney), thereby causing macromolecular extravasation and deposition. Following this acute
30 response to KDR stimulation which is believed to facilitate the subsequent angiogenic process, prolonged KDR tyrosine kinase stimulation results in the

proliferation and chemotaxis of vascular endothelial cells and formation of new vessels. By inhibiting KDR tyrosine kinase activity, either by blocking the production of the activating ligand, by blocking the activating ligand binding to the KDR tyrosine kinase receptor, by preventing receptor dimerization and
5 transphosphorylation, by inhibiting the enzyme activity of the KDR tyrosine kinase (inhibiting the phosphorylation function of the enzyme) or by some other mechanism that interrupts its downstream signaling (D. Mukhopedhyay *et al.*, *Cancer Res.* 58:1278-1284 (1998) and references therein), hyperpermeability, as well as associated extravasation, subsequent edema formation and matrix deposition,
10 and angiogenic responses, may be inhibited and minimized.

One group of preferred compounds of this invention have the property of inhibiting KDR tyrosine kinase activity without significantly inhibiting Flt-1 tyrosine kinase activity (Flt-1 tyrosine kinase is also referred to as VEGFR-1 tyrosine kinase). Both KDR tyrosine kinase and Flt-1 tyrosine kinase are activated
15 by VEGF binding to KDR tyrosine kinase receptors and to Flt-1 tyrosine kinase receptors, respectively. Certain preferred compounds of this invention are unique because they inhibit the activity of one VEGF-receptor tyrosine kinase (KDR) that is activated by activating ligands but do not inhibit other receptor tyrosine kinases, such as Flt-1, that are also activated by certain activating ligands. In this manner,
20 certain preferred compounds of this invention are, therefore, selective in their tyrosine kinase inhibitory activity.

In one embodiment, the present invention provides a method of treating a protein kinase-mediated condition in a patient, comprising administering to the patient a therapeutically or prophylactically effective amount of one or more
25 compounds of Formula I.

A "protein kinase-mediated condition" is a medical condition, such as a disease or other undesirable physical condition, the genesis or progression of which depends, at least in part, on the activity of at least one protein kinase. The protein kinase can be, for example, a protein tyrosine kinase or a protein serine/threonine
30 kinase.

The patient to be treated can be any animal, and is preferably a mammal,

such as a domesticated animal or a livestock animal. More preferably, the patient is a human.

A "therapeutically effective amount" is an amount of a compound of Formula I or a combination of two or more such compounds, which inhibits, totally or partially, the progression of the condition or alleviates, at least partially, one or more symptoms of the condition. A therapeutically effective amount can also be an amount which is prophylactically effective. The amount which is therapeutically effective will depend upon the patient's size and gender, the condition to be treated, the severity of the condition and the result sought. For a given patient, a therapeutically effective amount can be determined by methods known to those of skill in the art.

The method of the present invention is useful in the treatment of protein kinase-mediated conditions, such as any of the conditions described above. In one embodiment, the protein kinase-mediated condition is characterized by undesired angiogenesis, edema, or stromal deposition. For example, the condition can be one or more more ulcers, such as ulcers caused by bacterial or fungal infections, Mooren ulcers and ulcerative colitis. The condition can also be due to a microbial infection, such as Lyme disease, sepsis, septic shock or infections by Herpes simplex, Herpes Zoster, human immunodeficiency virus, protozoa, toxoplasmosis or parapoxvirus; an angiogenic disorders, such as von Hippel Lindau disease, polycystic kidney disease, pemphigoid, Paget's disease and psoriasis; a reproductive condition, such as endometriosis, ovarian hyperstimulation syndrome, preeclampsia or menometrorrhagia; a fibrotic and edemic condition, such as sarcoidosis, fibrosis, cirrhosis, thyroiditis, hyperviscosity syndrome systemic, Osler-Weber-Rendu disease, chronic occlusive pulmonary disease, asthma, and edema following burns, trauma, radiation, stroke, hypoxia or ischemia; or an inflammatory/immunologic condition, such as systemic lupus, chronic inflammation, glomerulonephritis, synovitis, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, osteoarthritis, multiple sclerosis and graft rejection. Suitable protein kinase-mediated conditions also include sickle cell anaemia, osteoporosis, osteopetrosis, tumor-induced hypercalcemia and bone metastases. Additional protein kinase-

mediated conditions which can be treated by the method of the present invention include ocular conditions such as ocular and macular edema, ocular neovascular disease, scleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser complications, conjunctivitis, Stargardt's disease and
5 Eales disease, in addition to retinopathy and macular degeneration.

The compounds of the present invention are also useful in the treatment of cardiovascular conditions such as atherosclerosis, restenosis, vascular occlusion and carotid obstructive disease.

The compounds of the present invention are also useful in the treatment of
10 cancer related indications such as solid tumors, sarcomas (especially Ewing's sarcoma and osteosarcoma), retinoblastoma, rhabdomyosarcomas, neuroblastoma, hematopoietic malignancies, including leukaemia and lymphoma, tumor-induced pleural or pericardial effusions, and malignant ascites.

The compounds of the present invention are also useful in the treatment of
15 Crow-Fukase (POEMS) syndrome and diabetic conditions such as glaucoma, diabetic retinopathy and microangiopathy.

The Src, Tec, Jak, Map, Csk, NF κ B and Syk families of kinases play pivotal roles in the regulation of immune function. The Src family currently includes Fyn, Lck, Fgr, Fes, Lyn, Src, Yrk, Fyk, Yes, Hck, and Blk. The Syk family is currently
20 understood to include only Zap and Syk. The TEC family includes Tec, Btk, Rlk and Itk. The Janus family of kinases is involved in the transduction of growth factor and proinflammatory cytokine signals through a number of receptors. Although BTK and ITK, members of the Tec family of kinases, play a less well understood role in immunobiology, their modulation by an inhibitor may prove therapeutically
25 beneficial. The Csk family is currently understood to include Csk and Chk. The kinases RIP, IRAK-1, IRAK-2, NIK, p38 MAP kinases, Jnk, IKK-1 and IKK-2 are involved in the signal transduction pathways for key pro-inflammatory cytokines, such as TNF and IL-1. By virtue of their ability to inhibit one or more of these kinases, compounds of formula I may function as immunomodulatory agents useful
30 for the maintenance of allografts, the treatment of autoimmune disorders and

treatment of sepsis and septic shock. Through their ability to regulate the migration or activation of T cells, B-cells, mast cells, monocytes and neutrophils, these compounds could be used to treat such autoimmune diseases and sepsis. Prevention of transplant rejection, either host versus graft for solid organs or graft versus host
5 for bone marrow, are limited by the toxicity of currently available immunosuppressive agents and would benefit from an efficacious drug with improved therapeutic index. Gene targeting experiments have demonstrated the essential role of Src in the biology of osteoclasts, the cells responsible for bone resorption. Compounds of formula I, through their ability to regulate Src, may also
10 be useful in the treatment of osteoporosis, osteopetrosis, Paget's disease, tumor-induced hypercalcemia and in the treatment of bone metastases.

A number of protein kinases have been demonstrated to be protooncogenes. Chromosome breakage (at the ltk kinase break point on chromosome 5), translocation as in the case of the Abl gene with BCR (Philadelphia chromosome),
15 truncation in instances such as c-Kit or EGFR, or mutation (e.g., Met) result in the creation of dysregulated proteins converting them from protooncogene to oncogene products. In other tumors, oncogenesis is driven by an autocrine or paracrine ligand/growth factor receptor interactions. Members of the src-family kinases are typically involved in downstream signal transduction thereby potentiating the
20 oncogenesis and themselves may become oncogenic by over-expression or mutation. By inhibiting the protein kinase activity of these proteins the disease process may be disrupted. Vascular restenosis may involve FGF and/or PDGF - promoted smooth muscle and endothelial cell proliferation. The ligand stimulation of FGFR, PDGFR, IGF1-R and c-Met *in vivo* is proangiogenic, and potentiates angiogenesis dependent
25 disorders. Inhibition of FGFR, PDGFR, c-Met, or IGF1-R kinase activities individually or in combination may be an efficacious strategy for inhibiting these phenomena. Thus compounds of formula I which inhibit the kinase activity of normal or aberrant c-kit, c-met, c-fms, src-family members, EGFR, erbB2, erbB4, BCR-Abl, PDGFR, FGFR, IGF1-R and other receptor or cytosolic tyrosine kinases
30 may be of value in the treatment of benign and neoplastic proliferative diseases.

In many pathological conditions (for example, solid primary tumors and

metastases, Kaposi's sarcoma, rheumatoid arthritis, blindness due to inappropriate ocular neovascularization, psoriasis and atherosclerosis) disease progression is contingent upon persistent angiogenesis. Polypeptide growth factors often produced by the disease tissue or associated inflammatory cells, and their corresponding

5 endothelial cell specific receptor tyrosine kinases (e.g., KDR/VEGFR-2, Flt-1/VEGFR-1, Tie-2/Tek and Tie) are essential for the stimulation of endothelial cell growth, migration, organization, differentiation and the establishment of the requisite new functional vasculature. As a result of the vascular permeability factor activity of VEGF in mediating vascular hyperpermeability, VEGF-stimulation of a

10 VEGFR kinase is also believed to play an important role in the formation of tumor ascites, cerebral and pulmonary edema, pleural and pericardial effusions, delayed-type hypersensitivity reactions, tissue edema and organ dysfunction following trauma, burns, ischemia, diabetic complications, endometriosis, adult respiratory distress syndrome (ARDS), post-cardiopulmonary bypass-related hypotension and

15 hyperpermeability, and ocular edema leading to glaucoma or blindness due to inappropriate neovascularization. In addition to VEGF, recently identified VEGF-C and VEGF-D, and virally-encoded VEGF-E or HIV-Tat protein can also cause a vascular hyperpermeability response through the stimulation of a VEGFR kinase. KDR/VEGFR-2 and/or Tie-2 are expressed also in a select population of

20 hematopoietic stem cells. Certain members of this population are pluripotent in nature and can be stimulated with growth factors to differentiate into endothelial cells and participate in vasculogenetic angiogenic processes. For this reason these have been called Endothelial Progenitor Cells (EPCs) (*J. Clin. Investig.* **103** : 1231-1236 (1999)). In some progenitors, Tie-2 may play a role in their recruitment,

25 adhesion, regulation and differentiation (*Blood* , 4317-4326 (1997)). Certain agents according to formula I capable of blocking the kinase activity of endothelial cell specific kinases could therefore inhibit disease progression involving these situations.

Vascular destabilization of the antagonist ligand of Tie-2 (Ang2) is believed

30 to induce an unstable "plastic" state in the endothelium. In the presence of high VEGF levels a robust angiogenic response may result; however, in the absence of

VEGF or a VEGF-related stimulus, frank vessel regression and endothelial apoptosis can occur (Genes and Devel. 13: 1055-1066 (1999)). In an analogous manner a Tie-2 kinase inhibitor can be proangiogenic or antiangiogenic in the presence or absence of a VEGF-related stimulus, respectively. Hence, Tie-2 inhibitors can be employed
5 with appropriate proangiogenic stimuli, such as VEGF, to promote therapeutic angiogenesis in situations such as wound healing, infarct and ischemia.

The compounds of formula I or a salt thereof or pharmaceutical compositions containing a therapeutically effective amount thereof may be used in the treatment of protein kinase-mediated conditions, such as benign and neoplastic proliferative
10 diseases and disorders of the immune system, as described above. For example, such diseases include autoimmune diseases, such as rheumatoid arthritis, thyroiditis, type 1 diabetes, multiple sclerosis, sarcoidosis, inflammatory bowel disease, Crohn's disease, myasthenia gravis and systemic lupus erythematosus; psoriasis, organ transplant rejection (eg. kidney rejection, graft versus host disease), benign and
15 neoplastic proliferative diseases, human cancers such as lung, breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma), and diseases involving inappropriate vascularization for example diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization due to age-related macular degeneration, and infantile
20 hemangiomas in human beings. In addition, such inhibitors may be useful in the treatment of disorders involving VEGF mediated edema, ascites, effusions, and exudates, including for example macular edema, cerebral edema, acute lung injury and adult respiratory distress syndrome (ARDS).

The compounds of the present invention may also be useful in the
25 prophylaxis of the above diseases.

It is envisaged that the disorders listed above are mediated to a significant extent by protein tyrosine kinase activity involving the VEGF receptors (e.g. KDR, Flt-1 and/or Tie-2). By inhibiting the activity of these receptor tyrosine kinases, the progression of the listed disorders is inhibited because the angiogenic component of
30 the disease state is severely curtailed. The action of the compounds of this invention, by their selectivity for specific tyrosine kinases, result in a minimization

of side effects that would occur if less selective tyrosine kinase inhibitors were used.

In another aspect the present invention provides compounds of formula I as defined initially above for use as medicaments, particularly as inhibitors of protein kinase activity for example tyrosine kinase activity, serine kinase activity and
5 threonine kinase activity. In yet another aspect the present invention provides the use of compounds of formula I as defined initially above in the manufacture of a medicament for use in the inhibition of protein kinase activity.

Physiologically acceptable salts can refer to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by
10 reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid or organic acids such as sulfonic acid, carboxylic acid, organic phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, lactic acid, tartaric acid and the like.

"Alkyl" refers to a saturated aliphatic hydrocarbon, including straight-chain
15 and branched-chain groups having 1 to 6 carbons or cyclic hydrocarbons having 3 to 6 carbons.

"Alkoxy" refers to an "O-alkyl" group, where "alkyl" is defined as described above.

20 Pharmaceutical Formulations

The compounds of this invention can be administered to a human patient by themselves or in pharmaceutical compositions where they are mixed with suitable carriers or excipient(s) at doses to treat or ameliorate vascular hyperpermeability, edema and associated disorders. Mixtures of these compounds can also be
25 administered to the patient as a simple mixture or in suitable formulated pharmaceutical compositions. A therapeutically effective dose further refers to that amount of the compound or compounds sufficient to result in the prevention or attenuation of inappropriate neovascularization, progression of hyperproliferative disorders, edema, VEGF-associated hyperpermeability and/or VEGF-related
30 hypotension. Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences,"

Mack Publishing Co., Easton, PA, latest edition.

Routes of Administration

Suitable routes of administration may, for example, include oral, eyedrop, 5 rectal, transmucosal, topical, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

Alternatively, one may administer the compound in a local rather than a 10 systemic manner, for example, via injection of the compound directly into an edematous site, often in a depot or sustained release formulation.

Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with endothelial cell-specific antibody.

15 Composition/Formulation

The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

20 Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration 25 chosen.

For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation.

30 Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by

combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.

- 5 Pharmaceutical preparations for oral use can be obtained by combining the active compound with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

- 15 Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

- 20 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

- 30 For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, 5 dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

10 The compounds can be formulated for parenteral administration by injection, e.g. bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory 15 agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or 20 synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly 25 concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases 30 such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may

also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly or by intramuscular injection). Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

An example of a pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.

Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the

therapeutic reagent, additional strategies for protein stabilization may be employed.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches,
5 cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

Many of the compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous
10 or other protonic solvents than are the corresponding free base forms.

Effective Dosage

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to
15 achieve its intended purpose. More specifically, a therapeutically effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art.

For any compound used in the method of the invention, the therapeutically
20 effective dose can be estimated initially from cellular assays. For example, a dose can be formulated in cellular and animal models to achieve a circulating concentration range that includes the IC_{50} as determined in cellular assays (i.e., the concentration of the test compound which achieves a half-maximal inhibition of a given protein kinase activity). In some cases it is appropriate to determine the IC_{50}
25 in the presence of 3 to 5% serum albumin since such a determination approximates the binding effects of plasma protein on the compound. Such information can be used to more accurately determine useful doses in humans. Further, the most preferred compounds for systemic administration effectively inhibit protein kinase signaling in intact cells at levels that are safely achievable in plasma.

30 A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms in a patient. Toxicity and therapeutic efficacy

of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the maximum tolerated dose (MTD) and the ED₅₀ (effective dose for 50% maximal response). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed
5 as the ratio between MTD and ED₅₀. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range
10 depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl *et al.*, 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p1). In the treatment of crises, the administration of an acute bolus or an infusion approaching the MTD may be
15 required to obtain a rapid response.

Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the kinase modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from *in vitro* data; e.g. the concentration necessary
20 to achieve 50-90% inhibition of protein kinase using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

Dosage intervals can also be determined using the MEC value. Compounds
25 should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90% until the desired amelioration of symptoms is achieved. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

30 The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the

manner of administration and the judgment of the prescribing physician.

Packaging

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.

- 5 The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.

- 10 In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.

- The use of compounds of the present invention in the manufacture of pharmaceutical compositions is illustrated by the following description. In this description the term "active compound" denotes any compound of the invention but particularly any compound which is the final product of one of the preceding Examples.

a) Capsules

20

In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose can be de-aggregated and blended. The mixture can be filled into hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound.

25

b) Tablets

Tablets can be prepared from the following ingredients.

Parts by weight

- | | | |
|----|-----------------|-----|
| 30 | Active compound | 10 |
| | Lactose | 190 |

Maize starch	22
Polyvinylpyrrolidone	10
Magnesium stearate	3

5 The active compound, the lactose and some of the starch can be de-
aggregated, blended and the resulting mixture can be granulated with a solution of
the polyvinyl- pyrrolidone in ethanol. The dry granulate can be blended with the
magnesium stearate and the rest of the starch. The mixture is then compressed in a
tableting machine to give tablets each containing a unit dose or a part of a unit dose
of active compound.

10

c) Enteric coated tablets

15 Tablets can be prepared by the method described in (b) above. The tablets
can be enteric coated in a conventional manner using a solution of 20% cellulose
acetate phthalate and 3% diethyl phthalate in ethanol:dichloromethane (1:1).

d) Suppositories

20 In the preparation of suppositories, 100 parts by weight of active compound
can be incorporated in 1300 parts by weight of triglyceride suppository base and the
mixture formed into suppositories each containing a therapeutically effective amount
of active ingredient.

In the compositions of the present invention the active compound may, if
desired, be associated with other compatible pharmacologically active ingredients.
25 For example, the compounds of this invention can be administered in combination
with one or more additional pharmaceutical agents that inhibit or prevent the
production of VEGF or angiopoietins, attenuate intracellular responses to VEGF or
angiopoietins, block intracellular signal transduction, inhibit vascular
hyperpermeability, reduce inflammation, or inhibit or prevent the formation of
30 edema or neovascularization. The compounds of the invention can be administered
prior to, subsequent to or simultaneously with the additional pharmaceutical agent,

whichever course of administration is appropriate. The additional pharmaceutical agents include but are not limited to anti-edemic steroids, NSAIDS, ras inhibitors, anti-TNF agents, anti-IL1 agents, antihistamines, PAF-antagonists, COX-1 inhibitors, COX-2 inhibitors, NO synthase inhibitors, Akt/PTB inhibitors, IGF-1R inhibitors, PKC inhibitors and PI3 kinase inhibitors. The compounds of the invention and the additional pharmaceutical agents act either additively or synergistically. Thus, the administration of such a combination of substances that inhibit angiogenesis, vascular hyperpermeability and/or inhibit the formation of edema can provide greater relief from the deleterious effects of a hyperproliferative disorder, angiogenesis, vascular hyperpermeability or edema than the administration of either substance alone. In the treatment of malignant disorders combinations with antiproliferative or cytotoxic chemotherapies or radiation are anticipated.

The present invention also comprises the use of a compound of formula I as a medicament.

A further aspect of the present invention provides the use of a compound of formula I or a salt thereof in the manufacture of a medicament for treating vascular hyperpermeability, angiogenesis-dependent disorders, proliferative diseases and/or disorders of the immune system in mammals, particularly human beings.

The present invention also provides a method of treating vascular hyperpermeability, inappropriate neovascularization, proliferative diseases and/or disorders of the immune system which comprises the administration of a therapeutically effective amount of a compound of formula I to a mammal, particularly a human being, in need thereof.

The *in vitro* potency of compounds in inhibiting these protein kinases may be determined by the procedures detailed below.

The potency of compounds can be determined by the amount of inhibition of the phosphorylation of an exogenous substrate (e.g., synthetic peptide (Z. Songyang *et al.*, *Nature*. 373:536-539)) by a test compound relative to control.

KDR Tyrosine Kinase Production Using Baculovirus System:

The coding sequence for the human KDR intra-cellular domain (aa789-1354).

was generated through PCR using cDNAs isolated from HUVEC cells. A poly-His₆ sequence was introduced at the N-terminus of this protein as well. This fragment was cloned into transfection vector pVL1393 at the Xba 1 and Not 1 site.

Recombinant baculovirus (BV) was generated through co-transfection using the
5 BaculoGold Transfection reagent (PharMingen). Recombinant BV was plaque purified and verified through Western analysis. For protein production, SF-9 cells were grown in SF-900-II medium at 2×10^6 /ml, and were infected at 0.5 plaque forming units per cell (MOI). Cells were harvested at 48 hours post infection.

10

Purification of KDR

SF-9 cells expressing (His)₆KDR(aa789-1354) were lysed by adding 50 ml of Triton X-100 lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 1mM PMSF, 10 μ g/ml aprotinin, 1 μ g/ml leupeptin) to the cell pellet
15 from 1L of cell culture. The lysate was centrifuged at 19,000 rpm in a Sorval SS-34 rotor for 30 min at 4°C. The cell lysate was applied to a 5 ml NiCl₂ chelating sepharose column, equilibrated with 50 mM HEPES, pH7.5, 0.3 M NaCl. KDR was eluted using the same buffer containing 0.25 M imidazole. Column fractions were analyzed using SDS-PAGE and an ELISA assay (below) which measures kinase
20 activity. The purified KDR was exchanged into 25mM HEPES, pH7.5, 25mM NaCl, 5 mM DTT buffer and stored at -80°C.

Human Tie-2 Kinase Production and Purification

The coding sequence for the human Tie-2 intra-cellular domain (aa775-1124)
25 was generated through PCR using cDNAs isolated from human placenta as a template. A poly-His₆ sequence was introduced at the N-terminus and this construct was cloned into transfection vector pVL 1939 at the Xba 1 and Not 1 site. Recombinant BV was generated through co-transfection using the BaculoGold Transfection reagent (PharMingen). Recombinant BV was plaque purified and
30 verified through Western analysis. For protein production, SF-9 insect cells were

grown in SF-900-II medium at 2×10^6 /ml, and were infected at MOI of 0.5. Purification of the His-tagged kinase used in screening was analogous to that described for KDR.

5 Human Flt-1 Tyrosine Kinase Production and Purification

The baculoviral expression vector pVL1393 (Phar Mingen, Los Angeles, CA) was used. A nucleotide sequence encoding poly-His6 was placed 5' to the nucleotide region encoding the entire intracellular kinase domain of human Flt-1 (amino acids 786-1338). The nucleotide sequence encoding the kinase domain was
10 generated through PCR using cDNA libraries isolated from HUVEC cells. The histidine residues enabled affinity purification of the protein as a manner analogous to that for KDR and ZAP70. SF-9 insect cells were infected at a 0.5 multiplicity and harvested 48 hours post infection.

15 EGFR Tyrosine Kinase Source

EGFR was purchased from Sigma (Cat # E-3641; 500 units/50 μ l) and the EGF ligand was acquired from Oncogene Research Products/Calbiochem (Cat # PF011-100).

20 Expression of ZAP70

The baculoviral expression vector used was pVL1393. (Pharmingen, Los Angeles, Ca.) The nucleotide sequence encoding amino acids M(H)6 LVPR₃S was placed 5' to the region encoding the entirety of ZAP70 (amino acids 1-619). The nucleotide sequence encoding the ZAP70 coding region was generated through PCR
25 using cDNA libraries isolated from Jurkat immortalized T-cells. The histidine residues enabled affinity purification of the protein (vide infra). The LVPR₃S bridge constitutes a recognition sequence for proteolytic cleavage by thrombin, enabling removal of the affinity tag from the enzyme. SF-9 insect cells were infected at a multiplicity of infection of 0.5 and harvested 48 hours post infection.

30

Extraction and purification of ZAP70

SF-9 cells were lysed in a buffer consisting of 20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 1 μ g/ml leupeptin, 10 μ g/ml aprotinin and 1 mM sodium orthovanadate. The soluble lysate was applied to a chelating sepharose HiTrap column (Pharmacia) equilibrated in 50 mM HEPES, pH 7.5, 0.3 M NaCl. Fusion protein was eluted with 250 mM imidazole. The enzyme was stored in buffer containing 50 mM HEPES, pH 7.5, 50 mM NaCl and 5 mM DTT.

10 Protein kinase source

Lck, Fyn, Src, Blk, Csk, and Lyn, and truncated forms thereof may be commercially obtained (e.g. from Upstate Biotechnology Inc. (Saranac Lake, N.Y) and Santa Cruz Biotechnology Inc. (Santa Cruz, Ca.)) or purified from known natural or recombinant sources using conventional methods.

15

Enzyme Linked Immunosorbent Assay (ELISA) For PTKs

Enzyme linked immunosorbent assays (ELISA) were used to detect and measure the presence of tyrosine kinase activity. The ELISA were conducted according to known protocols which are described in, for example, Voller, *et al.*, 1980, "Enzyme-Linked Immunosorbent Assay," In: *Manual of Clinical Immunology*, 2d ed., edited by Rose and Friedman, pp 359-371 Am. Soc. of Microbiology, Washington, D.C.

The disclosed protocol was adapted for determining activity with respect to a specific PTK. For example, preferred protocols for conducting the ELISA experiments is provided below. Adaptation of these protocols for determining a compound's activity for other members of the receptor PTK family, as well as non-receptor tyrosine kinases, are well within the abilities of those in the art. For purposes of determining inhibitor selectivity, a universal PTK substrate (e.g., random copolymer of poly(Glu₄ Tyr), 20,000-50,000 MW) was employed together with ATP (typically 5 μ M) at concentrations approximately twice the apparent K_m

in the assay.

The following procedure was used to assay the inhibitory effect of compounds of this invention on KDR, Flt-1, Tie-2, EGFR, FGFR, PDGFR, IGF-1-R, c-Met, Lck, Blk, Csk, Src, Lyn, Fyn and ZAP70 tyrosine kinase activity:

5

Buffers and Solutions:

PGTPoly (Glu,Tyr) 4:1

Store powder at -20°C. Dissolve powder in phosphate buffered saline (PBS) for 50mg/ml solution. Store 1ml aliquots at -20°C. When making plates dilute to

10 250µg/ml in Gibco PBS.

Reaction Buffer: 100mM Hepes, 20mM MgCl₂, 4mM MnCl₂, 5mM DTT, 0.02%BSA, 200µM NaVO₄, pH 7.10

ATP: Store aliquots of 100mM at -20°C. Dilute to 20µM in water

Washing Buffer: PBS with 0.1% Tween 20

15 Antibody Diluting Buffer: 0.1% bovine serum albumin (BSA) in PBS

TMB Substrate: mix TMB substrate and Peroxide solutions 9:1 just before use or use K-Blue Substrate from Neogen

Stop Solution: 1M Phosphoric Acid

20 Procedure

1. Plate Preparation:

Dilute PGT stock (50mg/ml, frozen) in PBS to a 250µg/ml. Add 125µl per well of Corning modified flat bottom high affinity ELISA plates (Corning #25805-96). Add 125µl PBS to blank wells. Cover with sealing tape and incubate overnight 37°C.

25 Wash 1x with 250µl washing buffer and dry for about 2hrs in 37°C dry incubator. Store coated plates in sealed bag at 4°C until used.

2. Tyrosine Kinase Reaction:

-Prepare inhibitor solutions at a 4x concentration in 20% DMSO in water.

30 -Prepare reaction buffer

- Prepare enzyme solution so that desired units are in 50 μ l, e.g. for KDR make to 1 ng/ μ l for a total of 50ng per well in the reactions. Store on ice.
- Make 4x ATP solution to 20 μ M from 100mM stock in water. Store on ice
- Add 50 μ l of the enzyme solution per well (typically 5-50 ng enzyme/well
- 5 depending on the specific activity of the kinase)
- Add 25 μ l 4x inhibitor
- Add 25 μ l 4x ATP for inhibitor assay
- Incubate for 10 minutes at room temperature
- Stop reaction by adding 50 μ l 0.05N HCl per well
- 10 -Wash plate

****Final Concentrations for Reaction: 5 μ M ATP, 5% DMSO**

3. Antibody Binding

- Dilute 1mg/ml aliquot of PY20-HRP (Pierce) antibody(a phosphotyrosine
- 15 antibody)to 50ng/ml in 0.1% BSA in PBS by a 2 step dilution (100x, then 200x)
- Add 100 μ l Ab per well. Incubate 1 hr at room temp. Incubate 1hr at 4C.
- Wash 4x plate

4. Color reaction

- Prepare TMB substrate and add 100 μ l per well
- 20 -Monitor OD at 650nm until 0.6 is reached
- Stop with 1M Phosphoric acid. Shake on plate reader.
- Read OD immediately at 450nm

Optimal incubation times and enzyme reaction conditions vary slightly with enzyme preparations and are determined empirically for each lot.

25

For Lck, the Reaction Buffer utilized was 100 mM MOPSO, pH 6.5, 4 mM MnCl₂, 20 mM MgCl₂, 5 mM DTT, 0.2% BSA, 200 mM NaVO₄ under the analogous assay conditions.

- 30 Compounds of formula I may have therapeutic utility in the treatment of diseases involving both identified, including those not mentioned herein, and as yet

unidentified protein tyrosine kinases which are inhibited by compounds of formula I. All compounds exemplified herein significantly inhibit either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn or Src at concentrations of 50 micromolar or below. Some compounds of this invention also significantly inhibit other tyrosine or
5 serine/threonine kinases such as cdc2 (cdk1) at concentrations of 50 micromolar or below.

Cdc2 source

The human recombinant enzyme and assay buffer may be obtained
10 commercially (New England Biolabs, Beverly, MA. USA) or purified from known natural or recombinant sources using conventional methods.

Cdc2 Assay

The protocol used was that provided with the purchased reagents with minor
15 modifications. In brief, the reaction was carried out in a buffer consisting of 50mM Tris pH 7.5, 100mM NaCl, 1mM EGTA, 2mM DTT, 0.01% Brij, 5% DMSO and 10mM MgCl₂ (commercial buffer) supplemented with fresh 300 μ M ATP (31 μ Ci/ml) and 30 μ g/ml histone type IIIss final concentrations. A reaction volume of 80 μ L, containing units of enzyme, was run for 20 minutes at 25 degrees C in the
20 presence or absence of inhibitor. The reaction was terminated by the addition of 120 μ L of 10% acetic acid. The substrate was separated from unincorporated label by spotting the mixture on phosphocellulose paper, followed by 3 washes of 5 minutes each with 75mM phosphoric acid. Counts were measured by a betacounter in the presence of liquid scintillant.

25

Certain compounds of this invention significantly inhibit cdc2 at concentrations below 50 uM.

PKC kinase source

30 The catalytic subunit of PKC may be obtained commercially (Calbiochem).

PKC kinase assay

A radioactive kinase assay was employed following a published procedure (Yasuda, I., Kirshimoto, A., Tanaka, S., Tominaga, M., Sakurai, A., Nishizuka, Y. *Biochemical and Biophysical Research Communication* 3:166, 1220-1227 (1990)). Briefly, all reactions were performed in a kinase buffer consisting of 50 mM Tris-HCl pH7.5, 10mM MgCl₂, 2mM DTT, 1mM EGTA, 100 μ M ATP, 8 μ M peptide, 5% DMSO and ³³P ATP (8Ci/mM). Compound and enzyme were mixed in the reaction vessel and the reaction initiated by addition of the ATP and substrate mixture. Following termination of the reaction by the addition of 10 μ L stop buffer (5 mM ATP in 75mM phosphoric acid), a portion of the mixture was spotted on phosphocellulose filters. The spotted samples were washed 3 times in 75 mM phosphoric acid at room temperature for 5 to 15 minutes. Incorporation of radiolabel was quantified by liquid scintillation counting.

Erk2 enzyme source

The recombinant murine enzyme and assay buffer may be obtained commercially (New England Biolabs, Beverly MA. USA) or purified from known natural or recombinant sources using conventional methods.

Erk2 enzyme assay

In brief, the reaction was carried out in a buffer consisting of 50 mM Tris pH 7.5, 1mM EGTA, 2mM DTT, 0.01% Brij, 5% DMSO and 10 mM MgCl₂ (commercial buffer) supplemented with fresh 100 μ M ATP (31 μ Ci/ml) and 30 μ M myelin basic protein under conditions recommended by the supplier. Reaction volumes and method of assaying incorporated radioactivity were as described for the PKC assay (*vide supra*).

In Vitro Models for T-cell Activation

Upon activation by mitogen or antigen, T-cells are induced to secrete IL-2, a

growth factor that supports their subsequent proliferative phase. Therefore, one may measure either production of IL-2 from or cell proliferation of, primary T-cells or appropriate T-cell lines as a surrogate for T-cell activation. Both of these assays are well described in the literature and their parameters well documented (in Current
5 Protocols in Immunology, Vol 2, 7.10.1-7.11.2).

In brief, T-cells may be activated by co-culture with allogenic stimulator cells, a process termed the one-way mixed lymphocyte reaction. Responder and stimulator peripheral blood mononuclear cells are purified by Ficoll-Hypaque gradient (Pharmacia) per directions of the manufacturer. Stimulator cells are
10 mitotically inactivated by treatment with mitomycin C (Sigma) or gamma irradiation. Responder and stimulator cells are co-cultured at a ratio of two to one in the presence or absence of the test compound. Typically 10^5 responders are mixed with 5×10^4 stimulators and plated (200 μ l volume) in a U bottom microtiter plate (Costar Scientific). The cells are cultured in RPMI 1640 supplemented with either
15 heat inactivated fetal bovine serum (Hyclone Laboratories) or pooled human AB serum from male donors, 5×10^{-5} M 2mercaptoethanol and 0.5% DMSO. The cultures are pulsed with 0.5 μ Ci of 3 H thymidine (Amersham) one day prior to harvest (typically day three). The cultures are harvested (Betaplate harvester, Wallac) and isotope uptake assessed by liquid scintillation (Betaplate, Wallac).

20 The same culture system may be used for assessing T-cell activation by measurement of IL-2 production. Eighteen to twenty-four hours after culture initiation, the supernatants are removed and the IL-2 concentration is measured by ELISA (R and D Systems) following the directions of the manufacturer.

25 *In-vivo* Models of T-Cell Activation

The *in vivo* efficacy of compounds can be tested in animal models known to directly measure T-cell activation or for which T-cells have been proven the effectors. T-cells can be activated *in vivo* by ligation of the constant portion of the T-cell receptor with a monoclonal anti-CD3 antibody (Ab). In this model, BALB/c
30 mice are given 10 μ g of anti-CD3 Ab intraperitoneally two hours prior to

exsanguination. Animals to receive a test drug are pre-treated with a single dose of the compound one hour prior to anti-CD3 Ab administration. Serum levels of the proinflammatory cytokines interferon- γ (IFN- γ) and tumor necrosis factor- α (TNF- α), indicators of T-cell activation, are measured by ELISA. A similar model employs *in vivo* T-cell priming with a specific antigen such as keyhole limpet hemocyanin (KLH) followed by a secondary *in vitro* challenge of draining lymph node cells with the same antigen. As previously, measurement of cytokine production is used to assess the activation state of the cultured cells. Briefly, C57BL/6 mice are immunized subcutaneously with 100 μ g KLH emulsified in complete Freund's adjuvant (CFA) on day zero. Animals are pre-treated with the compound one day prior to immunization and subsequently on days one, two and three post immunization. Draining lymph nodes are harvested on day 4 and their cells cultured at 6×10^6 per ml in tissue culture medium (RPMI 1640 supplemented with heat inactivated fetal bovine serum (Hyclone Laboratories) 5×10^{-5} M 2-mercaptoethanol and 0.5% DMSO) for both twenty-four and forty-eight hours. Culture supernatants are then assessed for the autocrine T-cell growth factor Interleukin-2 (IL-2) and/or IFN- γ levels by ELISA.

Lead compounds can also be tested in animal models of human disease. These are exemplified by experimental auto-immune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). EAE models which mimic aspects of human multiple sclerosis have been described in both rats and mice (reviewed FASEB J. 5:2560-2566, 1991; murine model: Lab. Invest. 4(3):278, 1981; rodent model: J. Immunol 146(4):1163-8, 1991). Briefly, mice or rats are immunized with an emulsion of myelin basic protein (MBP), or neurogenic peptide derivatives thereof, and CFA. Acute disease can be induced with the addition of bacterial toxins such as *bordetella pertussis*. Relapsing/remitting disease is induced by adoptive transfer of T-cells from MBP/ peptide immunized animals.

CIA may be induced in DBA/1 mice by immunization with type II collagen (J. Immunol:142(7):2237-2243). Mice will develop signs of arthritis as early as ten days following antigen challenge and may be scored for as long as ninety days after

immunization. In both the EAE and CIA models, a compound may be administered either prophylactically or at the time of disease onset. Efficacious drugs should reduce severity and/or incidence.

5 Certain compounds of this invention which inhibit one or more angiogenic receptor PTK, and/or a protein kinase such as lck involved in mediating inflammatory responses can reduce the severity and incidence of arthritis in these models.

Compounds can also be tested in mouse allograft models, either skin (reviewed in Ann. Rev. Immunol., 10:333-58, 1992; Transplantation: 57(12): 10 1701-17D6, 1994) or heart (Am.J.Anat.:113:273, 1963). Briefly, full thickness skin grafts are transplanted from C57BL/6 mice to BALB/c mice. The grafts can be examined daily, beginning at day six, for evidence of rejection. In the mouse neonatal heart transplant model, neonatal hearts are ectopically transplanted from C57BL/6 mice into the ear pinnae of adult CBA/J mice. Hearts start to beat four to 15 seven days post transplantation and rejection may be assessed visually using a dissecting microscope to look for cessation of beating.

Cellular Receptor PTK Assays

20 The following cellular assay was used to determine the level of activity and effect of the different compounds of the present invention on KDR/VEGFR2. Similar receptor PTK assays employing a specific ligand stimulus can be designed along the same lines for other tyrosine kinases using techniques well known in the art.

25 VEGF-Induced KDR Phosphorylation in Human Umbilical Vein Endothelial Cells (HUVEC) as Measured by Western Blots:

1. HUVEC cells (from pooled donors) were purchased from Clonetics (San Diego, CA) and cultured according to the manufacturer directions. Only early passages (3-8) were used for this assay. Cells were cultured in 100 mm dishes 30 (Falcon for tissue culture; Becton Dickinson; Plymouth, England) using complete EBM media (Clonetics).

2. For evaluating a compound's inhibitory activity, cells were trypsinized and seeded at $0.5-1.0 \times 10^5$ cells/well in each well of 6-well cluster plates (Costar; Cambridge, MA).

3. 3-4 days after seeding, plates were 90-100% confluent. Medium was removed from all the wells, cells were rinsed with 5-10ml of PBS and incubated 18-24h with 5ml of EBM base media with no supplements added (i.e., serum starvation).

4. Serial dilutions of inhibitors were added in 1ml of EBM media (25 μ M, 5 μ M, or 1 μ M final concentration to cells and incubated for one hour at 37 C. Human recombinant VEGF₁₆₅ (R & D Systems) was then added to all the wells in 2 ml of EBM medium at a final concentration of 50ng/ml and incubated at 37 C for 10 minutes. Control cells untreated or treated with VEGF only were used to assess background phosphorylation and phosphorylation induction by VEGF.

All wells were then rinsed with 5-10ml of cold PBS containing 1mM Sodium Orthovanadate (Sigma) and cells were lysed and scraped in 200 μ l of RIPA buffer (50mM Tris-HCl) pH7, 150mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1mM EDTA) containing protease inhibitors (PMSF 1mM, aprotinin 1 μ g/ml, pepstatin 1 μ g/ml, leupeptin 1 μ g/ml, Na vanadate 1mM, Na fluoride 1mM) and 1 μ g/ml of Dnase (all chemicals from Sigma Chemical Company, St Louis, MO). The lysate was spun at 14,000 rpm for 30min, to eliminate nuclei.

Equal amounts of proteins were then precipitated by addition of cold (-20 C) Ethanol (2 volumes) for a minimum of 1 hour or a maximum of overnight. Pellets were reconstituted in Laemli sample buffer containing 5% -mercaptoethanol (BioRad; Hercules, CA) and boiled for 5min. The proteins were resolved by polyacrylamide gel electrophoresis (6%, 1.5mm Novex, San Deigo, CA) and transferred onto a nitrocellulose membrane using the Novex system. After blocking with bovine serum albumin (3%), the proteins were probed overnight with anti-KDR polyclonal antibody (C20, Santa Cruz Biotechnology; Santa Cruz, CA) or with anti-phosphotyrosine monoclonal antibody (4G10, Upstate Biotechnology, Lake Placid, NY) at 4 C. After washing and incubating for 1 hour with HRP-conjugated F(ab)₂ of

goat anti-rabbit or goat-anti-mouse IgG the bands were visualized using the emission chemiluminescence (ECL) system (Amersham Life Sciences, Arlington Height, IL). Certain examples of the present invention significantly inhibit cellular VEGF-induced KDR tyrosine kinase phosphorylation at concentrations of less than 50 μ M.

5

In vivo Uterine Edema Model

This assay measures the capacity of compounds to inhibit the acute increase in uterine weight in mice which occurs in the first few hours following estrogen stimulation. This early onset of uterine weight increase is known to be due to edema caused by increased permeability of uterine vasculature. Cullinan-Bove and Koss (10 *Endocrinology* (1993), 133:829-837) demonstrated a close temporal relationship of estrogen-stimulated uterine edema with increased expression of VEGF mRNA in the uterus. These results have been confirmed by the use of neutralizing monoclonal antibody to VEGF which significantly reduced the acute increase in uterine weight following estrogen stimulation (WO 97/42187). Hence, this system can serve as a model for *in vivo* inhibition of VEGF signalling and the associated hyperpermeability and edema.

Materials: All hormones were purchased from Sigma (St. Louis, MO) or Cal Biochem (La Jolla, CA) as lyophilized powders and prepared according to supplier instructions.

Vehicle components (DMSO, Cremaphor EL) were purchased from Sigma (St. Louis, MO).

Mice (Balb/c, 8-12 weeks old) were purchased from Taconic (Germantown, NY) and housed in a pathogen-free animal facility in accordance with institutional Animal Care and Use Committee Guidelines.

25

Method:

Day 1: Balb/c mice were given an intraperitoneal (i.p.) injection of 12.5 units of pregnant mare's serum gonadotropin (PMSG).

Day 3: Mice received 15 units of human chorionic gonadotropin (hCG) i.p.

5 Day 4: Mice were randomized and divided into groups of 5-10. Test compounds were administered by i.p., i.v. or p.o. routes depending on solubility and vehicle at doses ranging from 1-100 mg/kg. Vehicle control group received vehicle only and two groups were left untreated.

Thirty minutes later, experimental, vehicle and 1 of the untreated groups
10 were given an i.p. injection of 17 β -estradiol (500 μ g/kg). After 2-3 hours, the animals were sacrificed by CO₂ inhalation. Following a midline incision, each uterus was isolated and removed by cutting just below the cervix and at the junctions of the uterus and oviducts. Fat and connective tissue were removed with care not to disturb the integrity of the uterus prior to weighing (wet weight). Uteri were blotted
15 to remove fluid by pressing between two sheets of filter paper with a one liter glass bottle filled with water. Uteri were weighed following blotting (blotted weight). The difference between wet and blotted weights was taken as the fluid content of the uterus. Mean fluid content of treated groups was compared to untreated or vehicle treated groups. Significance was determined by Student's test. Non-stimulated
20 control group was used to monitor estradiol response.

Results demonstrate that certain compounds of the present invention inhibit the formation of edema when administered systemically by various routes.

Certain compounds of this invention which are inhibitors of angiogenic receptor tyrosine kinases can also be shown active in a Matrigel implant model of
25 neovascularization. The Matrigel neovascularization model involves the formation of new blood vessels within a clear "marble" of extracellular matrix implanted subcutaneously which is induced by the presence of proangiogenic factor producing tumor cells (for examples see: Passaniti, A., *et al*, Lab. Investig. (1992), 67(4), 519-528; Anat. Rec. (1997), 249(1), 63-73; Int. J. Cancer (1995), 63(5), 694-701; Vasc.
30 Biol. (1995), 15(11), 1857-6). The model preferably runs over 3-4 days and


endpoints include macroscopic visual/image scoring of neovascularization, microscopic microvessel density determinations, and hemoglobin quantitation (Drabkin method) following removal of the implant versus controls from animals untreated with inhibitors. The model may alternatively employ bFGF or HGF as the stimulus.

Certain compounds of this invention which inhibit one or more oncogenic, protooncogenic, or proliferation-dependent protein kinases, or angiogenic receptor PTK also inhibit the growth of primary murine, rat or human xenograft tumors in mice, or inhibit metastasis in murine models.

EXAMPLES


Processes for the preparation of compounds of formula I will now be described. These processes form a further aspect of the present invention. The processes are preferably carried out at atmospheric pressure.

Compounds of formula I may be prepared by condensing a compound of formula



in which R₁, R₂, R₃, L and ring A are as previously defined with formamide at a temperature in the range of 50 to 250°C optionally in the presence of a catalyst for example 4-dimethylaminopyridine.

Compounds of formula I may be prepared by reacting a compound of formula (III)




(III)

wherein R_x is bromo or iodo bromo or iodo with one of the following compounds:
 $R_3B(OH)_2$, $R_3Sn(CH_3)_3$ or a compound represented by formula IV



or




IV

in which R_3 is as defined above, in the presence of a catalyst for example
 palladium (0) compounds eg. $Pd(PPh_3)_4$.


Compounds of formula I in which R_1 represents an alkyl group or an aralkyl

group may be prepared by alkylating a compound of formula (V)



in which R_2 and R_3 are as previously defined with a compound of formula R_1X' in
 15 which R_1 represents an alkyl group or an aralkyl group and X' represents a leaving group, for example halo, mesyloxy or tosyloxy.

Compounds of formula I in which R_1 represents an optionally substituted cyclic ether, such as tetrahydrofuryl or tetrahydropyranyl, may be prepared by alkylating a compound of formula VI




in which R_2 and R_3 are as previously defined with a compound of formula R_1X' in
 which X' is as previously defined and R_1 is an optionally substituted cyclic ether.

30 Compounds of formula I in which R_1 represents cyclic ether, such as

tetrahydrofuryl or tetrahydropyranyl, optionally substituted by formyl may be prepared by alkylating a compound of formula VI with a compound R₁X in which R₁ represents a cyclic ether substituted by a formyl group which has been protected, by a method known to those skilled in the art, for example by means of an acetal,
5 (See for example *Tet. Letts.* 30(46):6259-6262 (1989)) followed by deprotection. Compounds in which R₁ represents a cyclic ether, such as tetrahydrofuryl or tetrahydropyranyl, substituted by an (optionally substituted amino)methyl group may be prepared by reductive amination of a compound in which R₁ represents a cyclic ether substituted by formyl.

10 Compounds of formula I in which R₁ represents optionally substituted furyl, thienyl or pyrrolyl may be prepared by reacting 4-chloro-5-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine with the appropriate heteroarylboronic acid in the presence of a copper salt catalyst, for example copper (II) acetate in the presence of a solvent for the reactants, e.g. a halogenated solvent for example, dichloromethane, in the presence
15 of a drying agent, for example 4Å molecular sieves, in the presence of an organic base, e.g. triethylamine or pyridine, at a temperature in the range of 0-50°C, preferably at ambient temperature. (For conditions see *Tet. Letts.* (1998), 39:2942-2944 and references cited therein. This paper is incorporated herein by reference.) These compounds may be formulated by methods known to those
20 skilled in the art to give compounds in which R₁ represents furyl, thienyl or pyrrolyl substituted by formyl. The formyl group in these compounds may be productively aminated by methods known to those skilled in the art to give compounds in which R₁ represents furyl, thienyl or pyrrolyl substituted by aminomethyl groups. Alternatively intermediates in which R₁ represents furyl, thienyl or pyrrolyl may be
25 subjected to a Mannich reaction to give intermediates in which R₁ represents furyl, thienyl or pyrrolyl substituted by an aminomethyl group.


Compounds of formula I may be prepared by reacting a compound of formula VII



10

in which R_1 , R_2 , R_3 , L and ring A are as previously defined and R_y represents a leaving group, for example halo or phenoxy, with ammonia or an ammonium salt, for example ammonium acetate, at a temperature in the range of 15-250°C, preferably in a pressure vessel.

Compounds of formula I in which R_2 represents chloro, bromo or iodo may be prepared by reacting a compound of formula VIII




in which R_1 , R_3 , L and ring A are as previously defined with a halogenating agent for example an iodinating agent, e.g. N-iodosuccinimide, or a brominating agent, e.g. N-bromosuccinimide, or a chlorinating agent, e.g. N-chlorosuccinimide.

30

Compounds of formula I in which $-L-R_3$ represents $-NHC(O)R_3$ may be prepared by reacting a compound of formula IX

5

10




IX

in which R_1 , R_2 and ring A are as previously defined and Y represents a protected amine, with a compound of formula R_3COR_x in which R_x represents a leaving group, for example chloro. Alternatively compounds of formula IX in which Y represents halo, for example chloro, may be reacted with a compound of formula R_3COR_x and the product reacted with ammonia to give a compound of formula I. Analogous methods may be used to prepare compounds of formula I in which $-L-R_3$ is -
 20 $NRSO_2R_3$. Analogous methods may be used to prepare compound of formula I in which $-L-R_3$ is $-NRCO_2-R_3$ or $-NRCONR'$. R and R' are as previously defined.

Compounds of formula I in which $-L-R_3$ is $-OSO_2-$ may be prepared by reacting a compound of formula X

25

30



X


in which R_1 , R_2 and ring A are as previously defined with a compound of formula $R_4SO_2R_x$.

Compounds of formula I may then be prepared from such intermediates following Scheme 2 or the alternative for Scheme 2, which is described later.


5 Compounds of formula II may be prepared as shown in Scheme 1 in which IPA represents propan-2-ol,

Scheme I


10




15




20



25



30




It will be appreciated by those skilled in the art that compounds of formula I may be converted into other compounds of formula I by known chemical reactions. For example, an alkoxy group may be cleaved to give hydroxy, nitro groups may be reduced to amines, amines may be acylated or sulfonylated and N-acyl compounds may be hydrolyzed to amines. Compounds of formula I in which -L- is S may be oxidized to give compounds of formula I in which -L- represents SO and SO₂, respectively, by methods known to those skilled in the art.

Compounds of formula III are commercially available or may be prepared by methods known to those skilled in the art.

Compounds of formula V in which R₂ represents hydrogen may be prepared as shown in Scheme 2. The amino group may be protected prior to the final step and then deprotected after the final step of scheme 2 by methods known to those skilled in the art. Compounds of formula V in which R₂ is other than hydrogen may be prepared by analogous methods. (see *J. Med. Chem.* (1990), 33, 1984.)

Scheme 2




Alternatively in Scheme 2, (ring A)-L-R₃ may be coupled first, prior to amination. Alternatively a substituent R₁ as defined previously may be present prior

to carrying out either process.


Compounds of formula VII, in which R_y is a $-Cl$, may be prepared as shown in Scheme 3.

Scheme 3



Compounds in which (ring A)-L- R_3 is absent may be prepared as in Scheme 4 and as described in *J. Med. Chem.*, (1988), 31:390 and references cited therein.

Compounds in which (ring A)-L- R_3 is other than hydrogen may be prepared by analogous methods.



Compounds of formula VII may be prepared by coupling a 5-iodo compound in an analogous manner to that described for the preparation of compounds of Scheme 4

formula V.

R_1 may be modified by the method depicted in Schemes 5 and 6. In Schemes 5 and 6 P represents a protecting group.

Scheme 5


5

10

15


20

25



-97-

Scheme 6



It will be appreciated by those skilled in the art that in cases where a substituent is identical with, or similar to, a functional group which has been modified in one of the above processes that these substituents will require protection before the process is undertaken, followed by deprotection after the process.

Otherwise competing side reactions will occur. Alternatively, another of the processes described above, in which the substituent does not interfere, may be used. Examples of suitable protecting groups and methods for their addition and removal may be found in the textbook "Protective Groups in Organic Synthesis" by T.W.

- 5 Green, John Wiley and Sons, 1981. For example suitable protecting groups for amines are formyl or acetyl.

The following synthetic examples were prepared using the general preparative procedures described above:

- 10 Example 1: Benzyl N-(4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl)carbamate

- a) Tetrahydro-2H-4-pyranyl trifluoromethanesulfonate. Pyridine (1.7 ml, 20.97 mmol) was added to a solution of tetrahydro-2H-4-pyranol (2 ml, 20.97 mmol) in dichloromethane (16 ml). The flask was immersed in an ice water bath and trifluoromethanesulfonic anhydride (3.6 ml, 20.97 mmol) in dichloromethane (7 ml) was added dropwise over 10 minutes. After 20 minutes, the reaction mixture was filtered and the solid was washed with minimum amount of dichloromethane. The combined filtrate was washed with water, 1.0 N HCl, water and brine. The organic layer was dried (MgSO₄) and filtered. The solvent was evaporated to give tetrahydro-2H-4-pyranyl trifluoromethanesulfonate. ¹H NMR (CDCl₃) δ 1.99 (m, 2H), 2.11 (m, 2H), 3.58 (m, 2H), 3.96 (m, 2H), 5.17 (m, 1H).

- 25 b) 4-chloro-5-iodo-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidine. 4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (3.0 g, 10.73 mmol) was added in small portions to a solution of sodium hydride (0.891g 22.2 mmol) in N,N-dimethylformamide (40 ml) at 0°C. After completed the addition the ice water bath was removed and the resulting mixture was stirred for 30 minutes.
- 30 Tetrahydro-2H-4-pyranyl trifluoromethanesulfonate was added dropwise and the

reaction mixture was stirred at ambient temperature for 24 hours. The mixture was poured to ice water (100ml) and the solid was collected by filtration and purified by re-crystallization to give 4-chloro-5-iodo-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidine. ¹H NMR (CDCl₃) δ 2.06 (m, 2H), 3.63 (m, 2H), 4.16 (m, 2H), 5.00 (m, 1H), 7.45 (s, 1H), 8.61 (s, 1H). LC/MS (MH⁺=364)

- c) tert-Butyl N-(4-(4-chloro-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl)carbamate. tert-Butyl N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate (1.66g, 4.75 mmol) in water was degassed by sonication under vacuum for 1 minute. 4-Chloro-5-iodo-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidine (1.1g, 3.17 mmol), tetrakis(triphenylphosphine) palladium(0) (0.22g, 0.19 mmol), Sodium carbonate (0.8g, 7.60 mmol) and 1,2-dimethoxyethane (30 ml) was added to the aqueous mixture. The resulting suspension was degassed again for 2 minutes and then heated to 85°C for 24 hours. The reaction mixture was cooled to ambient temperature and solvent was evaporated. The residue was dissolved in ethyl acetate. The organic layer washed and dried (MgSO₄). The solid was purified by flash column chromatography on silica using heptane/ethyl acetate (7:3) as the mobile phase to give tert-butyl N-(4-(4-chloro-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl) carbamate. ¹H NMR (CDCl₃) δ 1.55 (s, 9H), 2.10 (m, 4H), 3.66 (m, 2H), 3.92 (s, 3H), 4.16 (m, 2H), 5.05 (m, 1H), 7.06 (m, 2H), 7.14 (s, 1H), 7.32 (s, 1H), 8.13 (br.d, J=8 Hz, 1H), 8.64(s, 1H). LC/MS (MH⁺=459)
- d) 4-(4-chloro-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyaniline. A solution of ten percent trifluoroacetic acid in dichloromethane (50 ml) was added to tert-butyl N-(4-(4-chloro-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl)carbamate at 0°C. After 20 minutes, the ice water bath was removed and the resulting solution was stirred at ambient temperature for 4 hours. The solvent was removed and

the residue taken into dichloromethane. Saturated sodium bicarbonate was added and the layers separated. The aqueous layer was extracted with dichloromethane. The combined organic layer was washed with brine, dried (MgSO₄), filtered and concentrated. The solid was purified by passing through a
5 pat of silica gel using heptane/ethyl acetate (3:2) as the mobile phase to give 4-(4-chloro-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyaniline. ¹H NMR (CDCl₃) δ 2.09 (m, 4H), 2.51 (br. s, NH₂), 3.66 (m, 2H), 3.91 (s, 3H), 4.16 (m, 2H), 5.05 (m, 1H), 6.79 (d, J=8 Hz, 2H), 6.93 (d, J=8 Hz, 1H), 6.98 (s, 1H), 7.28 (s, 1H), 8.63 (s, 1H). LC/MS (MH⁺=359)

10

e) 5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine. Ammonium hydroxide (25 ml) was added to a solution of 4-(4-chloro-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyaniline (0.73g, 2.03 mmol) in dioxane (25 ml) in a pressure tube. The
15 pressure tube was sealed and heated to 122°C for 2 days. The tube was cooled to ambient temperature and the solvent was evaporated. Ethyl acetate was added and the organic layer was washed, dried (MgSO₄), filtered and concentrated to give 5-(4-amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine. ¹H NMR (DMSO-d₆) δ 1.87 (m, 2H), 2.11 (m, 2H), 3.52 (m, 2H), 3.79 (s, 3H), 3.99 (m, 2H), 4.87 (m, 3H), 6.02 (br. s, NH₂), 6.73 (d, J=8 Hz, 2H), 6.77 (d, J=8 Hz, 1H), 6.88 (s, 1H), 7.33 (s, 1H), 8.10 (s, 1H). LC/MS (MH⁺=340)

20

f) Benzyl N-(4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl)carbamate. Benzylchloroformate(16 uL, 0.110 mmol) was added dropwise to a stirring solution of 5-(4-amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (25 mg, 0.074 mmol) in pyridine (0.7 ml) and dichloromethane (0.7 ml) under nitrogen at 0°C. After 10 minutes, the ice water bath was removed and the resulting mixture was
25 stirred for 4 hours. The solvent was evaporated and the residue was purified by
30

preparative TLC using dichloromethane/methanol (95:5) as the mobile phase to give benzyl N-(4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl) carbamate. ¹H NMR (CDCl₃) δ 2.07 (m, 4H), 3.65 (m, 2H), 3.9 (s, 3H), 4.13 (m, 2H), 4.97 (m, 1H), 5.23 (s, 2H), 6.96 (s, 1H), 7.03 (s, 1H), 7.08 (d, J=8 Hz, 1H), 7.42 (m, 6H), 8.20 (br. s, J=8 Hz, 1H). 8.32 (s, 1H). LC/MS (MH⁺=474).

Example 2: Neopentyl N-(4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl)carbamate.

10 Neopentylchloroformate(13 uL, 0.110 mmol) was added dropwise to a stirring solution of 5-(4-amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (25 mg, 0.074 mmol) in pyridine (0.7 ml) and dichloromethane (0.7 ml) under nitrogen at 0°C. After 10 minutes, the ice water bath was removed and the resulting mixture was stirred for 4 hours. The solvent was
15 evaporated and the residue was purified by preparative TLC using dichloromethane/methanol (95:5) as the mobile phase to give neopentyl N-(4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl)carbamate. ¹H NMR (CDCl₃) δ 1.00 (s, 3H), 2.07 (m, 4H), 3.65 (m, 2H), 3.91 (s, 2H), 3.94 (s, 3H), 4.13 (m, 2H), 4.97 (m, 1H), 5.18 (s, 2H), 6.97 (s, 1H), 7.03 (s, 1H), 7.07 (d, J=8 Hz, 1H), 7.25 (s, 1H), 8.19 (br. s, J=8 Hz, 1H). 8.33
20 (s, 1H). LC/MS (MH⁺=454).

Example 3: Phenyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

25 5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (100 mg, 0.294 mmol) was dissolved in dichloromethane (2 mL). Pyridine (2mL) was added followed by phenylchloroformate (44 uL, 0.353 mmol). After stirring for 3 hours, another 44 uL of phenylmethanesulfonyl chloride was added and the reaction mixture was stirred overnight. The solvent was removed
30 and the residue was purified by preparative LC/MS to give phenyl N-[4-(4-amino-7-

tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl] carbamate (52 mg, 0.113 mmol). ¹H NMR (CDCl₃-d) δ 2.09 (m, 4H), 3.66 (m, 2H), 3.98 (s, 3H), 4.16 (m, 2H), 4.98 (m, 1H), 5.24 (s, 2H), 7.09 (m, 3H), 7.23 (m, 4H), 7.41 (m, 2H), 7.62 (s, 1H), 8.20(bd, J=7.80 Hz, 1H), 8.33 (s, 1H). LC/MS MH⁺=460.

5

Example 4: Tetrahydro-2H-4-pyranyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate 4-nitrophenyl tetrahydro-2H-4-pyranyl carbonate

Tetrahydro-2H-4-pyranol (1.0 ml, 10.5 mmol) was mixed with 4-methylmorpholine (2.0 ml) in dichloromethane (20 mL). 4-Nitrochloroformate (1.98 g, 9.82 mmol) was added slowly to the reaction mixture. After stirring for 5 hours, the reaction mixture was diluted with dichloromethane. The organic layer was washed with water, 1.0 N HCl, saturated sodium bicarbonate, brine, dried over MgSO₄, filtered and evaporated. The crude product was purified by flash column chromatography using ethyl acetate/heptane (4:1) as the mobile phase to give 4-nitrophenyl tetrahydro-2H-4-pyranyl carbonate (1.5 g, 5.62 mmol). ¹H NMR (CDCl₃-d) δ 1.87 (m, 2H), 2.06 (m, 2H), 3.58 (m, 2H), 3.98 (m, 2H), 4.97 (m, 1H), 7.40(d, J=9.0Hz, 2H), 8.30 (d, J=9.0Hz, 2H).

20 a) Tetrahydro-2H-4-pyranyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate. 5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (57 mg, 0.168 mmol) and 4-nitrophenyl tetrahydro-2H-4-pyranyl carbonate (90 mg, 0.336 mmol) was mixed in pyridine (1 mL). After stirring for 25 5 hours, another 90 mg of 4-nitrophenyl tetrahydro-2H-4-pyranyl carbonate was added and the reaction mixture was stirred for 2 days. The reaction mixture was heated at 70°C for 2 hours. The solvent was removed and the residue was purified by preparative thin layer chromatography to give tetrahydro-2H-4-pyranyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.064 mmol). ¹H NMR (CDCl₃-d) δ 30

1.78 (m, 4H), 2.08 (m, 4H), 3.60 (m, 4H), 3.94 (s, 3H), 3.97 (m, 2H), 4.15 (m, 2H), 4.98 (m, 2H), 5.23 (s, 2H), 6.78 (s, 1H), 7.04 (s, 1H), 7.07 (d, J=8.3 Hz, 1H), 8.16 (bd, J=7.90 Hz, 1H), 8.33 (s, 1H). LC/MS MH^+ =468.

5

Example 5: 3-Pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride

10 a) 4-Nitrophenyl (3-pyridylmethyl) carbonate. 4-Nitrochloroformate (2.49 g, 12.3 mmol) in dichloromethane (20 mL) was cooled on an ice-water bath. 3-pyridylmethanol (1.0 mL, 10.3 mmol) and 4-methylmorpholine (2.0 mL, 18.5 mmol) was added slowly. After 20 minutes, the ice-water bath was removed and the reaction mixture was allowed to warm up to room temperature. 30 minutes later, ethyl acetate was added and the reaction mixture was filtered. The filtrate
15 was washed with water, saturated sodium bicarbonate, brine, dried over $MgSO_4$, filtered and evaporated to give a dark brown solid which was re-crystallized with ethyl acetate/heptane to give 4-nitrophenyl (3-pyridylmethyl) carbonate (1.52 g, 5.54 mmol). 1H NMR ($CDCl_3$ -d) δ 7.38 (m, 3H), 7.79 (m, 1H), 8.28 (d, J=9.09 Hz, 2H), 8.65 (m, 1H), 8.72 (s, 1H).

20

b) 3-Pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate. 5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (25 mg, 0.074 mmol) was dissolved in dichloromethane (0.7 mL). Pyridine (0.7 mL) was
25 added followed by 4-nitrophenyl (3-pyridylmethyl) carbonate (30 mg, 0.110 mmol). After heating at 100°C overnight, the solvent was removed and the residue was purified by preparative LC/MS to give 3-pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (12 mg, 0.025 mmol). 1H NMR ($CDCl_3$ -d) δ 2.08 (m, 4H), 3.65 (m, 2H), 3.92 (s, 3H), 4.15 (m, 2H), 4.96 (m, 1H), 5.26 (s, 2H), 5.54
30

(bs, 2H), 6.97 (s, 1H), 7.04(s, 1H), 7.08 (d, J=8.2Hz, 1H), 7.35 (m, 2H), 7.79 (d, J=7.8Hz, 1H), 8.15 (m, 1H), 8.29 (s, 1H), 8.61 (s, 1H), 8.71 (s, 1H). LC/MS $MH^+=475$

- 5 c) 3-Pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride. 3-Pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (12 mg, 0.025 mmol) was dissolved in ethyl acetate (2.0mL). 1.0N HCl in ether (1 mL) was added slowly. The precipitate was
10 collected through filtration under nitrogen to give 3-pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride(13 mg, 0.25 mmol). 1H NMR (DMSO- d_6) δ 1.91 (m, 2H), 2.17(m, 2H), 3.54 (m, 2H), 3.87 (s, 3H), 4.03 (m, 2H), 4.97(m, 1H), 5.23 (s, 2H), 7.05 (d, J=8.2Hz, 1H), 7.13 (s, 1H), 7.51 (m,
15 1H), 7.81 (d, J=8.2Hz, 1H), 7.84 (s, 1H), 7.95 (m, 1H), 8.42 (s, 1H), 8.60(s, 1H), 8.71 (s, 1H), 8.82 (s, 1H). LC/MS $MH^+=475$.

Example 6: 2-Morpholinoethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride

- 20 Phenyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (25 mg, 0.054 mmol) was mixed with 2-morpholino-1-ethanol (0.1 mL) in pyridine (0.7 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase HPLC to give 2-morpholinoethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl] carbamate (24 mg, 0.048mmol). The solid was dissolved in ethyl acetate (2 mL) and 1.0N HCl in ether (0.2 mL) was added slowly. The precipitate was collected through filtration under nitrogen to give 2-morpholinoethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl] carbamate hydrochloride (24 mg, 0.045 mmol). 1H NMR (DMSO-
30

δ 1.88(m, 2H), 2.16(m, 2H), 3.55 (m, 8H), 3.90 (s, 3H), 4.03 (m, 4H), 4.49(m, 2H), 4.92 (m, 1H), 7.07 (m, 1H), 7.15 (s, 1H), 7.65 (bs, 2H), 7.84 (s, 1H), 8.45 (s, 1H), 8.75(s, 1H) 10.95 (bs, 1H). LC/MS $MH^+ = 497$.

5

Example 7 (4-Bromo-1,3-thiazol-5-yl)methyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate.

- 10 a) 2,4-Dibromo-1,3-thiazole-5-carbaldehyde. 1,3-Thiazolane-2,4-dione (3.52 g, 30 mmol) and phosphorus oxybromide (43 g, 150 mmol) were mixed with dimethyl formamide (2.56 mL, 34 mmol). The mixture was then heated at 75°C for 1 hours and at 100°C for 5 hours. After cooled to room temperature, the mixture was added to ice-water (500ml) and the aqueous layer was extracted with dichloromethane. The combined organic layer was washed with saturated sodium bicarbonate, dried over $MgSO_4$, filtered and evaporated to give a brown solid which was washed with petroleum ether. Evaporation of solvent gave 2,4-dibromo-1,3-thiazole-5-carbaldehyde (1.74 g, 6.42 mmol). 1H NMR ($CDCl_3$ -d) δ 9.90 (S, 1H).
- 15 b) (2,4-Dibromo-1,3-thiazol-5-yl)methanol. 2,4-Dibromo-1,3-thiazole-5-carbaldehyde (1.74 g, 6.42 mmol) was dissolved in methanol (70 ml) at 0°C. Sodium borohydride (0.244 g, 6.42 mmol) was added in small portions. The ice-water bath was removed 10 minutes later and the reaction mixture was stirred at room temperature overnight. Solvent was removed and saturated ammonium chloride was added. 1.0N NaOH was added to adjust the pH to 10. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over $MgSO_4$, filtered and evaporated. The residue was purified by flash column chromatography to give (2,4-dibromo-1,3-thiazol-5-yl)methanol (0.946 g, 3.47 mmol). 1H NMR ($CDCl_3$ -d) δ 2.11 (bs, 1H) δ 4.79 (S, 2H).
- 20
- 25
- 30

- c) (4-Bromo-1,3-thiazol-5-yl)methanol. (2,4-Dibromo-1,3-thiazol-5-yl)methanol (0.94 g, 3.44 mmol), sodium carbonate tri-hydrate (1.34 g) and palladium on carbon (10%, 0.07g) were mixed in methanol (33 mL). The resulting mixture was hydrogenated at 60 psi for 2 days. The solid was filtered off through a pat of celite. The solvent was evaporated and the residue was purified by frash column chromatography to give (4-bromo-1,3-thiazol-5-yl)methanol (0.32 g, 2.78 mmol). ¹H NMR (CDCl₃-d) δ 2.29 (bs, 1H) δ 4.86 (s, 2H), 8.72 (s, 1H).
- d) (4-Bromo-1,3-thiazol-5-yl)methyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate. Phenyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (28 mg, 0.061 mmol) was mixed with (4-bromo-1,3-thiazol-5-yl)methanol (50 mg, 0.434 mmol) in pyridine (0.5 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase LC/MS to give (4-bromo-1,3-thiazol-5-yl)methyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate. ¹H NMR (CDCl₃-d) δ 2.07(m, 4H), 3.65 (m, 2H), 3.92 (s, 3H), 4.13 (m, 2H), 4.98 (m, 1H), 5.35 (s, 1H), 5.40(s, 2H), 6.97 (s, 1H), 7.04 (s, 1H), 7.09 (m, 1H), 7.35 (s, 1H), 8.17 (s, 1H), 8.32 (s, 1H), 8.78(s, 1H). LC/MS MH⁺=481.

Example 8: Tetrahydro-3-furanyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

- Phenyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed with tetrahydro-3-furanol (0.05 mL) in pyridine (0.5 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase PHLC to give tetrahydro-3-furanyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (14 mg, 0.031mmol). ¹H NMR (CDCl₃-d) δ 2.07(m, 6H), 3.66 (m, 2H),

3.96 (m, 7H), 4.13 (m, 2H), 4.98 (m, 1H), 5.26 (s, 2H), 5.40(m, 1H), 6.97 (s, 1H), 7.04 (s, 1H), 7.08 (d, J=8.2Hz, 1H), 7.26 (s, 1H), 8.30 (s, 1H), 8.32 (s, 1H). LC/MS $MH^+=455$.

5 Examples 9 and 10: 1,3-Dioxan-5-yl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

1,3-Dioxolan-4-ylmethyl N-(4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl)carbamate

Phenyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed
10 glycerol formal (0.05 mL) in pyridine (0.5 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase PHLC to give tetrahydro-3-furanyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]
15 carbamate (2 mg, 0.004mmol). 1H NMR ($CDCl_3$ -d) δ 2.06(m, 4H), 3.66 (m, 2H), 3.92 (m, 3H), 4.07 (m, 6H), 4.79 (m, 1H), 4.83 (d, J=6.3Hz, 1H), 4.96 (m, 1H), 5.04(d, J=6.3Hz, 1H), 6.15 (vbs, 2H), 6.96 (s, 1H), 7.05 (m, 2H), 7.53 (s, 1H), 8.15 (d, J=8.2Hz, 1H), 8.22 (s, 1H). LC/MS $MH^+=471$ and 1,3-dioxolan-4-ylmethyl N-(4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl) carbamate(6.0mg, 0.013 mmol). 1H NMR ($CDCl_3$ -d) δ 2.06(m, 4H), 3.66 (m, 2H), 3.75 (m, 1H), 3.92 (m, 3H), 4.03 (m, 1H), 4.13 (m, 1H), 4.34 (m, 2H), 4.94 (s, 1H), 4.97 (m, 1H), 5.10(s, 1H), 5.32 (bs, 2H), 6.97 (s, 1H), 7.03 (m, 2H), 7.06 (d, J=8.2Hz, 1H), 7.38(s, 1H), 8.15 (d, J=7.9Hz, 1H), 8.31 (s, 1H). LC/MS $MH^+=471$.

25

Example 11: 2-Pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride

Phenyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed 2-
30 pyridylmethanol (0.05 mL) in pyridine (0.5 mL). The reaction mixture was heated

-108-

at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase LC/MS to give 2-pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl] carbamate (11 mg, 0.023 mmol). The solid was dissolved in ethyl acetate (2 mL) and 1.0N HCl in ether (0.1 mL) was added slowly. The precipitate was collected through filtration under nitrogen to give 2-pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl] carbamate hydrochloride (12 mg, 0.023 mmol). ¹H NMR (DMSO-d₆) δ 1.92(m, 2H), 2.16(m, 2H), 3.55 (m, 2H), 3.89 (s, 3H), 4.02 (m, 2H), 4.91 (m, 1H), 5.23 (s, 2H), 7.05 (d, J=8.2Hz, 1H), 7.14 (s, 1H), 7.37 (m, 1H), 7.53 (d, J=7.8Hz, 1H), 7.87 (m, 3H), 8.42(s, 1H), 8.57 (d, J=4.2Hz, 1H), 8.85 (s, 1H). LC/MS MH⁺=475.

Example 12: 4-Pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate Hydrochloride

Phenyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed 4-pyridylmethanol (0.05 mL) in pyridine (0.5 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase LC/MS to give 2-pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl] carbamate (11 mg, 0.023 mmol). The solid was dissolved in ethyl acetate (2 mL) and 1.0N HCl in ether (0.1 mL) was added slowly. The precipitate was collected through filtration under nitrogen to give 4-pyridylmethyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl] carbamate hydrochloride (12 mg, 0.023 mmol). ¹H NMR (DMSO-d₆) δ 1.91(m, 2H), 2.16(m, 2H), 3.55 (m, 2H), 3.90 (s, 3H), 4.03 (m, 2H), 4.92 (m, 1H), 5.34 (s, 2H), 7.06 (d, J=8.2Hz, 1H), 7.16 (s, 1H), 7.73 (m, 1H), 7.81 (m, 1H), 7.87 (s, 1H), 8.46(s, 1H), 8.76 (d, J=5.6Hz, 1H), 9.05 (s, 1H). LC/MS: MH⁺=475.

Example 13: (5-Methyl-3-isoxazolyl)methyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

Phenyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed
5 with (5-methyl-3-isoxazolyl)methanol (0.05 mL) in pyridine (0.5 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase LC/MS to give (5-methyl-3-isoxazolyl)methyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (18 mg, 0.038mmol). 1H NMR
10 (CDCl₃-d) δ 2.06(m, 4H), 2.44 (s, 3H), 3.64 (m, 2H), 3.91 (s, 3H), 4.13 (m, 2H), 4.96 (m, 1H), 5.26 (s, 2H), 6.12(s, 1H), 6.95 (s, 1H), 7.06 (m, 2H), 7.39 (s, 1H), 8.17 (bs, 1H), 8.21(s, 1H). LC/MS: MH⁺ 479.

Example 14: [(2S)-5-Oxotetrahydro-1H-2-pyrrolyl]methyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

Phenyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed
with (5S)-5-(hydroxymethyl)tetrahydro-1H-2-pyrrolone (0.05 mL) in pyridine (0.5
20 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase LC/MS to give [(2S)-5-oxotetrahydro-1H-2-pyrrolyl]methyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (10 mg, 0.021mmol).
1H NMR (CDCl₃-d) δ 1.90 (m, 1H), 2.06(m, 4H), 2.34 (m, 1H), 2.41 (m, 2H), 3.64
25 (m, 2H), 3.94 (s, 3H), 4.04(m, 2H), 4.14 (m, 2H), 4.98 (m, 1H), 5.33 (m, 3H), 6.10(s, 1H), 6.98 (s, 1H), 7.04 (s, 1H), 7.09 (m, 1H), 7.31(s, 1H), 8.11 (bs, 1H), 8.32 (s, 1H). LC/MS: MH⁺ 481.

Example 15: 4-Aminobenzyl N-(4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl)carbamate

- a) tert-Butyl N-(4-(hydroxymethyl)phenyl)carbamate. (4-Aminophenyl)methanol (1.23 g, 10 mmol) and diisopropylethylamine (2.6 mL, 15 mmol) was mixed with di-tert-butyl dicarbonate (2.62 g, 12 mmol) in dichloromethane (50 mL).
5 The mixture was stirred at room temperature overnight. Ethyl acetate was added and the organic layer was washed with water, 1.0N HCl, saturated sodium carbonate, water, brine, dried over MgSO₄, filtered and evaporated. The crude product was purified by flash column chromatography with Ethyl acetate/heptane (2:3) to give tert-butyl N-(4-(hydroxymethyl)phenyl) carbamate (2.16g, 10 9.67 mmol). ¹H NMR (CDCl₃-d) δ 1.52 (s, 9H), 4.63 (s, 2H), 6.47 (bs, 1H), 7.30 (d, 8.5Hz, 2H), 7.36 (d, 8.5Hz, 2H).
- b) 4-Aminobenzyl N-(4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl)carbamate. Phenyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (51mg, 0.111 mmol) was mixed with tert-butyl N-(4-(hydroxymethyl)phenyl)carbamate (119 mg, 0.533) in pyridine (0.8 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase LC/MS to give 4-aminobenzyl N-(4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl)carbamate (9 mg, 0.015mmol). ¹H NMR (CDCl₃-d) δ 1.52(s, 1H), 2.08(m, 4H), 3.65 (m, 2H), 3.90 (s, 3H), 4.14(m, 2H), 4.97 (m, 1H), 5.17 (s, 2H), 5.37(bs, 1H), 6.55 (s, 1H), 6.95 (s, 1H), 7.03 (s, 1H), 7.06 (m, 1H), 7.31(s, 1H), 7.38 (m, 3H), 8.16 (bs, 1H), 8.30 (s, 1H). LC/MS: 25 MH⁺ 589.

Example 16: N1-[4-(4-Amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]benzamide

5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (80mg, 0.236 mmol) was dissolved in dichloromethane (2.0 mL). Pyridine (2.0 mL) was added followed by benzoyl chloride (41 uL, 0.353

- mmol). After stirring at room temperature for 2 hours, the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give N1-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]benzamide (64 mg, 0.144 mmol). ¹H NMR (CDCl₃-d) δ 2.12 (m, 4H), 3.67 (m, 2H), 3.99 (s, 3H), 4.17(m, 2H), 4.99 (m, 1H), 7.03(s, 1H), 7.04 (s, 1H), 7.14 (d, J=8.2Hz, 1H), 7.53 (m, 3H), 7.94(d, J=7.8Hz, 1H), 8.33 (s, 1H), 8.58 (s, 1H), 8.63 (d, J=8.2Hz, 1H). LC/MS: MH⁺=444
- 5
- 10 Example 17: N2-[4-(4-Amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-2-pyridinecarboxamide
- 5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (80mg, 0.236 mmol) was dissolved in dichloromethane (2.0 mL). Pyridine (2.0 mL) was added followed by 2-pyridinecarbonyl chloride hydrochloride (63 mg, 0.353 mmol). After stirring at room temperature for 2 hours, the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give N1-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]benzamide (84 mg, 0.189 mmol). ¹H NMR (CDCl₃-d) δ 2.12 (m, 4H), 3.67 (m, 2H), 4.03 (s, 3H), 4.14(m, 2H), 5.00 (m, 1H), 5.37 (s, 1H), 7.04(s, 1H), 7.09 (s, 1H), 7.14 (d, J=8.2Hz, 1H), 7.50 (m, 1H), 7.92 (m, 1H), 8.33 (s, 1H), 8.70(d, J=8.2Hz, 1H), 10.62 (s, 1H). LC/MS: MH⁺=445.
- 15
- 20

- Example 18: N5-[4-(4-Amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-1,3-dimethyl-1H-5-pyrazolecarboxamide
- 25
- 5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (80mg, 0.236 mmol) was dissolved in dichloromethane (2.0 mL). Pyridine (2.0 mL) was added followed by 2-pyridinecarbonyl chloride hydrochloride (63 mg, 0.353 mmol). After stirring at room temperature for 2 hours,

the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give N5-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-1,3-dimethyl-1H-5-pyrazolecarboxamide (30 mg, 0.065 mmol).

5 ¹H NMR (CDCl₃-d) δ 2.11 (m, 4H), 2.32 (s, 3H), 3.66 (m, 2H), 3.99 (s, 3H), 4.13(m, 2H), 4.17 (s, 3H), 4.99 (m, 1H), 5.22 (bs, 2H), 6.46 (s, 1H), 7.03 (s, 1H), 7.07 (s, 1H), 7.12 (d, J=8.2Hz, 1H), 8.33 (2, 2H), 8.49(d, J=8.2Hz, 1H). LC/MS: MH⁺=462.

10 Example 19: N1-[4-(4-Amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-2,2-dimethylpropanamide

5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (50mg, 0.147 mmol) was dissolved in dichloromethane (1.5 mL). Pyridine (1.5 mL) was added followed by 2,2-dimethylpropanoyl chloride (31 mg, 0.221 mmol). After stirring at room temperature for 2 hours, the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give N1-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-2,2-dimethylpropanamide (27 mg, 0.064 mmol). ¹H NMR (CDCl₃-d) δ 1.35 (s, 9H), 2.09 (m, 4H), 3.66 (m, 2H), 3.96 (s, 3H), 4.13(m, 2H), 4.97 (m, 1H), 5.46(bs, 2H), 6.98 (s, 1H), 7.04 (s, 1H), 7.07 (d, J=8.2Hz, 1H), 8.15 (s, 1H), 8.29 (s, 1H), 8.49(d, J=8.2Hz, 1H). LC/MS: MH⁺=424.

25 Example 20: N1-[4-(4-Amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-1-cyclopentanecarboxamide

5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (50mg, 0.147 mmol) was dissolved in dichloromethane (1.5 mL). Pyridine (1.5 mL) was added followed by 1-cyclopentanecarbonyl chloride (31 mg, 0.221 mmol). After stirring at room temperature for 2 hours, the solvent

was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give N1-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-2,2-dimethylpropanamide (33 mg, 0.076mmol). ¹H NMR (CDCl₃-d) δ 1.66 (m, 2H), 1.81 (m, 2H), 1.95 (m, 4H), 2.06 (m, 4H), 2.77 (m, 1H), 3.65 (m, 2H), 3.94 (s, 3H), 4.15(m, 2H), 4.96 (m, 1H), 5.37(bs, 2H), 6.98 (s, 1H), 7.03 (s, 1H), 7.07 (d, J=8.2Hz, 1H), 7.84 (s, 1H), 8.30 (s, 1H), 8.49(d, J=8.2Hz, 1H). LC/MS: MH⁺=437.

10 Example 21: N1-[4-(4-Amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-3-phenylpropanamide

5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (50mg, 0.147 mmol) was dissolved in dichloromethane (1.5 mL). Pyridine (1.5 mL) was added followed by 3-phenylpropanoyl chloride (37 mg, 0.221 mmol). After stirring at room temperature for 2 hours, the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give N1-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-2,2-dimethylpropanamide (7 mg, 0.015mmol). ¹H NMR (CDCl₃-d) δ 2.07 (m, 4H), 2.75 (m, 2H), 3.09 (m,2H), 3.65 (m, 2H), 3.88 (s, 3H), 4.13(m, 2H), 4.96 (m, 1H), 5.97(bs, 2H), 6.93 (s, 1H), 7.05 (m, 2H), 7.26 (m, 5H), 7.70 (s, 1H), 8.24 (s, 1H), 8.46(d, J=8.2Hz, 1H). LC/MS: MH⁺=472.

Example 22: 5-(4-phenoxyphenyl)-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine.

a) Tosyl chloride (12.0 g) was added in portions to a mixture of 3-hydroxytetrahydrofuran (5.0 g) in pyridine (100 ml) at 0 C under nitrogen with stirring. The mixture was stirred at 0°C for 2 hours and then warmed to ambient temperature. The mixture was stirred at ambient temperature for 72 hours. The

mixture was cooled to 0°C and 5M hydrochloric acid (200 ml) was added. The mixture was extracted with ethyl acetate and the combined ethyl acetate extracts were washed with 2M hydrochloric acid and then with brine, then dried, filtered and evaporated to give 3-tosyloxytetrahydrofuran as an oil.

5

- b) Sodium hydride (120 mg, of a 60% dispersion in mineral oil) was added to a solution of 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (906 mg) and dimethylformamide (30 ml) with stirring under nitrogen. The mixture was stirred for 30 minutes and then a solution of 3-(tosyloxy) tetrahydrofuran (750 mg) in dimethyl formamide (10 ml) was added with stirring. The mixture was stirred and heated at 95°C for 18 hours and then evaporated under vacuum. The residue was partitioned between ethyl acetate and water. The ethyl acetate layer was separated, dried and evaporated to give a residual gummy solid which was triturated with ether and filtered to give 5-(4-phenoxyphenyl)-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine m.p. 196-196.5°C.

10
15

Example 23: 5-(4-phenoxyphenyl)-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine.

20

In a similar manner to Example 1, 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine was reacted with 4-tosyloxytetrahydropyran to give after flash column chromatography 5-(4-phenoxyphenyl)-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, m.p. 193-193.5°C.

25

Example 24: 4-amino-5-(4-phenoxyphenyl)-7-[4-(N-tert-butoxycarbonyl) tetrahydroisoxazolyl]-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine.

30

- a) Di-tert-butyl dicarbonate (4.56 g) was added to a solution of 4-hydroxytetrahydroisoxazole (2.4 g) and triethylamine (4.2 g) in tetrahydrofuran (100 ml) with stirring at 0°C under nitrogen. The mixture was stirred at ambient

temperature for 72 hours and then filtered. The filtrate was evaporated under reduced pressure to give N-(tert-butoxycarbonyl)-4-hydroxytetrahydroisoxazole as an oil which was used directly in the next part of this example.

- 5 b) The product from a) above (3.6 g) was stirred in pyridine (50 ml) at 0°C under nitrogen and then tosyl chloride (3.62 g) was added in portions at 0°C with stirring. The mixture was stirred at 0°C for 1 hour and then allowed to warm to ambient temperature over 18 hours. The pyridine was removed under reduced pressure and ethyl acetate (50 ml) and citric acid (50 ml of a 1M solution in
10 water) were added. The organic layer was separated and washed with 1M citric acid solution and then brine, then dried, filtered and evaporated to give an oil which was purified by flash column chromatography using petroleum ether, b.p 40-60°C containing 20-30% of ethyl acetate as the mobile phase. Appropriate fractions were collected and combined to give N-(tert-
15 butoxycarbonyl)-4-tosyloxy tetrahydroisoxazole, m.p. 63-65°C.
- c) A solution of 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (1.0 g) in dimethylformamide (40 ml) was added dropwise with stirring to a suspension of sodium hydride (0.145 g, of a 60% dispersion in mineral oil) in
20 dimethylformamide (60 ml) with stirring under nitrogen at 0°C. The mixture was stirred at 0°C for 1 hour and then the product from b) (1.25 g) was added. The mixture was heated at 100°C for 3 hours and then cooled to ambient temperature, quenched with water and extracted with ethyl acetate to give an oil. The oil was triturated with ethyl acetate and the solid obtained was collected by
25 filtration to give 4-amino-5-(4-phenoxyphenyl)-7-[4-(N-tert-butoxycarbonyl)tetrahydroisoxazolyl]-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, m.p. 162-163°C.

Example 25: 5-(4-phenoxyphenyl)-7-(4-tetrahydroisoxazolyl)-7H-pyrrolo[2,3-d]-pyrimidin-4-ylamine dihydrochloride.

The product from Example 3 (0.29 g) was dissolved in dichloromethane (8 ml) and then stirred at 0°C whilst trifluoroacetic acid (2.0 ml) was added. The mixture was allowed to warm to ambient temperature and stirred at ambient temperature for 2 hours. The mixture was basified with sodium bicarbonate solution and extracted with dichloromethane to give an oil which was purified by flash column chromatography using ethyl acetate and then ethyl acetate/methanol (9:1) as the mobile phase. The appropriate fractions were collected and combined, then evaporated to give a solid which was dissolved in ethyl acetate and then treated with ethereal hydrogen chloride (3.0 ml, of a 1M solution). The solid obtained was collected by filtration, washed with ether and dried under vacuum at 45°C for 2 hours to give 5-(4-phenoxyphenyl)-7-(4-tetrahydroisoxazolyl)-7H-pyrrolo[2,3-d]-pyrimidin-4-ylamine dihydrochloride, m.p. 208°C (with decomposition).

Example 26: 4-chloro-5-iodo-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidine

15

a) 4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (5.0 g) was added to a mixture of sodium hydride (0.79 g of a 60% dispersion in mineral oil) in dimethylformamide (100 ml) with stirring under nitrogen at 0°C. The mixture was stirred until hydrogen evolution ceased. 3-Tosyloxytetrahydrofuran (4.65 g) was added at 0°C and then the mixture was warmed to 90°C. The mixture was stirred at this temperature for 2 hours and then overnight at ambient temperature. Water (100 ml) was added cautiously and the mixture was extracted with ethyl acetate to give 4-chloro-5-iodo-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidine, m.p. 184-186°C.

25

b) A mixture of 4-iodophenol (25.0 g), 2-fluorobenzaldehyde (14.14 g), potassium carbonate (31.5 g) and dimethylformamide (500 ml) was heated at 120°C under nitrogen with stirring for 15 hours. The mixture was cooled to ambient temperature and filtered. Water (500 ml) was added to the filtrate and the mixture was extracted with ethyl acetate to give a solid which was triturated

30

with hot hexane (500 ml). The supernatant liquid was decanted from a residual gum and cooled. The solid which precipitated was collected by filtration to give 2-(4-iodophenoxy) benzaldehyde, m.p. 84.5-86°C.

- 5 c) Toluene (250 ml) was deoxygenated and then nitrogenated for 30 minutes. 2-(4-Iodophenoxy)benzaldehyde (6.46 g), hexamethylditin (10.0 g) and tetrakis (triphenylphosphine) palladium (0) (1.4 g) were added to the toluene. The mixture was boiled under reflux under nitrogen with stirring for 7 hours. The mixture was cooled to ambient temperature then filtered. The filtrate was
10 evaporated and the residue was purified by flash column chromatography on silica using 3% ethyl acetate in petroleum ether, b.p. 40-60°C as the mobile phase to give 2-(4-trimethylstannylphenoxy)benzaldehyde as an oil.
- 15 d) A mixture of the product from c) (1.80 g), the product from b) (1.76 g), tris(dibenzylideneacetone)dipalladium (228 mg), triphenylarsine (383 mg) and dimethylformamide (75 ml) was heated at 65°C under nitrogen with stirring for 70 hours. The mixture was cooled to ambient temperature and quenched with water. The mixture was extracted with ethyl acetate to give a residue which was purified by flash column chromatography on silica using increasing amounts of
20 ethyl acetate from 30-50% in petroleum ether, b.p. 40-60°C as the mobile phase to give a solid which was triturated with diethyl ether and filtered to give 2-[(4-(4-chloro-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzaldehyde as a solid.
- 25 e) The product from d) (360 mg) was dissolved in methanol (5 ml) and sodium borohydride (65 mg) was added at 0°C with stirring. The mixture was warmed to ambient temperature and stirred at this temperature for 1 hour. The mixture was quenched with dilute sodium hydroxide solution and then evaporated under reduced pressure to give a residue which was extracted with ethyl acetate to give
30 2-[(4-(4-chloro-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-

-118-

ylphenoxy]benzyl alcohol.

- 5 f) A mixture of the product from e) (280 mg), 1,4-dioxane (15 ml) and concentrated aqueous ammonia solution (15 ml, S.G. 0.88) was heated at 120°C in a pressure vessel for 20 hours. The mixture was cooled to ambient temperature and the solvent removed under reduced pressure. The residue was taken up in ethyl acetate, washed with water, then dried, filtered and evaporated to give an oil which was purified by flash column chromatography on silica using ethyl acetate/methanol (9:1) as the mobile phase to give 2-[(4-(4-amino-7-
- 10 (3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzyl alcohol as a glassy solid, m.p. 92-96°C.

Example 27: 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-N,N-diethylbenzylamine

15

- a) Sodium triacetoxymethylborohydride (264 mg) was added to a mixture of 2-[(4-(4-chloro-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzaldehyde (330 mg) and diethylamine (121 mg) in 1,2-dichloroethane in a vial (5 ml) and the vial septum sealed. The mixture was stirred at ambient temperature for 20 hours then quenched with saturated aqueous sodium bicarbonate solution (5 ml). The mixture was extracted with ethyl acetate to give 2-[4-(4-chloro-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-N,N-diethylbenzylamine.
- 20
- 25 b) A mixture of the product from a) (280 mg), concentrated aqueous ammonia solution (10 ml, S.G. 0.88) and 1,4-dioxane (10 ml) was heated in a pressure vessel for 16 hours at 120°C. The mixture was cooled and the solvent removed under reduced pressure. The residue was taken up in ethyl acetate, washed with water, then dried, filtered and evaporated to give an oil which was purified by
- 30 flash column chromatography using ethyl acetate/methanol as a mobile phase to

give 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-N,N-diethylbenzylamine, m.p. 107-110°C.

Example 28: 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-benzonitrile

- 10 a) A mixture of 2-fluorobenzonitrile (28.8 g), 4-bromophenol (36.9 g), potassium carbonate (58.9 g) and dimethylformamide (30 ml) was heated with stirring under nitrogen at 120°C for 5 hours. The mixture was allowed to stand overnight at ambient temperature and then partitioned between ethyl acetate and water. The organic layer was separated, washed, dried and evaporated to give an oil which solidified on standing. The solid was triturated with petroleum ether b.p. 40-60°C and filtered to give 2-(4-bromophenoxy)benzonitrile.
- 15 b) A mixture from the product of part a) (5.57 g), hexamethylditin (10.0 g), tetrakis (triphenylphosphine) palladium (0) (1.4 g) and degassed toluene (250 ml) was heated at 110°C with stirring under nitrogen for 4.5 hours. The mixture was allowed to stand for 18 hours at ambient temperature and then filtered through a silica pad. The pad was washed with ethyl acetate and the combined filtrate and washes evaporated to dryness. The residue was purified by flash column chromatography on silica using petroleum ether b.p. 40-60°C and diethyl ether (2%) increasing to 5% as the mobile phase. Appropriate fractions were collected combined and evaporated to give 2-(4-trimethylstannylphenoxy)benzonitrile.
- 20 c) A mixture 4-chloro-5-iodo-7-(3-tetrahydrofuryl)pyrrolo[2,3-d]pyrimidine (1.8 g, prepared as described in Example 5) and the product from part b) (1.23 g) were reacted and then worked up in a similar manner to Example 5d) to give 2-[4-(4-chloro-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzonitrile.

- d) A mixture of the product from c) (470 mg), concentrated aqueous ammonia (33 ml, SG 0.880) and 1,4-dioxane (33 ml) were heated together in a pressure vessel at 120°C for 18 hours and then worked up on a similar manner to Example 5 to give 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-benzonitrile, m.p. 201-203°C.

Example 29: 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzaldehyde

- a) In a similar manner to Example 2, 3-tosyloxytetrahydrofuran (1.84 g) was reacted with 5-(4-benzyloxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (2.9 g) using sodium hydride (0.30 g, of a 60% dispersion in mineral oil) and dimethylformamide (40 ml) except that the mixture was heated for 4.5 hours at 90°C to give 5-(4-benzyloxyphenyl)-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine as a solid.
- b) A mixture of the product from part a) (6.0 g), 10% palladium on charcoal (3.0 g), ammonium formate (4.9 g) and ethanol (500 ml) was heated on a steam bath with stirring under nitrogen for 2 hours. The mixture was cooled and filtered and the solvent evaporated. The filtrate was concentrated to half volume and filtered to give a solid which was identified as 4-[4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenol m.p. 257-259°C.
- c) A mixture of 4-[4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenol (2.55 g), 2-fluorobenzaldehyde (1.07 g), potassium carbonate (2.13 g) and dimethylformamide (80 ml) was heated at 120°C with stirring under nitrogen for 5 hours. The mixture was cooled to ambient temperature quenched with water and extracted with ethyl acetate to give 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzaldehyde, m.p. 185-187°C.

Example 30: 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo-[2,3-d]pyrimidin-7-yl]tetrahydrofuran-3-ol

Sodium hydride (120 mg of a 60% dispersion in mineral oil) was added to a solution of 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (902 mg) and dimethylformamide (30 ml) with stirring under nitrogen. The mixture was stirred for 30 minutes and then 3,6-dioxabicyclo[3.1.0]hexane (300 mg) was added and the mixture was warmed to 80°C. The mixture was left for 64 hours and then evaporated under reduced pressure. The residue was triturated with water which left an oily gum. Ether was added and the mixture was stirred rapidly for 30 minutes which gave a solid which was collected by filtration and washed with methanol. The solid was discarded. The filtrate produced a second crop of solid which was recrystallised from ethanol to give 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo-[2,3-d]pyrimidin-7-yl]tetrahydrofuran-3-ol, m.p. 234.5-235.5°C.

15

Example 31: 5-[4-(2-morpholinomethylphenoxy)phenyl]-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

A mixture of 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzaldehyde (0.15 g), morpholine (64 mg), sodium triacetoxyborohydride (117 mg) and 1,2 dichloroethane (5 ml) was stirred at ambient temperature for 18 hours. Saturated aqueous sodium bicarbonate solution was added and the mixture was filtered through an EMPORE® cartridge. The filtrate was evaporated and the residue was dissolved in dichloromethane (5 ml) and then tris(2-aminoethyl)amine-polymer bound (0.3 g) and 2 drops of glacial acetic acid were added and the mixture was stirred at ambient temperature overnight. The polymer was removed by filtration and washed with dichloromethane and then with methanol. The combined organic filtrate and washings were evaporated under reduced pressure to give an oil which was triturated with diethyl ether/ethyl acetate with warming to dissolve the solid and then the solution was cooled in ice and

25

filtered to give 5-[4-(2-morpholinomethylphenoxy)phenyl]-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, m.p. 169-171°C.

Example 32: 5-[4-(2-piperidinomethylphenoxy)phenyl]-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

In a similar manner to Example 10, 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzaldehyde (0.15 g) was reacted with piperidine (63 mg) to give 5-[4-(2-piperidinomethylphenoxy)phenyl]-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine m.p. 76-78°C (glassy foam).

Example 33: 5-{4-[2-(2-methoxyethyl)aminomethylphenoxy]phenyl}-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

In a similar manner to Example 10, 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzaldehyde (0.15 g) and 2-methoxyethylamine (56 mg) were reacted together to give 5-{4-[2-(2-methoxyethyl)aminomethylphenoxy]phenyl}-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine m.p. 66-68°C (glassy foam).

Example 34: 4-[(4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzyl alcohol

20

a) In a similar manner to Example 9, 4-[4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenol was reacted with 4-fluorobenzaldehyde to give 4-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy] benzaldehyde.

25

b) The product from a) (0.35 g) was dissolved in methanol (10 ml) and to this solution was added sodium borohydride (32 mg) at 0°C. The mixture was warmed at ambient temperature and stirred at this temperature for 10 minutes. 1,2-Dichloroethane (4 ml) was added to aid solubility. The mixture was stirred

to ambient temperature for 18 hours and then glacial acetic acid (1 ml) was added and the mixture evaporated under reduced pressure. The residue was partitioned between ethyl acetate and saturated aqueous sodium carbonate solution. The ethyl acetate was separated, dried, filtered and evaporated to give
5 4-[(4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]-pyrimidin-5-yl)phenoxy]benzyl alcohol, m.p. 92-95°C.

Example 35: 5-[4-(4-fluorophenoxy)phenyl]-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

10 A mixture of 4-[4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenol (0.59 g), 4-fluorophenylboronic acid (0.56 g), copper (II) acetate (0.36 g), triethylamine (1.01 g), dichloromethane (20 ml) and activated ground 4 molecular sieves (0.5 g) was stirred under nitrogen in a dry atmosphere for 64 hours. The reaction mixture was filtered through a small pre-flushed silica pad and eluted with
15 dichloromethane (200 ml) then ethyl acetate (250 ml) and finally ethyl acetate/methanol 9:1 (250 ml). The dichloromethane and ethyl acetate fractions were combined and purified by flash column chromatography on silica using ethyl acetate/methanol as the mobile phase to give 5-[4-(4-fluorophenoxy)phenyl]-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, m.p. 198-199°C.

20

Example 36: 5-[4-(4-morpholinomethylphenoxy)-phenyl]-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

In a similar manner to Example 10 a mixture of 4-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzaldehyde (336 mg),
25 and morpholine (146 mg) were reacted to give 5-[4-(4-morpholinomethylphenoxy)-phenyl]-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, m.p. 142-144°C.

Example 37: 5-[4-(3-morpholinomethylphenoxy)phenyl]-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

- 5 a) A mixture of 4-[4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenol (0.297 g), was reacted with 3-formylphenylboronic acid in a similar manner to Example 14 to give 3-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzaldehyde.
- 10 b) The product from part a) (100 mg) and morpholine (44 mg) were reacted together using similar reagents and conditions as described in Example 10 to give 5-[4-(3-morpholinomethylphenoxy)phenyl]-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, m.p. 83-85°C.

Example 38: 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-6-(2-(4-pyridyl)ethylamino)-benzonitrile

- 15 A mixture of 4-[4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-phenol (0.517 g), 2-fluoro-6-(2-(4-pyridinyl)ethylamino)benzonitrile (0.42 g), potassium carbonate (0.48 g) and dimethylformamide (20 ml) were heated at 120°C under nitrogen for 8 hours. The mixture was allowed to cool, diluted with water
- 20 then extracted with ethyl acetate to give a solid which was recrystallised from ethyl acetate to give solid which was purified by flash column chromatography on silica using ethyl acetate and then ethyl acetate/methanol (9:1, 8:1, 4:1) to give 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-6-(2-(4-pyridyl) ethylamino)-benzonitrile, m.p 212-213°C.

25

Example 39: 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-6-(3-imidazol-1-yl)propylaminobenzonitrile

4-[4-Amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenol (0.49 g), 2-fluoro-6-(3-imidazol-1-yl)propylamino benzonitrile, potassium carbonate

(0.45 g) and dimethylformamide were reacted in a similar manner to Example 17 to give 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-6-(3-imidazol-1-yl)propylaminobenzonitrile, m.p. 110°C (glassy foam).

Example 40: 4-amino-6-bromo-5-(4-phenoxyphenyl)-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidine

- a) A mixture of 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (302 mg) was dissolved in dimethylacetamide (10 ml) and dichloromethane (50 ml) and then treated with N-bromosuccinimide (178 mg) in dichloromethane (10 ml). The mixture was left stirring ambient temperature for 16 hours. The mixture was evaporated under reduced pressure and the residue was triturated with water to give a solid which was collected by filtration and dried to give 4-amino-6-bromo-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine, m.p. 282-283°C.
- b) A mixture of the product from a) (1.14 g) in dry dimethylformamide (30 ml) was stirred under nitrogen whilst sodium hydride (120 mg of a 60% dispersion in mineral oil) was added. This was followed by 3-tosyloxyltetrahydrofuran (0.8 g) in dimethylformamide (10 ml). The mixture was heated at 90°C overnight. The mixture was evaporated under reduced pressure and the residue was triturated with water to give a solid which was collected by filtration and dried to give a solid which was purified by dissolving in ethanol, adding water to cloud point and filtering. The filtrate was evaporated under reduced pressure to give a residue which was purified by flash column chromatography on silica to give 4-amino-6-bromo-5-(4-phenoxyphenyl)-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidine, m.p. 205-206°C.

Example 41: 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-6-(3-methoxypropylamino) benzonitrile

In a similar manner to Example 17, 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (0.65 g), 2-fluoro-6-(3-methoxypropylamino)benzonitrile (0.46 g), potassium carbonate (0.61 g) and dimethylformamide (40 ml) was heated under nitrogen at 120°C for 8 hours to give, after workup, 2-[4-(4-amino-7-(3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-6-(3-methoxypropylamino) benzonitrile, m.p.183-184°C.

Example 42: 2-[4-(4-amino-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]benzonitrile

- 10 a) A mixture of 5-(4-benzyloxyphenyl)-7-(tetrahydropyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (2.83 g), 10% palladium on carbon (1.41 g), ammonium formate (2.31 g) and ethanol (250 ml) was boiled under reflux under nitrogen with stirring for 1.5 hours. The mixture was cooled to ambient temperature, filtered, then the filtrate cooled and filtered. The filtrate was evaporated to give
- 15 a solid 4-[4-amino-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenol.
- b) A warm solution of 4-[4-amino-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenol (0.082 g) in dimethylformamide (3.4 ml) was added to a
- 20 mixture of 2-fluorobenzonitrile (80 mg) and potassium carbonate (76 mg) in a vial. The vial was flushed with nitrogen then sealed. The mixture was shaken at 120°C for 6 hours and then left to cool to ambient temperature over 16 hours. The mixture was diluted with water (11 ml) and then extracted with ethyl acetate to give 2-[4-(4-amino-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-5-
- 25 yl)phenoxy]benzonitrile, m.p. 125°C (softens).

Examples 43-48 were prepared in a similar manner to the previous example by reacting 4-[4-amino-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenol with the appropriate nitrile except that the mixtures were shaken together

30 for periods up to 48 hours. The reactions were monitored for the disappearance of

starting material and heated for the appropriate time.

Example 49: 2-[4-(4-Amino-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-6-(3-imidazol-1-yl)propylaminobenzonitrile from 2-fluoro-6-(3-
5 (imidazol-1-yl)propylamino)-benzonitrile.

Example 50: 2-(4-(4-Amino-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy)-6-(2-morpholinoethoxy)benzonitrile, m.p. 110°C (glass), from 2-
10 fluorobenzonitrile.

Example 51: 2-[4-(4-Amino-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-6-(2-(4-pyridyl)ethylamino)benzonitrile, m.p. 120-123°C (glass),
from 2-fluoro-6-(2-(4-pyridyl)ethylamino)benzonitrile.
15

Example 52: 2-[4-(4-Amino-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy)-6-(3-methoxypropylamino)benzonitrile, m.p. 205-207°C, from 2-
fluoro-6-(3-methoxy-propylamino)benzonitrile.

20 Example 53: 2-[4-(4-Amino-7-(4-tetrahydropyranyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenoxy]-5-fluorobenzonitrile, m.p. 216-217°C, from 2,5-difluorobenzonitrile.

Examples 54-101

General Method

25 Portions of the amines listed in Table 1 (9 molar equivalents with respect to the ester employed, weights ranging from 47.5 mg to 184.5 mg) were weighed into separate vials and methanol (1 ml) was added to each vial. A solution of ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl acetate (1 molar equivalent) in a mixture of methanol and triethylamine (4 ml, ratio of methanol to

triethylamine is 23.2:1 v/v. The reaction mixtures were shaken at 60-65° C for 36 hours. The methanol and triethylamine were removed under reduced pressure at 50°C for 3 hours and to each vial was added water (3 ml) followed by dichloromethane (3 ml). The vials were agitated for 15 seconds and then allowed to stand for 18 hours. The mixtures were poured into EMPORE®(10 mm/6 ml) extraction disk cartridges and the dichloromethane phases were collected and evaporated at 50°C for 3 hours. During work-up it was observed that solid had separated out in the vials on standing for 18 hours. Consequently the aqueous layer in each cartridge was forced through with compressed air. Dichloromethane (4 ml) was added to each extraction cartridge. Each filtrate was evaporated under reduced pressure at 50°C for 3 hours. The desired products were either found in the original dichloromethane extract, in which case they are indicated as being present in the liquid, or were found in the insoluble solid on reworking and are referred to as being found in the solid. Certain products were found in both phases. These phases are indicated in Table 1.

Each sample was analysed by LCMS and in each case the target ion was found. The retention time for each product is given in Table 1. The conditions used are given below.

Column: 5 μ m hypersil BDS c18 (100 x 2.1 mm).
 Mobile Phase: 0.1M NH₄OAc [pH 4.55] : MeCN (gradient - see below).
 Conditions: 10-100% MeCN in 8 minutes.
 (Gradient) 100% MeCN for 1 minute.
 5 100-10% MeCN in 2 minutes.
 (Total analysis run time 11 minutes).
 Flow Rate: 1 ml/minute (no split in MS).
 Wavelength Range: 250-320 nm
 Injection Volume: 20 μ l.
 10 MS
 Method: APCI11H.
 Ionisation APcI +ve/-ve.
 Mass Range: 100-700 m/z.
 Cone voltage: 20.

15

In a similar manner to Examples 54-101, the amines listed in Table 2 were reacted, respectively, with ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]-pyrimidin-7-yl]propionate to give the products listed in Examples 102-146 respectively. The work-up and the analysis conditions were identical to those used
 20 for Examples 54-101. In each case the target ion was found by LCMS.

TABLE 1

Amine Number	Name	Phase	RT / min Product
54	Ethanolamine	Solid	3.44
55	dl-2-Amino-1-propanol	Solid	3.58
56	1-Amino-2-propanol	Solid	3.56
57	2-Methoxyethylamine	Liquid	3.78
58	3-Amino-1-propanol	Both	3.50
59	(S)-(+)-2-Amino-1-propanol	Both	3.58

Amine Number	Name	Phase	RT / min Product
60	(R)-(-)-1-Amino-2-propanol	Both	3.56
61	N,N-Dimethylethylenediamine	Both	3.31
62	(+/-)-2-Amino-1-butanol	Solid	3.77
63	1-Amino-2-butanol	Both	3.77
64	3-Amino-1,2-propanediol	Solid	3.32
65	(S)-3-Amino-1,2-propanediol	Solid	3.32
66	(R)-3-Amino-1,2-propanediol	Solid	3.32
67	1-Methylpiperazine	Both	3.28
68	N,N-Dimethyl-1,3-propanediamine	Liquid	3.29
69	N2,N2-Dimethyl-1,2-propanediamine	Both	3.37
70	1-Dimethylamino-2-propylamine	Liquid	3.44
71	dl-2-Amino-3-methyl-1-butanol	Solid	3.98
72	N-{2-[1-(N-Morpholine)-1-oxo]ethyl}piperazine	Liquid	3.56
73	2-Amino-2-methyl-1-propanol	Both	3.86
74	2-Amino-2-methyl-1,3-propanediol	Both	3.49
45	2-(2-Aminoethoxy)ethanol	Both	3.47
76	1-(2-Aminoethyl)pyrrolidine	Liquid	3.40
77	N-Methylhomopiperazine	Liquid	3.32
78	1-Amino-1-cyclopentane methanol	Both	4.16
79	2-Aminocyclohexanol	Solid	3.98
80	N,N-Diethylethylenediamine	Liquid	3.44
81	N-(3-Hydroxypropyl)ethylenediamine	Both	3.24
82	2-((2-Aminoethyl)thio)ethanol	Both	3.69
83	2-(2-Aminoethyl)pyridine	Liquid	3.89
84	3-(2-Aminoethyl)pyridine	Liquid	3.79
85	N-(3-Aminopropyl)imidazole	Liquid	3.37
86	1-[2-(N-Morpholine)ethyl]piperazine	Liquid	3.39

Amine Number	Name	Phase	RT / min Product
87	2-(Aminomethyl)-1-ethylpyrrolidine	Both	3.48
88	1-(2-Aminoethyl)piperidine	Both	3.49
89	1-Pyrrolidinepropanamine	Liquid	3.37
90	(R)-(+)-2-Aminomethyl-1-ethylpyrrolidine	Both	3.48
91	4-(2-Aminoethyl)morpholine	Both	3.39
92	3-Diethylaminopropylamine	Both	3.43
93	N,N-Dimethylnepentanediamine	Both	3.47
94	Ethyl 1-piperazinecarboxylate	Liquid	4.34
95	2-(Aminomethyl)-2-ethyl-1,3-propanediol	Both	3.69
96	1-(3-Aminopropyl)-2-pyrrolidinone	Both	3.68
97	1-Piperidinepropylamine	Liquid	3.46
98	4-(3-Aminopropyl)morpholine	Liquid	3.33
99	N,N-Diisopropylethylenediamine	Liquid	3.59
100	N,N-Bis(3-aminopropyl)methylamine	Liquid	3.03
101	Tris(2-aminoethyl)amine	Liquid	3.01

The compounds prepared are given below.

Example 54: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-
5 (2-hydroxyethyl)acetamide

Example 55: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-
(1-hydroxyprop-2-yl)acetamide

10 Example 56: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-
(2-hydroxypropyl)acetamide

Example 57: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(2-methoxyethyl)acetamide

5 Example 58: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(3-hydroxypropyl)acetamide

Example 59: (S)-4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(1-hydroxyprop-2-yl)acetamide

10 Example 60: (R)-4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(2-hydroxypropyl)acetamide

15 Example 61: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[2-(N,N-dimethylamino)ethyl]acetamide

Example 62: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(1-hydroxybut-2-yl)acetamide

20 Example 63: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(2-hydroxybutyl)acetamide

Example 64: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(2,3-dihydroxypropyl)acetamide

25 Example 65: (S)-4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(2,3-dihydroxypropyl)acetamide

30 Example 66: (R)-4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(2,3-dihydroxypropyl)acetamide

Example 67: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N,N-(3-azapentamethylene)acetamide

5 Example 68: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[3-(N,N-dimethylamino)propyl]acetamide

Example 69: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[1-(N,N-dimethylamino)prop-2-yl]acetamide

10 Example 70: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[2-(N,N-dimethylamino)propyl]acetamide

Example 71: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(1-hydroxy-3-methylbut-2-yl)acetamide

15

Example 72: 7-{2-[4-(2-Morpholino-2-oxoethyl)piperazin-1-yl]-2-oxo-ethyl}-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

20 Example 73: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(1-hydroxy-3-methylprop-2-yl)acetamide

Example 74: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(1,3-dihydroxy-2-methylprop-2-yl)acetamide

25 Example 75: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[2-(2-hydroxyethoxy)ethyl]acetamide

Example 76: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[2-(pyrrolidin-1-yl)ethyl]acetamide

30

Example 77: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N,N-(3-azahexamethylene)acetamide

Example 78: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-
5 [1-(hydroxymethyl)cyclopentyl]acetamide

Example 79: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(2-hydroxycyclohexyl)acetamide

10 Example 80: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[2-(N,N-diethylamino)ethyl]acetamide

Example 81: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[2-(3-hydroxypropylamino)ethyl]acetamide

15

Example 82: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[2-(2-hydroxyethylthio)ethyl]acetamide

Example 83: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-
20 [2-(pyrid-2-yl)ethyl]acetamide

Example 84: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[2-(pyrid-3-yl)ethyl]acetamide

25 Example 85: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[3-(imidazol-1-yl)propyl]acetamide

Example 86: 7-{2-[4-(2-Morpholinoethyl)piperazin-1-yl]-2-oxo-ethyl}-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

30

Example 87: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(N-ethylpyrrolidin-2-yl)methylacetamide

5 Example 88: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(2-piperidinoethyl)acetamide

Example 89: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[3-(pyrrolidin-1-yl)propyl]acetamide

10 Example 90: (R)-4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(N-ethylpyrrolidin-2-yl)methylacetamide

Example 91: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(2-morpholinoethyl)acetamide

15

Example 92: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[3-(N,N-diethylamino)propyl]acetamide

20 Example 93: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[3-(N,N-dimethylamino)-2,2-dimethylpropyl]acetamide

Example 94: 7-[2-(4-Ethoxycarbonylpiperazin-1-yl)-2-oxoethyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

25 Example 95: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[2,2-bis(hydroxymethyl)butyl]acetamide

Example 96: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[3-(2-pyrrolidinon-1-yl)propyl]acetamide

30

Example 97: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(3-piperidinopropyl)acetamide

Example 98: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(3-morpholinopropyl)acetamide

Example 99: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-(3-hydroxy-1-methylprop-2-yl)acetamide

Example 100: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[3-(N-3-aminopropyl,N-methyl)aminopropyl]acetamide

Example 101: 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-N-[N-bis(2-aminoethyl)aminoethyl]acetamide

15

TABLE 2

Amine Number	Name	Phase	RT / min Product
102	Ethanolamine	Both	3.68
103	dl-2-Amino-1-propanol	Both	3.78
104	1-Amino-2-propanol	Both	3.81
105	2-Methoxyethylamine	Both	4.08
106	3-Amino-1-propanol	Both	3.73
107	(S)-(+)-2-Amino-1-propanol	Both	3.78
108	(R)-(-)-1-Amino-2-propanol	Liquid	3.81
109	N,N-Dimethylethylenediamine	Liquid	3.50
110	(+/-)-2-Amino-1-butanol	Both	3.96

Amine Number	Name	Phase	RT / min Product
111	1-Amino-2-butanol	Both	4.06
112	3-Amino-1,2-propanediol	Both	3.52
113	(S)-3-Amino-1,2-propanediol	Both	3.53
114	(R)-3-Amino-1,2-propanediol	Both	3.53
115	N,N-Dimethyl-1,3-propanediamine	Liquid	3.47
116	N2,N2-Dimethyl-1,2-propanediamine	Liquid	3.57
117	1-Dimethylamino-2-propylamine	Liquid	3.67
118	Dl-2-Amino-3-methyl-1-butanol	Both	4.15
119	2-(2-Aminoethylamino)ethanol	Liquid	3.40
120	2-Amino-2-methyl-1-propanol	Both	4.17
121	2-Amino-2-methyl-1,3-propanediol	Both	3.76
122	2-(2-Aminoethoxy)ethanol	Liquid	3.71
123	1-(2-Aminoethyl)pyrrolidine	Both	3.61
124	1-Amino-1-cyclopentane methanol	Both	4.48
125	2-Aminocyclohexanol	Both	4.19
126	N,N-Diethylethylenediamine	Both	3.68
127	N-(3-Hydroxypropyl)ethylenediamine	Both	3.42
128	2-((2-Aminoethyl)thio)ethanol	Liquid	3.94
129	2-(2-Aminoethyl)pyridine	Liquid	4.13
130	3-(2-Aminoethyl)pyridine	Both	4.05
131	N-(3-Aminopropyl)imidazole	Liquid	3.58
132	2-(2-Aminoethylamino)-1-methylpyrrolidine	Both	3.56
133	2-(Aminomethyl)-1-ethylpyrrolidine	Both	3.70
134	1-(2-Aminoethyl)piperidine	Both	3.70
135	1-Pyrrolidinepropanamine	Both	3.60
136	(R)-(+)-2-Aminomethyl-1-ethylpyrrolidine	Both	3.70
137	4-(2-Aminoethyl)morpholine	Both	3.63

-138-

Amine Number	Name	Phase	RT / min Product
138	3-Diethylaminopropylamine	Both	3.64
139	N,N-Dimethylneopentanediamine	Both	3.68
140	2-(Aminomethyl)-2-ethyl-1,3-propanediol	Both	3.94
141	1-(3-Aminopropyl)-2-pyrrolidinone	Liquid	3.91
142	1-Piperidinepropylamine	Both	3.70
143	4-(3-Aminopropyl)morpholine	Liquid	3.53
144	N,N-Diisopropylethylenediamine	Liquid	3.86
145	N,N-Bis(3-aminopropyl)methylamine	Solid	3.21
146	Tris(2-aminoethyl)amine	Both	3.17

Example 102: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(2-hydroxyethyl)propanamide

- 5 Example 103: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(1-hydroxyprop-2-yl)propanamide

Example 104: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(2-hydroxypropyl)propanamide

10

Example 105: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(2-methoxyethyl)propanamide

15

Example 106: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(3-hydroxypropyl)propanamide

Example 107: (S)-1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(1-hydroxyprop-2-yl)propanamide

Example 108: (R)-1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(2-hydroxypropyl)propanamide

Example 109: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
5 N-[2-(N,N-dimethylamino)ethyl]propanamide

Example 110: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
N-(1-hydroxybut-2-yl)propanamide

10 Example 111: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
N-(2-hydroxybutyl)propanamide

Example 112: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
N-(2,3-dihydroxypropyl)propanamide

15

Example 113: (S)-1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
N-(2,3-dihydroxypropyl)propanamide

Example 114: (R)-1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
20 N-(2,3-dihydroxypropyl)propanamide

Example 115: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
N-[3-(N,N-dimethylamino)propyl]propanamide

25 Example 116: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
N-[2-(N,N-dimethylamino)propyl]propanamide

Example 117: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
N-[1-(N,N-dimethylamino)prop-2-yl]propanamide

30

Example 118: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(1-hydroxy-3-methylbut-2-yl)propanamide

Example 119: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
5 N-[2-(2-hydroxyethylamino)ethyl]propanamide

Example 120: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(1-hydroxy-2-methylprop-2-yl)propanamide

10 Example 121: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(1,3-dihydroxy-2-methylprop-2-yl)propanamide

Example 122: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(2-hydroxyethoxy)ethyl]propanamide
15

Example 123: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(pyrrolidin-1-yl)ethyl]propanamide

Example 124: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
20 N-[1-(hydroxymethyl)cyclopentyl]propanamide

Example 125: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(2-hydroxycyclohexyl)propanamide

25 Example 126: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(N,N-diethylamino)ethyl]propanamide

Example 127: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(3-hydroxypropylamino)ethyl]propanamide
30

Example 128: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(2-hydroxyethylthio)ethyl]propanamide

5 Example 129: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(pyrid-2-yl)ethyl]propanamide

Example 130: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(pyrid-3-yl)ethyl]propanamide

10 Example 131: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[3-(imidazol-1-yl)propyl]propanamide

Example 132: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(N-methylpyrrolidin-2-yl)ethyl]propanamide

15

Example 133: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[(N-ethylpyrrolidin-2-yl)methyl]propanamide

20 Example 134: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(2-piperidinoethyl)propanamide

Example 135: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[3-(pyrrolidin-1-yl)propyl]propanamide

25 Example 136: (R)-1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[(N-ethylpyrrolidin-2-yl)methyl]propanamide

Example 137: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(2-morpholinoethyl)propanamide

30

Example 138: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[3-(N,N-diethylamino)propyl]propanamide

Example 139: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
5 N-[3-(N,N-dimethylamino)-2,2-dimethylpropyl]propanamide

Example 140: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2,2-bis(hydroxymethyl)butyl]propanamide

10 Example 141: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[3-(2-pyrrolidinon-1-yl)propyl]propanamide

Example 142: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(3-piperidinopropyl)propanamide
15

Example 143: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(3-morpholinopropyl)propanamide

Example 144: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-
20 N-[2-(N,N-di-isopropylamino)ethyl]propanamide

Example 145: 1-[Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[3-(N-3-aminopropyl,N-methyl)aminopropyl]propanamide

25 Example 146: 1-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[N-bis(2-aminoethyl)aminoethyl]propanamide

Example 147: 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]--butyrolactone

30 a) 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (1.0 g) was added

to a mixture of sodium hydride (0.158 g of a 60% dispersion in mineral oil) in dimethyl formamide (70 ml) with stirring under nitrogen at 0°C. The mixture was stirred at 0°C for 1 hour and then α -bromo- γ -butyrolactone (0.60 g) in dimethylformamide (6 ml) was added dropwise with stirring at 0°C. The mixture was stirred at ambient temperature for 18 hours and then quenched with water (100 ml). The mixture was extracted with ethyl acetate. The combined extracts were dried and evaporated to give 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- γ -butyrolactone as an oil which was used directly in b).

- b) N,N-Dimethylethylenediamine (5.0 ml) was added to a mixture of the product from a) (1.2 g) and pyridin-2-one (50 mg) in toluene (100 ml). The mixture was heated to 100°C for 2 hours and then evaporated to dryness under reduced pressure. The residue was suspended in ethyl acetate and washed with water. The organic extracts were then extracted with 5M hydrochloric acid (3 x 50 ml) and the acidic extracts were washed with ethyl acetate then basified with 6M sodium hydroxide solution at 0°C and then back extracted with ethyl acetate and then dichloromethane. The combined organic extracts were dried, filtered and evaporated to give an oil which was crystallised from ethyl acetate/ether to give 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-4-hydroxy-N-[2-dimethylamino)ethyl]utyramide, m.p. 178-179°C.

Example 148: Ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]propionate

- Sodium hydride (120 mg, of a 60% dispersion in mineral oil) was added to a mixture of 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (906 mg) in dry dimethylformamide (30 ml) and the mixture was stirred under nitrogen for 30 minutes at ambient temperature. A solution of ethyl 2-bromopropionate (543 mg) in dry DMF (10 ml) was added dropwise via a syringe over 10 minutes. The mixture was stirred at ambient temperature for 2 hours and then left for 18 hours. The

mixture was evaporated under vacuum and the residue was washed with water to give a solid which was triturated with ether and filtered to give ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]propionate, m.p. 139-140°C.

- 5 Example 149: N-(2-dimethylaminoethyl)-2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]propionamide

 A mixture of ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]propionate (425 mg), N,N-dimethylethylenediamine (2 ml) and methanol (20 ml) was boiled under reflux for 18 hours with the exclusion of carbon
10 dioxide. The mixture was cooled and filtered, the filtrate was diluted with water (50 ml) and stirred with ether. The mixture was left standing for 18 hours and the solid which precipitated was collected by filtration, washed with water and then ether and dried to give N-(2-dimethylaminoethyl)-2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]propionamide, m.p. 163-164°C.

15

- Example 150: Ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]acetate

 A mixture of 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (906 mg), sodium hydride (120 mg, of a 60% dispersion in mineral oil) and dry
20 dimethylformamide (30 ml) was stirred at ambient temperature under nitrogen for 30 minutes. Ethyl bromoacetate (0.5 g) in dimethylformamide (10 ml) was added over 5 minutes at 0-5°C with stirring. The mixture was stirred for 30 minutes at ambient temperature and then allowed to stand for 18 hours. The mixture was evaporated under vacuum and the residue was triturated with water and ether. The solid
25 obtained was collected by filtration, washed with water and then with ether to give ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]acetate, m.p. 161-161.3°C.

Examples 151-156

General Method

Ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]acetate (194 mg) was heated at 62°C and stirred with 10 molar equivalents of the appropriate amine as listed below in methanol (12 ml) for 18 hours to give after work up the following compounds:

Example 151

N-[2-hydroxyethyl-1,1-di(hydroxymethyl)]-2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]acetamide, m.p. 222-223°C with decomposition, from 2-hydroxyethyl-1,1-di(hydroxymethyl)ethylamine.

Example 152

N-[2-(piperazin-1-yl)ethyl]-2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]acetamide, m.p. 138-140°C, from 2-(piperazin-1-yl)ethylamine.

Example 153

N-(2-morpholinoethyl)-2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]acetamide, m.p. 164-165°C, from 2-morpholinoethylamine.

Example 154

N-[3-(1-imidazol)propyl]-2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]acetamide, m.p. 170-171°C, from 3-(1-imidazolyl)propylamine.

Example 155

N-(N-ethylpyrrolidin-2-ylmethyl)-2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]-pyrimidin-7-yl]acetamide, m.p. 122-122.5°C, from 1-(N-ethylpyrrolidin-2-yl)methyl-amine.

5

Example 156

N-[-2(2-hydroxyethoxy)ethyl]-2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]-pyrimidin-7-yl]acetamide, m.p. 145-147°C, from 2-(2-hydroxyethoxy)ethylamine.

10

Example 157: 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]propionic acid

A mixture of ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]propionate (201 mg), aqueous potassium hydroxide solution (4 ml of 2M solution) and methanol (20 ml) was boiled under reflux for 1 hour. The mixture was concentrated under reduced pressure to around 5 ml and then diluted with water (30 ml). The mixture was hot filtered and filtrate was cooled and then acidified with dilute acetic acid until no further precipitation occurred. The mixture was heated on a hot plate until the gel which had been obtained became a finely divided solid. The solid was collected by filtration to give 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]propionic acid, m.p. 239.5-241°C.

15

20

Example 158: Ethyl 4-[4-amido-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]butyrate

A mixture of 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (1.5 g) was dissolved in DMF (30 ml) and treated with sodium hydride (0.22 g of a 60% dispersion in mineral oil) and then with ethyl 4-bromobutyrate (1.08 g) in DMF (15 ml) in a similar manner to Example 95 to give ethyl 4-[4-amido-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]butyrate, m.p. 104-104.5°C.

25

30

Example 159: ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]carbox-amide

In a similar manner to Example 97, 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]-pyrimidin-4-yl amine (1.0 g), sodium hydride (1.032 g of a 60% dispersion in mineral oil), 2-bromoacetamide (0.55 g) and dimethylformamide (50 ml) were reacted together to give after work-up a solid which was recrystallised from isopropanol to give ethyl 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]carbox-amide, m.p. 232-233°C.

Example 160: 2-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]-2-methylpropionamide

4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (200 mg) was dissolved in 1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (1.5 ml) with stirring and sodium hydroxide (0.158 g) was added at ambient temperature and the mixture stirred for 15 minutes. 2-Bromo-2-methylpropanamide (0.5 g) was added and the mixture was stirred vigorously for 18 hours at ambient temperature under a water-free atmosphere, then further 2-bromo-2-methylpropanamide (0.15 g) was added and stirred for a further 24 hours. Water (3 ml) was added to the reaction mixture together with dilute hydrochloric acid (5M) to adjust the pH to 0. The suspension was added to water (60 ml) and the mixture left to stand for 18 hours at ambient temperature. The solid was collected by filtration, washed well with water and dried under high vacuum at 50°C. The solid was purified by preparative HPLC (reverse phase). Appropriate fractions were collected and combined and extracted with dichloromethane. Evaporation of the dichloromethane gave 2-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]-2-methylpropionamide, m.p. 227-228°C.

Example 161: 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl] N-(2-dimethylaminoethyl)butyramide

A mixture of ethyl 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimin-7-yl]butyrate (100 mg) in 30 ml methanol was heated under reflux with 0.6 ml 2-dimethylaminoethylamine for 18 hours. The mixture was evaporated under reduced pressure and the residue was heated with 2-dimethylaminoethylamine (10 ml) on a steam bath for 18 hours. Excess amine was removed under reduced pressure. Water was added to the residue and the mixture filtered to give 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimin-7-yl] N-(2-dimethylaminoethyl)butyramide.

Examples 162, 163 and 164 were prepared in a similar manner to Example 108 by reacting the same ester with the appropriate amine listed.

Example 165

4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimin-7-yl]-N-[3-(1-imidazolyl)propyl]butyramide from 3-(1-imidazolyl)propylamine.

Example 166

4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimin-7-yl]-N-(2-morpholinoethyl)butyramide from 2-morpholinoethylamine.

Example 167

4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimin-7-yl]-N-(3-morpholinopropyl)butyramide from 3-morpholinopropylamine.

Preparation of Starting Materials

a) Tert-butylamine (15 ml) was added with stirring to a solution of 2-bromo-4'-phenoxyacetophenone (12.7 g, prepared by bromination of 4'-phenoxyacetophenone according to Tetrahedron Letters, 1993, 34, 3177) in

propan-2-ol and the mixture heated at 80°C for 3 hours. The mixture was cooled to 0°C and concentrated hydrochloric acid (10 ml) added. The suspension was stirred at ambient temperature for 18 hours and the solid collected by filtration to give 4'-phenoxy-2-(tert-butylamino)acetophenone hydrochloride (3.75 g), m.p. 210-212°C.

1) 4'-Phenoxy-2-(tert-butylamino)acetophenone hydrochloride (3.75 g) was added in one portion to sodium ethoxide (prepared by dissolving sodium (93 mg) in ethanol (50 ml)) and the mixture was stirred at 40°C for 30 minutes under nitrogen.

2) In a separate flask sodium (331 mg) was dissolved in ethanol (50 ml) and malononitrile (858 mg) was added. The solution was stirred at ambient temperature for 5 minutes and then to this solution was added the solution of 4'-phenoxy-2-(tert-butylamino)acetophenone obtained in part (1) in one portion excluding the precipitated sodium chloride. The resultant mixture was heated at 50°C for 3 hours and then at 80°C for 2 hours. The solvent was removed under reduced pressure and the resultant oil was partitioned between water and ethyl acetate. The organic phase was separated, dried and evaporated to give a black solid. This solid was dissolved in hot ethanol and triturated with water, filtered and dried to give 2-amino-3-cyano-4-(4-phenoxyphenyl)-1-(tert-butyl)pyrrole.

b) A mixture of 2-amino-3-cyano-4-(4-phenoxyphenyl)-1-(tert-butyl)pyrrole (1.9 g), formamide (30 ml) and 4-dimethylaminopyridine (10 mg) was heated at 180°C for 6 hours. The mixture was cooled to ambient temperature and water was added to precipitate a dark solid. The solid was collected by filtration, washed with water, then boiled up in ethanol and the insoluble material collected by hot filtration and dried. The solid was purified by preparative HPLC on a silica column using dichloromethane/propan-2-ol/ethanol, 98:1:1 as the mobile phase to give 7-tert-butyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-

ylamine (4-amino-5-(4-phenoxyphenyl)-7-(tert-butyl)pyrrolo[2,3-d]pyrimidine), m.p. 157-158°C. ¹H NMR (d₆ DMSO) δ 8.15 (1H,s), 7.50-7.35 (4H,m), 7.30 (1H,s), 7.15 (1H,t), 7.10 (4H,m), 6.05 (2H,brs), 1.75 (9H,s).

- 5 c) A mixture of 4-amino-5-(4-phenoxyphenyl)-7-(tert-butyl)pyrrolo[2,3-d]-pyrimidine (5.8 g), glacial acetic acid (55 ml) and hydrobromic acid (55 ml of a 48% solution) was boiled under reflux for 18 hours under nitrogen. The mixture was allowed to cool and a solid was collected by filtration. This solid was washed with methanol and then with ether to give 4-amino-5-(4-
10 phenoxyphenyl)-7H-pyrrolo[2,3-d]-pyrimidine hydrobromide, m.p. 288-292°C. The hydrobromide salt was converted into the free base by warming with dilute sodium hydroxide solution (100 ml of 5% w/v solution) and ethanol (60 ml) with stirring and removing the ethanol by distillation. The mixture was cooled and the solid was collected by filtration and washed well with water to give 5-(4-
15 phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, m.p. 272°C.

Example 168: 7-cyclopentanesulphonyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

- Sodium hydride (0.132 g of a 60% dispersion in mineral oil) was added to a
20 solution of 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (1.0 g) in dry dimethylformamide (30 ml) with stirring under nitrogen. The mixture was stirred for 30 minutes and then cyclopentanesulphonyl chloride (0.558 g, prepared as described in J.O.C.1952, 17, 1529-1533) in dry dimethylformamide (5 ml) was added dropwise. The mixture was allowed to stand for 72 hours and then evaporated
25 under vacuum. The residue was triturated with water and filtered to give a solid which was washed well with water, then stirred with ethyl acetate then filtered. The filtrate was purified by flash column chromatography on silica using ethyl acetate as the mobile phase. Appropriate fractions were collected and evaporated to give 7-cyclopentanesulphonyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-
30 ylamine, m.p. 188-188.5°C.

Example 169: 5-(4-phenoxyphenyl)-7-(8-phthalimidooctyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

Sodium hydride (120 mg of a 60% dispersion in mineral oil) was added to a
5 solution of 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (906 mg) in
dry dimethylformamide (30 ml) with stirring under nitrogen. The mixture was
stirred for 30 minutes under nitrogen and then N-(8-bromooctyl)phthalimide (1.4 g)
in dimethyl-formamide (5 ml) was added. The mixture was stirred at ambient
temperature for 18 hours under nitrogen and then partitioned between water and
10 ethyl acetate. The ethyl acetate layer was separated and purified by flash column
chromatography using ethyl acetate as the mobile phase to give 5-(4-
phenoxyphenyl)-7-(8-phthalimidooctyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine,
m.p. 85-86°C.

15 Example 170: 7-(8-aminooctyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-
4-ylamine dihydrochloride dihydrate

A mixture of 5-(4-phenoxyphenyl)-7-(8-phthalimidooctyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-ylamine (1.0 g), hydrazine hydrate (1.0 ml) and ethanol (40 ml) was
boiled under reflux for 2 hours with the exclusion of carbon dioxide. The mixture
20 was cooled for 18 hours and a solid which precipitated was collected by filtration
and discarded. The filtrate was evaporated under reduced pressure and the residue
was dissolved in ethyl acetate, dried and then treated with a solution of concentrated
hydrochloric acid in isopropanol dropwise until no further precipitation occurred.
The mixture was left to stand overnight, then supernatant liquid was decanted off
25 and the semi-solid residue was triturated with ethyl acetate to give 7-(8-aminooctyl)-
5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine dihydrochloride
dihydrate, m.p 120°C.

Example 171: N-{2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-
30 yl]ethyl}phthalimide

In a similar manner to Example 468, but with additional heating at 90°C for 3 hours, 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine was reacted with 2-bromoethylphthalimide to give N-{2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]ethyl}phthalimide, m.p. 111-112°C.

5

Example 172: 7-(2-aminoethyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine hydrochloride

In a similar manner to Example 469, the product from the previous example was treated with hydrazine hydrate to give 7-(2-aminoethyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine hydrochloride, m.p. 284-285°C.

10

Example 173: 7-isobutyryl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

Isobutyryl chloride (1.8 g) was added dropwise to a mixture of 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (4.32 g), dry dimethylformamide (200 ml) and dry pyridine (2 ml) with stirring under nitrogen at 20°C. The mixture was stirred at ambient temperature for 1 hour and evaporated under vacuum. The residue was partitioned between water and ethyl acetate. The ethyl acetate was separated, dried and evaporated and the residue obtained was recrystallised from toluene to give 7-isobutyryl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, m.p. 160.5-161°C.

15

20

Example 174: 5-(4-phenoxyphenyl)-7-(1,4-dioxaspiro[4,5]decan-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

Sodium hydride (0.26 g of a 60% dispersion in mineral oil) was added to a mixture of 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (1.94 g) in dimethylformamide (50 ml) at ambient temperature with stirring. The mixture was stirred until the evolution of hydrogen ceased and then 8-tosyloxy-1,4-dioxaspiro[4,5] decane (2.0 g, prepared as described in US 4,360,531 from 1,4-dioxaspiro[4,5]decan-8-one, (which was prepared according to J. Med. Chem. 1992,

25

2246)) was added. The mixture was heated at 120°C for 5 hours under nitrogen, cooled to ambient temperature, quenched with water and extracted with ethyl acetate to give a residue which was purified by flash column chromatography on silica using ethyl acetate followed by ethyl acetate containing increasing amounts of methanol up to 6% to give 5-(4-phenoxyphenyl)-7-(1,4-dioxaspiro[4,5]decan-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, m.p. 193-194°C..

Example 175: 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanone

10 The product from the previous example (500 mg), acetone (20 ml) and 3M hydrochloric acid (10 ml) was stirred under nitrogen at ambient temperature for 20 minutes. The mixture was then heated at 60°C for 1 hour and then the acetone was removed under reduced pressure. The residue was basified with aqueous 5M sodium hydroxide solution and then extracted with ethyl acetate to give a solid which was
15 trituated with diethyl ether and filtered to give 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanone, m.p. 252-254°C.

Example 176 and 177: cis-5-(4-phenoxyphenyl)-7-(4-morpholinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, and trans-5-(4-phenoxyphenyl)-7-(4-morpholinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine
20

 Sodium triacetoxyborohydride (42 mg) and glacial acetic acid (18 mg) were added to the product from the previous example (120 mg) and morpholine (31 mg) in 1,2-dichloroethane. The mixture was stirred at 40°C for 2 hours and then a further portion of morpholine (0.15 g) and sodium triacetoxyborohydride (0.21 g) were
25 added. The mixture was stirred at ambient temperature for 20 hours then quenched with saturated aqueous bicarbonate solution. The mixture was filtered through an EMPORE® cartridge and the filtrate was extracted with 3M hydrochloric acid. The acidic extracts were basified with 5M sodium hydroxide solution and extracted with dichloromethane to give a residue which was purified by chromatography on silica
30 to give cis-5-(4-phenoxyphenyl)-7-(4-morpholinocyclohex-1-yl)-7H-pyrrolo[2,3-

d]pyrimidin-4-ylamine, and trans-5-(4-phenoxyphenyl)-7-(4-morpholinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine.

Examples 178 and 179: cis-7-(4-N-ethoxycarbonyl)piperazin-1-ylcyclohexyl)-5-(4-phenoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine and trans-7-(4-N-ethoxycarbonyl)-piperazin-1-ylcyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

In a similar manner to the previous Example, 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanone (0.4 g from 1.0 g of 40% pure material) and 1-ethoxycarbonyl-piperidine (158 mg) were reacted together in the presence of sodium triacetoxyborohydride (296 mg) in dichloromethane (15 ml) containing glacial acetic acid (60 mg) to give after workup and chromatography cis-7-(4-N-ethoxycarbonyl)piperazin-1-ylcyclohexyl)-5-(4-phenoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine and trans-7-(4-N-ethoxycarbonyl)-piperazin-1-ylcyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine.

Example 180: 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]pyridine-3-carbonitrile

5-(4-Phenoxyphenyl)-7H-pyrrolo[2,3-d]-pyrimidin-4-ylamine (906 mg) was reacted with 2-chloronicotinonitrile (510 mg) in the presence of sodium hydride (150 mg) in dimethylformamide (30 ml) at 100°C for 5 hours to give 2-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]pyridine-3-carbonitrile, m.p. 242-242.5°C, after workup.

Example 181: 7-[3-(aminomethyl)pyrid-2-yl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]-pyrimidin-4-ylamine dimaleate

The product from the previous example (468 mg), ethanol saturated with ammonia (200 ml) and Raney® nickel (2 ml) was shaken under hydrogen at a pressure of 26 bar at 80°C for 6 hours and then left standing at ambient temperature

for 68 hours. The mixture was filtered and the residue was washed well with ethanol. The filtrate was evaporated under reduced pressure and the residue was taken up in ethyl acetate and filtered. Maleic acid (135 mg) dissolved in ethyl acetate (20 ml) was added in portions to the filtrate until no further precipitation
5 occurred. The mixture was warmed and decanted from a small residual amount of gum. The gum was further heated with ethyl acetate and decanted. The combined ethyl acetate extracts were cooled and the solid which precipitated was collected by filtration to give 7-[3-(aminomethyl)pyrid-2-yl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]-pyrimidin-4-ylamine dimaleate, m.p. 131-134°C.

10

Example 182: 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-8-methyl-8-azabicyclo[3.2.1]octane

Sodium hydride (168 mg, of a 60% dispersion in mineral oil) was added to a mixture of 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (770 mg, in
15 dimethylformamide (30 ml). 3-Mesyloxy-8-methyl-8-azabicyclo[3.2.1]octane (900 mg, prepared as described in J.A.C.S. 1958, 80, 4679) in dimethylformamide (10 ml) was added under nitrogen with stirring. The mixture was warmed at 75°C for 5 hours (and left standing at ambient temperature for 7 days). The solvent was removed under reduced pressure. Water was added to the residue and the mixture
20 was extracted with ethyl acetate to give a residue which was purified by flash column chromatography on silica using ethyl acetate/methanol (50:50) as the mobile phase to remove starting material and then a mixture of ethyl acetate/methanol/triethylamine (5:5:1) as the mobile phase to elute the product. Appropriate fractions were combined and evaporated to give a solid which was triturated with ether and
25 filtered to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-8-methyl-8-azabicyclo[3.2.1]octane, m.p. 238-250°C.

Examples 183 and 184: cis-7-(N-methylhomopiperazin-1-ylcyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine and trans 7-(N-methylhomopiperazin-1-ylcyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine
30

In a similar manner to Examples 176 and 177, 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanone (0.4 g from 1.0 g of a 40% pure material), N-methylhomopiperazine (114 mg), sodium triacetoxyborohydride (296 mg), glacial acetic acid (60 mg) and 1,2-dichloroethane (15 ml) were reacted together. After filtration, the filtrate was evaporated and the residue was purified by chromatography on silica to give cis-7-(N-methylhomopiperazin-1-ylcyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine and trans 7-(N-methylhomopiperazin-1-ylcyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine.

Examples 185 and 186: cis 7-(N-methylpiperazin-1-ylcyclohexyl)-5-(4-phenoxyphenyl)-7-pyrrolo[2,3-d]pyrimidin-4-ylamine and trans 7-(N-methylpiperazin-1-ylcyclohexyl)-5-(4-phenoxyphenyl)-7-pyrrolo[2,3-d]pyrimidin-4-ylamine

In a similar manner to the previous Example, N-methylpiperazine (100 mg) was reacted with the same amounts of cyclohexanone derivative and other reagents to give cis 7-(N-methylpiperazin-1-ylcyclohexyl)-5-(4-phenoxyphenyl)-7-pyrrolo[2,3-d]pyrimidin-4-ylamine and trans 7-(N-methylpiperazin-1-ylcyclohexyl)-5-(4-phenoxyphenyl)-7-pyrrolo[2,3-d]pyrimidin-4-ylamine.

Example 187: 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-cyclopentan-1-one

A mixture of 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-cyclopentan-1-ol (100 mg), activated manganese dioxide (500 mg) and dichloromethane (100 ml) was stirred at ambient temperature for 18 hours to give, after filtration, a solution of 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-cyclopentan-1-one in dichloromethane which was used in the next Example.

Example 188: cis-7-(3-morpholinocyclopent-1-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine and trans-7-(3-morpholinocyclopent-1-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

- Morpholine (45 mg) was added to the solution obtained in the previous
- 5 Example followed by sodium triacetoxyborohydride (151 mg) and glacial acetic acid (47 mg). The mixture was stirred at ambient temperature under nitrogen for 18 hours during which time the dichloromethane evaporated. Tetrahydrofuran (100 ml) was added and the mixture was stirred for a further 8 hours. The mixture was worked up to give cis-7-(3-morpholinocyclopent-1-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine and trans-7-(3-morpholinocyclopent-1-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine.
- 10

Example 189: 3-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentyl N-(2-morpholinoethyl)-carbamate hydrochloride

15

- a) To a solution of 3-(4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentanol (20 mg) in dichloromethane (1 ml) at 0°C was added N-methylmorpholine (7 ml) and the mixture stirred for 20 minutes. The cooling bath was removed and 4-nitrophenylchloroformate (12.5 mg) was added and the
- 20 resulting mixture stirred overnight at ambient temperature. The mixture was diluted with dichloromethane, washed with water, saturated aqueous sodium bicarbonate solution and brine. The organic solution was dried over magnesium sulphate and evaporated to give crude product.
- b) The crude product from a) in dichloromethane (2 ml) was added to 2-
- 25 morpholinoethylamine (0.2 ml) and the mixture stirred overnight at ambient temperature. The mixture was diluted with ethyl acetate and washed with water and brine. The organics were dried, filtered and evaporated to give a crude product which was purified by preparative HPLC to give 3-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentyl N-(2-
- 30 morpholinoethyl)carbamate.

-158-

- c) The product from b) was dissolved in ethyl acetate (2 ml) and hydrogen chloride gas was bubbled through the solution for 2 minutes. A precipitate formed and stirring was continued for a further 10 minutes. The solvent was evaporated and water added to dissolve the solid. Lyophilisation gave 3-(4-amino-5-(4-
5 phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentyl N-(2-morpholinoethyl)-carbamate hydrochloride as a solid.

Example 190: 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl 2-aminoacetate hydrochloride

10

- a) 3-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentanol (50 mg, 0.129 mmol) and N-tert-butoxycarbonyl glycine (34 mg, 0.194 mmol) was mixed in N,N-dimethylformamide (1 ml). 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (31 mg, 0.155 mmol)
15 and 4-dimethylamino pyridine (16 mg, 0.129 mmol) was added. The resulting mixture was stirred under nitrogen at ambient temperature for 24 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic extracts were washed with brine, dried (MgSO₄), filtered and evaporated. The solid was purified by flash column chromatography on silica
20 using ethyl acetate as the mobile phase to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl 2-[(tert-butoxycarbonyl)amino]acetate. The structure was confirmed by ¹H NMR.
- b) 3-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl
25 2-[(tert-butoxycarbonyl)amino]acetate (39 mg, 0.072 mmol) was dissolved in ethyl acetate (2.5 ml). Hydrogen chloride gas was passed through for 1 minute. The flask was capped and the solution stirred for additional 30 minutes. Diethyl ether was added and precipitate formed. The solid was collected by filtration to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl 2-aminoacetate hydrochloride. The structure was confirmed by ¹H
30

NMR and LC/MS ($MH^+ = 444$).

Example 191: 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl (2S)-2-amino-3-methylbutanoate hydrochloride

5

a) (2S)-1-[(tert-Butoxycarbonyl)amino]-2-methylbutanoic 2,5-dioxo-2,5-dihydro-1H-1-pyrrolicarboxylic anhydride (114 mg, 0.362 mmol) was added to a solution of 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentanol (66 mg, 0.171 mmol) in dichloromethane (1 ml). The resulting mixture was stirred under nitrogen at ambient temperature for 24 hours. The reaction mixture was diluted with ethyl acetate and washed, dried ($MgSO_4$), filtered and evaporated. The solid was purified by flash column chromatography on silica using ethyl acetate as the mobile phase to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutanoate. The structure was confirmed by 1H NMR and LC/MS ($MH^+ = 586$).

b) 3-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutanoate (35 mg, 0.060 mmol) was dissolved in ethyl acetate (2.5 ml). Hydrogen chloride gas was passed through for 5 minutes. The flask was capped and the solution stirred for additional 30 minutes. Diethyl ether was added and precipitate formed. The solid was collected by filtration to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl (2S)-2-amino-3-methylbutanoate hydrochloride. The structure was confirmed by 1H NMR and LC/MS ($MH^+ = 486$).

Example 192: 3-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentyl N-(2-morpholinoethyl)carbamate hydrochloride

- 5 a) N-Methylmorpholine (0.007 ml, 0.062 mmol) was added dropwise to solution of 4-nitrophenyl chloroformate (12.5 mg, 0.062 mmol) in dichloromethane (1 ml) with stirring under nitrogen at 0°C. After 20 minutes, the ice-water bath was removed and the mixture was allowed to warm up to ambient temperature. 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentanol (20 mg, 0.052 mmol) was added to the mixture and the resulting solution was stirred
10 for 24 hours. The reaction mixture was diluted with dichloromethane and washed with water, saturated sodium bicarbonate, and brine. The organic layer was dried (MgSO₄), filtered and evaporated to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl (4-nitrophenyl) carbonate. The structure was confirmed by ¹H NMR.
15
- b) 3-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl (4-nitrophenyl) carbonate (0.052 mmol) in dichloromethane (1 ml) was added to 2-morpholinoethylamine (0.2 ml). The resulting mixture was stirred under nitrogen at ambient temperature for 24 hours. The reaction mixture was diluted
20 with ethyl acetate and washed, dried (MgSO₄), filtered and evaporated. The solid was purified by preparative HPLC to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl N-(2-morpholinoethyl)carbamate. The structure was confirmed by ¹H NMR and LC/MS (MH⁺ = 543).
25
- c) 3-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl N-(2-morpholinoethyl)carbamate (10 mg, 0.018 mmol) was dissolved in ethyl acetate (2.5 ml). Hydrogen chloride gas was passed through for 2 minutes, and a precipitate formed. The flask was capped and the solution stirred for additional
30 10 minutes. The solid was collected by filtration to give 3-(4-amino-5-(4-

-161-

phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentyl N-(2-morpholinoethyl)carbamate hydrochloride. The structure was confirmed by ¹H NMR and LC/MS (MH⁺ = 543).

5 Preparation of Starting Materials

- a) Tert-butylamine (15 ml) was added with stirring to a solution of 2-bromo-4'-phenoxyacetophenone (12.7 g, prepared by bromination of 4'-phenoxyacetophenone according to Tetrahedron Letters, 1993, 34, 3177) in propan-2-ol and the mixture heated at 80°C for 3 hours. The mixture was cooled to 0°C and concentrated hydrochloric acid (10 ml) added. The suspension was stirred at ambient temperature for 18 hours and the solid collected by filtration to give 4'-phenoxy-2-(tert-butylamino)acetophenone hydrochloride (3.75 g), m.p. 210-212°C.
- b) (1) 4'-Phenoxy-2-(tert-butylamino)acetophenone hydrochloride (3.75 g) was added in one portion to sodium ethoxide (prepared by dissolving sodium (93 mg) in ethanol (50 ml)) and the mixture was stirred at 40°C for 30 minutes under nitrogen.
- (2) In a separate flask sodium (331 mg) was dissolved in ethanol (50 ml) and malononitrile (858 mg) was added. The solution was stirred at ambient temperature for 5 minutes and then to this solution was added the solution of 4'-phenoxy-2-(tert-butylamino)acetophenone obtained in part (1) in one portion excluding the precipitated sodium chloride. The resultant mixture was heated at 50°C for 3 hours and then at 80°C for 2 hours. The solvent was removed under reduced pressure and the resultant oil was partitioned between water and ethyl acetate. The organic phase was separated, dried and evaporated to give a black solid. This solid was dissolved in hot ethanol and triturated with water, filtered and dried to give 2-amino-3-cyano-4-(4-

-162-

phenoxyphenyl)-1-(tert-butyl)pyrrole.

- 5 c) A mixture of 2-amino-3-cyano-4-(4-phenoxyphenyl)-1-(tert-butyl)pyrrole (1.9 g), formamide (30 ml) and 4-dimethylaminopyridine (10 mg) was heated at 180°C for 6 hours. The mixture was cooled to ambient temperature and water was added to precipitate a dark solid. The solid was collected by filtration, washed with water, then boiled up in ethanol and the insoluble material collected by hot filtration and dried. The solid was purified by preparative HPLC on a silica column using dichloromethane/propan-2-ol/ ethanol, 98:1:1 as the mobile
10 phase to give 7-tert-butyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (4-amino-5-(4-phenoxyphenyl)-7-(tert-butyl)pyrrolo[2,3-d]pyrimidine), m.p. 157-158°C. ¹H NMR (d₆ DMSO) δ 8.15 (1H,s), 7.50-7.35 (4H,m), 7.30 (1H,s), 7.15 (1H,t), 7.10 (4H,m), 6.05 (2H,brs), 1.75 (9H,s).
- 15 d) A mixture of 4-amino-5-(4-phenoxyphenyl)-7-(tert-butyl)pyrrolo[2,3-d]-pyrimidine (5.8 g), glacial acetic acid (55 ml) and hydrobromic acid (55 ml of a 48% solution) was boiled under reflux for 18 hours under nitrogen. The mixture was allowed to cool and a solid was collected by filtration. This solid was washed with methanol and then with ether to give 4-amino-5-(4-
20 phenoxyphenyl)-7H-pyrrolo[2,3-d]-pyrimidine hydrobromide, m.p. 288-292°C. The hydrobromide salt was converted into the free base by warming with dilute sodium hydroxide solution (100 ml of 5% w/v solution) and ethanol (60 ml) with stirring and removing the ethanol by distillation. The mixture was cooled and the solid was collected by filtration and washed well with water to give 5-(4-
25 phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine.
- e) A mixture of 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (600 mg) and tetrakis(triphenylphosphine) palladium (40 ml) and dry dimethyl sulphoxide (30 ml) was stirred under nitrogen in an ice/water bath and then a
30 solution of cyclopentadiene monoepoxide (200 mg) in tetrahydrofuran (10 ml)

-163-

- was added via syringe under nitrogen at 0°C. The mixture was stirred at ambient temperature (with exclusion of light) for 66 hours and then the tetrahydrofuran was removed under reduced pressure and water was added to the residue. The mixture was allowed to stand for 18 hours and then extracted with ethyl acetate to give a residue which was purified by flash column chromatography on silica using ethyl acetate/industrial methylated spirit (9:1) as the mobile phase to give 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-cyclopent-2-enol, as an oil. The structure was confirmed by ¹Hnmr and mass spectra.
- 5
- 10 f) 4-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopent-2-enol (110 mg) was hydrogenated in ethanol (20 ml) with gaseous hydrogen at atmospheric pressure using 10% palladium on charcoal (50 mg) as the catalyst. The catalyst was removed by filtration and the filtrate was evaporated to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentanol, as an oil. The structure was confirmed by ¹H nmr and mass spectra.
- 15

Example 193: Cis-5-(4-phenoxyphenyl)-7-(4-pyrrolidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

Trans-5-(4-phenoxyphenyl)-7-(4-pyrrolidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

20

To a stirred suspension of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidinyl-7-yl]cyclohexanone (2.34 g, 5.9 mmol) in 1,2 dichloroethane (250 mL) was added, under an atmosphere of nitrogen, pyrrolidine (1.25 g, 17.6 mmol) and glacial acetic acid (1.00 mL, 17.6 mmol), and the resultant mixture stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (1.87 g, 8.8 mmol) was added in one portion, and the resultant mixture stirred for 70 hours. The mixture was extracted with 2M aqueous hydrochloric acid (2 x 200 mL). The combined extracts were washed with dichloromethane (300 mL), made basic with 12.5M aqueous sodium hydroxide solution, and extracted with dichloromethane (3 x 200 mL). The combined extracts were dried over sodium sulphate, and purified by

25

30

chromatography with a Biotage 40S column using ethyl acetate / triethylamine (95:5) and ethyl acetate / triethylamine / methanol (85:10:5) as a mobile phase to yield Cis-5-(4-phenoxyphenyl)-7-(4-pyrrolidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine as an off-white solid (0.65 g, 1.4 mmol), melting point 101 – 104 deg.C., LC/MS Hypersil BDS c18 (100 x 2.1 mm) 0.1M ammoniumacetate/acetonitrile, 10-100% acetonitrile in 8 min.): MH^+ 454 t_r = 3.56 minutes and Trans-5-(4-phenoxyphenyl)-7-(4-pyrrolidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine as an off-white solid (0.93 g, 2.1 mmol), melting point 183 – 185 deg.C, LC/MS (Hypersil BDS c18 (100 x 2.1 mm) 0.1M ammoniumacetate/acetonitrile, 10-100% acetonitrile in 8 min.): MH^+ 454 , t_r = 3.68 minutes

Example 194: Cis-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine hydrochloride
Trans-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

To a stirred suspension of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanone (2.34 g, 5.9 mmol) in 1,2 dichloroethane (250 mL) was added, under an atmosphere of nitrogen, piperidine (1.50 g, 17.6 mmol) and glacial acetic acid (1.00 mL, 17.6 mmol), and the resultant mixture stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (1.87 g, 8.8 mmol) was added in one portion, and the resultant mixture stirred for 70 hours. The mixture was extracted with 2M aqueous hydrochloric acid (2 x 200 mL). The combined extracts were washed with dichloromethane (300 mL), made basic with 12.5M aqueous sodium hydroxide solution, and extracted with dichloromethane (3 x 200 mL). The combined extracts were dried over sodium sulphate, and purified by chromatography with a Biotage 40S column using ethyl acetate / triethylamine (95:5) as a mobile phase to yield Cis-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (0.23 g) as a clear oil., LC/MS :ypersil BDS c18 (100 x 2.1 mm) 0.1M ammoniumacetate/acetonitrile, 10-100% acetonitrile in 8 min.) MH^+ 468 t_r = 3.67 minutes and Trans-5-(4-phenoxyphenyl)-7-(4-

piperidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine as an off-white solid (193 mg, 0.4 mmol), melting point 192 - 195 deg.C, LC/MS: Hypersil BDS c18 (100 x 2.1 mm) 0.1M ammoniumacetate/acetonitrile, 10-100% acetonitrile in 8 min.)MH⁺ 468 t_r = 3.71 minutes

5

Example 195: Cis-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine was dissolved in ethyl acetate (50 mL), diluted with diethyl ether (50 mL) and treated with a 1M solution of hydrogen chloride in diethyl ether until no further precipitation occurred. The resultant solid was collected
10 and re-crystallised from absolute ethanol to give Cis-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohex-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine hydrochloride as a colourless solid (75 mg, 0.2 mmol) melting point 185 – 189 deg.C.

Example 196: Trans-7-(4-dimethylaminocyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine
15

Cis-7-(4-dimethylaminocyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

To a stirred solution of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanone (3.24 g, 8.1 mmol) in dichloromethane (1000 mL)
20 was added, under an atmosphere of nitrogen, N-methylpiperazine (1.20 g, 12.0 mmol) and glacial acetic acid (0.69 mL, 12.0 mmol), and the resultant solution stirred at room temperature for 10 minutes. Sodium triacetoxyborohydride (1.70 g, 8.0 mmol) was added in one portion, and the resultant solution stirred for 6 hours. The additions were repeated on the same scale and the resultant solution stirred for
25 70 hours. The solution was extracted with 2M aqueous hydrochloric acid (2 x 300 mL). The combined extracts were washed with dichloromethane (300 mL), made basic with .880 aqueous ammonia solution, and extracted with ethyl acetate (3 x 250 mL). The combined extracts were washed with saturated aqueous sodium chloride solution, dried over sodium sulphate, and purified by chromatography with a
30 Biotage 40M column using ethyl acetate / methanol / triethylamine (8:1:1) as a mobile phase to yield Cis-7-(4-dimethylaminocyclohexyl)-5-(4-phenoxyphenyl)-

7H-pyrrolo[2,3-d]pyrimidin-4-ylamine as an off-white solid (220 mg, 0.5 mmol.) melting point 180 – 182 deg.C, LC/MS: Hypersil BDS c18 (100 x 2.1 mm) 0.1M ammoniumacetate/acetonitrile, 10-100% acetonitrile in 8 min.) MH^+ 428 t_r = 3.43 minutes

- 5 The column was flushed with ethyl acetate / methanol / triethylamine (4:1:1, 500 mL), and the solvent removed under reduced pressure. The residue was dissolved in dichloromethane (200 mL) and purified by chromatography with a Biotage 40M column using dichloromethane/methanol (9:1 to 7:3) to yield Trans-7-(4-dimethylamino-cyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine as an off-white solid (320 mg, 0.75 mmol) melting point 207.5 – 210 deg. C, LC/MS: Hypersil BDS c18 (100 x 2.1 mm) 0.1M ammoniumacetate/acetonitrile, 10-100% acetonitrile in 8 min.) MH^+ 428 t_r = 3.48 minutes

R - (+) - 4 - [4-amino-5-(4-phenoxyphenyl)-7- (3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidine.

15

Example 197: 4 - {(S) - tetrahydrofuran-3-yl} toluenesulphonate

- To a solution of (S)-3-hydroxytetrahydrofuran (2.0 g, 23 mmol) in pyridine (40 ml) at 0°C was added tosylchloride portionwise (4.8 g, 25 mmol). The solution was stirred at 0°C for 1 hr and then at room temperature overnight. The pyridine was
20 evaporated in vacuo and the residue was partitioned between EtOAc and saturated aqueous citric acid (200 ml each). The aqueous layer was extracted with EtOAc (2 x 200 ml) and the combined organics were dried (sodium sulphate), filtered and evaporated to leave an oil (4.5 g, 85%). 1H NMR ($CDCl_3$, 250 MHz): 7.78 (2H, d), 7.35 (2H, d), 5.12 (1H, m), 3.76-3.93 (4H, m), 2.45 (3H, s), 2.01-2.20 (2H, m).

- 25 To a stirred suspension of 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (4.83 g, 16 mmol) in N,N-dimethylformamide (80 mL), under an atmosphere of nitrogen, was added 60% sodium hydride in mineral oil (0.75 g, 19 mmol), and the mixture stirred at room temperature for 30 minutes. The resultant dark solution was treated with a solution of 4 - {(S) - tetrahydrofuran-3-yl} toluenesulphonate (4.20 g, 18 mmol) in N,N-dimethylformamide (20 mL) in 2
30 mL aliquots. The resultant solution was stirred at room temperature for 30 minutes,

then at 95 deg.C. for 18 hours. The solution was allowed to cool to ambient temperature, then poured onto ice/water (200 mL). The aqueous was extracted with ethyl acetate (3 x 200 mL). The combined organic extracts were washed with water (4 x 150 mL), dried over sodium sulphate, and the solvent was removed under reduced pressure. The residue was warmed with dichloromethane (1000 mL) until a solution was obtained, cooled to ambient temperature, and purified by chromatography with a Biotage 40M column using ethyl acetate/ triethylamine (95:5), then ethyl acetate / triethylamine / methanol (90:5:5) as a mobile phase, to yield R - (+) - 4 -[4-amino-5-(4-phenoxyphenyl)-7- (3-tetrahydrofuryl)-7H-pyrrolo[2,3-d]pyrimidine as an off-white solid (4.35 g, 12 mmol) melting point 165-166 deg. C, LC/MS : Hypersil BDS c18 (100 x 2.1 mm) 0.1M ammoniumacetate/acetonitrile, 10-100% acetonitrile in 8 min.) MH^+ 373 t_r = 4.44 minutes. $[\alpha]_D + 20.5 \pm 0.6$ (dichloromethane, 22.6 deg.C.)

Example 198: 5-(4-phenoxyphenyl)-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine
N-tert-butoxycarbonylpiperidinol

To a solution of N-tert-butoxycarbonylpiperidone (10.0 g, 50 mmol) in MeOH (100 ml) at 0°C was added sodium borohydride (1.9 g, 50 mmol) portionwise. Stir at 0°C for 1 hr and then at room temperature for 20 hr. Quench with 2N NaOH (20 ml), evaporate solvent and partition residue between ethylacetate and water (100 ml each). Extract the aqueous layer with ethylacetate (3 x 100ml) and wash the combined organic layers with brine and water (1 x 100 ml each). Dry (Na_2SO_4), filter and concentrate to leave N-tert-butoxycarbonylpiperidinol as a colourless oil (10.5 g, 100%). R_f in 20% EtOAc / hexane = 0.05 ($KMnO_4$ dip). IR (thin film) : 3428, 2939, 1693 cm^{-1}

Example 199: tert-butyl 4-[(4-methylphenyl)sulfonyl]oxy-1-piperidinecarboxylate

To a solution of N-tert-butoxycarbonylpiperidinol (10.5 g, 0.052 mol) in pyridine (150 ml) at 0°C under nitrogen was added tosylchloride (9.94 g, 0.052 mol)

portionwise. Stir at 0°C for 2 hr. Warm to room temperature and stir at room temperature overnight. Evaporate the solvent and partition between citric acid solution (1M, 100 ml) and ethylacetate (200 ml). Extract acidic layer with ethylacetate (1 x 100 ml) and wash combined organics with citric acid solution (1M, 5 2 x 100 ml), brine (100 ml) and water (100 ml). Dry (Na₂SO₄), filter and evaporate to leave an oil which was purified by flash column chromatography using 10% EtOAc / cyclohexane then 15% EtOAc / cyclohexane to give in F 30-68 tert-butyl 4-[(4-methylphenyl)sulfonyl]oxy-1-piperidinecarboxylate as a white solid (11.0 g, 60%) R_f in 20% EtOAc / cyclohexane = 0.17 ¹H NMR (CDCl₃, 250 MHz): δ 7.79 10 (2H, d), 7.34 (2H, d), 4.67 (1H, m), 3.58 (2H, m), 3.27 (2H, m), 2.45 (3H, s), 1.59 – 1.83 (4H, m), 1.43 (9H, s)

Example 200: tert-butyl 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-piperidinecarboxylate

15 To a solution of 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (2.0 g, 6.6 mmol) in dry DMF (100 ml) under nitrogen at 0°C was added NaH (0.264 g, 60% dispersion, 6.6 mmol) and the reaction mixture warmed to room temperature and stirred for 1hr. Tert-butyl 4-[(4-methylphenyl)sulfonyl]oxy-1-piperidinecarboxylate (2.34 g, 6.6 mmol) was added and the resulting solution 20 heated at 95°C for 72 hr. The reaction was quenched by careful addition of water (150 ml). Extract with EtOAc (3 x 100 ml) and wash with water (4 x 100 ml) and brine (2 x 100 ml). The organic solution was dried (Na₂SO₄), filtered and evaporated to leave a solid which was adsorbed onto silica and purified by flash silica gel column chromatography using EtOAc then 5% MeOH/EtOAc as eluent to give in F 25 13-22 tert-butyl 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-piperidinecarboxylate (1.0 g, 31%) as a white solid, m.pt. 168.5-169.5°C. R_f in 10% EtOAc/MeOH = 0.4. ¹H NMR (d₆ DMSO, 250 MHz): δ 8.14 (1H, s), 7.38-7.49 (5H, m), 7.07-7.23 (5H, m), 6.14 (2H, bs), 4.76 (1H, m), 4.11 (2H, m), 2.93 (2H, m), 1.92-2.02 (4H, m), 1.43 (9H, s). Mass spec. C₂₈H₃₁O₃N₅ (485.2430).IR 30 (KBr disc): 3059, 1695, 1588, 1235 cm⁻¹

Example 201: 5-(4-phenoxyphenyl)-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

To a solution of tert-butyl 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-piperidinecarboxylate (0.69 g, 1.4 mmol) in dry CH₂Cl₂ (25 ml) at 0°C was added TFA (5 ml). The solution was stirred at room temperature for 20 hr and the solvent evaporated. NaOH solution (5N, 10 ml) was added and the resulting slurry was extracted with EtOAc (3 x 50 ml). Wash with brine (1 x 50 ml). Dry, filter and concentrate to leave a solid which was triturated with diethylether and filtered to leave 5-(4-phenoxyphenyl)-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (433258) as a white solid (500 mg, 91%). M.pt 209-211°C. R_f in 1:1 EtOAc : MeOH = 0.1. . ¹H NMR (d₆ DMSO, 250 MHz) 8.13 (1H, s), 7.36-7.48 (4H, m), 7.29 (1H, s), 7.04-7.16 (5H, m), 5.80 (2H, bs), 4.64 (1H, m), 3.10 (2H, m), 2.80 (1H, bs), 2.67 (2H, m), 1.94 (4H, m). Mass spec. C₂₃H₂₃ON₃ (385.1902). IR (KBr disc) : 3278, 1620, 1585, 1490, 1245 cm⁻¹

Example 202: 5-(4-phenoxyphenyl)-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine dihydrochloride

To 5-(4-phenoxyphenyl)-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (433258) (200 mg) in EtOAc/MeOH (15 ml, 1:1) was added ether.HCl solution (1.0 M, 3 ml). The resulting white precipitate was filtered under a stream of nitrogen and dried in vacuo for 6 hr to leave 5-(4-phenoxyphenyl)-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine dihydrochloride (1.4 hydrate) as a white solid (120 mg), m.pt. 304°C (dec.). ¹H NMR (D₂O, 250 MHz) 8.48(1H, s), 7.69 (1H, s), 7.50-7.58 (4H, m), 7.18-7.34 (5H, m), 5.16 (1H, m), 3.81 (2H, d), 3.46 (2H, m), 2.49 (4H, m).). IR (KBr disc) : 3937, 1657. 1231 cm⁻¹

Example 203: tert-butyl 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-pyrrolidinecarboxylate

N-tert-butoxycarbonylpyrrolidin-3-ol

To a solution of pyrrolidin-3-ol (10.0 g, 0.11 mol) in dichloromethane (200 mL) was added triethylamine (22.2 g, 30.5 ml, 0.22 mol) followed by di-tert-butylidicarbonate (28.8 g, 0.13 mol) at 0°C. Warm to room temperature and stir at room temperature overnight. Quench with saturated aqueous citric acid (150 ml) and wash the organic layer with water, brine and water again (1 x 100 ml each). The organic layer was dried (sodium sulphate), filtered and evaporated to leave N-tert-butoxycarbonylpyrrolidin-3-ol (20.0g, 93% crude) as a golden oil.

Example 204: tert-butyl 3-[(4-methylphenyl)sulfonyl]oxy-1-pyrrolidinecarboxylate

To a solution of N-tert-butoxycarbonylpyrrolidin-3-ol (19.8 g, 0.106 mol) in pyridine (200 ml) at 0°C under nitrogen was added tosyl chloride (22.3 g, 0.117 mol) portionwise. Stir at 0°C for 2 hr, warm to room temperature and stir at room temperature overnight. The pyridine was evaporated in vacuo and the residue was partitioned between EtOAc and saturated aqueous citric acid (200 ml each). The aqueous layer was extracted with EtOAc (2 x 200 ml) and the combined organics were dried (sodium sulphate), filtered and evaporated to leave an oil which was purified by flash silica gel column chromatography using 10% EtOAc/cyclohexane as eluent to give in F40-85 an oil. The oil was dissolved in a small volume of cyclohexane/ diethylether (5:1, 50 ml), cooled and scratched with a spatula to induce crystallisation. The resulting solid was filtered to give tert-butyl 3-[(4-methylphenyl)sulfonyl]oxy-1-pyrrolidinecarboxylate (10.5 g, 29%) as a white solid.

R_f in EtOAc/cyclohexane = 0.13. ^1H NMR (CDCl_3 , 250 MHz): 7.79 (2H, d), 7.35 (2H, d), 5.04 (1H, m), 3.43 (4H, m), 2.46 (3H, s), 2.03-2.20 (2H, bm), 1.43 (9H, s)

To a solution of 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (2.0 g, 6.6 mmol) in dry DMF (120 ml) under nitrogen at 0°C was added NaH (0.264 g, 60% dispersion, 6.6 mmol) and then reaction mixture warmed to room

-171-

temperature and stirred for 1 hr. tert-butyl 3-[(4-methylphenyl)sulfonyl]oxy-1-pyrrolidinecarboxylate (2.25 g, 6.6 mmol) was added portionwise and the mixture heated at 95°C for 72 hr. Quench with water and extract with EtOAc (4 x 100 ml). Wash the combined organic solutions with water (4 x 100 ml) and brine (2 x 100 ml). The organics were dried (sodium sulphate), filtered and evaporated to leave a solid which was dissolved in EtOAc/MeOH and adsorbed onto silica. Purification using flash silica gel column chromatography with 5% MeOH/ EtOAc as eluent gave in F17-25 tert-butyl 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-pyrrolidinecarboxylate (1.0 g, 32%) as a white solid m.pt. 168-170°C. R_f in 9:1 EtOAc: MeOH = 0.46. ^1H NMR (d_6 DMSO, 250 MHz): 8.17 (1H, s), 7.38–7.50 (5H, m), 6.19 (2H, bs), 5.31 (1H, m), 3.77 (1H, m), 3.42–3.60 (3H, m), 2.38 (2H, m), 1.40 (9H, s). Mass spec. 471.2250 ($\text{C}_{27}\text{H}_{29}\text{O}_3\text{N}_5$) IR (KBr disc): 3130, 1683, 1585, 1404, 1245 cm^{-1}

Example 205: 5-(4-phenoxyphenyl)-7-(3-pyrrolidinyl) -7H-pyrrolo[2,3-d]pyrimidin-4-ylamine

To a solution of tert-butyl 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-pyrrolidinecarboxylate (0.8 g, 1.7 mmol) in dichloromethane (25 ml) at 0°C was added trifluoroacetic acid (5 ml). The reaction mixture was warmed to room temperature and stirred at room temperature for 20 hr. The solvent was evaporated and dilute NaOH added (5N, 10 ml). The resulting residue solution was extracted with EtOAc (3 x 50 ml) and the combined organics were washed with brine (1 x 75 ml). The organic solution was dried (sodium sulphate), filtered and evaporated in vacuo to leave 5-(4-phenoxyphenyl)-7-(3-pyrrolidinyl) -7H-pyrrolo[2,3-d]pyrimidin-4-ylamine as a white solid (0.5 g, 79%) m.pt. 182–184°C. R_f in 1:1 EtOAc : MeOH = 0.15. ^1H NMR (d_6 DMSO, 250 MHz): 8.14 (1H, s), 7.37–7.50 (5H, m), 7.05–7.18 (5H, m), 6.14 (2H, bs), 5.23 (1H, m), 3.09–3.27 (2H, m), 2.83–2.98 (2H, m), 2.19–2.33 (1H, m), 1.88–2.01 (1H, m). Mass spec. 371.1758 ($\text{C}_{22}\text{H}_{21}\text{ON}_5$). IR (KBr disc): 3106, 1585, 1489, 1232 cm^{-1}

Example 206: 5-(4-phenoxyphenyl)-7-(3-pyrrolidinyl) -7H-pyrrolo[2,3-d]pyrimidin-4-ylamine dihydrochloride

To a solution of 5-(4-phenoxyphenyl)-7-(3-pyrrolidinyl) -7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (200 mg) in EtOAc/MeOH (2:1, 20 ml) was added ether.HCl (1.0 M, 3 ml) and the resulting precipitate was filtered under nitrogen to give 5-(4-phenoxyphenyl)-7-(3-pyrrolidinyl) -7H-pyrrolo[2,3-d]pyrimidin-4-ylamine dihydrochloride (0.4 hydrate) as a white solid (190 mg) m.pt. 298°C (dec.). IR (KBr disc): 2909, 1658, 1249 cm^{-1}

10 Example 207: 7-perhydro-1-pyrroliziny-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3,d]pyrimidin-4-amine dihydrochloride salt

a) perhydro-1-pyrrolizinol

Prepared as described by Schnekenburger J, Briet E, Arch. Pharm. (Wienheim) 310, 152-160 (1977).

b) perhydro-1-pyrroliziny methanesulfonate

A mixture of perhydro-1-pyrrolizinol (0.5 g, 3.94 mmol) and triethylamine (0.60 g, 5.91 mmol) in dichloromethane (10 ml) was stirred at 0°C under an atmosphere of nitrogen. Methanesulfonyl chloride (0.68 g, 5.91 mmol) was added, then the mixture was allowed to warm to ambient temperature and stirred for 8 hours. Saturated aqueous ammonium chloride (10 ml), dichloromethane (25 ml) and saturated aqueous sodium bicarbonate (10 ml) were added. The organic layer was dried over magnesium sulfate filtered and the filtrate evaporated under reduced pressure to give a residue. Purification of the material by flash chromatography on silica gel using heptane/ethyl acetate (1:3) as an eluent yielded perhydro-1-pyrroliziny methanesulfonate (0.54 g): ^1H NMR (DMSO- d_6 , 400MHz) δ 4.96 (m, 1H), 3.61 (m, 1H), 2.9-3.3 (m, 6H), 2.35 (m, 1H), 1.55-2.25 (m, 6H).

c) 7-perhydro-1-pyrroliziny-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dihydrochloride salt

A mixture of 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (0.49g, 1.62 mmol) and 60% sodium hydride in oil (100 mg, 2.43 mmol) in DMF was stirred at ambient temperature for 15 minutes under an atmosphere of nitrogen. The mixture was heated at 100°C for 18 hours then cooled to ambient temperature. Additional 60% sodium hydride in oil (100 mg, 2.43 mmol) was added and heating continued for another 2 hours. The mixture was cooled to ambient temperature and the solvents removed under reduced pressure. The residue was partitioned between water (10 ml) and dichloromethane (30 ml). The organic layer was dried over magnesium sulfate, filtered and the solvent was removed from the filtrate under reduced pressure. The resulting residue was purified by preparative C-18 RP HPLC to give 150 mg of white solid which was dissolved in ethyl acetate (10 ml) and treated with 1 N hydrogen chloride in diethyl ether to give 7-perhydro-1-pyrroliziny-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dihydrochloride salt as a white solid: ¹H NMR (DMSO-d₆, 400MHz) δ 8.52 (s, 1H), 7.95 (s, 1H), 7.02-7.58 (m, 1H), 5.38 (m, 1H), 4.40 (m, 1H), 1.9-3.9 (m, 10H); (Hypersil HS C18, 5 μm, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r=7.62 min; MS: MH⁺ 412.

Example 208: 7-(2-methylperhydrocyclopenta[c]pyrrol-5-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dihydrochloride salt

a) 2-methylperhydrocyclopenta[c]pyrrol-5-ol

Prepared as described by Bohme H, Setiz G, Arch. Pharm. (Wienheim) 301, 341 (1968).

b) 4-chloro-5-iodo-7-(2-methylperhydrocyclopenta[c]pyrrol-5-yl)-7H-pyrrolo[2,3-d]pyrimidine

A mixture of 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (0.38 g, 1.36 mmol),

-174-

2-methylperhydrocyclopenta[c]pyrrol-5-ol (0.23 g, 1.63 mmol) and triphenylphosphine (0.71 g, 2.72 mmol) in tetrahydrofuran (20 mL) was treated with diethylazodicarboxylate (0.474 g, 2.72 mmol) and stirred for 2 hours at ambient temperature. The solvent was removed under reduced pressure and the residue was partitioned between dichloromethane (30 ml) and water (10 ml). The organic layer was washed with saturated aqueous sodium chloride (10 ml) then dried over magnesium sulfate then filtered and the filtrate evaporated under reduced pressure to give a residue. The residue was purified by flash chromatography on silica using dichloromethane/ methanol (8:2) as mobile phase to yield 4-chloro-5-iodo-7-(2-methylperhydrocyclopenta[c]pyrrol-5-yl)-7H-pyrrolo[2,3-d]pyrimidine (0.25 g): ¹H NMR (DMSO-d₆, 400MHz) δ 8.62 (s, 1H), 7.44 (s, 1H), 7.26 (s, 2H), 5.36 (m, 1H), 2.88 (m, 2H), 2.68 (m, 2H), 2.43 (m, 2H), 2.36 (s, 3H), 2.06-2.02 (m, 4H); TLC (dichloromethane/methanol 8:2) R_f = 0.29; RP-HPLC (Hypersil HS C18, 5 μm, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1 ml/min) t_r=6.50 min; MS: MH⁺ 403.

c) 7-(2-methylperhydrocyclopenta[c]pyrrol-5-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dihydrochloride salt

A mixture of 4-chloro-5-iodo-7-(2-methylperhydrocyclopenta[c]pyrrol-5-yl)-7H-pyrrolo[2,3-d]pyrimidine (0.25 g, 0.622 mmol), 4-phenoxyphenyl boronic acid (0.16 g, 0.746 mmol), tetrakis(triphenylphosphine)palladium (0.043 g, 0.037 mmol) and sodium carbonate (0.172 g, 1.62 mmol) was heated in a mixture of ethylene glycol dimethyl ether (8 mL) and water (4 mL) at 90° C for 18 hours under an atmosphere of nitrogen. The mixture was allowed to cool to ambient temperature and solvents were removed under reduced pressure. The residue was partitioned between water (10 mL) and dichloromethane (30 ml) The layers were separated and the organic solution was dried over magnesium sulfate, filtered and the filtrate concentrated to a residue under reduced pressure (0.354 g). The material was dissolved in 1,4-dioxane (10 ml) and concentrated (28%) ammonium hydroxide (10 ml). The mixture was heated in a sealed tube at 120°C for 20 hours then cooled to ambient temperature.

The solvents were evaporated under reduced pressure then purified by flash column chromatography on silica using dichloromethane/methanol 7:3) as an eluent to give 7-(2-methylperhydrocyclopenta [c]pyrrol-5-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (0.05 g): ¹H NMR (DMSO-d₆, 400MHz) shows two sets of peaks due to the cis and trans isomers of the desired compound δ 10.6-10.8 (bs, 1H), 8.49 (s, 1H), 6.99-7.98 (m, 11H), 5.39 and 5.48 (m, 1H), 2-3.8 (m, 10H); PH 454098: RP-HPLC (Hypersil HS C18, 5 μm, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r=7.53 min; MS: MH⁺ 426. The dihydrochloride salt of 7-(2-methylperhydrocyclopenta[c]pyrrol-5-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine was prepared by dissolving the free base in 10 ml 1 N hydrochloric acid and lyophilizing.

Example 209: Cis and trans-7-[4-(N-tert-butoxycarbonyl-1S, 4S-2,5-diaza[2.2.1]heptanyl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

A suspension of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanone (0.67 g, 1.68 mmol) in dichloroethane (40 ml) was treated with tert-Butyl (1S, 4S)-(-) 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (1.0 g, 5.04 mmol) and glacial acetic acid (0.30 g, 5.04 mmol) at room temperature for 1 h. Subsequently, Na(OAc)₃BH (0.46 g, 2.17 mmol) was added and stirred for 8 days at 80°C. To the cooled reaction solution, a solution of NaHCO₃ (0.377 g, 10.08 mmol) in water (15 ml) was added and stirred for 15 min. The layers were separated and the organic layer was washed with water and brine (3 x 100 ml each). The aqueous layer was extracted with CH₂Cl₂, the organic layers combined , dried (MgSO₄), filtered and concentrated. The solid was purified by flash silica gel column chromatography , (2 L, 6% MeOH in CH₂Cl₂, then 2 L 10% MeOH / 5% NH₄OH in CH₂Cl₂) to give :

Example 210: Cis-7-[4-(N-tert-butoxycarbonyl-1S, 4S-2,5-diaza[2.2.1]heptanyl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (605 mg, 64%)

¹H NMR (d₆ DMSO, 400 MHz) : δ 8.13 (1H, s), 7.39-7.49 (4H, m), 7.32 (1H, m), 7.07-7.17 (5H, m), 6.09 (2H, bs), 4.63 (1H, m), 4.15 (1H, m), 3.30-3.70 (2H, m), 3.03-3.08 (2H, m), 2.80-2.90 (1H, m), 2.70-2.75 (1H, m), 2.29-2.35, (1H, m), 2.09-2.21 (1H, m), 1.81-1.93 (4H, m), 1.60-1.80 (4H, m), 1.39 (9H, m).

5 HPLC/MS: Perkin Elmer Pecosphere C18, 3μM, 33 x 4.6, 3.5 ml/min 100 – 100% 50 mM ammonium acetate to acetonitrile in 4.5 minutes, C₃₆H₄₄N₆O₃ (581.2), 95%.

Example 211: Trans-7-[4-(N-tert-butoxycarbonyl-1S, 4S-2,5-diaza[2.2.1]heptanyl) cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (183 mg,
10 20%)

¹H NMR (d₆ DMSO, 400 MHz) : δ 8.13 (1H, s), 7.39-7.47 (5H, m), 7.15-7.17 (1H, m), 7.07-7.11 (4H, m), 6.10 (2H, bs), 4.62 (1H, m), 4.1-4.2 (1H, m), 3.71 (1H, bs), 3.03 (2H, m), 2.35 (2H, m), 1.93-2.01 (6H, m), 1.60-1.68 (2H, m), 1.40 (9H, s). HPLC/MS Perkin Elmer Pecosphere C18, 3μM, 33 x 4.6, 3.5 ml/min 100 –
15 100% 50 mM ammonium acetate to acetonitrile in 4.5 minutes, C₃₀H₃₆N₆O (581.2), 99%.

Example 212: Cis-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl] cyclohexyl}-N1,N2,N2-trimethyl-1,2-ethanaediamine trimaleate
20 salt

• Trans-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N1,N2,N2-trimethyl-1,2-ethanaediamine trimaleate salt

A mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-7-yl]-1-cyclohexanone (1.0 g, 2.51 mmol), N,N,N'-trimethylethylenediamine (0.77
25 g, 7.54 mmol) and acetic acid (0.45 g, 7.54 mmol) in 1,2-dichloroethane (50 ml) was stirred at ambient temperature under an atmosphere of nitrogen for 30 minutes. Sodium triacetoxymethylborohydride (0.69 g, 3.26 mmol) was added and the mixture stirred at ambient temperature for 18 hours. Water (20 ml) and sodium bicarbonate (1.26 g, 15.1 mmol) were added, the mixture was stirred for one hour, filtered
30 through a pad of celite and the pad was washed with dichloromethane (75 ml). The

filtrate was transferred to a separatory funnel and the layers were separated. The organic layer was dried over magnesium sulfate, filtered and the filtrate evaporated under reduced pressure. The cis and trans isomers were purified by flash chromatography on silica gel using dichloromethane/methanol (7:3) as an eluent to give cis-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N1,N2,N2-trimethyl-1,2-ethanaediamine (0.442 g) and trans-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N1,N2,N2-trimethyl-1,2-ethanaediamine (0.336 g). The cis-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N1,N2,N2-trimethyl-1,2-ethanaediamine (0.44 g, 0.909 mmol) was dissolved in warm ethyl acetate (100 ml) then maleic acid (0.32 g, 2.73 mmol) in ethyl acetate (30 ml) was added. The resulting salt formed an oily residue on the bottom and sides of the flask. The supernatant was poured off and the residue was dissolved in water and lyophilized to give cis-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N1,N2,N2-trimethyl-1,2-ethanaediamine trimaleate salt (0.55 g): ¹H NMR (DMSO-d₆, 400MHz) δ 8.22 (s, 1H), 7.41-7.50 (m, 5H), 7.08-7.19 (m, 5H), 6.5 (bs, 2H), 6.15 (s, 6H), 4.78 (m, 1H), 3.28 (m, 2H), 3.00 (m, 2H), 2.80 (m, 1H), 2.79 (s, 6H), 2.50 (s, 3H), 2.19 (m, 2H), 1.99 (m, 2H), 1.78 (m, 4H); RP-HPLC (Hypersil CPS, 5 μm, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r=9.27 min; MS: MH⁺ 485.

trans-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N1,N2,N2-trimethyl-1,2-ethanaediamine trimaleate salt was prepared from the free base in the same manner: ¹H NMR (DMSO-d₆, 400MHz) δ 8.20 (s, 1H), 7.41-7.48 (m, 5H), 7.08-7.19 (m, 5H), 6.45 (bs, 2H), 6.15 (s, 6H), 4.62 (m, 1H), 2.9-3.3 (m, 5H), 2.74 (s, 6H), 2.56 (s, 3H), 1.9-2.2 (m, 6H), 1.73 (m, 2H); RP-HPLC (Hypersil CPS, 5 μm, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r=8.17 min; MS: MH⁺ 485.

The following compounds were made in a similar manner to cis-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N1,N2,N2-trimethyl-1,2-ethanedi-amine

- 5 Example 214: Cis-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine: ¹H NMR (d₆ DMSO, 400 MHz): δ 8.13 (1H, s), 7.39-7.50 (4H, m), 7.28 (1H, s), 7.07-7.16 (5H, m), 6.08 (2H, bs), 4.67 (1H, m), 2.49-2.67 (9H, m), 2.06-2.16 (5H, m), 1.70-1.72 (2H, m), 1.53-1.59 (2H, m), 0.97 (d, J = 6.5 Hz, 6H). Mass spec. C₃₁H₃₈N₆O (511.2). HPLC: (Hypersil HS C18, 5 μm, 254 nm, 250 x 4.6 mm; 25-100% acetonitrile-0.1N ammonium acetate over 10 min, 1 ml/min) t_r=7.817 min., 99% TLC: R_f in 90% CH₂Cl₂/MeOH = 0.30 (UV visible).

- Example 215: Trans-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine: ¹H NMR (d₆ DMSO, 400 MHz): δ 8.13 (1H, s), 7.40-7.47 (5H, m), 7.08-7.18 (5H, m), 6.08 (2H, bs), 4.53 (1H, m), 2.45-2.55 (9H, m), 2.17-2.20 (1H, m), 1.86-1.96 (6H, m), 1.44-1.49 (2H, m), 0.97 (d, J = 5.5 Hz, 6H). Mass spec. C₃₁H₃₈N₆O (511.2). HPLC: (Hypersil HS C18, 5 μm, 254 nm, 250 x 4.6 mm; 25-100% acetonitrile-0.1N ammonium acetate over 10 min, 1 ml/min) t_r=7.367 min., 91% TLC: R_f in 90% CH₂Cl₂/MeOH = 0.21 (UV visible).

- Example 216: Cis-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine: ¹H NMR (d₆ DMSO, 400 MHz): δ 8.13 (1H, s), 7.39-7.50 (4H, m), 7.27 (1H, s), 7.07-7.11 (5H, m), 6.09 (2H, bs), 4.68 (1H, m), 3.42 (2H, t, J = 5.9 Hz), 3.22 (3H, s), 2.43-2.55 (9H, m), 2.03-2.16 (6H, m), 1.60-1.71 (2H, m), 1.52-1.59 (2H, m). Mass spec. C₃₁H₃₈N₆O₂ (527.2). HPLC: (Hypersil HS C18, 5 μm, 254 nm, 250 x 4.6 mm; 25-100% acetonitrile-0.1N ammonium acetate over 10 min, 1 ml/min) t_r=7.317 min, 95% TLC: R_f in 90% CH₂Cl₂/MeOH = 0.22 (UV visible).

Example 217: Trans-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine: ¹H NMR (d₆ DMSO, 400 MHz): δ 8.13 (1H, s), 7.39-7.47 (5H, m), 7.07-7.16 (5H, m), 6.09 (2H, bs), 4.55
5 (1H, m), 3.36-3.42 (2H, m), 3.23 (3H, s), 2.33-2.55 (11H, m), 1.90-1.96 (6H, m), 1.44-1.47 (2H, m). Mass spec. C₃₁H₃₈N₆O₂ (527.2). HPLC: (Hypersil HS C18, 5μm, 254 nm, 250 x 4.6 mm; 25-100% acetonitrile-0.1N ammonium acetate over 10 min, 1 ml/min) t_r=7.200 min, 99% TLC: R_f in 90% CH₂Cl₂/MeOH = 0.31 (UV visible).

10

Example 218: Cis-7-[-4-(4-ethylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

¹H NMR (d₆ DMSO, 400 MHz) : δ 8.23 (1H, s), 7.41-7.49 (4H, m), 7.07-7.17 (6H, m), 6.57 (2H, bs), 6.20 (5H, s), 4.77 (1H, m), 2.04-2.13 (8H, m), 1.62-1.77
15 (5H, m), 1.21 (3H, t). HPLC (Waters delta pack C18, 150 x 3.9 mm; 5 - 95% acetonitrile-0.1 M ammonium acetate over 30min, 1ml/min) t_r=13.851, 100%.

trans-7-[4-(4-ethylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

¹H NMR (d₆ DMSO, 400 MHz) : δ 8.19 (1H, s), 7.40-7.47 (4H, m), 7.19 (1H, m), 7.08-7.19 (5H, m), 6.40 (2H, bs), 6.18 (6H, s), 4.95 (1H, m), 3.17 (2H, bs), 2.98 (2H, bs), 2.69 (2H, bs), 1.94-2.01 (8H, m), 1.54-1.57 (2H, d, J=7.5 Hz), 1.17 (3H, t). HPLC (Waters delta pack C18, 150 x 3.9 mm; 5 - 95% acetonitrile-0.1 M ammonium acetate over 30min, 1ml/min) t_r=13.701, 96%.

25

The following compounds were prepared as salts in a similar manner to that of trans-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N1,N2,N2-trimethyl-1,2-ethanedi-amine trimaleate salt:

Example 219: Cis-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tris maleate: ^1H NMR (d_6 DMSO, 400 MHz): δ 8.23 (1H, s), 7.40-7.49 (5H, m), 7.07-7.19 (5H, m), 6.55 (2H, bs), 6.16 (6H, s), 4.74 (1H, m), 3.26 (6H, bs), 2.04-2.49 (13H, m), 1.63-1.75 (5H, m), 1.25 (d, $J = 6.6$ Hz, 6H). Mass spec. $\text{C}_{31}\text{H}_{38}\text{N}_6\text{O}$ (511.1). HPLC: (Hypersil HS C18, 5 μm , 254 nm, 250 x 4.6 mm; 25-100% acetonitrile-0.1N ammonium acetate over 10 min, 1 ml/min) $t_r = 7.967$ min, 99%

Example 220: Trans-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tris maleate: ^1H NMR (d_6 DMSO, 400 MHz): δ 8.20 (1H, s), 7.40-7.65 (5H, m), 7.08-7.19 (5H, m), 6.46 (2H, bs), 6.14 (6H, s), 4.60 (1H, m), 2.50-3.45 (17H, m), 1.95-2.02 (5H, m), 1.56-1.59 (2H, m), 1.20 (d, $J = 6.5$ Hz, 6H). Mass spec. $\text{C}_{31}\text{H}_{38}\text{N}_6\text{O}$ (511.2). HPLC: (Hypersil HS C18, 5 μm , 254 nm, 250 x 4.6 mm; 25-100% acetonitrile-0.1N ammonium acetate over 10 min, 1 ml/min) $t_r = 7.733$ min, 90%

Example 221: Cis-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tris maleate: ^1H NMR (d_6 DMSO, 400 MHz): δ 8.23 (1H, s), 7.41-7.49 (5H, m), 7.07-7.19 (5H, m), 6.55 (2H, bs), 6.16 (6H, s), 4.75 (1H, m), 3.62 (2H, m), 3.30 (3H, s), 3.17 (6H, bs), 2.50 (9H, m), 2.02-2.16 (5H, m), 1.74 (5H, m). Mass spec. $\text{C}_{31}\text{H}_{38}\text{N}_6\text{O}_2$ (527.2). HPLC: (Hypersil HS C18, 5 μm , 254 nm, 250 x 4.6 mm; 25-100% acetonitrile-0.1N ammonium acetate over 10 min, 1 ml/min) $t_r = 7.750$ min, 99%

Example 222: Trans-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tris maleate: ^1H NMR (d_6 DMSO, 400 MHz): δ 8.21 (1H, s), 7.41-7.48 (5H, m), 7.08-7.17 (5H, m), 6.53 (2H, bs), 6.17 (6H, s), 4.61 (1H, m), 3.45 (3H, s), 2.50-3.56 (19H, m), 1.99-2.08 (6H, m), 1.64 (2H, m). Mass spec. $\text{C}_{31}\text{H}_{38}\text{N}_6\text{O}_2$ (527.2). HPLC: (Hypersil HS C18, 5 μm , 254

nm, 250 x 4.6 mm; 25-100% acetonitrile-0.1N ammonium acetate over 10 min, 1 ml/min) t_r =7.383 min, 99%

Example 223: Cis-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N2,N2-dimethyl-1,2-ethanaediamine trimaleate salt
5 Trans-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N2,N2-dimethyl-1,2-ethanaediamine monomaleate salt
cis-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N2,N2-dimethyl-1,2-ethanaediamine trimaleate salt: ^1H NMR
10 (DMSO- d_6 , 400MHz) δ 8.19 (s, 1H), 7.40-7.49 (m, 5H), 7.08-7.19 (m, 5H), 6.35 (bs, 2H), 6.13 (s, 6H), 4.78 (m, 1H), 3.15-3.45 (m, 5H), 2.74 (s, 6H), 1.8-2.25 (m, 8H); RP-HPLC (Hypersil CPS, 5 μm , 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r =8.90 min; MS: MH^+ 471.

15 Example 224: trans-N1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-N2,N2-dimethyl-1,2-ethanaediamine monomaleate salt: ^1H NMR (DMSO- d_6 , 400MHz) δ 9.5 (bs, 1H), 8.26 (s, 1H), 7.41-7.55 (m, 5H), 7.08-7.19 (m, 5H), 6.7 (bs, 2H), 6.16 (s, 2H), 4.63 (m, 1H), 3.12-3.55 (m, 5H), 2.85 (s, 3H), 2.27 (m, 2H), 1.99-2.05 (m, 4H), 1.67-1.75 (m, 2H); RP-HPLC (Hypersil
20 CPS, 5 μm , 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r =8.6 min; MS: MH^+ 471.

Example 225: Cis-7-(4-{[3-(1H-1-imidazolyl)propyl]amino}cyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trimaleate salt
25 Trans-7-(4-{[3-(1H-1-imidazolyl)propyl]amino}cyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dimaleate salt

Example 227: cis-7-(4-{[3-(1H-1-imidazolyl)propyl]amino}cyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trimaleate salt: ^1H NMR
30 (DMSO- d_6 , 400MHz) δ 8.78 (bs, 1H), 8.48 (bs, 2H), 8.18 (s, 1H), 7.66 (s, 1H), 7.55

(s, 1H), 7.41-7.49 (m, 5H), 7.08-7.19 (m, 5H), 6.33 (bs, 2H), 6.12 (s, 6H), 4.78 (m, 1H), 4.27 (t, 2H), 2.99 (m, 3H), 1.8-2.25 (m, 10 H); RP-HPLC (Hypersil CPS, 5 μ m, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r =9.07 min; MS: MH^+ 508.

5

Example 228: trans-7-(4-{[3-(1H-1-imidazolyl)propyl]amino}cyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dimaleate salt: 1H NMR (DMSO- d_6 , 400MHz) δ 8.76 (bs, 1H), 8.51 (bs, 2H), 8.18 (s, 1H), 7.66 (s, 1H), 7.55 (s, 1H), 7.40-7.47 (m, 5H), 7.08-7.21 (m, 5H), 6.3 (bs, 2H), 6.11 (s, 4H), 4.60 (m, 1H), 4.26 (t, 2H), 3.14 (m, 1H), 2.97 (m, 2H), 1.9-2.25 (m, 8H), 1.53-1.61 (m, 2H); RP-HPLC (Hypersil CPS, 5 μ m, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r =8.72 min; MS: MH^+ 508.

Example 229: Cis-7-[4-(dimethylamino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dimaleate salt

1H NMR (DMSO- d_6 , 400MHz) δ 9.06 (bs, 1H), 8.2 (s, 1H), 7.41-7.50 (m, 5H), 7.08-7.19 (m, 5H), 6.4 (bs, 2H), 6.13 (s, 4H), 4.83 (m, 1H), 3.34 (m, 1H), 2.88 (s, 6H), 2.10-2.17 (m, 4H), 1.88-1.99 (m, 4H); RP-HPLC (Hypersil HS C-18, 5 μ m, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r =7.38 min; MS: MH^+ 428.

Example 230: Trans-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dimaleate salt

1H NMR (DMSO- d_6 , 400MHz) δ 8.92 (bs, 1H), 8.18 (s, 1H), 7.4-7.5 (m, 5H), 7.08-7.19 (m, 5H), 6.3 (bs, 2H), 6.13 (s, 4H), 4.63 (m, 1H), 3.15-3.5 (m, 3H), 2.9-3.1 (m, 2H), 1.16-2.18 (m, 14H); RP-HPLC (Hypersil HS C-18, 5 μ m, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r =7.98 min; MS: MH^+ 468. Trans-5-(4-phenoxyphenyl)-7-(4-tetrahydro-1H-1-pyrrolylcyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dimaleate salt

30

¹H NMR (DMSO-d₆, 400MHz) δ 9.54 (bs, 1H), 8.18 (s, 1H), 7.40-7.47 (m, 5H), 7.08-7.18 (m, 5H), 6.3 (bs, 1H), 6.12 (s, 4H), 4.63 (m, 1H), 3.1-3.55 (m, 5H), 2.24 (m, 2H), 2.00 (m, 6H), 1.86 (m, 2H), 1.67 (m, 2H); RP-HPLC (Hypersil HS C-18, 5 μm, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r=7.82 min; MS: MH⁺ 454.

Example 231: Cis-7-[4-(4-methyl-1,4-diazepan-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dihydrochloride salt
Trans-7-[4-(4-methyl-1,4-diazepan-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dihydrochloride salt
cis-7-[4-(4-methyl-1,4-diazepan-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dihydrochloride salt: ¹H NMR (DMSO-d₆, 400MHz) δ 11.7 (d, 1H), 11.38 (d, 1H), 8.57 (s, 1H), 8.34 (d, 1H), 7.42-7.51 (m, 4H), 7.03-7.20 (m, 5H), 4.93 (m, 1H), 4.7 (bs, 2H), 3.4-3.99 (m, 9H), 2.8 (s, 3H), 1.86-2.57 (10 H); RP-HPLC (Hypersil HS C-18, 5 μm, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r=7.67 min; MS: MH⁺ 497.

trans-7-[4-(4-methyl-1,4-diazepan-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine dihydrochloride salt: ¹H NMR (DMSO-d₆, 400MHz) δ 11.94 (d, 1H), 11.52 (d, 1H), 8.56 (s, 1H), 7.8 (s, 1H), 7.42-7.51 (m, 4H), 7.10-7.20 (m, 5H), 4.76 (1H, m) < 3.2-4.0 (m, 9H), 2.80 (s, 3H), 1.78-2.4 (m, 10H); RP-HPLC (Hypersil HS C-18, 5 μm, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r=7.42 min; MS: MH⁺ 497.

25

Example 232: Cis-5-(4-phenoxyphenyl)-7-(4-piperazinocyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trimaleate salt

Trans-5-(4-phenoxyphenyl)-7-(4-piperazinocyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trimaleate salt

30

- a) cis and trans-tert-butyl 4-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-1-piperazinecarboxylate

Example 233: cis-tert-butyl 4-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-1-piperazinecarboxylate: ¹H NMR (DMSO-d₆, 400MHz) δ 8.14 (s, 1H), 7.3-7.5 (m, 6H), 7.07-7.16 (m, 5H), 6.1 (bs, 2H), 4.69 (m, 1H), 3.2-3.4 (4H, m), 2.38 (m, 4H), 2.0-2.25 (m, 5H), 1.5-1.8 (m, 4H), 1.41 (s, 9H); RP-HPLC (Hypersil HS C-18, 5 μm, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r=13.60 min.

10

trans-tert-butyl 4-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-1-piperazinecarboxylate: ¹H NMR (DMSO-d₆, 400MHz) δ 8.13 (s, 1H), 7.40-7.47 (m, 6H), 7.08-7.16 (m, 5H), 6.1 (bs, 2H), 4.55 (m, 1H), 3.34 (m, 4H), 2.35-2.51 (m, 3H), 1.89-1.99 (m, 6H), 1.38-1.49 (m, 4H), 1.39 (s, 9H); RP-HPLC (Hypersil HS C-18, 5 μm, 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r=10.40 min.

15

- b) Cis-5-(4-phenoxyphenyl)-7-(4-piperazinocyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trimaleate salt

20

The cis-tert-butyl 4-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-1-piperazinecarboxylate (1.85 g, 3.27 mmol) was treated with a 20% trifluoroacetic acid/dichloromethane solution (60 ml) and stirred for 30 minutes at ambient temperature. The solvents were removed under reduced pressure then the residue was partitioned between dichloromethane (200 ml) and aqueous saturated sodium bicarbonate solution (30 ml). The organic solution was dried over magnesium sulfate, filtered and the filtrate evaporated to a residue (1.55 g). A portion of this material (1.0 g, 2.15 mmol) was dissolved in warm ethyl acetate (220 ml) then treated with maleic acid (0.75 g, 0.44 mmol) in warm ethyl acetate (75 ml). The mixture was cooled to ambient temperature then the solid was collected by filtration and dried to give Cis-5-(4-phenoxyphenyl)-7-(4-

25

30

piperazinocyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trimaleate salt (1.15 g) as a white solid: ^1H NMR (DMSO- d_6 , 400MHz) δ 8.5 (bs, 1H), 8.23 (s, 1H), 7.41-7.51 (m, 5H), 7.08-7.19 (m, 5H), 6.65 (bs, 2H), 6.16 (s, 6H), 4.74 (m, 1H), 1.16-3.2 (m, 17H); RP-HPLC (Hypersil CPS, 5 μm , 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r =8.63 min; MS: MH^+ 469.

c) *trans*-5-(4-phenoxyphenyl)-7-(4-piperazinocyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trimaleate salt

10 ^1H NMR (DMSO- d_6 , 400MHz) δ 8.22 (s, 1H), 7.41-7.51 (m, 5H), 7.08-7.19 (m, 5H), 6.6 (bs, 2H), 6.16 (s, 6H), 4.58 (m, 1H), 1.4-3.2 (m, 17 H); RP-HPLC (Hypersil HS C-18, 5 μm , 100A, 250 x 4.6 mm; 25-100% acetonitrile-0.1 M ammonium acetate over 10min, 1ml/min) t_r =8.08 min; MS: MH^+ 469.

15 Example 234: 7-[3-(4-methylpiperazino)cyclopentyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tri-maleate

3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentan-1-ol (2.14 g, 0.0055 mol) in 1 l dichloromethane was stirred with 12 g active manganese dioxide for 5 hours, filtered and fresh manganese dioxide (8 g) added to the filtrate. After stirring for a further 17 hours, the mixture was filtered and used directly. HPLC/MS showed starting material and 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclopentanone 62.7% t_r 4.38 minutes. The dichloromethane solution was stirred with 1.0 g N-methylpiperazine (0.01 mol) and acetic acid (0.6 g, 0.01 mol) for 15 minutes then sodium triacetoxyborohydride (0.89 g, 0.0042 mol) was added. After 2 hours 1.0 g N-methylpiperazine, 0.6 g acetic acid and 0.89 g sodium triacetoxyborohydride was added and the mixture stirred for 17 hours. Further addition of 2.0 g N-methylpiperazine, 1.2 g acetic acid and 1.2 g sodium triacetoxyborohydride and stirring for 3 days gave a mixture which was evaporated under reduced pressure. The residue was treated with water (200 ml) and 6M – hydrochloric acid (50 ml) then

20

25

30

washed with ethyl acetate (discarded) and basified with excess aqueous ammonia. The mixture was extracted with ethyl acetate and the extract dried (sodium sulphate) then purified by flash chromatography in 9:1 ethyl acetate : ethanol to remove impurities followed by 8:1:1 ethyl acetate : ethanol : triethylamine to elute the product. Solvent was removed under reduced pressure, the residue dissolved in ethyl acetate and treated with a solution of maleic acid in ethyl acetate giving 7-[3-(4-methylpiperazino) cyclopentyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tri-maleate (444395) as a 1.4 solvate with ethyl acetate after drying at 80° C under reduced pressure (0.95 g, 0.001 mol) m.pt. 168-170° C (decomposes).

10

Example 235: [4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl](phenyl)-methanol, Sodium borohydride (0.052 g, 0.0013 mol) was added to a solution of [4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl](phenyl)methanone (0.1 g, 0.00026 mol) in tetrahydrofuran (4 mL) followed by the addition of Amberlyst-15 H⁺. The mixture was stirred at ambient temperature under an atmosphere of nitrogen for 15 min, filtered through a celite pad and the solvent removed under reduced pressure. The residue was purified by preparative RP-HPLC (Rainin, Hypersil C18, 8 µm, 100A, 25 cm; 5%-85% acetonitrile – 0.1% ammonium acetate over 20 min, 21 mL/min) to yield [4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl](phenyl)methanol (0.005 g, 0.000013 mol):

¹H NMR (DMSO-d₆, 400MHz) δ 8.12 (s, 1H), 7.31 (m, 10H), 6.01 (br, 2H), 5.91 (d, 1H), 5.75 (d, 1H), 5.06 (m, 1H), 2.10(br, 2H), 1.88 (br, 4 H), 1.67 (br, 2H) RP-HPLC(Delta Pak C18, 5µm, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL / min) R_t 16.74 min. MH⁺ 385

25

Example 236: Trans-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tri-maleate

trans-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1.30 g, 0.0027 mol) in 300 ml warm ethyl acetate

30

was treated with a solution of maleic acid (0.94 g, 0.0081 mol) in 100 ml ethyl acetate and allowed to cool. The colourless solid was collected, washed with ethyl acetate and dried to constant weight at 90° C / 3 mbar giving 1.85 g (0.0022 mol) of trans-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tri-maleate solvated with 0.18 mol ethyl acetate m.p. 189° C (decomposes).

Example 237: trans-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tri-hydrochloride

trans-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (0.36 g, 0.00075 mol) in 25 ml warm isopropanol was treated with a solution of 0.225 ml 12M hydrochloric acid (0.0027 mol) in 2 ml isopropanol and the suspension heated briefly to boiling then volatile material was removed under reduced pressure. The resulting colourless solid was dried to constant weight at 84° C / 5 mbar giving the trans-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tri-hydrochloride (444626) solvated with 1 mol water and 0.25 mol isopropanol (0.25 g, 0.0004 mol) m.p. 304-306° C(dec).

Example 238: cis-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tri-maleate salt

cis-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1.45 g, 0.0030 mol) in ethyl acetate with 1.05 g (0.0091 mol) maleic acid giving colourless solid after drying to constant weight at 90° C / 3 mbar. 2.15 g cis-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tri-maleate salt solvated with 0.14 mol ethyl acetate and 0.5 mol water (0.0025 mol) obtained m.p. 186 (dec).

Example 239: cis-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tri-hydrochloride

cis-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 0.80 g (0.0017 mol) in isopropanol was treated with 0.5 ml 12M hydrochloric acid (0.006 mol). The resulting solid was filtered to give cis-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine tri-hydrochloride as a hygroscopic solid until
5 dried at 80° C / 3 mbar to constant weight. (0.75 g, 0.0011 mol) m.p. 224.5-226.5 (dec).

Example 240: Trans-5-(2-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine trimaleate
10

A mixture of 3-phenoxytoluene (2.5 g, 0.0136 mol) and N-bromosuccinimide (2.54 g, 0.0142 mol) was stirred in acetonitrile (20 mL) for 2.5 hours under an atmosphere of nitrogen. The solvent was removed under reduced pressure. Carbon tetrachloride was added to the residue and the resulting solid was removed by
15 filtration. The filtrate was concentrated to yield 4-bromo-3-methylphenyl phenyl ether as yellow oil (3.5 g, 0.0133 mol):

¹H NMR (Chloroform-d, 400 MHz) δ 7.45 (d, 1H), 7.33 (m, 2H), 7.12 (t, 1H), 7.00 (d, 2H), 6.89 (s, 1H), 6.71 (d, 1H), 2.34 (s, 3H) RP-HPLC (Hypersil C18, 5µm, 250 x 4.6 mm; 25% - 100% over 23 min with 0.1 M ammonium acetate,
20 1mL/min) R_t 14.72 min.

A mixture of 4-bromo-3-methylphenyl phenyl ether (1.7 g, 0.00646 mol), diboron pinacol ester (2.0 g, 0.00775 mol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) complex with dichloromethane (1:1) (0.16 g, 0.00019 mol) and potassium acetate (1.9 g, 0.01938 mol) in N,N-dimethylformamide (65 mL) was
25 heated at 80 °C under an atmosphere of nitrogen for 22 hours. The mixture was allowed to cool to ambient temperature and the solvent was removed under reduced pressure. Dichloromethane was added to the residue and the resulting solid was removed by filtration through a pad of celite. The filtrate was concentrated into black mixture, which was purified by flash chromatography on silica using ethyl
30 acetate/n-heptane (3:97) as mobile phase to yield 3-methyl-4-(4,4,5,5-tetramethyl-

1,3,2-dioxaborolan-2-yl)phenyl phenyl ether (1.05 g, 0.00338 mol):

¹H NMR (Chloroform-d, 400 MHz) δ 7.73 (d, 1H), 7.33(m, 2H), 7.08 (t, 1H), 7.01 (d, 2H), 6.79 (d, 2H), 2.51 (s, 3H), 1.34 (s, 12H) TLC (ethyl acetate / n-heptane = 3 : 97) R_f 0.28

5 A mixture of 4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (20 g, 47.7 mmol) and 6 N HCl(aq) (60 mL, 360 mmol) in tetrahydrofuran (120 mL) and acetone (600 mL) was stirred at ambient temperature under an atmosphere of nitrogen for 17 hours. The solvent was removed under reduced pressure and 6N HCl(aq) (20 mL), tetrahydrofuran (60 mL), and acetone
10 (300 mL) were added to the mixture. The mixture was stirred at ambient temperature under an atmosphere of nitrogen for 4.5 hour. The solvent was removed under reduced pressure and the yellow colored residue was washed with water to yield 4-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-cyclohexanone (12.3 g, 32.7 mmol). RP-HPLC (Hypersil C18, 5 μ m, 250 x 4.6 mm; 25% - 100% over 15
15 min with 0.05 M ammonium acetate, 1mL/min) R_t 10.20 min.

 A mixture of 4-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-cyclohexanone (5.6 g, 14.9 mmol), N-methylpiperazine (3.3 mL, 29.8 mmol), acetic acid (2.6 mL, 44.7 mmol), and trimethylorthoformate (9.9 mL, 89.4 mmol) in dichloroethane (100 mL) was stirred at ambient temperature under an atmosphere of
20 nitrogen for 1 hr. Sodium triacetoxyborohydride (14.2 g, 67.05 mmol) was added into the mixture and stirred at ambient temperature under an atmosphere of nitrogen for 18 hours. The solvent was removed under reduced pressure. The residue was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The water phase was further extracted with ethyl acetate and the combined
25 organic extracts were dried over sodium sulfate. The solvent was removed under reduced pressure and the residue was purified by flash chromatography on silica gel using triethylamine/ dichloromethane (2:98) followed by methanol/triethylamine/dichloromethane (2:3:95) as mobile phase to yield trans-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine
30 (1.7 g, 3.7 mmol). ¹H NMR (DMSO-d₆, 400 MHz) 8.63(s, 1H), 8.12 (s, 1H), 4.63

(br, 1H), 2.15 (s, 3H), 1.94 (br, 6H), 1.45 (br, 2H) RP-HPLC (Hypersil C18, 5 μ m, 250 x 4.6 mm; 25% - 100% over 15 min with 0.05 M ammonium acetate, 1mL/min) R_t 6.17 min.

Trans-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine (0.89 g, 1.9 mmol) in concentrated ammonium hydroxide (40 mL) and dioxane (40 mL) was heated at 120 °C in a pressure vessel for 18 hours. The mixture was allowed to cool to ambient temperature and the solvent was removed under reduced pressure. The residue was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The water phase was further extracted with ethyl acetate and the combined organic extracts were washed with brine and dried over sodium sulfate. The solvent was removed under reduced pressure to yield trans-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (0.35 g, 0.8 mmol). RP-HPLC (Hypersil C18, 5 μ m, 250 x 4.6 mm; 25% - 100% over 15 min with 0.1 M ammonium acetate, 1mL/min) R_t 4.01 min. MS: MH⁺ 441

A mixture of trans-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (0.347 g, 0.000788 mol), 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl phenyl ether (0.27 g, 0.000867 mol), tetrakis(triphenyl-phosphine)palladium(0) (0.054 g, 0.000047 mmol), and sodium carbonate (0.209 g, 0.00197 mol) in N,N-dimethylformamide (15 mL) and water (10 mL) was heated at 80 °C under an atmosphere of nitrogen for 16 hours. The mixture was allowed to cool to ambient temperature and the solvent removed under reduced pressure. The residue was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The water phase was further extracted with ethyl acetate and the combined organic extracts were dried over sodium sulfate. The solvent was removed under reduced pressure and the residue was purified by flash chromatography on silica gel using triethylamine/dichloromethane (5:95) followed by methanol/ triethylamine/ dichloromethane (3:5:92) as mobile phase to yield trans-5-(2-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-

-191-

pyrrolo[2,3-d]pyrimidin-4-amine (0.376 g, 0.000757 mol). Trans-5-(2-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)-cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (0.376 g, 0.000757 mol) was dissolved in refluxing ethanol (10 mL) and a preheated solution of maleic acid (0.264 g, 0.00227 mol) in ethanol (5 mL) was added. The mixture was refluxed for 15 minutes, cooled to ambient temperature and the precipitate collected by filtration, washed with cool ethanol and dried to give trans-5-(2-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)-cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine trimaleate (0.153 g, 0.000181 mol): ¹H NMR (DMSO-d₆, 400 MHz) 8.22 (s, 1H), 7.42 (m, 3H), 7.25 (d, 1H), 7.17 (t, 1H), 7.09 (d, 2H), 7.02 (s, 1H), 6.89 (d, 1H), 6.16 (s, 6H), 4.58 (m, 1H), 3.3 (br, 9H), 2.68 (s, 3H), 2.22 (s, 3H), 2.01 (br, 6H), 1.57 (br, 2H) RP-HPLC (Hypersil C18, 5µm, 250 x 4.6 mm; 25% - 100% over 23 min with 0.1 M ammonium acetate, 1mL/min) R_t 7.30 min. MS: MH⁺ 497

Example 241: 3-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl 2-aminoacetate hydrochloride

A mixture of 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclopentanol (50 mg, 0.129 mmol), 2-[(tert-butoxycarbonyl)amino]acetic acid (34 mg, 0.194 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (31 mg, 0.155 mmol) and 4-(dimethylamino)pyridine (16 mg, 0.129 mmol) in DMF (1 mL) was stirred under nitrogen for 24 hours. The mixture was pour onto ice-water. The aqueous layer was extracted with ethyl acetate three times. The combined organic layer was washed with brine, dried over MgSO₄, filtered and evaporated. The residue was purified by flash column chromatography using ethyl acetate as mobile phase to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl 2-[(tert-butoxycarbonyl)amino]acetate (39 mg, 0.072 mmol). HPLC: t_r=19.22 min. (Delta-Pack, C-18, 5µm, 300A, 3.9x150 mm; 5-85% acetonitrile-0.1 M ammonium acetate over 20 min, 1ml/min)

3-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl 2-[(tert-butoxycarbonyl)amino]acetate (39 mg, 0.072 mmol) was

dissolved in ethyl acetate (2.5 mL). Hydrochloride gas was bubbled through the solution for 3 minutes. The reaction mixture was stirred for additional 30 minutes. Ether was added and the precipitate was collected through filtration under nitrogen to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-

5 yl]cyclopentyl 2-aminoacetate hydrochloride (39 mg) as white solid. ¹H NMR (DMSO-*d*₆) δ 2.20 (m, 5H), 2.67 (m, 1H), 3.83 (s, 2H), 5.25 (m, 1H), 5.31 (m, 1H), 7.14 (m, 2H), 7.43, (m, 1H), 7.50 (m, 1H), 7.68 (m, 1H), 8.26 (bs, 2H), 8.40 (s, 1H). LC/MS: MH⁺=444, t_r=2.25 min. (Pecospher, 3C-18, 3μm, 4.6x33 mm; 0-100% acetonitrile-0.1 M ammonium acetate over 5 min, 3.5 ml/min)

10

Example 242: 3-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl N-(2-morpholinoethyl)carbamate hydrochloride

4- Nitrochloroformate (12.5 mg, 0.062 mmol) in dichloromethane (1 mL) was cooled on an ice-water bath. 4-Methylmorpholine (7 μL, 0.062 mmol) was added slowly. After 20 minutes, the ice-water bath was removed and the reaction mixture was allowed to warm up to room temperature. 3-(4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-cyclopentanol (20 mg, 0.052 mmol) was added and the reaction mixture was stirred for 4days. The reaction mixture was diluted with dichloromethane. The organic layer was washed with water, saturated sodium bicarbonate, brine, dried over MgSO₄, filtered and evaporated to give a yellow solid. A solution of the yellow solid in dichloromethane (1 mL) was added to 2-morpholino-1-ethanamine (0.2 mL). After stirring at room temperature overnight, the reaction mixture was diluted with ethyl acetate. The organic layer was washed with water (3 times), brine, dried over MgSO₄, filtered and evaporated. The crude product was purified by HPLC to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl N-(2-morpholinoethyl)carbamate (17 mg, 0.031 mmol). ¹H NMR (CDCl₃-*d*) δ 2.08 (m, 4H), 2.43 (m, 7H), 2.73 (m, 1H), 3.29 (m, 2H), 3.67, (m, 4H), 5.28 (m, 5H), 7.09 (m, 6H), 7.40 (m, 4H), 8.30 (s, 1H). LC/MS: MH⁺=543, t_r=2.13 min. (Pecospher, 3C-18, 3μm, 4.6x33 mm; 0-100% acetonitrile-0.1 M ammonium acetate over 5 min, 3.5

ml/min).

3-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl N-(2-morpholinoethyl)carbamate (10 mg, 0.0184 mmol) was dissolved in ethyl acetate (2.5 mL). Hydrochloride gas was bubbled through the solution for 3 minutes. The reaction mixture was stirred for additional 10 minutes. The precipitate was collected through filtration under nitrogen to give 3-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl N-(2-morpholinoethyl)carbamate hydrochloride as white solid. ¹H NMR (DMSO-d₆) δ 1.99 (m, 4H), 2.55(m, 2H), 3.32 (m, 12H), 5.08(m, 1/2H), 5.19 (m, 1/2H), 7.16 (m, 5H), 7.45, (m, 5H), 8.26 (s, 1H). LC/MS: MH⁺=543, t_r=2.16 min. (Pecospher, 3C-18, 3μm, 4.6x33 mm; 0-100% acetonitrile-0.1 M ammonium acetate over 5 min, 3.5 ml/min).

Example 243: 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanol

Sodium borohydride (500mg, 13 mmol) was added in one portion to a stirred solution of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-one (780mg, 2.0 mmol) in methanol (500 mL), and the mixture stirred under an atmosphere of nitrogen for 1 hour, then left to stand overnight. The solvent was removed under reduced pressure, and the residue partitioned between 2M aqueous sodium hydroxide solution (100 mL) and dichloromethane (100 mL). The organic layer was separated and the aqueous layer further extracted with dichloromethane (2 x 100 mL). The combined organic extracts were washed with water (150 mL), dried over potassium carbonate, and purified by chromatography with a Biotage 40S column using ethyl acetate / triethylamine (98:2 to 95:5) and ethyl acetate / ethanol (95:5) as a mobile phase to yield 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanol as a white solid (750mg, 1.9 mmol), melting point: 199-200 deg. C. LC/MS: Hypersil BDS c18 (100 x 2.1 mm) 0.1M ammoniumacetate/acetonitrile, 10-100% acetonitrile in 8 min.) MH⁺ 401, t_r = 4.12 minutes.

Example 244

Phenyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

5 -(4-Amino-3-methoxyphenyl)-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (100 mg, 0.294 mmol) was dissolved in dichloromethane (2 mL). Pyridine (2mL) was added followed by phenylchloroformate (44 uL, 0.353 mmol). After stirring for 3 hours, another 44 uL of phenylmethanesulfonyl chloride was added and the reaction mixture was stirred overnight. The solvent was removed and the residue was purified by preparative LC/MS to give phenyl *N*-[4-(4-amino-7-
10 tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (52 mg, 0.113 mmol). ¹H NMR (CDCl₃-*d*) δ 2.09 (m, 4H), 3.66 (m, 2H), 3.98 (s, 3H), 4.16 (m, 2H), 4.98 (m, 1H), 5.24 (s, 2H), 7.09 (m, 3H), 7.23 (m, 4H), 7.41 (m, 2H), 7.62 (s, 1H), 8.20(bd, J=7.80 Hz, 1H), 8.33 (s, 1H). LC/MS MH⁺=460.

15

Example 245

Tetrahydro-2*H*-4-pyranyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate 4-nitrophenyl tetrahydro-2*H*-4-pyranyl carbonate

20 Tetrahydro-2*H*-4-pyranol (1.0 ml, 10.5 mmol) was mixed with 4-methylmorpholine (2.0 ml) in dichloromethane (20 mL). 4- Nitrochloroformate (1.98 g, 9.82 mmol) was added slowly to the reaction mixture. After stirring for 5 hours, the reaction mixture was diluted with dichloromethane. The organic layer was washed with water, 1.0 N HCl, saturated sodium bicarbonate, brine, dried over
25 MgSO₄, filtered and evaporated. The crude product was purified by flash column chromatography chromatography using ethyl acetate/heptane (4:1) as the mobile phase to give 4-nitrophenyl tetrahydro-2*H*-4-pyranyl carbonate (1.5 g, 5.62 mmol). ¹H NMR (CDCl₃-*d*) δ 1.87 (m, 2H), 2.06 (m, 2H), 3.58 (m, 2H), 3.98 (m, 2H), 4.97 (m, 1H), 7.40(d, J=9.0Hz, 2H), 8.30 (d, J=9.0Hz, 2H).

30

a) Tetrahydro-2*H*-4-pyranyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate
5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (57 mg, 0.168 mmol) and 4-nitrophenyl tetrahydro-2*H*-4-pyranyl carbonate (90 mg, 0.336 mmol) was mixed in pyridine (1 mL). After stirring for 5 hours, another 90 mg of 4-nitrophenyl tetrahydro-2*H*-4-pyranyl carbonate was added and the reaction mixture was stirred for 2 days. The reaction mixture was heated at 70°C for 2 hours. The solvent was removed and the residue was purified by preparative thin layer chromatography to give tetrahydro-2*H*-4-pyranyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.064 mmol). ¹H NMR (CDCl₃-*d*) δ 1.78 (m, 4H), 2.08 (m, 4H), 3.60 (m, 4H), 3.94 (s, 3H), 3.97 (m, 2H), 4.15 (m, 2H), 4.98 (m, 2H), 5.23 (s, 2H), 6.78 (s, 1H), 7.04 (s, 1H), 7.07 (d, *J*=8.3 Hz, 1H), 8.16(bd, *J*=7.90 Hz, 1H), 8.33 (s, 1H). LC/MS *MH*⁺=468.

15

Example 246

3-Pyridylmethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride

a) 4-Nitrophenyl (3-pyridylmethyl) carbonate
4-Nitrochloroformate (2.49 g, 12.3 mmol) in dichloromethane (20 mL) was cooled on an ice-water bath. 3-pyridylmethanol (1.0 mL, 10.3 mmol) and 4-methylmorpholine (2.0 mL, 18.5 mmol) was added slowly. After 20 minutes, the ice-water bath was removed and the reaction mixture was allowed to warm up to room temperature. 30 minutes later, ethyl acetate was added and the reaction mixture was filtered. The filtrate was washed with water, saturated sodium bicarbonate, brine, dried over MgSO₄, filtered and evaporated to give a dark brown solid which was re-crystallized with ethyl acetate/heptane to give 4-nitrophenyl (3-pyridylmethyl) carbonate (1.52 g, 5.54 mmol). ¹H NMR (CDCl₃-*d*) δ 7.38 (m, 3H), 7.79 (m, 1H), 8.28 (d, *J*=9.09 Hz, 2H), 8.65 (m, 1H), 8.72 (s, 1H).

b) 3-Pyridylmethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

5 5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (25 mg, 0.074 mmol) was dissolved in dichloromethane (0.7 mL). Pyridine (0.7 mL) was added followed by 4-nitrophenyl (3-pyridylmethyl) carbonate (30 mg, 0.110 mmol). After heating at 100°C overnight, the solvent was removed and the residue was purified by preparative LC/MS to give 3-pyridylmethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (12 mg, 0.025 mmol). ¹H NMR (CDCl₃-*d*) δ 2.08 (m, 4H), 3.65 (m, 2H), 3.92 (s, 3H), 4.15 (m, 2H), 4.96 (m, 1H), 5.26 (s, 2H), 5.54 (bs, 2H), 6.97 (s, 1H), 7.04(s, 1H), 7.08 (d, J=8.2Hz, 1H), 7.35 (m, 2H), 7.79 (d, J=7.8Hz, 1H), 8.15 (m, 1H), 8.29 (s, 1H), 8.61 (s, 1H), 8.71 (s, 1H). LC/MS MH⁺=475

15

b) 3-Pyridylmethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride

3-Pyridylmethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (12 mg, 0.025 mmol) was dissolved
20 in ethyl acetate (2.0mL). 1.0N HCl in ether (1 mL) was added slowly. The precipitate was collected through filtration under nitrogen to give 3-pyridylmethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride(13 mg, 0.25 mmol). ¹H NMR (DMSO-*d*₆) δ 1.91 (m, 2H), 2.17(m, 2H), 3.54 (m, 2H), 3.87 (s, 3H), 4.03 (m, 2H), 4.97(m, 1H),
25 5.23 (s, 2H), 7.05 (d, J=8.2Hz, 1H), 7.13 (s, 1H), 7.51 (m, 1H), 7.81 (d, J=8.2Hz, 1H), 7.84 (s, 1H), 7.95 (m, 1H), 8.42 (s, 1H), 8.60(s, 1H), 8.71 (s, 1H), 8.82 (s, 1H). LC/MS MH⁺=475.

Example 247

2-Morpholinoethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride

- Phenyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (25 mg, 0.054 mmol) was mixed
5 with 2-morpholino-1-ethanol (0.1 mL) in pyridine (0.7 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase HPLC to give 2-morpholinoethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-
10 methoxyphenyl]carbamate (24 mg, 0.048mmol). The solid was dissolved in ethyl acetate (2 mL) and 1.0*N* HCl in ether (0.2 mL) was added slowly. The precipitate was collected through filtration under nitrogen to give 2-morpholinoethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride (24 mg, 0.045 mmol). ¹H NMR (DMSO-
15 *d*₆) δ 1.88(m, 2H), 2.16(m, 2H), 3.55 (m, 8H), 3.90 (s, 3H), 4.03 (m, 4H), 4.49(m, 2H), 4.92 (m, 1H), 7.07 (m, 1H), 7.15 (s, 1H), 7.65 (bs, 2H), 7.84 (s, 1H), 8.45 (s, 1H), 8.75(s, 1H) 10.95 (bs, 1H). LC/MS *MH*⁺=497.

Example 248

- 20 (4-Bromo-1,3-thiazol-5-yl)methyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

a)2,4-Dibromo-1,3-thiazole-5-carbaldehyde

- 1,3-Thiazolane-2,4-dione (3.52 g, 30 mmol) and phosphorus oxybromide (43 g, 150
25 mmol) were mixed with dimethyl formamide (2.56 mL, 34 mmol). The mixture was then heated at 75°C for 1 hours and at 100°C for 5 hours. After cooled to room temperature, the mixture was added to ice-water (500ml) and the aqueous layer was extracted with dichloromethane. The combined organic layer was washed with saturated sodium bicarbonate, dried over MgSO₄, filtered and evaporated to give a
30 brown solid which was washed with petroleum ether. Evaporation of solvent gave

2,4-dibromo-1,3-thiazole-5-carbaldehyde (1.74 g, 6.42 mmol). ¹H NMR (CDCl₃-*d*) δ 9.90 (S, 1H).

b) (2,4-Dibromo-1,3-thiazol-5-yl)methanol

5 2,4-Dibromo-1,3-thiazole-5-carbaldehyde (1.74 g, 6.42 mmol) was dissolved in methanol (70 ml) at 0°C. Sodium borohydride (0.244 g, 6.42 mmol) was added in small portions. The ice-water bath was removed 10 minutes later and the reaction mixture was stirred at room temperature overnight. Solvent was removed and saturated ammonium chloride was added. 1.0N NaOH was added to adjust the pH to
10 10. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over MgSO₄, filtered and evaporated. The residue was purified by flash column chromatography to give (2,4-dibromo-1,3-thiazol-5-yl)methanol (0.946 g, 3.47 mmol). ¹H NMR (CDCl₃-*d*) δ 2.11 (bs, 1H), 4.79 (S, 2H).

15

c) (4-Bromo-1,3-thiazol-5-yl)methanol

(2,4-Dibromo-1,3-thiazol-5-yl)methanol (0.94 g, 3.44 mmol), sodium carbonate trihydrate (1.34 g) and palladium on carbon (10%, 0.07g) were mixed in methanol (33 mL). The resulting mixture was hydrogenated at 60 psi for 2 days. The solid was
20 filtered off through a pad of celite. The solvent was evaporated and the residue was purified by flash column chromatography to give (4-bromo-1,3-thiazol-5-yl)methanol (0.32 g, 2.78 mmol). ¹H NMR (CDCl₃-*d*) δ 2.29 (bs, 1H), 4.86 (s, 2H), 8.72 (s, 1H).

25 d) (4-Bromo-1,3-thiazol-5-yl)methyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate
Phenyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (28 mg, 0.061 mmol) was mixed with (4-bromo-1,3-thiazol-5-yl)methanol (50 mg, 0.434 mmol) in pyridine (0.5 mL). The reaction
30 mixture was heated at 100°C overnight. The solvent was removed and the residue

was purified by preparative reverse phase LC/MS to give (4-bromo-1,3-thiazol-5-yl)methyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate. ¹H NMR (CDCl₃-*d*) δ 2.07(m, 4H), 3.65 (m, 2H), 3.92 (s, 3H), 4.13 (m, 2H), 4.98 (m, 1H), 5.35 (s, 1H), 5.40(s, 2H), 6.97 (s, 1H), 7.04 (s, 1H), 7.09 (m, 1H), 7.35 (s, 1H), 8.17 (s, 1H), 8.32 (s, 1H), 8.78(s, 1H). LC/MS MH⁺=481.

Example 249

Tetrahydro-3-furanyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

Phenyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed with tetrahydro-3-furanol (0.05 mL) in pyridine (0.5 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase PHLC to give tetrahydro-3-furanyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (14 mg, 0.031mmol). ¹H NMR (CDCl₃-*d*) δ 2.07(m, 6H), 3.66 (m, 2H), 3.96 (m, 7H), 4.13 (m, 2H), 4.98 (m, 1H), 5.26 (s, 2H), 5.40(m, 1H), 6.97 (s, 1H), 7.04 (s, 1H), 7.08 (d, J=8.2Hz, 1H), 7.26 (s, 1H), 8.30 (s, 1H), 8.32 (s, 1H). LC/MS MH⁺=455.

Examples 250

1,3-Dioxan-5-yl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate
1,3-Dioxolan-4-ylmethyl *N*-(4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl)carbamate

Phenyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed glycerol formal (0.05 mL) in pyridine (0.5 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by

preparative reverse phase PHLC to give tetrahydro-3-furanyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (2 mg, 0.004mmol). ¹H NMR (CDCl₃-*d*) δ 2.06(m, 4H), 3.66 (m, 2H), 3.92 (m, 3H), 4.07 (m, 6H), 4.79 (m, 1H), 4.83 (d, J=6.3Hz, 1H), 4.96 (m, 1H), 5.04(d, J=6.3Hz, 1H), 6.15 (vbs, 2H), 6.96 (s, 1H), 7.05 (m, 2H), 7.53 (s, 1H), 8.15 (d, J=8.2Hz, 1H), 8.22 (s, 1H). LC/MS MH⁺=471 and 1,3-dioxolan-4-ylmethyl *N*-(4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl)carbamate(6.0mg, 0.013 mmol). ¹H NMR (CDCl₃-*d*) δ 2.06(m, 4H), 3.66 (m, 2H), 3.75 (m, 1H), 3.92 (m, 3H), 4.03 (m, 1H), 4.13 (m, 1H), 4.34 (m, 2H), 4.94 (s, 1H), 4.97 (m, 1H), 5.10(s, 1H), 5.32 (bs, 2H), 6.97 (s, 1H), 7.03 (m, 2H), 7.06 (d, J=8.2Hz, 1H), 7.38(s, 1H), 8.15 (d, J=7.9Hz, 1H), 8.31 (s, 1H). LC/MS MH⁺=471.

Example 251

2-Pyridylmethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride

Phenyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed 2-pyridylmethanol (0.05 mL) in pyridine (0.5 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase LC/MS to give 2-pyridylmethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (11 mg, 0.023 mmol). The solid was dissolved in ethyl acetate (2 mL) and 1.0N HCl in ether (0.1 mL) was added slowly. The precipitate was collected through filtration under nitrogen to give 2-pyridylmethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate hydrochloride (12 mg, 0.023 mmol). ¹H NMR (DMSO-*d*₆) δ 1.92(m, 2H), 2.16(m, 2H), 3.55 (m, 2H), 3.89 (s, 3H), 4.02 (m, 2H), 4.91 (m, 1H), 5.23 (s, 2H), 7.05 (d, J=8.2Hz, 1H), 7.14 (s, 1H), 7.37 (m, 1H), 7.53 (d, J=7.8Hz, 1H), 7.87 (m, 3H), 8.42(s, 1H), 8.57 (d,

$J=4.2\text{Hz}$, 1H), 8.85 (s, 1H). LC/MS $\text{MH}^+=475$.

Example 252

4-Pyridylmethyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-
5 *d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate Hydrochloride

Phenyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-
d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed 4-
pyridylmethanol (0.05 mL) in pyridine (0.5 mL). The reaction mixture was heated
at 100°C overnight. The solvent was removed and the residue was purified by
10 preparative reverse phase LC/MS to give 2-pyridylmethyl *N*-[4-(4-amino-7-
tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-
methoxyphenyl]carbamate (11 mg, 0.023 mmol). The solid was dissolved in ethyl
acetate (2 mL) and 1.0N HCl in ether (0.1 mL) was added slowly. The precipitate
was collected through filtration under nitrogen to give 4-pyridylmethyl *N*-[4-(4-
15 amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-
methoxyphenyl]carbamate hydrochloride (12 mg, 0.023 mmol). ¹H NMR (DMSO-
*d*₆) δ 1.91(m, 2H), 2.16(m, 2H), 3.55 (m, 2H), 3.90 (s, 3H), 4.03 (m, 2H), 4.92 (m,
1H), 5.34 (s, 2H), 7.06 (d, $J=8.2\text{Hz}$, 1H), 7.16 (s, 1H), 7.73 (m, 1H), 7.81 (m, 1H),
7.87 (s, 1H), 8.46(s, 1H), 8.76 (d, $J=5.6\text{Hz}$, 1H), 9.05 (s, 1H). LC/MS: $\text{MH}^+=475$.

20

Example 253

(5-Methyl-3-isoxazolyl)methyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-
pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

Phenyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-
25 *d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed
with (5-methyl-3-isoxazolyl)methanol (0.05 mL) in pyridine (0.5 mL). The reaction
mixture was heated at 100°C overnight. The solvent was removed and the residue
was purified by preparative reverse phase LC/MS to give (5-methyl-3-
isoxazolyl)methyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-
30 *d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (18 mg, 0.038mmol). ¹H NMR

(CDCl₃-*d*) δ 2.06(m, 4H), 2.44 (s, 3H), 3.64 (m, 2H), 3.91 (s, 3H), 4.13 (m, 2H), 4.96 (m, 1H), 5.26 (s, 2H), 6.12(s, 1H), 6.95 (s, 1H), 7.06 (m, 2H), 7.39 (s, 1H), 8.17 (bs, 1H), 8.21(s, 1H). LC/MS: MH⁺ 479.

5 Example 254

[(2*S*)-5-Oxotetrahydro-1*H*-2-pyrrolyl]methyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate

Phenyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (30 mg, 0.065 mmol) was mixed
10 with (5*S*)-5-(hydroxymethyl)tetrahydro-1*H*-2-pyrrolone (0.05 mL) in pyridine (0.5 mL). The reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase LC/MS to give [(2*S*)-5-oxotetrahydro-1*H*-2-pyrrolyl]methyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (10 mg, 0.021 mmol).
15 ¹H NMR (CDCl₃-*d*) δ 1.90 (m, 1H), 2.06(m, 4H), 2.34 (m, 1H), 2.41 (m, 2H), 3.64 (m, 2H), 3.94 (s, 3H), 4.04(m, 2H), 4.14 (m, 2H), 4.98 (m, 1H), 5.33 (m, 3H), 6.10(s, 1H), 6.98 (s, 1H), 7.04 (s, 1H), 7.09 (m, 1H), 7.31(s, 1H), 8.11 (bs, 1H), 8.32 (s, 1H). LC/MS: MH⁺ 481.

20 Example 255

4-Aminobenzyl *N*-(4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl)carbamate

a) *tert*-Butyl *N*-(4-(hydroxymethyl)phenyl)carbamate

25 (4-Aminophenyl)methanol (1.23 g, 10 mmol) and diisopropylethylamine (2.6 mL, 15 mmol) was mixed with di-*tert*-butyl dicarbonate (2.62 g, 12 mmol) in dichloromethane (50 mL). The mixture was stirred at room temperature overnight. Ethyl acetate was added and the organic layer was washed with water, 1.0N HCl, saturated sodium carbonate, water, brine, dried over MgSO₄, filtered and
30 evaporated. The crude product was purified by flash column chromatography with

Ethyl acetate/heptane (2:3) to give *tert*-butyl *N*-(4-

(hydroxymethyl)phenyl)carbamate (2.16g, 9.67 mmol). ¹H NMR (CDCl₃-*d*) δ 1.52 (s, 9H), 4.63 (s, 2H), 6.47 (bs, 1H), 7.30 (d, 8.5Hz, 2H), 7.36 (d, 8.5Hz, 2H).

- 5 b) 4-Aminobenzyl *N*-(4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl)carbamate

Phenyl *N*-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]carbamate (51mg, 0.111 mmol) was mixed with *tert*-butyl *N*-(4-(hydroxymethyl)phenyl)carbamate (119 mg, 0.533) in pyridine (0.8 mL). The
10 reaction mixture was heated at 100°C overnight. The solvent was removed and the residue was purified by preparative reverse phase LC/MS to give 4-aminobenzyl *N*-(4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl)carbamate

(9 mg, 0.015mmol). ¹H NMR (CDCl₃-*d*) δ 1.52(s, 1H), 2.08(m, 4H), 3.65 (m, 2H),
15 3.90 (s, 3H), 4.14(m, 2H), 4.97 (m, 1H), 5.17 (s, 2H), 5.37(bs, 1H), 6.55 (s, 1H), 6.95 (s, 1H), 7.03 (s, 1H), 7.06 (m, 1H), 7.31(s, 1H), 7.38 (m, 3H), 8.16 (bs, 1H), 8.30 (s, 1H). LC/MS: MH⁺ 589.

Example 256

- 20 *N*1-[4-(4-Amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]benzamide

5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (80mg, 0.236 mmol) was dissolved in dichloromethane (2.0 mL). Pyridine (2.0 mL) was added followed by benzoyl chloride (41 uL, 0.353
25 mmol). After stirring at room temperature for 2 hours, the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give *N*1-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]benzamide (64 mg, 0.144 mmol). ¹H NMR (CDCl₃-*d*) δ 2.12 (m,
30 4H), 3.67 (m, 2H), 3.99 (s, 3H), 4.17(m, 2H), 4.99 (m, 1H), 7.03(s, 1H), 7.04 (s,

1H), 7.14 (d, J=8.2Hz, 1H), 7.53 (m, 3H), 7.94(d, J=7.8Hz, 1H), 8.33 (s, 1H), 8.58 (s, 1H), 8.63 (d, J=8.2Hz, 1H). LC/MS: MH⁺=444

Example 257

- 5 *N*2-[4-(4-Amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]-2-pyridinecarboxamide

5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (80mg, 0.236 mmol) was dissolved in dichloromethane (2.0 mL). Pyridine (2.0 mL) was added followed by 2-pyridinecarbonyl chloride hydrochloride (63 mg, 0.353 mmol). After stirring at room temperature for 2 hours, the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give *N*1-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]benzamide (84 mg, 0.189 mmol). 1H NMR (CDCl₃-*d*) δ 2.12 (m, 4H), 3.67 (m, 2H), 4.03 (s, 3H), 4.14(m, 2H), 5.00 (m, 1H), 5.37 (s, 1H), 7.04(s, 1H), 7.09 (s, 1H), 7.14 (d, J=8.2Hz, 1H), 7.50 (m, 1H), 7.92 (m, 1H), 8.33 (s, 1H), 8.70(d, J=8.2Hz, 1H), 10.62 (s, 1H). LC/MS: MH⁺=445.

Example 258

- 20 *N*5-[4-(4-Amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]-1,3-dimethyl-1*H*-5-pyrazolecarboxamide

5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (80mg, 0.236 mmol) was dissolved in dichloromethane (2.0 mL). Pyridine (2.0 mL) was added followed by 2-pyridinecarbonyl chloride hydrochloride (63 mg, 0.353 mmol). After stirring at room temperature for 2 hours, the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give *N*5-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]-1,3-dimethyl-1*H*-5-pyrazolecarboxamide (30 mg, 0.065 mmol).

¹H NMR (CDCl₃-*d*) δ 2.11 (m, 4H), 2.32 (s, 3H), 3.66 (m, 2H), 3.99 (s, 3H), 4.13(m, 2H), 4.17 (s, 3H), 4.99 (m, 1H), 5.22 (bs, 2H), 6.46 (s, 1H), 7.03 (s, 1H), 7.07 (s, 1H), 7.12 (d, J=8.2Hz, 1H), 8.33 (2, 2H), 8.49(d, J=8.2Hz, 1H). LC/MS: MH⁺=462.

5

Example 259

*N*1-[4-(4-Amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]-2,2-dimethylpropanamide

5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (50mg, 0.147 mmol) was dissolved in dichloromethane (1.5 mL). Pyridine (1.5 mL) was added followed by 2,2-dimethylpropanoyl chloride (31 mg, 0.221 mmol). After stirring at room temperature for 2 hours, the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give *N*1-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]-2,2-dimethylpropanamide (27 mg, 0.064 mmol). ¹H NMR (CDCl₃-*d*) δ 1.35 (s, 9H), 2.09 (m, 4H), 3.66 (m, 2H), 3.96 (s, 3H), 4.13(m, 2H), 4.97 (m, 1H), 5.46(bs, 2H), 6.98 (s, 1H), 7.04 (s, 1H), 7.07 (d, J=8.2Hz, 1H), 8.15 (s, 1H), 8.29 (s, 1H), 8.49(d, J=8.2Hz, 1H). LC/MS: MH⁺=424.

20

Example 260

*N*1-[4-(4-Amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]-1-cyclopentanecarboxamide

5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (50mg, 0.147 mmol) was dissolved in dichloromethane (1.5 mL). Pyridine (1.5 mL) was added followed by 1-cyclopentanecarbonyl chloride (31 mg, 0.221 mmol). After stirring at room temperature for 2 hours, the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give *N*1-

25

-206-

[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]-2,2-dimethylpropanamide (33 mg, 0.076mmol). ¹H NMR (CDCl₃-*d*) δ 1.66 (m, 2H), 1.81 (m, 2H), 1.95 (m, 4H), 2.06 (m, 4H), 2.77 (m, 1H), 3.65 (m, 2H), 3.94 (s, 3H), 4.15(m, 2H), 4.96 (m, 1H), 5.37(bs, 2H), 6.98 (s, 1H), 7.03 (s, 1H), 7.07 (d, J=8.2Hz, 1H), 7.84 (s, 1H), 8.30 (s, 1H), 8.49(d, J=8.2Hz, 1H).
LC/MS: MH⁺=437.

Example 261

N1-[4-(4-Amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]-3-phenylpropanamide
5-(4-Amino-3-methoxyphenyl)-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (50mg, 0.147 mmol) was dissolved in dichloromethane (1.5 mL). Pyridine (1.5 mL) was added followed by 3-phenylpropanoyl chloride (37 mg, 0.221 mmol). After stirring at room temperature for 2 hours, the solvent was removed and the residue was dissolved in 1 ml DMSO, methanol (1 mL) was added and precipitate was formed. The solid was collected by filtration to give N1-[4-(4-amino-7-tetrahydro-2*H*-4-pyranyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl]-2,2-dimethylpropanamide (7 mg, 0.015mmol). ¹H NMR (CDCl₃-*d*) δ 2.07 (m, 4H), 2.75 (m, 2H), 3.09 (m,2H), 3.65 (m, 2H), 3.88 (s, 3H), 4.13(m, 2H), 4.96 (m, 1H), 5.97(bs, 2H), 6.93 (s, 1H), 7.05 (m, 2H), 7.26 (m, 5H), 7.70 (s, 1H), 8.24 (s, 1H), 8.46(d, J=8.2Hz, 1H). LC/MS: MH⁺=472.

Examples 262-267 were synthesized using the following procedure:


a)

A mixture of cis-5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.25 g, 0.575 mmol), pyridine (2.5 ml) and dichloromethane (2.5 ml) was treated with the appropriate acid chloride (0.862 mmol) and then stirred at ambient temperature under an atmosphere of nitrogen for 1 hour. The solvents were removed under

-207-

reduced pressure and the residue was purified by preparative reverse phase chromatography. The compound (280 mg, 0.460 mmol) was dissolved in hot ethyl acetate (25 ml) then treated with maleic acid (160 mg, 1.38 mmol) dissolved in ethyl acetate (10 ml) the mixture was allowed to cool to ambient temperature then stirred for 1 hour. The solid was collected by filtration and dried to give the compound as the trimaleate salt. (370 mg).

Analytical RP-HPLC RT listed in the table were obtained on a Hypersil HS C18 column ((5 μ m, 100A) 250 x 4.6 mm) using a linear gradient of 25-100% acetonitrile/0.1 M ammonium acetate over 10 min at 1ml/min. Retention time is indicated by "RT" Mass spectrum molecular weights are indicated by "MH⁺".



Example 262


RT 6.62

MH⁺ 576.3

15

Gradient a

-208-




Example 263

RT 7.7

MH⁺ 608.2

5

Gradient a



Example 264

10


RT 14.23

MH⁺ 588.3

Gradient b

15

-210-



Example 267

RT 8.15

MH⁺ 642.3

5

-211-





General salt formation procedure:

Trans- benzyl *N*-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)carbamate was dissolved in ethylacetate and treated with maleic acid (280 mg) in ethylacetate. The resulting solid was filtered under a stream of nitrogen and dried *in vacuo* for 4 hr to give *Cis*-benzyl *N*-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)carbamate tri-maleate salt (580 mg) as a cream solid. M.pt. 158°C (dec.) ¹H NMR (d₆ DMSO, 400 MHz): 8.74 (1H, s), 8.27 (1H, s), 7.78 (1H, d), 7.35-7.77 (5H, m), 7.10 (1H, s), 7.04 (1H, s), 6.16 (6H, s), 5.17 (2H, s), 4.74 (1H, m), 3.82 (3H, s), 3.23 (5H, m), 2.78 (3H, s), 2.51 (3H, m), 2.41 (1H, s), 2.09 (4H, m), 1.70 (4H, m). HPLC: (5 to 95% CH₃CN in 0.1 N aqueous ammonium acetate over 20 min.) t_r = 13.30 min , 94%.

In a similar manner were prepared the following salts. The LCMS conditions are described below.

-212-


LSMS data: Perkin Elmer
Pecosphere C18, 3mM, 33
x 4.6, 3.5 ml/min 100 –
100% 50 mM ammonium
acetate to acetonitrile in 4.5
minutes

Structure	Ret. Time	MH+
	2.92	497.1
	3.02	497.2
	2.64	481.2
	2.7	481.2

- Example 268: *Cis* and *trans*-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-
 5 7H-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide
 To 4-[4-amino-5-(4-amino-3-methoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-
 7-yl]-1-cyclohexanone (0.8 g, 2.3 mmol) in pyridine/dichloromethane (1:2.5, 45 ml)
 was added hydrocinnamylchloride (0.57 g, 3.4 mmol) in dichloromethane (2 ml) at
 0°C under a flow of nitrogen. The solution was stirred at 0°C for 2 hr. The solution
 10 was quenched with saturated aqueous citric acid solution (50 ml) and the organic
 layer was washed with saturated aqueous citric acid solution (2 x 50 ml). Dry, filter
 and concentrate to leave a brown foam (1.0 g). This was dissolved in dichloroethane

-213-

- (100 ml) and N-methylpiperazine (0.63 g, 6.3 mmol) and acetic acid (0.38 g, 6.3 mmol) was added. Sodium triacetoxyborohydride (0.67 g, 3.15 mmol) was added portionwise under nitrogen and the mixture stirred overnight at room temperature. Quench with saturated aq. NaHCO₃ solution (50 ml) and extract with
- 5 dichloromethane (3 x 100 ml). The combined organics were dried (sodium sulphate), filtered and evaporated to leave a sludge which was purified by flash silica gel column chromatography using dichloromethane / methanol (100/0 to 50/50 in 5% increments). The fractions corresponding to the faster running material were combined to give *cis*-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide (0.26 g) as a
- 10 glass. This was dissolved in ethylacetate (5 ml) and maleic acid (160 mg) in ethylacetate (2 ml) added. The resulting solid was filtered to give *cis*-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide trimaleate salt (260 mg) as a white solid.
- 15 Analytical LC/MS conditions: Column: Pecosphere, C18, 3 μ m, 33x4.6 mm. Eluent: 0% B/A to 100% B/A in 4.5 min. (B: acetonitrile, A: 50 mM ammonia acetate buffer, PH 4.5) , 3.5 mL/min. (r_t = 2.86 mins, 568.4).
- The fractions corresponding to the slower running material were combined to give trans-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-
- 20 *d*]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide (0.11 g) as a glass. This was dissolved in ethylacetate (5 ml) and treated with a solution of maleic acid (68 mg) in ethylacetate (2 ml). The resulting solid was filtered to give trans-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide tri-maleate (94 mg) as a white solid.
- 25 Analytical LC/MS conditions: Column: Pecosphere, C18, 3 μ m, 33x4.6 mm. Eluent: 0% B/A to 100% B/A in 4.5 min. (B: acetonitrile, A: 50 mM ammonia acetate buffer, PH 4.5) , 3.5 mL/min. (r_t = 2.68mins, 568.2).



4-[4-amino-5-(4-amino-3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanone (2.25 g, 6.5 mmol), acetic acid (1.17 g, 19.5 mmol) and N-methylpiperazine (1.95 g, 19.5 mmol) were dissolved in dichloroethane (200 ml). Sodium triacetoxyborohydride (2.07 g, 9.75 mmol) was added portionwise and the mixture stirred at room temperature overnight. Saturated sodium bicarbonate solution (150 ml) was added and the aqueous layer extracted with dichloromethane (3 x 100 ml). The combined organics were washed with water, dried (sodium sulphate), filtered and evaporated to leave a semi-solid which was purified by flash silica gel column chromatography using CH₂Cl₂ / methanol (0% MeOH to 50% MeOH in 5% increments). The fractions corresponding to the faster running material were combined and evaporated to give *cis*- 5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1.2 g, 43%) as a cream solid. ¹H NMR (d₆-DMSO): δ 8.1 (1H, s), 7.11 (1H, s), 6.87 (1H, s), 6.79 (1H, d), 6.05 (2H, bs), 4.80 (2H, bs), 4.64 (1H, m), 4.08 (1H, m), 3.82 (3H, s), 3.17 (2H, m), 2.37 (6H, m), 2.21 (3H, s), 2.08 (4H, m), 1.70 (2H, m), 1.53 (2H, m). HPLC (r_t = 11.24 min, 97.6%).


The fractions corresponding to the slower running material were combined and evaporated to give *trans*- 5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (0.4 g, 14%) as a white solid. ¹H NMR (d₆-DMSO): δ 8.10 (1H, s), 7.26 (1H, s), 6.87 (1H, s), 6.77

-215-

(1H, d), 6.71 (1H, d), 6.05 (2H, bs), 4.79 (2H, s), 4.52 (1H, m), 3.81 (3H, s), 3.35 (1H, m), 2.50 (5H, m), 2.31 (5H, m), 2.14 (1H, m), 1.97 (6H, m), 1.45 (2H, m).
HPLC (t_r = 10.13 min, 97.9%).

- 5 To a solution of *cis*- 5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (30 mg, 0.069 mmol) in pyridine (0.5 ml) was added the appropriate acid chloride (2 eq., 0.138 mmol). . The vials were capped and shaken overnight on an orbital shaker. Another
10 two equivalent of acid chlorides (0.138 mmol) was added in two portions (1 equivalent each) and the resulting mixtures were shaken overnight again. LCMS (Micromass- Column: Pecosphere, C18, 3 μ m, 33x4.6 mm. Eluents: 0% B/A to 100% B/A in 4.5 min.(B: acetonitrile, A: 50 mM ammonia acetate buffer, PH 4.5) , 3.5 mL/min.) of the resulting mixtures showed presence of product in all cases. The
15 solutions were evaporated to dryness and the resulting residues were re- dissolved in a small volume of DMF and purified by reverse phase prep. HPLC. The structures are detailed below alongwith the appropriate LCMS data.

Examples 269 to 293 were made by methods analogous to Example 268.




20

Example 269
RT 2.61
MH⁺ 576.3


25

-216-



Example 270
RT 3.02
MH+ 570.3


5



10

Example 271
RT 2.61
MH+ 600.3


15



20


Example 272
RT 3.26
MH+ 608.3

-217-



5


Example 273
RT 2.74
MH⁺ 570.3



10

Example 274
RT 2.78
MH⁺ 558.4


15



20

Example 275
RT 3.00
MH⁺ 574.3

5




Example 276

RT 2.76

570.3

10



Example 277

RT 3.26


MH⁺ 608.3

15

20

-219-

5




Example 278

RT 2.94

MH⁺ 570.3

10




Example 279

RT 3.13

MH⁺ 604.3

15

20



5


Example 280

RT 3.16

580.3

10

15



20

Example 281


RT 2.68

MH⁺ 565.3

25

-221-


5



10

Example 282
RT 2.90
MH⁺ 585.3

15




20

Example 283
RT 2.84
MH⁺ 585.3

25


-222-



5

Example 284
RT 2.90
MH⁺ 576.3

10




15

Example 285
RT 2.90
MH⁺ 584.4

20

25

-223-




Example 286
RT 2.74
MH+ 565.6

5

10


15



Example 287
RT 3.06
MH+ 576.3

20

25




5

Example 288
RT 2.53
MH⁺ 575.3

10


15



20


Example 289
RT 3.32
MH⁺ 624.3

-225-




Example 290
RT 2.85
MH+ 594.4

5



10

Example 291
RT 2.76
MH+ 592.3




15

Example 292

-226-

RT 2.86
MH⁺ 583.3

5



Example 293
RT 2.29
MH⁺ 508.3

10

15

General Synthesis for examples 294-301:

20 Method A

A mixture of the appropriate piperazine (7.60 mmol), 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanone (2.53 mmol), and glacial acetic acid (7.60 mmol) in 50 mL of dichloroethane was stirred at room temperature for 1.5 hours.

Sodium triacetoxyborohydride (3.28 mmol) was added and the mixture was stirred at
25 room temperature for 16 hours. A solution of 1.35 g of sodium bicarbonate in 50 mL of water was added and the reaction mixture was stirred for 1 hour. The organic portion was separated, dried over magnesium sulfate, filtered, and the filtrate concentrated to afford a brown oil. Purification by flash chromatography on silica gel afforded the *cis*- and *trans*-7-[(4-piperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amines.
30

-227-


Method B

A mixture of the appropriate pyrrolidine (7.53 mmol), 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanone (2.51 mmol), and glacial acetic acid (7.35 mmol) in 45 mL of dichloroethane was stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (3.26 mmol) was added and the mixture was stirred at room temperature for 22 hours. A solution of 1.35 g of sodium bicarbonate in 50 mL of water was added and the reaction mixture was stirred for 1 hour. The organic portion was separated, dried over magnesium sulfate, filtered, and the filtrate concentrated to afford a brown oil. Purification by flash chromatography on silica gel afforded the *cis*- and *trans*-7-(4-pyrrolidino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amines.

Salt Formation

To a warm solution of pyrrolopyrimidine (2.48 mmol; from methods A or B, above) in ethanol was added a solution of maleic acid (7.28 mmol) in ethanol. A white precipitate formed as the solution was cooled to ambient temperature. The resulting solid was isolated by filtration and dried under vacuum to yield the desired tris maleate salt.

Analytical RP-HPLC RT listed in the table were obtained on a Hypersil HyPurity Elite C18 column ((5uM, 200 Å) 250 x 4.6 mm) using a linear gradient of 25-100% acetonitrile/0.1 M ammonium acetate over 10 min. (gradient a) or 25 min. (gradient b) at 1 mL/min.




Example 294

-228-

RT 7.967

MH+ 511.1

Gradient a




5

Example 295

RT 7.383

MH+ 527.2

Gradient a



10


Example 296

RT 13.941

MH+ 497.1

Gradient b

-229-




Example 297

RT 7.733

MH+ 511.2

Gradient a

5



Example 298


RT 14.067

MH+ 497.1

Gradient b

10

-230-




Example 299

RT 13.891

MH⁺ 497.1

Gradient b

5



Example 300


RT 14.076

MH⁺ 497.1

Gradient b

10

15



Example 301

RT 7.750

MH⁺ 527.2

Gradient a

- 5
- 10 Example 302: Cis and trans 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-hydroxycyclohexylmethyl cyanide

15 A solution of diisopropylamine (0.649 g, 0.0050 mol) in tetrahydrofuran (10 mL) was cooled to 0° C. A solution of 1.6 M n-butyl lithium (3.14 mL, 0.0050 mol) in hexanes was added dropwise, keeping the temperature less than 5° C. After the addition was complete, the mixture was stirred for 20 minutes at 0° C. The mixture was cooled to -78° C, and dry acetonitrile (0.175 g, 0.0043 mol) was added, keeping the temperature less than -70° C. After the addition was complete, the mixture was stirred for 20 minutes at -78° C, and a mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanone (1.000 g, 0.0025 mmol) in tetrahydrofuran (10 mL) and hexamethylphosphoramide (10 mL) was added, keeping the temperature less than -70° C. After the addition was complete, the mixture was stirred for 30 minutes at -78° C, then stirred at ambient temperature for 18 hours. The

20

mixture was partitioned between dichloromethane and saturated ammonium chloride (aq). The organic phase was washed with water and saturated sodium bicarbonate (aq), and dried over magnesium sulfate. The solvent was removed *in vacuo* and the cis and trans isomers were separated by flash column chromatography on silica using
5 dichloromethane/methanol (95:5) as an eluent to give less polar 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexylmethyl cyanide (0.120g, 0.00027 mol) and more polar 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexylmethyl cyanide (0.170g, 0.00038 mol):

10

Less polar:

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.48 (d, 2H), 7.41 (t, 2H), 7.37 (s, 1H), 7.15 (t, 1H), 7.093 (d, 2H), 7.088 (d, 2H), 6.11 (b, 2H) 5.05 (s, 1H), 4.53-4.61 (m, 1H), 2.66 (s, 2H), 2.18 (q, 2H), 1.80 (t, 4H) 1.66 (t, 2H); RP-HPLC (Delta Pak
15 C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 15.90. MH⁺ 440.

More polar: (Probably trans, aryl-axial, OH-axial)

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.63 (s, 1H), 7.48 (d, 2H), 7.41 (t, 2H), 7.15 (t, 1H), 7.11 (d, 2H), 7.08 (d, 2H), 6.11 (b, 2H) 5.22 (s, 1H), 4.62-4.67 (m, 1H), 2.98 (s, 2H), 1.82-1.99 (m, 6H), 1.65-1.73 (m, 2H); RP-HPLC (Delta Pak C18,
20 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 15.88. MH⁺ 440.

25 Example 303: *cis- and trans- 5-(4-amino-3-fluorophenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine*

a) tert-Butyl N-(4-bromo-2-fluorophenyl)carbamate

Sodium bis(trimethylsilyl)amide solution (1.0M soln. in THF, 2.05 equiv., 270 mL,
30 270 mmol) was added dropwise to a solution of 4-bromo-2-fluoroaniline (24.78 g, 130.4 mmol) in THF (250 mL) over 15 min. under nitrogen. After a further 15 min.,

di-*tert*-butyl dicarbonate (1.2 equiv., 34.12 g, 156.3 mmol) was added portionwise (note: a slight exotherm was observed). The reaction became very viscous and after 4 h. reached completion (t.l.c. analysis using 1:9 EtOAc:heptane as the eluent). The reaction was concentrated *in vacuo* and the residue was partitioned between EtOAc
5 (300 mL) and saturated aq. NaHCO₃ (150 mL). The aqueous layer was further extracted EtOAc (2 x 200 mL) and the combined organic layers were dried (Na₂SO₄) and concentrated under reduced pressure. Purification by column chromatography using a 10% to 15% EtOAc : heptane gradient afforded *tert*-butyl *N*-(4-bromo-2-fluorophenyl)carbamate a light yellow waxy solid (30.0 g, 79%), ¹H NMR (400
10 MHz, CDCl₃) 1.51 (9H, *s*), 7.22 (1H, *m*), and 7.24 (2H, *m*).

b) *tert*-Butyl *N*-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate

A solution of the *tert*-butyl *N*-(4-bromo-2-fluorophenyl)carbamate (54.0 g,
15 0.186 mmol), *bis*-pinacolatodiborane (1.2 equiv, 56.8 g, 223.3 mmol), potassium acetate (3.0 equiv, 54.7 g, 558 mmol) and PdCl₂(dppf) (0.03 equiv, 4.65 g, 5.58 mmol) in degassed DMF (1 l) was heated at 80°C under nitrogen for 16 h. The DMF was removed under reduced pressure and the resulting dark solid residue was dissolved in CH₂Cl₂ (500 mL). The inorganic residues were removed by filtration
20 through a silica gel pad and the filtrate was purified by column chromatography using a 10% to 15% EtOAc : heptane gradient to afford the product as a yellow viscous oil which crystallized on standing to give *tert*-butyl *N*-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate (56.5 g, 92 %), ¹H NMR (400 MHz, CDCl₃) 1.33 (12 H, *s*), 1.53 (9 H, *s*), 6.82 (1H, *br s*), 7.46 (1H, *d*, *J* 11
25 Hz), 7.55 (1 H, *br d*), and 8.12 (1 H, *br t*), *m/z* 337.2, and RP-HPLC (5 to 100 % CH₃CN in 0.1 N aqueous ammonium acetate over 15 min at 1 mL/min using a Hypersil HyPurity Elite C18, 5m, 200 Å, 250 x 4.6 mm column) *t*_r = 10.16 min, 90%.

c) *tert*-Butyl *N*-4-[4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-
30 d]pyrimidin-5-yl]-2-fluorophenylcarbamate

A suspension of the 4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-5-iodo-7H-

pyrrolo[2,3-d]pyrimidine (31.18 g, 74.41 mmol), tert-butyl N-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate (1.5 equiv, 37.6 g, 111.6 mmol), sodium carbonate (2.5 equiv, 19.72 g, 186 mmol) and Pd(PPh₃)₄ (4 mol%, 3.44 g, 2.98 mmol) in DME (1.2 l) and degassed H₂O (230 mL) was heated at 80°C under nitrogen for 17 h. Additional Pd catalyst (1 mol%, .86 g, 0.74 mmol) was added and the reaction was continued heating at 80°C for a further 24 h. at which point the reaction had proceeded to completion (t.l.c. analysis using 3:7 EtOAc:heptane as the eluent, R_f=0.7). The solvent was removed under reduced pressure and the residue dissolved in EtOAc (500 mL) and the inorganics were removed by filtration through a celite pad. The filtrate was washed with 10% aq. Na₂CO₃ (200 mL) and brine (200 mL), dried (MgSO₄) and concentrated in vacuo. Column chromatography purification over silica gel using 1:2 EtOAc:heptane afforded tert-butyl N-4-[4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenylcarbamate as an off-white solid (21.0 g, 56%), ¹H NMR (400 MHz, CDCl₃) 1.55 (9 H, s), 1.89 (4 H, m), 2.07 (4 H, m), 4.01 (4 H, s), 4.89 (1 H, m), 6.75 (1 H, br s), 7.23 (1 H, br s), 7.25 (1 H, br s), 7.34 (1 H, br s), 8.14 (1 H, br t), and 8.64 (1 H, s) and RP-HPLC (5 to 100 % CH₃CN in 0.1 N aqueous ammonium acetate over 15 min at 1 mL/min using a Hypersil HyPurity Elite C18, 5µm, 200Å, 250 x 4.6 mm column) t_r = 10.48 min., 100%.

d) 5-(4-Amino-3-fluorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

A cloudy mixture of tert-butyl N-4-[4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenylcarbamate (10.5 g, 20.92 mmol), aq. ammonium hydroxide (28 - 30 %, 100 mL) and dioxane (100 mL) was placed in a sealed vessel at ambient temperature then heated to 120°C with stirring for 24 h. (t.l.c. analysis using 9:1 EtOAc:heptane as the eluent). The reaction was concentrated *in vacuo*, diluted with EtOAc (300 mL), washed with brine (2x 150 mL), dried (Na₂SO₄) and concentrated under reduced pressure and scrupulously dried to afford 5-(4-Amino-3-fluorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a yellow solid (7.93 g, 99 %), ¹H NMR (400

MHz, d_6 -DMSO) 1.74 (4 H, *m*), 1.90 (2 H, *m*), 2.06 (2 H, *m*), 3.90 (4 H, *m*), 4.64 (1 H, *m*), 5.18 (2 H, *br s*), 6.02 (2 H, *br s*), 6.84 (1 H, *t*), 6.97 (1 H, *d*), 7.08 (1 H, *d*), 7.26 (1 H, *s*) and 8.10 (1 H, *s*) and m/z 384.2 (MH^+).

- 5 e) 4-[4-amino-5-(4-amino-3-fluorophenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone

5M HCl (300 mL) was added slowly to a solution of 5-(4-amino-3-fluorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (18.49 g, 48.28 mmol) in acetone (800 mL) at 0°C the resulting dark orange-brown solution was heated at 60°C for 4 h. (t.l.c. analysis using 10% MeOH in CH_2Cl_2). The acetone was removed under reduced pressure and the acidic layer was basified to approx. pH 8 using sat. aq. Na_2CO_3 . The resulting precipitate was collect by filtration and scrupulously dried to afford 4-[4-amino-5-(4-amino-3-fluorophenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone as a light brown solid (12.67 g, 77%). A second crop was also obtained from the mother liquor on standing (2.01 g, 12%), 1H NMR (400 MHz, d_6 -DMSO) 2.27 (2 H, *m*), 2.30 (4 H, *br d*), 2.73 (2 H, *m*), 5.14 (1 H, *m*), 5.20 (2 H, *br s*), 6.05 (2 H, *br s*), 6.85 (1 H, *t*), 6.97 (1 H, *dd*), 7.06 (1 H, *dd*), 7.35 (1 H, *s*) and 8.12 (1 H, *s*) and m/z 340.1 (MH^+).

- 20 *cis- and trans- 5-(4-Amino-3-fluorophenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine*

Example 304: *cis*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide tri-
25 maleate

To a solution of 4-[4-amino-5-(4-amino-3-fluorophenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone (1.0 g, 2.95 mmol), N-methylpiperazine (3 equiv, 0.885 g, 8.85 mmol, 0.98 mL) and glacial acetic acid (3 equiv., 0.51 mL, 8.85 mmol) in dichloroethane (50 mL) under nitrogen was added sodium
30 triacetoxyborohydride (1.3 equiv., 0.81 g, 3.84 mmol). The solution was stirred for 18 hr then additional sodium triacetoxyborohydride (0.40 g, 1.9 mmol) was added

- and the reaction continued for a further 48 hr. The reaction was concentrated *in vacuo*, partitioned between dichloromethane (100 mL) and sat. aq. NaHCO₃ (100 mL). The aqueous layer was further extracted with dichloromethane (4 x 100 mL) and the combined organic layers were dried over magnesium sulfate and evaporated to dryness to give a yellow foam (0.95 g). Purification by column chromatography over silica gel using a dichloromethane:methanol (9:1 to 5:1) gradient afforded *cis*-5-(4-amino-3-fluorophenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine, the higher running component, as a cream solid (400 mg, 32 %). ¹H NMR (d₆ DMSO, 400 MHz) 1.56 (3H, br t), 1.68 (2H, br d), 1.99 (5H, m), 2.20 (3H, s), 2.43 (7H, br m), 4.65 (1H, m), 5.20 (2H, s), 6.01 (2H, br s), 6.85 (1H, t, *J*= 9.6 Hz), 6.98 (1H, dd, *J*= 8.0 and 1.6 Hz), 7.10 (1H, dd, *J*=12.4 and 1.6 Hz), 7.12 (1H, s), and 8.10 (1H, s) and RP-HPLC (10 to 90 % CH₃CN in 0.1 N aqueous ammonium acetate over 12 min at 2 mL/min using a Waters Symmetry C18, 250 x 4.6 mm column) *t*_r= 8.619 min., 96%
- A mixed fraction was obtained which contained both *cis*- and *trans*-isomers (440 mg, 50:50 mixture), and in addition the lower running fraction contained *trans*-5-(4-amino-3-fluorophenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine, as a yellow solid (110 mg, 9%), ¹H NMR (d₆ DMSO, 400 MHz) 1.94 (6H, m), 2.17 (3H, s), 2.33 (7H, br m), 2.51 (3H, m), 3.28 (1H, m), 4.51 (1H, m), 5.18 (2H, s), 6.01 (2H, br s), 6.84 (1H, t), 6.96 (1H, dd), 7.04 (1H, dd), 7.30 (1H, s), and 8.08 (1H, s) and RP-HPLC (10 to 40 % CH₃CN in 0.1 N aqueous ammonium acetate over 12 min at 2 mL/min using a Waters Symmetry C18, 250 x 4.6 mm column) *t*_r= 7.595 min, 97%
- Example 305: *trans*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide tri-maleate
- 4-Fluorobenzenesulfonyl chloride (45.9 mg, 0.236 mmol) was added to a solution of *trans*-5-(4-amino-3-fluorophenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (100 mg, 0.236

mmol) in pyridine (2 mL) at 40°C. After 27 hr at 40°C the reaction had reached completion and was concentrated in vacuo. Purification by column chromatography over silica gel using 10% to 50% MeOH in dichloromethane as the gradient afforded as a colorless oil (0.78 mmol). The product was dissolved in ethanol and maleic
5 acid (3 equiv., 27 mg, 0.233 mmol) added. The mixture was heated until homogeneous and *trans-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide trimaleate* crystallised on cooling as a fawn solid (37 mg, 17 %), RP-HPLC (10 to 40 % CH₃CN in 0.1 N aqueous ammonium acetate over 12 min at 2 mL/min using a
10 Waters Symmetry C18, 250 x 4.6 mm column) t_r = 14.528 min., 96% and m/z 582.0 (MH^+).

Example 306: *cis-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide*
15 *cis-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide* was prepared using the same procedure as detailed for the free base of *trans-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide* except on a 3.36 mmol scale.
20 (400 mg, 32%), RP-HPLC (10 to 40 % CH₃CN in 0.1 N aqueous ammonium acetate over 12 min at 2 mL/min using a Waters Symmetry C18, 250 x 4.6 mm column) t_r = 15.232, 94% min. and m/z = 582.1 (MH^+).

25 Example 307: *5-(4-amino-3-fluorophenyl)-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine*

a) 7-(1-benzyl-4-piperidyl)-4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine
Diethyl diazodicarboxylate (2.0 equiv., 18.19 g, 41.2 mL, 104.8 mmol) was
30 added dropwise over approx. 1 h to a solution of 4-chloro-3-iodopyrrolo[2,3-d]pyrimidine (14.55 g, 52.4 mmol), 1-benzyl-4-hydroxypiperidine (3.0 equiv., 30.06

g, 157.16 mmol) and triphenylphosphine (2.0 equiv., 27.51 g, 104.8 mmol) in THF (730 mL) at room temperature under nitrogen. The reaction reached completion after 72 h (t.l.c. analysis using 1:1 EtOAc:heptane as the eluent, $R_f = 0.2$). The reaction was concentrated in vacuo and 1:4 ethyl acetate : heptane was added until a precipitate in a clear solution was observed. The precipitate was collected by filtration (Ph₃PO) and the filtrate was concentrated, dissolved in ethyl acetate (500 mL) and extracted with aq. HCl (1M, 3 x 200 mL). The combined acidic layers were basified with aq NaOH (4 N) to pH 12 then extracted into ethyl acetate (3 x 300 mL), dried (MgSO₄) and concentrated in vacuo. Purification by column chromatography using 5:4 light petroleum (30-60 °C):ethyl acetate over silica gel gave 2 main fractions of which the first fraction contained the product as a pale yellow crystalline solid which was recrystallised from ethyl acetate to give 7-(1-benzyl-4-piperidyl)-4-chloro-5-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine as a cream crystalline solid (5.7 g, 24 %); ¹H NMR (400 MHz, CDCl₃) 2.02 (4H, m), 2.24 (2H, m), 3.06 (2H, br d), 3.58 (2H, s), 4.76 (1H, m), 7.27 (2H, m), 7.32 (3H, m), 7.49 (1H, s) and 8.60 (1H, s) and $m/z = 452.8$ (MH^+).

b) *tert*-butyl *N*-4-[7-(1-benzyl-4-piperidyl)-4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-fluorophenylcarbamate

A suspension of 7-(1-benzyl-4-piperidyl)-4-chloro-5-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine (5.7 g, 12.6 mmol), *tert*-butyl *N*-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate (1.5 equiv, 18.9 g, 6.38 mmol), sodium carbonate (2.5 equiv, 3.34 g, 31.5 mmol) and Pd(PPh₃)₄ (4 mol%, 0.58 g, 0.5 mmol) in DME (210 mL) and degassed water (37 mL) was heated at 80°C under nitrogen for 17 h (t.l.c. analysis using 1:1 EtOAc:heptane as the eluent). The reaction mixture was concentrated *in vacuo*, dissolved in ethyl acetate (400 mL) and washed with 10 % aq. Na₂CO₃ (3 x 200 mL). The organic layer was dried (MgSO₄), concentrated and purified by column chromatography using 1:1 ethyl acetate:heptane as the eluent to afford *tert*-butyl *N*-4-[7-(1-benzyl-4-piperidyl)-4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-fluorophenylcarbamate as a white crystalline solid (5.2 g, 9.7 mmol, 77%), ¹H NMR (400 MHz, CDCl₃) 1.55 (9 H, s), 2.05 (4H, m), 2.24 (2H, m),

3.06 (2H, *br d*), 3.60 (2H, *s*), 4.83 (1H, *m*), 7.25 (2H, *m*), 7.29 (1H, *m*), 7.33 (6H, *m*), 8.12 (1H, *br t*) and 8.64 (1H, *s*).

5 c) 5-(4-amino-3-fluorophenyl)-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-amine

A mixture of the *tert*-butyl *N*-4-[7-(1-benzyl-4-piperidyl)-4-chloro-7H-pyrrolo[2,3-
d]pyrimidin-5-yl]-2-fluorophenylcarbamate (5.2 g, 9.7 mmol), aq.
ammonium hydroxide (28 - 30 %, 100 mL) and 1,4-dioxane (100 mL) was placed in
a sealed vessel at ambient temperature then heated to 120 °C with stirring for 16 h.
10 (t.l.c. analysis using EtOAc as the eluent). The reaction was concentrated *in vacuo*,
diluted with EtOAc (300 mL), washed with brine (2x 200 mL), dried (Na₂SO₄) and
concentrated under reduced pressure to afford a brown solid which was triturated
with ether (approx. 50 mL) to give 5-(4-amino-3-fluorophenyl)-7-(1-benzyl-4-
piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a cream solid (3.0 g, 74 %), ¹H
15 NMR (400 MHz, CDCl₃) 2.06 (4 H, *m*), 2.27 (2 H, *m*), 3.06 (2 H, *m*), 3.59 (2H, *br s*),
3.70 (2 H, *br s*), 4.73 (1H, *m*), 5.12 (2 H, *s*), 6.85 (1 H, *t*), 7.01(1 H, *s*), 7.06 (1 H,
dd), 7.10 (1 H, *dd*), 7.28 (2 H, *m*), 7.34 (3H, *m*) and 8.31 (1 H, *s*) and m.p. 141-142
°C.

20 Example 308: N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-
d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide

N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-
2-fluorophenyl-4-fluoro-1-benzenesulfonamide (470981) was prepared using the
same procedure as detailed for trans-N1-(4-{4-amino-7-[4-(4-
25 methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-
fluoro-1-benzenesulfonamide tri-maleate except on a 6.96 mmol scale. N1-4-[4-
amino-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-
fluoro-1-benzenesulfonamide was obtained as a cream solid (3.2 g, 80%), m/z 575
(MH⁺) and m.p. 265-6 °C.

30

Example 309: N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-

d]pyrimidin-5-yl]-2-fluorophenyl-2,3-dichloro-1-benzenesulfonamide

N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-2,3-dichloro-1-benzenesulfonamide was prepared in the same manner as detailed above on a 5.04 mmol scale. The resulting N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide was obtained as a brown solid (1.0 g, 32%), m/z 625 (MH^+) and RP-HPLC (5 to 85 % CH_3CN in 0.1 N aqueous ammonium acetate over 20 min at 1 mL/min using a Waters Delta pack 5m C18, 300Å, 150 x 3.9 mm column) t_r = 14.963 min., 95%.

10

Example 310: N1-4-[4-amino-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide

A mixture containing N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide (2.40 g, 4.18 mmol), ammonium formate (10 equiv., 41.8 mmol, 2.62 g), palladium on carbon (10%, 1.2g) and ethanol (100 mL) was heated at reflux with vigorous stirring for 6h., filtered and concentrated *in vacuo*. The solid was partitioned between dichloromethane (50 mL) and water (50 mL). The brown solid which formed at the phase boundary was collected and analysed for N1-4-[4-amino-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide (0.33 g), m/z 485 (MH^+) and m.p. 238-9 °C (dec.).

20

Example 311: N1-4-[4-amino-7-(1-formyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide

25

The procedure detailed for the preparation of N1-4-[4-amino-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide was performed on a smaller scale (0.35 mmol) where the combined organic layers from the work up were isolated, dried (Na_2SO_4) and the solvent removed under reduced pressure to afford a white oil which was purified by preparative HPLC (100% pH 4.5 50mM ammonium acetate to 100% CH_3CN in 8.5 minutes with a 1.5 minute hold at 25 mL/min using a Hypersil 5m BDS C18, 100x 21.2mm column) to

30

yield *N1-4-[4-amino-7-(1-formyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide* as a white solid (50 mg, 27 %), m/z = 512.9 (MH^+) and RP-HPLC (5 to 85 % CH_3CN in 0.1 N aqueous ammonium acetate over 20 min at 1 mL/min using a Waters Delta pack 5m C18, 300Å, 150 x 3.9 mm column) t_r = 13.091 min., 95%.

Example 312: *N1-[4-(4-amino-7-1-[(1-methyl-1H-4-imidazolyl)sulfonyl]-4-piperidyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide dimaleate*

1-Methylimidazol-4-yl sulphonyl chloride (1.1 equiv., 0.068 mmol, 12.3 mg) was added to a suspension of 5-(4-amino-3-fluorophenyl)-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (30 mg, 0.062 mmol) and triethylamine (3 equiv., 0.186 mmol, 26 l) in dichloromethane (1 mL) and stirred at ambient temperature for 24 h. The reaction was concentrated *in vacuo*, partitioned between dichloromethane (100 mL) and water (50 mL) and the aqueous layer was further extracted with dichloromethane (3 x 100 mL). The combined organic layers were dried over magnesium sulfate and concentrated *in vacuo*. Purification by column chromatography over silica gel using 10 % methanol in dichloromethane yielded a waxy white solid (10 mg). Maleic acid (2 equiv., 4 mg) was added to the product in hot ethanol and *N1-[4-(4-amino-7-1-[(1-methyl-1H-4-imidazolyl)sulfonyl]-4-piperidyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide dimaleatesalt* crystallized on cooling (10 mg), RP-HPLC (5 to 85 % CH_3CN in 0.1 N aqueous ammonium acetate over 20 min at 1 mL/min using a Waters Delta pack 5m C18, 300Å, 150 x 3.9 mm column) t_r = 14.186, 100% min. and m/z = 629 (MH^+).

Example 313: *N1-[4-(4-amino-7-1-[(1,2-dimethyl-1H-4-imidazolyl)sulfonyl]-4-piperidyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide*

Using the procedure detailed for the synthesis of the free base of *N1-[4-(4-amino-7-1-[(1-methyl-1H-4-imidazolyl)sulfonyl]-4-piperidyl-7H-pyrrolo[2,3-*

d]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide dimaleate, *N1*-[4-(4-amino-7-1-[(1,2-dimethyl-1*H*-4-imidazolyl)sulfonyl]-4-piperidyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide was prepared as a cream solid (9 mg), m.p. 217-8 °C and *m/z* = 643.2 (*MH*⁺).

5

Example 314: *N1*-[4-(4-amino-7-1-[(1,3-dimethyl-1*H*-5-pyrazolyl)carbonyl]-4-piperidyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide

1,3-Dimethylpyrazole-5-carbonyl chloride (1.5 equiv., 14.8 mg, 0.093 mmol)
10 was added to a stirred suspension of 5-(4-amino-3-fluorophenyl)-7-(1-benzyl-4-piperidyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (30 mg, 0.062 mmol) and potassium carbonate (2 equiv., 17.1 mg, 0.124 mmol) in *N*-methylpyrrolidinone (2 mL) and the resulting mixture was stirred at ambient temperature under nitrogen for 16 h. The solvent was removed in vacuo and the mixture purified by column chromatography
15 over silica gel using 5 % methanol in dichloromethane as the eluent to give *N1*-[4-(4-amino-7-1-[(1,3-dimethyl-1*H*-5-pyrazolyl)carbonyl]-4-piperidyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide as a colourless glass (10 mg), RP-HPLC HPLC (100% pH 4.5 50mM ammonium acetate to 100% CH₃CN in 4.5 minutes with a 0.5 minute hold at 3.5 mL/min using a Perkin Elmer
20 Pecosphere 3m C18 (33 x 4.6mm) column) *t*_r = 2.98 min., 96% and *m/z* = 629 (*MH*⁺).

Example 315: *N1*-(4-{4-amino-7-[1-(2-pyridylcarbonyl)-4-piperidyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide

25 *N1*-(4-{4-amino-7-[1-(2-pyridylcarbonyl)-4-piperidyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide was prepared using the same procedure as detailed for *N1*-[4-(4-amino-7-1-[(1,3-dimethyl-1*H*-5-pyrazolyl)carbonyl]-4-piperidyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide, (12 mg), RP-HPLC HPLC (100% pH 4.5 50mM
30 ammonium acetate to 100% CH₃CN in 4.5 minutes with a 0.5 minute hold at 3.5

mL/min using a Perkin Elmer Pecosphere 3m C18 (33 x 4.6mm) column) t_r = 2.73 min., 98% and m/z = 590.2 (MH^+).

Example 316: N1-4-(4-amino-7-{4-[1-(1-methylpiperid-4-yl)piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl})-2-fluorophenyl-4-fluoro-1-benzenesulfonamide tri-maleate

Sodium triacetoxyborohydride (28.1 mg, 0.134 mmol) was added to a solution of N1-4-[4-amino-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide (50 mg, 0.103 mmol) and 1-methylpiperid-4-one (0.92 ml, 0.155 mmol) in glacial acetic acid (0.025 mL) and NMP (3 mL). The reaction was stirred for 20 h at room temperature then additional sodium triacetoxyborohydride (1.3 equiv.) was added. After a further 24 h the reaction had proceeded to completion and was concentrated *in vacuo*, partitioned between dichloromethane (100 mL) and sat. aq. NaHCO₃ (100 mL). The aqueous layer was further extracted with dichloromethane (4 x 100 mL) and the combined organic layers were dried over magnesium sulfate and evaporated to dryness. Purification by column chromatography over silica gel using dichloromethane:methanol:ammonium hydroxide (78:19:3) as the eluent to afford a brown solid. The tri maleate salt was then formed by standard methods to give N1-4-(4-amino-7-{4-[1-(1-methylpiperid-4-yl)piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl})-2-fluorophenyl-4-fluoro-1-benzenesulfonamide tri-maleate as a brown solid (45 mg, 75%), m/z 582 (MH^+) and RP-HPLC (5 to 85 % CH₃CN in 0.1 N aqueous ammonium acetate over 20 min at 1 mL/min using a Waters Delta pack 5m C18, 300Å, 150 x 3.9 mm column) t_r = 10.658 min., 95%.

25

Example 317: N1-4-[4-amino-7-(4-oxocyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-methoxyphenylbenzamide

a) To a solution of 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (25.0 g, 0.09 mol), 1,4-dioxaspiro[4.5]decan-8-ol (35.8 g, 0.0267 mol) and triphenylphosphine (46.7 g, 0.178 mol) in THF (1.2 L) was added diethylazodicarboxylate (30.9 g, 0.178 mol)

30

under nitrogen. The solution was stirred for 20 hr and the majority of solvent was then evaporated (250 mL remaining). EtOAc (450 mL) was then added and the resulting solid was filtered, washed with EtOAc (2 x 50 mL) and dried *in vacuo* to give 4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-5-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine
5 (22.5 g, 60%) as a cream solid. ¹H NMR (d₆ DMSO, 400 MHz) 8.64 (1H, s), 8.10 (1H, s), 4.74 (1H, m), 3.90 (4H, m), 2.12 (2H, m), 1.91 (2H, m), 1.71-1.83 (4H, m). R_f in 1:4 EtOAc : heptane = 0.12.

b) A solution of *tert*-butyl *N*-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate (8.2 g, 23.5 mmol), 4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-5-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine (6.57 g, 15.7 mmol), tetrakis(triphenylphosphine)palladium (1.1 g, 0.93 mmol), sodium carbonate (4.16 g, 39.2 mmol) in dimethoxyethane (200 mL) and water (100 mL) was heated at 80°C for 20 hr under nitrogen. The resulting solution was cooled to room temperature and
15 partitioned between EtOAc (300 mL) and water (100 mL). The aqueous layer was extracted with EtOAc (3 x 150 mL) and the combined organics were washed with water (1 x 150 mL). The organics were dried (sodium sulphate), filtered and evaporated to leave a solid. On attempting to dissolve in EtOAc/heptane (1:4), a cream solid (2.5 g) crashed out. The filtrate was adsorbed onto silica and purified by
20 flash silica gel column chromatography using 10:1 heptane:EtOAc, 4:1 heptane : EtOAc, 1:1 heptane:EtOAc and 4:1 EtOAc:heptane. The appropriate fractions were combined to give a white solid which was triturated with heptane/EtOAc (5:1) to give *tert*-butyl *N*-4-[4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-methoxyphenylcarbamate
25 as a solid (3.2 g), combined yield is 71%.

¹H NMR (d₆ DMSO, 400 MHz): 8.66 (1H, s), 7.93 (2H, m), 7.74 (1H, m), 7.19 (1H, s), 7.07 (1H, d), 4.81 (1H, m), 3.93 (4H, m), 3.91 (3H, s), 2.18 (2H, m), 1.99 (2H, m), 1.79 (4H, m), 1.48 (9H, s). HPLC (conditions: 5 to 95% CH₃CN in 0.1 N aqueous ammonium acetate over 20 min.) t_r = 21.24 min, 100%.

30

c) *tert*-Butyl *N*-4-[4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7*H*-pyrrolo[2,3-

d]pyrimidin-5-yl]-2-methoxyphenylcarbamate (5.7 g, 0.011 mol), conc. ammonia solution (100 mL) and dioxan (100 mL) were heated in a pressure vessel for 20 hr at 120°C. The solvent was evaporated and the residue reconstituted in EtOAc/water (250 mL/100 mL). The organic layer was separated, dried (sodium sulphate),
5 filtered and evaporated to give a solid which by HPLC (conditions: 5 to 95% CH₃CN in 0.1 N aqueous ammonium acetate over 20 min.) was observed to be a 2:1 mixture of *tert*-butyl *N*-4-[4-amino-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-methoxyphenylcarbamate and 5-(4-amino-3-methoxyphenyl)-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine. The mixture was
10 dissolved in acetone (200 mL) and HCl (5N, 100 mL) was added dropwise over 0.5 hr. The resulting solution was stirred at room temperature overnight and the solvent was then evaporated. The acidic solution was basified with 2N NaOH (ice-cooling) and extracted with EtOAc (3 x 150 mL). The combined organics were washed with water (2 x 100 mL). During the extraction process a solid precipitated. This solid
15 was filtered and triturated in hot EtOAc/MeOH. The insolubles were filtered, the filtrate evaporated and then resulting solid triturated with diethylether/ethyl acetate to give a yellow solid. The organic layers from the original extraction were dried (sodium sulphate), filtered and evaporated. The resulting solid was triturated with diethyl ether/ethyl acetate (5:1) and filtered to give 4-[4-amino-5-(4-amino-3-methoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone as a yellow
20 solid. (2.3 g, combined yield = 78%). ¹H NMR (d₆ DMSO, 400 MHz): 8.17 (1H, s), 7.32 (1H, s), 6.88 (1H, s), 6.77 (1H, m), 6.73 (1H, m), 6.71 (1H, m), 6.07 (2H, bs), 5.14 (1H, m), 3.81 (3H, s), 2.72 (2H, m), 2.35 (4H, m), 2.18 (2H, m). HPLC: (5 to 95% CH₃CN in 0.1 N aqueous ammonium acetate over 20 min.) t_r = 11.24 min ,
25 95%

d) To a solution of 4-[4-amino-5-(4-amino-3-methoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone (0.105 g, 0.3 mmol) in pyridine (2 mL) and dichloromethane (5 mL) was added benzoyl chloride (63 mg, 0.45 mmol) in
30 dichloromethane (1 mL) at 0°C under nitrogen. The solution was stirred at 0°C for 2 hr and then quenched with water (5 mL). HCl (1N, 40 mL) was added and the

aqueous layer extracted with dichloromethane (3 x 25 mL). The combined organic layers were washed with water (1 x 30 mL). The organic layer was dried (sodium sulphate), filtered and evaporated to leave an oil which was purified by flash silica gel column chromatography using 2%-10% MeOH/EtOAc as eluent to give *N*1-4-[4-amino-7-(4-oxocyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-methoxyphenylbenzamide as a white solid (0.130 g, 96%). M.pt 234-237°C. Rf in 9 : 1 EtOAc : MeOH = 0.30. HPLC: (5 to 95% CH₃CN in 0.1 N aqueous ammonium acetate over 20 min.) *t*_r = 14.82 min , 96%. ¹H NMR (d₆ DMSO, 400 MHz): 9.43 (1H, s), 8.19 (1H, s), 7.94 (3H, m), 7.59 (4H, m), 7.18 (1H, s), 7.06 (1H, d, *J* = 8 Hz), 6.18 (2H, bs), 5.20 (1H, m), 3.92 (3H, s), 2.76 (2H, m), 2.35 (4H, m), 2.22 (2H, m).

Example 318: Benzyl *N*-4-[4-amino-7-(4-oxocyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-methoxyphenylcarbamate

To a solution of give 4-[4-amino-5-(4-amino-3-methoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone (0.40 g, 1.15 mmol) in pyridine (5 mL) and dichloromethane (10 mL) was added benzylchloroformate (0.29 g, 1.73 mmol) at -5°C under nitrogen. The solution was warmed to 0°C and stirred for 1 hr. The reaction was quenched with water (5 mL) and the solvent evaporated. The residue was partitioned between EtOAc and water (100 mL each) and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organics were dried (sodium sulphate), filtered and evaporated to leave a solid which was triturated with EtOAc/Et₂O to give benzyl *N*-4-[4-amino-7-(4-oxocyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-methoxyphenylcarbamate (0.28 g) as a yellow solid. M.pt 175-176°C. Rf in 9:1 EtOAc : MeOH = 0.24. HPLC: (5 to 95% CH₃CN in 0.1 N aqueous ammonium acetate over 20 min.) *t*_r = 16.69 min , 98%. ¹H NMR (d₆ DMSO, 400 MHz): 8.64 (1H, s), 8.17 (1H, s), 7.75 (1H, d, *J* = 8.4 Hz), 7.50 (1H, s), 7.36 (5H, m), 7.10 (1H, s), 7.02 (1H, d, *J* = 8 Hz), 6.15 (2H, bs), 5.19 (3H, m), 3.81 (3H, s), 2.72 (2H, m), 2.35 (4H, m), 2.22 (2H, m).

Example 319: *Cis*- benzyl *N*-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)carbamate tri-maleate and

5 *Trans*- benzyl *N*-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)carbamate tri-maleate

To a solution of benzyl *N*-4-[4-amino-7-(4-oxocyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-methoxyphenylcarbamate (0.83 g, 1.74 mmol), *N*-methylpiperazine (0.52 g, 5.22 mmol) and glacial acetic acid (0.31 g, 5.22 mmol) in dichloroethane (100 mL) under nitrogen was added sodium triacetoxyborohydride
10 (0.55 g, 2.61 mmol) portionwise. The solution was stirred for 6 hr and then quenched by the addition of sodium hydroxide (2*N*, 20 mL). The organic layer was separated and the aqueous layer was extracted with dichloromethane (2 x 50 mL). The combined organics were washed with brine (1 x 50 mL), dried (sodium sulphate), filtered and evaporated to leave an oil which was purified by flash silica
15 gel column chromatography using EtOAc, 9:1 EtOAc:MeOH, CH₂Cl₂ and 9:1 CH₂Cl₂:MeOH to give in F20-25 an oil (480 mg). This oil was dissolved in ethyl acetate and treated with maleic acid (280 mg) in ethyl acetate. The resulting solid was filtered under a stream of nitrogen and dried *in vacuo* for 4 hr to give *Cis*-benzyl *N*-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)carbamate tri-maleate salt (580 mg) as a cream
20 solid. M.pt. 158°C (dec.) ¹H NMR (d₆ DMSO, 400 MHz): 8.74 (1H, s), 8.27 (1H, s), 7.78 (1H, d), 7.35-7.77 (5H, m), 7.10 (1H, s), 7.04 (1H, s), 6.16 (6H, s), 5.17 (2H, s), 4.74 (1H, m), 3.82 (3H, s), 3.23 (5H, m), 2.78 (3H, s), 2.51 (3H, m), 2.41 (1H, s), 2.09 (4H, m), 1.70 (4H, m). HPLC: (5 to 95% CH₃CN in 0.1 *N* aqueous ammonium acetate over 20 min.) t_r = 13.30 min , 94%.

F28-45 gave a glassy foam (186 mg) which was dissolved in in ethyl acetate (10 mL) and treated with maleic acid (114 mg) in ethyl acetate (3 mL). The resulting solid was filtered under nitrogen and dried *in vacuo* for 4 hr to give *trans*- benzyl *N*-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)carbamate tri-maleate salt (250 mg) as a cream solid. M.pt
30 146-148°C. HPLC: (5 to 95% CH₃CN in 0.1 *N* aqueous ammonium acetate over 20

min.) t_r = 13.54 min, 94.6%. ^1H NMR (d_6 DMSO, 400 MHz): 8.72 (1H, s), 8.25 (1H, s), 7.77 (1H, d), 7.51 (1H, s), 7.35 (5H, m), 7.10 (1H, s), 7.04 (1H, d), 6.16 (6H, s), 5.17 (2H, s), 4.59 (1H, m), 3.86 (3H, s), 2.70-3.10 (11H, m), 2.50 (3H, s), 1.97 (6H, m), 1.56 (2H, m).

5

Example 320: *Trans*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)benzamide

To a solution of N1-4-[4-amino-7-(4-oxocyclohexyl)-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-methoxyphenylbenzamide (1.2 g, 2.66 mmol), N-methylpiperazine (0.80 g, 7.98 mmol) and glacial acetic acid (0.48 g, 7.98 mmol) in dichloroethane (150 mL) under nitrogen was added sodium triacetoxyborohydride (0.85 g, 3.99 mmol) portionwise. The solution was stirred at room temperature overnight and then quenched by the addition of sodium hydroxide (2 N, 20 mL). The aqueous layer was extracted with dichloromethane (3 x 50 mL) and the combined organics were dried (sodium sulphate), filtered and evaporated to leave a solid which was purified by flash silica gel column chromatography using dichloromethane then 5% MeOH/dichloromethane to 20% MeOH/ dichloromethane in 5% increments. F23-36 were combined and evaporated to give a cream solid (0.11 g) which was dissolved in EtOAc (10 mL) and treated with a solution of maleic acid () in EtOAc (5 mL). The resulting fine solid was filtered under a stream of nitrogen to give *trans*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)benzamide (0.108 g) as a cream solid. ^1H NMR (d_6 DMSO, 400 MHz): 9.48 (1H, s), 8.28 (1H, s), 7.97 (3H, m), 7.53-7.63 (4H, m), 7.18 (1H, s), 7.08 (1H, d), 6.85 (1H, bs), 6.16 (6H, s), 4.61 (1H, m), 3.92 (3H, s), 2.70-3.11 (11H, m), 2.01 (7H, m), 1.58 (2H, m). HPLC/MS (Column = Pecosphere 3 C₁₈ 3 micron, conditions = 100% 100mM ammonium acetate to 100% acetonitrile over 5 min), t_r = 1.83 min, MH^+ = 540.8

Example 321: *Cis*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)-3-phenylpropanamide and

Trans- *N*1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)-3-phenylpropanamide

- a) To a solution of 4-[4-amino-5-(4-amino-3-methoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone (0.8 g, 2.3 mmol) in pyridine (13 mL) and
5 dichloromethane (32 mL) at 0°C was added hydrocinnamoylchloride (0.57 g, 3.4 mmol) in dichloromethane (5 mL) under nitrogen. The solution was stirred at 0°C for 2 hr, warmed to room temperature and quenched by addition of saturated aqueous citric acid solution (50 mL). The organic layer was washed with saturated aqueous citric acid solution (2 x 50 mL), dried (sodium sulphate), filtered and
10 evaporated to leave *N*1-{4-[4-amino-7-(4-oxocyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-methoxyphenyl}-3-phenylpropanamide (1.0 g, 92% crude) as a brown foam. ¹H NMR (d₆ DMSO, 400 MHz): 9.17 (1H, s), 8.18 (1H, s), 8.06 (1H, d), 7.51 (1H, s), 7.18-7.29 (6H, m), 7.09 (1H, m), 6.99 (1H, d), 6.21 (2H, bs), 5.18 (1H, m), 3.88 (3H, s), 1.99 – 2.93 (12H, m). HPLC: (5 to 95% CH₃CN in 0.1 N aqueous
15 ammonium acetate over 20 min.) t_r = 14.48 min , 92.2%.

- c) To a solution of 92% pure *N*1-{4-[4-amino-7-(4-oxocyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-2-methoxyphenyl}-3-phenylpropanamide (1.0 g, 2.1 mmol), *N*-methylpiperazine (0.63 g, 6.3 mmol), acetic acid (0.38 g, 6.3 mmol) in
20 dichloroethane (100 mL) was added sodium triacetoxymethylborohydride (0.67 g, 3.15 mmol) portionwise under nitrogen. The solution was stirred for 20 hr and then quenched by the addition of saturated aqueous sodium bicarbonate solution (50 mL). The aqueous layer was extracted with dichloromethane (3 x 50 mL), dried (sodium sulphate), filtered and evaporated to leave a sludge which was purified
25 by flash silica gel column chromatography using dichloromethane to 50% MeOH/dichloromethane in 10% increments. F84-96 were combined and evaporated to leave *cis-N*1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methoxyphenyl)-3-phenylpropanamide (0.26 g) as a cream foamy glass. HPLC: (5 to 95% CH₃CN in 0.1 N aqueous
30 ammonium acetate over 20 min.) t_r = 12.65 min , 95.2%. ¹H NMR (d₆ DMSO, 400 MHz): 9.17 (1H, s), 8.14 (1H, s), 8.05 (1H, d), 7.28 (5H, m), 7.18 (1H, m),

7.10 (1H, s), 6.99 (1H, d), 6.11 (2H, bs), 4.67 (1H, m), 3.88 (3H, s), 2.90 (2H, m), 2.73 (2H, m), 2.50 (7H, m), 2.28 (3H, s), 2.06 (3H, m), 1.71 (2H, m), 1.55 (2H, m). F121-138 were combined and evaporated to leave *trans*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-methoxyphenyl)-3-phenylpropanamide (0.11 g) as a white solid. HPLC: (5 to 95% CH₃CN in 0.1 N aqueous ammonium acetate over 20 min.) *t*_r = 12.61 min, 96.2%. ¹H NMR (d₆ DMSO, 400 MHz): 9.16 (1H, s), 8.13 (1H, s), 8.04 (1H, d), 7.44 (1H, s), 7.29 (4H, m), 7.18 (1H, m), 7.09 (1H, s), 6.97 (1H, d), 6.11 (2H bs), 4.53 (1H, m), 3.88 (3H, s), 2.93 (2H, m), 2.71 (2H, m), 2.50 (4H, m), 2.30 (5H, m), 2.14 (3H, s), 1.89 (6H, m), 1.46 (2H, m).

General Procedure for Substituted Pyrrolopyrimidine Aryl sulfonamides are as follows:

A 0.19 M solution of 5-(4-amino-3-fluorophenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine in pyridine was added one equivalent of substituted aryl sulfonyl chloride. The mixture was heated to 45°C while being shaken in an Incubator Shaker for 24h. The reaction mixture was purified by using mass actuated preparative RP-HPLC (Micromass/Gilson, Hypersil BDS C18, 5μ, 100x21.2mm; 100-100% ammonium acetate (0.05 M, pH 4.5)-acetonitrile over 12.5 min, 25 mL/min).

Compounds synthesized by the above procedure include:

Name	HPLC rt min	m/z
Example 322: <i>Trans</i> -N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-(trifluoromethoxy)-1-benzenesulfonamide trimaleate	3.18	648.39

Example 323: Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-5-chloro-2-thiophenesulfonamide benzenesulfonamide trimaleate	3.14	604.03
Example 324: Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-4-fluoro-1-benzenesulfonamide benzenesulfonamide trimaleate	3.07	616.1
Example 325: Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate	3.39	632.12
Example 326: cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-4-fluoro-1-benzenesulfonamide trimaleate	2.82	616.2
Example 327: cis-N-1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl)-2,6-difluoro-1-benzenesulfonamide trimaleate	2.66	600.3

Example 328: Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,6-difluoro-1-benzenesulfonamide trimaleate	2.53	600.3
Example 329: Trans- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzothiadiazole-4-sulfonamide trimaleate	2.63	622.1
Example 330: Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trifluoro-1-benzenesulfonamide trimaleate	2.87	618.1
Example 331: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-nitro-1-benzenesulfonamide trimaleate	3.13	609.1
Example 332: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-fluoro-1-benzenesulfonamide trimaleate	2.89	582.1
Example 333: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,4,6-trichloro-1-benzenesulfonamide trimaleate	3.4	668
Example 334: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,6-dichloro-1-benzenesulfonamide trimaleate	3.04	632.1
Example 335: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-1-benzenesulfonamide trimaleate	2.94	598.1

Example 336: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-fluoro-1-benzenesulfonamide dimaleate	2.76	582.1
Example 337: cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-5-chloro-2-thiophenesulfonamide dimaleate	3.01	604.3
Example 338: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-bromo-2,5-difluoro-1-benzenesulfonamide trimaleate	3.38	718.3
Example 339: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-chloro-4-fluoro-1-benzenesulfonamide trimaleate	2.98	616.3
Example 340: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-iodo-1-benzenesulfonamide trimaleate	3.02	690.3
Example 341: cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-(trifluoromethoxy)-1-benzenesulfonamide trimaleate	3.22	648.3
Example 342: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate	2.97	600.3
Example 343: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-6-methyl-1-benzenesulfonamide trimaleate	3.12	612.3

Example 344: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-4-cyano-1-benzenesulfonamide trimaleate	3.02	623.2
Example 345: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trifluoro-1-benzenesulfonamide trimaleate	3.08	618.3
Example 346: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3,4-difluoro-1-benzenesulfonamide trimaleate	2.98	600.3
Example 347: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-bromo-2-fluoro-1-benzenesulfonamide trimaleate	3.13	660.2
Example 348: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-5-bromo-2-thiophenesulfonamide trimaleate	3.16	648.1
Example 349: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,4-dichloro-1-benzenesulfonamide trimaleate	3.09	632.1
Example 350: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trichloro-1-benzenesulfonamide trimaleate	3.41	668.1
Example 351: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-bromo-5-chloro-2-thiophenesulfonamide trimaleate	3.29	683.9

Example 352: Cis- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzothiadiazole-4-sulfonamide trimaleate	2.73	622.1
Example 353: cis- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzoxadiazole-4-sulfonamide trimaleate	2.8	606.1
Example 354: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,5-dichloro-1-thiophenesulfonamide trimaleate	3.18	638
Example 355: cis- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(7-chloro-2,1,3-benzoxadiazole)-4-sulfonamide trimaleate	2.84	640.2
Example 356: Cis- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(7-methyl-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate	2.89	636.2
Example 357: Cis- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(5-methyl-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate	2.82	636.2
Example 358: Cis- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(5-chloro-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate	2.82	656.2
Example 359: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-chloro-2-methyl-1-benzenesulfonamide trimaleate	3.01	612

Example 360: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-bromo-1-benzenesulfonamide trimaleate	2.81	644.2
Example 361: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,5-dibromo-3,6-difluoro-1-benzenesulfonamide trimaleate	3.29	758.1
Example 362: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate	2.77	632
Example 363: Cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(2-nitrophenyl)methanesulfonamide trimaleate	2.73	623.2

General Synthesis

Method (a)

- 5 A mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-7-yl]-1-cyclohexanone (1.0 g, 2.51 mmol), the appropriate amine (7.54 mmol) and acetic acid (0.45 g, 7.54 mmol) in 1,2-dichloroethane (50 mL) was stirred at ambient temperature under an atmosphere of nitrogen for 30 minutes. Sodium triacetoxyborohydride (0.69 g, 3.26 mmol) was added and the mixture stirred at
- 10 ambient temperature for 18 hours. Water (20 mL) and sodium bicarbonate (1.26 g, 15.1 mmol) were added to the mixture and stirred for one hour. The mixture was then filtered through a pad of celite and the pad was washed with dichloromethane (75 mL). The organic layer was extracted from the filtrate, dried over magnesium sulfate, filtered and evaporated to dryness under reduced pressure. The cis and trans
- 15 isomers were purified by flash chromatography on silica gel using a methanol:dichloromethane gradient.

Method (b)

Where appropriate the salts were made as follows.

- The above amine (0.909 mmol) was dissolved in warm ethyl acetate (100 mL) then
 5 maleic acid (0.32 g, 2.73 mmol) in ethyl acetate (30 mL) was added. The resulting
 salt formed an oily residue on the bottom and sides of the flask. The supernatant
 was poured off and the residue was dissolved in water and lyophilized to give the
 salt

10 Method (c)

Guanidines were made as follows. The amine (0.536 mmol) was dissolved in DMF
 (5 mL) and cooled to -5°C and then 1-H pyrazole-1-carbonamide (95 mg, 0.644
 mmol) followed by diisopropylethylamine (208 mg, 1.6 mmol) were added. The
 reaction mixture was allowed to warm to rt over 16h and then concentrated in vacuo.

- 15 The reaction was partitioned between water (10 mL) and ethyl acetate (10 mL).
 The aqueous phase was lyophilized and purified by RP-HPLC.

HPLC protocols:

1. RP-HPLC - Hypersil HyPurity Elite C18, 5 mm, 200A, 250 x 4.6 mm; 25-100%
 acetonitrile-0.1 M ammonium acetate over 15 min, 1ml/min.
- 20 2. RP-HPLC - Hypersil HyPurity Elite C18, 5 mm, 200A, 250 x 4.6 mm; 5-100%
 acetonitrile-0.1 M ammonium acetate over 15 min, 1ml/min.

It should be appreciated that protecting group chemistry is used where appropriate.

The following examples were prepared using the methods described above:

Name	Synthetic method	HPLC-RT (Min) (Protocol)	m/z (MH^+)	Additional chemistry
Example 364: Cis-4-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-1-piperazinecarboximidamide	c	14.56 (2)	511.7	

Example 365: Trans-4-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-1-piperazinecarboximidamide	c	14.25 (2)	511.7	
Example 366: Trans-7-(4-{methyl[2-(2-pyridyl)ethyl]amino}cyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trimaleate	a, b	8.55 (2)	519.6	
Example 367: Cis-3-({4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl} amino)propanoic acid	a	10.21 (2)	472.6	Made by hydrolysis of the ester
Example 368: 3-({4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl} amino)propanoic acid	a	6.33 (1)	472.6	Made by hydrolysis of the ester
Example 369: Ethyl cis-3-({4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl} amino)propanoate dimaleate	a, b	10.42 (1)	500.6	

General Synthesis

5 Method (d)

To a solution of sodium hydride (22 mg, 0.553 mmol) in THF (2 mL) was added the appropriate phosphonate (0.553 mmol) at 0°C and the resultant mixture was stirred

at this temperature for 20 min and then at ambient temperature for 10 min. The reaction mixture was cooled to 0°C and 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimin-7-yl]cyclohexanone (200 mg, 0.503 mmol) added in THF (10 mL) and the resultant mixture allowed to warm to ambient temperature and stirred for 16h. The solvents were removed *in vacuo* and the residue partitioned between ethyl acetate (10 mL) and water (10 mL). The aqueous layer was further extracted into ethyl acetate (3 x 5 mL) and the combined organics were washed with water (3 x 5 mL), dried (MgSO₄) and concentrated *in vacuo*. Purification by flash column chromatography on silica gel (for intermediates) or RP-HPLC (for final compounds) gave the desired compound.

Method (e)

Hydrogenations were carried out as follows. A mixture of the alkene, (0.068 mmol) and 10% Pd/C (12 mg) in ethanol (18 mL) was stirred under hydrogen (4 atm) for 14h. The solids were removed by filtration and the filtrate concentrated *in vacuo*. Purification by RP-HPLC gave the final compound.

Method (f)

Lithium aluminum hydride reactions were carried out as follows. A mixture of the substrate (0.19 mmol), lithium aluminum hydride (40 mg, 1.07 mmol) in THF (5 mL) was stirred at room temperature for 16h. Fieser work up followed by purification by RP-HPLC gave the desired compound.

HPLC conditions : RP-HPLC Pecosphere3 C18, 33 x 4.6 mm, 3m column; 0-100% acetonitrile-0.1 M ammonium acetate over 5 min, flow 4ml/min.

It should be appreciated that protecting group chemistry is used where appropriate.

Name	Synthetic Method	HPLC-RT (Min)	m/z (MH ⁺)	Additional Chemistry
------	------------------	---------------	------------------------	----------------------

Example 370: {4-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyliden} methyl cyanide	d	3.1	422.5	
Example 371: tert-Butyl 2-[4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyliden} acetate	d	3.97	497.1	
Example 372: Ethyl 2-[4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyliden} acetate	d	3.56	469.0	
Example 373: 2-[4-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyliden} acetate	d	2.69	441.5	Made by hydrolysis of the ethyl ester
Example 374: 7-[4-(2-aminoethyl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	f	2.11	428.5	Made by lithium aluminum hydride reduction of the unsaturated cyanide
Example 375: 2-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl} acetic acid	e	2.64	443.5	Made by hydrogenation of the unsaturated acid

Example 376: *Trans*-5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-phenoxybenzonitrile bisacetate

a) 5-bromo-phenoxybenzonitrile

A mixture of 4-bromo-2-fluorobenzonitrile (5.0 g, 25 mmol), phenol (4.7 g, 50 mmol) and potassium carbonate (6.9 g, 50 mmol) in dimethylsulfoxide (30 mL) was heated at 100°C for 18 hours. The mixture was cooled and water (200 mL) was added. The mixture was extracted with dichloromethane (2 x 50 mL). The combined
5 organic solutions were washed with 15% aqueous sodium hydroxide (50 mL), saturated aqueous sodium bicarbonate (50 mL), dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to give 5-bromo-phenoxybenzonitrile (7.25 g, quant.): ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.20 (d, 1H), 7.84 (dd, 1H), 7.47 (t, 2H), 7.30 (t, 1H), 7.20 (dd, 2H), 6.87 (d, 1H); RP-HPLC
10 (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) *t*_r 12.50 min.

b) 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile

A mixture of 5-bromo-phenoxybenzonitrile (2.0 g, 7.22 mmol), diboron
15 pinacol ester (2.2 g, 8.66 mmol), potassium acetate (2.12 g, 21.7 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) complex with dichloromethane (1:1) (0.35 g, 0.49 mmol) in *N,N*-dimethylformamide (40 mL) was heated at 85°C for 20 hours then cooled and the solvents evaporated under reduced pressure. The residue was triturated with dichloromethane (40 mL), then filtered
20 through a pad of celite and the filtrate concentrated to give an oil which was purified by flash chromatography on silica gel using heptane/ethyl acetate (9:1) as an eluent to give 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile (1.56 g, 67%): ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.01 (s, 1H), 7.88 (d, 1H), 7.49 (t, 2H), 7.32 (t, 1H), 7.22 (d, 2H), 6.90 (d, 1H), 1.29 (s, 12H); RP-HPLC (Hypersil HS,
25 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) *t*_r 13.85 min.

c) *trans*-5-(4-chloro-7-(4-(4-methylpiperazino)cyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-phenoxybenzonitrile

30 A mixture of *trans*-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-

7*H*-pyrrolo[2,3-*d*]pyrimidine (500 mg, 1.09 mmol), 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile (425 mg, 1.31 mmol), sodium carbonate monohydrate (325 mg, 2.62 mmol) and tetrakis(triphenylphosphine)palladium(0) (75 mg, 0.065 mmol) in ethylene glycol dimethyl ether (8 mL) and water (4 mL) was heated at 85°C for 18 hours. The mixture was cooled and evaporated under reduced pressure then partitioned between water (10 mL) and dichloromethane (25 mL). The combined organic solutions were dried over magnesium sulfate and then filtered. The filtrate was concentrated to give a material which was then purified by flash chromatography on silica gel using dichloromethane/methanol (9:1) as an eluent to give *trans*-5-(4-chloro-7-(4-(4-methylpiperazino)cyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-phenoxybenzonitrile: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.11 (s, 1H), 8.07 (d, 1H), 7.5-7.55 (m, 3H), 7.01 (d, 1H), 4.71 (m, 1H), 2.2-2.6 (m, 9H), 2.17 (s, 3H), 1.8-2.1 (m, 6H), 1.4-1.6 (m, 2H); RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) *t*_r 9.20 min.

d) *trans*-5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxybenzonitrile bisacetate

A mixture of *trans*-5-(4-chloro-7-(4-(4-methylpiperazino)cyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-phenoxybenzonitrile (150 mg) in 1,4-dioxane (25 mL) and 30% aqueous ammonium hydroxide (25 mL) was heated at 120°C in a sealed tube for 18 hours then cooled and evaporated under reduced pressure. The residue was purified by preparative RP-HPLC to give 5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxybenzonitrile bisacetate: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.14 (s, 1H), 7.91 (s, 1H), 7.70 (d, 1H), 7.55 (s, 1H), 7.48 (t, 2H), 7.27 (t, 1H), 7.20 (d, 2H), 7.06 (d, 1H), 6.27 (bs, 2H), 4.55 (m, 1H), 2.53 (m, 4H), 2.36 (m, 5H), 2.17 (s, 3H), 2.0 (m, 6H), 1.96 (s, 6H); MS *MH*⁺ 508.3; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) *t*_r 7.27 min.

Example 377: *Trans*-5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxybenzamide

5 A mixture of (50 mg, 0.1 mmol) was dissolved in dimethylsulfoxide (1.6 mL) then treated with 30% aqueous hydrogen peroxide (1.25 mL) and 15% aqueous sodium hydroxide (1 mL). The mixture was stirred at ambient temperature for 18 hours then evaporated and the residue purified by preparative RP-HPLC then lyophilized. The material was dissolved in methanol (8 mL) and acetic acid (2 mL)
10 then hydrogenated for 4 hours at atmospheric pressure and ambient temperature in the presence of 10% Pd-C (15 mg). The mixture was filtered through a pad of celite, evaporated under reduced pressure and then lyophilized to give *trans*-5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxybenzamide (10 mg, 20%): ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.14 (s, 1H),
15 7.78 (d, 1H), 7.65 (s, 1H), 7.58 (s, 1H), 7.39-7.50 (m, 4H), 7.16 (t, 1H), 7.10 (d, 2H), 6.98 (d, 1H), 6.15 (bs, 2H), 4.55 (m, 1H), 2.2-2.6 (m, 9H), 2.14 (s, 3H), 1.8-2.0 (m, 6H), 1.41-1.48 (m, 2H); MS MH⁺ 526.4; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 5.83 min

20

Example 378: *Trans*-5-(3-methoxy-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate

a) 4-bromo-2-methoxy-1-phenoxybenzene

25 A mixture of 4-bromoguaiacol (2.23 g, 11 mmol), phenyl boronic acid (4.03 g, 33 mmol), copper(II) acetate (2.18 g, 12 mmol) and 4A powdered molecular sieves (20 g) in dichloromethane (100 mL) was treated with triethylamine (5.5 g, 55 mmol) then stirred at ambient temperature for 20 hours. The mixture was filtered, concentrated under reduced pressure and purified by flash chromatography on silica
30 gel using heptane/ethyl acetate (75:25) as an eluent to give 4-bromo-2-methoxy-1-

phenoxybenzene (350 mg, 12%): ^1H NMR (DMSO- d_6 , 400 MHz) δ 7.3-7.4 (m, 3H), 7.15 (d, 1H), 7.05 (t, 1H), 6.98 (d, 1H), 6.85 (d, 2H), 3.77 (s, 3H); RP-HPLC (Hypersil HS, 5 μm , 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 13.12 min.

5

b) 2-(3-methoxy-4-phenoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

The title compound was prepared from 4-bromo-2-methoxy-1-phenoxybenzene and pinacol diboron ester in the same manner as described for 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile (58% yield)

10 ^1H NMR (DMSO- d_6 , 400 MHz) δ 7.34 (m, 4H), 7.07 (t, 1H), 7.06 (d, 1H), 6.87 (d, 2H), 3.77 (s, 3H), 1.31 (s, 12H); TLC (heptane/ethyl acetate 9:1) R_f 0.23.

c) *trans*-4-chloro-5-(3-methoxy-4-phenoxyphenyl)-7-[4-(methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidine

The title compound (223 mg, 64%) was prepared from *trans*-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidine (300 mg, 0.655 mmol) and 2-(3-methoxy-4-phenoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (235 mg, 0.727 mmol) in a similar manner to that described for the preparation of *trans*-5-(4-chloro-7-(4-(4-methylpiperazino)cyclohexyl)-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-phenoxybenzonitrile: ^1H NMR (DMSO- d_6 , 400

20 MHz) δ 8.67 (s, 1H), 8.04 (s, 1H), 7.32 (m, 4H), 7.12 (d, 1H), 7.08 (d, 1H), 6.88 (d, 2H), 4.71 (m, 1H), 3.80 (s, 3H), 2.2-2.6 (m, 9H), 2.15 (s, 3H), 1.9-2.1 (m, 6H), 1.49 (m, 2H); MS MH^+ 532.4; RP-HPLC (Hypersil HS, 5 μm , 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 9.58 min.

25 d) *trans*-5-(3-methoxy-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate

A mixture of *trans*-4-chloro-5-(3-methoxy-4-phenoxyphenyl)-7-[4-(methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidine (220 mg, 0.414 mmol) in 1,4-dioxane (20 mL) and 30% aqueous ammonium hydroxide (20 mL) was heated
30 at 120°C in a sealed tube for 18 hours then cooled, concentrated under reduced pressure and purified by preparative RP-HPLC to give *trans*-5-(3-methoxy-4-

phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate (122 mg, 58%): ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.14 (s, 1H), 7.49 (s, 1H), 7.32 (t, 2H), 7.22 (s, 1H), 7.10 (d, 1H), 7.05 (m, 2H), 6.92 (d, 2H), 6.2 (bs, 2H), 4.56 (m, 1H), 3.79 (s, 3H), 2.2-2.6 (m, 9H), 2.15 (s, 3H), 1.8-2.05 (m, 6H), 1.90 (s, 6H), 1.45 (m, 2H); MS MH⁺ 513.4; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 14.77 min.

Example 379: *Trans*-5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxyphenol

A mixture of *trans*-5-(3-methoxy-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate (50 mg, 0.098 mmol) in 48% aqueous hydrobromic acid (1 mL) was heated at 120°C for 2 hours. The solution was cooled and concentrated under reduced pressure then purified by preparative RP-HPLC to give *trans*-5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxyphenol (32 mg, 66%): ¹H NMR (DMSO-*d*₆, 400 MHz) δ 9.8 (bs, 1H), 8.13 (s, 1H), 7.39 (s, 1H), 7.31 (t, 2H), 7.03 (m, 3H), 6.89 (m, 3H), 6.17 (bs, 2H), 4.55 (m, 1H), 2.2-2.6 (m, 9H), 2.15 (s, 3H), 1.8-2.2 (m, 6H), 1.44 (m, 2H); MS MH⁺ 499.4; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 13.47 min.

Example 380: *Trans*-5-(3-chloro-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

a) 4-bromo-2-chloro-1-phenoxybenzene

A mixture of 4-bromo-2-chlorophenol (2.07 g, 10 mmol), phenyl boronic acid (3.66 g, 30 mmol), copper(II) acetate (2.0 g, 1.1 mmol) and 4A powdered molecular sieves (20 g) in dichloromethane (100 mL) was treated with triethylamine (5.0 g, 50 mmol)

then stirred at ambient temperature for 5 days. The mixture was diluted with heptane (100 mL), then filtered through a bed of celite. The filtrate was concentrated under reduced pressure to remove dichloromethane. The mixture was extracted with 1N hydrochloric acid, 15 wt% aqueous sodium hydroxide, brine and then dried over magnesium sulfate. The mixture was filtered and the filtrate concentrated under reduced pressure to provide (1.27 g, 45%): ¹H NMR (DMSO-*d*₆, 400 MHz) δ 7.87 (s, 1H), 7.55 (d, 1H), 7.40 (t, 2H), 7.17 (t, 1H), 6.99 (m, 3H); MS MH⁺ 283; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 14.42min.

10

b) 2-(3-chloro-4-phenoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

The title compound (472 mg, 81%) was prepared from 4-bromo-2-chloro-1-phenoxybenzene (500 mg, 1.77 mmol) in a similar manner to that described for the preparation 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile:

15 ¹H NMR (DMSO-*d*₆, 400 MHz) δ 7.75 (s, 1H), 7.60 (d, 1H), 7.42 (t, 2H), 7.21 (t, 1H), 7.02 (m, 3H), 1.30 (s, 12H); RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 15.53 min.

20 c) *Trans*-5-(3-chloro-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

The title compound was prepared from 2-(3-chloro-4-phenoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and *trans*-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidine in a similar manner to that described for the preparation of *trans*-5-{4-amino-7-[4-(4-

25 methylypiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxybenzonitrile: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.14 (s, 1H), 7.79 (s, 1H), 7.65 (s, 1H), 7.38 (m, 3H), 7.16 (t, 2H), 7.04 (d, 2H), 6.24 (bs, 2H), 4.55 (m, 1H), 2.2-2.6 (m, 9H), 2.16 (s, 3H), 1.89 (m, 6H), 1.48 (m, 2H); MS MH⁺ 517.3; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M

30

ammonium acetate over 10 min, 1 ml/min) t_r 15.75 min.

Example 381: *Trans*-5-(3-fluoro-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine bisacetate

5 a) 4-bromo-2-fluoro-1-phenoxybenzene

The title compound was prepared in a 33% yield from 4-bromo-2-fluorophenol and phenyl boronic acid in a manner similar to that described for the preparation of 4-bromo-2-chloro-1-phenoxybenzene: ^1H NMR (DMSO- d_6 , 400 MHz) δ 7.75 (dd, 1H), 7.40 (m, 3H), 7.15 (m, 2H), 7.01 (dd, 2H); MS MH^+ 267.2; RP-HPLC

10 (Hypersil HS, 5 μm , 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 13.57 min.

b) 2-(3-fluoro-4-phenoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

The title compound was prepared in a 65% from 4-bromo-2-fluoro-1-phenoxybenzene in a similar manner to that described for the preparation 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile: ^1H NMR (DMSO- d_6 , 400 MHz) δ 7.49 (dd, 2H), 7.41 (m, 2H), 7.18 (t, 1H), 7.08 (d, 1H), 7.05 (d, 2H), 1.30 (s, 12H); RP-HPLC (Hypersil HS, 5 μm , 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 14.63 min.

20 c) *trans*-4-{4-chloro-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-fluorophenyl phenyl ether

The title compound was prepared in an 85% yield from *trans*-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidine and 2-(3-fluoro-4-phenoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in a similar manner to that described for the preparation of *trans*-5-(4-chloro-7-(4-(4-methylpiperazino)cyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-

phenoxybenzonitrile: ^1H NMR (DMSO- d_6 , 400 MHz) δ 8.67 (s, 1H), 8.07 (s, 1H), 7.58 (d, 1H), 7.41 (m, 3H), 7.22 (m, 1H), 7.16 (m, 1H), 7.04 (d, 2H), 4.70 (m, 1H), 2.2-2.6 (m, 9H), 2.16 (s, 3H), 1.94-2.03 (m, 6H), 1.48 (m, 2H); MS MH^+ 520.3; RP-

30 HPLC (Hypersil HS, 5 μm , 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M

ammonium acetate over 10 min, 1 ml/min) t_r 9.45 min.

d) *Trans*-5-(3-fluoro-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine bisacetate

- 5 The title compound was prepared in a 75% yield from *trans*-4-{4-chloro-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-fluorophenyl phenyl ether in a similar manner to that described for the preparation of *trans*-5-(3-methoxy-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate: ^1H NMR (DMSO- d_6 , 400 MHz) δ 8.14 (s, 1H), 7.52 (s, 1H), 7.40 (m, 3H), 7.27 (m, 2H), 7.13 (t, 1H), 7.06 (d, 2H), 6.25 (bs, 2H), 4.55 (m, 1H), 2.2-2.6 (m, 9H), 2.14 (s, 3H), 1.8-2.0 (m, 6H), 1.92 (s, 6H), 1.44 (m, 2H); MS MH^+ 501; RP-HPLC (Hypersil HS, 5 μm , 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 7.52 min.
- 10

- 15 Example 382: *Trans*-5-(3-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

a) 4-bromo-2-methyl-1-phenoxybenzene

- The title compound was prepared in a 35% yield from 4-bromo-2-methylphenol and phenyl boronic acid in a manner similar to that described for the preparation of 4-bromo-2-chloro-1-phenoxybenzene: ^1H NMR (DMSO- d_6 , 400 MHz) δ 7.54 (s, 1H), 7.35 (m, 3H), 7.12 (t, 1H), 6.93 (d, 2H), 6.82 (d, 2H), 2.18 (s, 3H); RP-HPLC (Hypersil HS, 5 μm , 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 14.25min.
- 20

- 25 b) 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl phenyl ether

- The title compound was prepared in a 77% from 4-bromo-2-methyl-1-phenoxybenzene in a similar manner to that described for the preparation 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile: ^1H NMR (DMSO- d_6 , 400 MHz) δ 7.67 (s, 1H), 7.50 (d, 1H), 7.38 (t, 2H), 7.14 (t, 1H), 6.94 (d, 2H), 6.80 (d, 1H), 2.21 (t, 3H); TLC (heptane/ethyl acetate 9:1) R_f 0.6.
- 30

c) *trans*-4-{4-chloro-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methylphenyl phenyl ether

The title compound was prepared in an 82% yield from from *trans*-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidine and 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl phenyl ether in similar manner to that described for the preparation of *trans*-5-(4-chloro-7-(4-(4-methylpiperazino)cyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-phenoxybenzonitrile: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.65 (s, 1H), 7.98 (s, 1H), 7.49 (s, 1H), 7.37 (m, 3H), 7.10 (t, 1H), 6.95 (m, 3H), 4.72 (m, 1H), 2.2-2.6 (m, 9H), 2.23 (s, 3H), 2.17 (s, 3H), 2.01 (m, 6H), 1.48 (m, 2H); MS MH⁺ 516.4; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 10.53 min.

d) *Trans*-5-(3-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

The title compound was prepared in a 75% yield from *trans*-4-{4-chloro-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-methylphenyl phenyl ether in a similar manner to that described for the preparation of *trans*-5-(3-methoxy-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.13 (s, 1H), 7.42 (m, 4H), 7.37 (t, 2H), 7.27(m, 1H), 7.10 (t, 1H), 6.97 (m, 3H), 6.11 (bs, 2H), 4.55 (m, 1H), 2.2-2.6 (m, 9H), 2.22 (s, 3H), 2.14 (s, 3H), 1.7-2.0 (m, 6H), 1.45 (m, 2H); MS MH⁺ 497.4; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 5%-100% acetonitrile-0.05 M ammonium acetate over 25 min, 1 ml/min) t_r 15.93 min.

Example 383: *Trans*-7-[4-(4-methylpiperazino)cyclohexyl]- 5-(3-nitro-4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate

a) 4-bromo-2-nitro-1-phenoxybenzene

The title compound was prepared in a quantitative yield from 5-bromo-2-fluoro-

nitrobenzene and phenol in a manner similar to that described for the preparation of 5-bromo-phenoxybenzonitrile: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.31 (d, 1H), 7.86 (dd, 1H), 7.45 (t, 2H), 7.25 (t, 1H), 7.13 (d, 1H), 7.08 (d, 2H); RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) *t*_r 12.70 min.

b) 2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl phenyl ether

The title compound was prepared in a 56% from 4-bromo-2-nitro-1-phenoxybenzene in a similar manner to that described for the preparation 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.19 (d, 1H), 7.91 (d, 1H), 7.46 (t, 2H), 7.27 (t, 1H), 7.14 (d, 2H), 7.06 (d, 1H), 1.31 (s, 12H); RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) *t*_r 14.02 min.

c) *trans*-7-[4-(4-methylpiperazino)cyclohexyl]-5-(3-nitro-4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate

The title compound was prepared from *trans*-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidine and 2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl phenyl ether in a similar manner to that described for the preparation of *trans*-5-(4-chloro-7-(4-(4-methylpiperazino)cyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-phenoxybenzonitrile: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.15 (s, 1H), 8.08 (d, 1H), 7.74 (d, 1H), 7.46 (s, 1H), 7.42 (t, 2H), 7.23 (m, 2H), 7.12 (d, 2H), 6.36 (bs, 2H), 4.56 (m, 1H), 2.2-2.6 (m, 9H), 2.16 (s, 3H), 1.8-2.0 (m, 6H), 1.92 (s, 3H), 1.45 (m, 2H); MS *MH*⁺ 528.4; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 5%-100% acetonitrile-0.05 M ammonium acetate over 25 min, 1 ml/min) *t*_r 14.88 min.

Example 384: *Trans*-5-(3-amino-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

-271-

A mixture of (135 mg, 0.256 mmol) in ethanol (5 mL) and water (2 mL) was heated at 80°C then treated with sodium dithionite (270 mg, 1.54 mmol) in three portions over approximately 15 minutes. Heating was continued for 15 minutes then more sodium dithionite (135 mg, 0.75 mmol) was added and heating was continued for 10 minutes. The mixture was treated with 15 wt % sodium hydroxide in water (1 mL) and then cooled to ambient temperature after 10 minutes. Acidification with acetic acid and preparative RP-HPLC followed by lyophilization gave a residue which was dissolved in ethanol (20 mL) and acetic acid (1 mL) then hydrogenated for 1 hour at ambient temperature and atmospheric pressure in the presence of 10% Pd-C (30 mg). Filtration and purification by RP-HPLC gave *trans*-5-(3-amino-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (26 mg, 20%): ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.13 (s, 1H), 7.35 (m, 3H), 7.06 (t, 1H), 6.97 (d, 2H), 6.89 (m, 2H), 6.60 (m, 1H), 6.2 (bs, 2H), 5.08 (bs, 2H), 4.54 (m, 1H), 2.2-2.6 (m, 9H), 2.15 (s, 3H), 1.8-2.1 (m, 6H), 1.45 (m, 2H); MS MH⁺ 498.4; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 6.90 min

Example 385: *Trans*-5-(3-(dimethylamino)-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine

A mixture of *Trans*-5-(3-amino-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (120 mg, 0.241 mmol), 37% aqueous formaldehyde (80 mg, 0.966 mmol) and acetic acid (45 mg, 0.724) in 1,2-dichloroethane (5 mL) was stirred at ambient temperature for 30 minutes then sodium triacetoxyborohydride (154 mg, 0.72 mmol) was added. The mixture was stirred at ambient temperature for an additional 18 hours then the mixture was concentrated under reduced pressure and the residue was purified by preparative RP-HPLC to give *trans*-5-(3-(dimethylamino)-4-phenoxyphenyl)-7-[4-

(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (10 mg, 12%): ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.13 (s, 1H), 7.45 (s, 1H), 7.34 (t, 2H), 7.05 (m, 2H), 6.9-7.0 (m, 4H), 6.16 (bs, 2H), 4.55 (m, 2H), 2.78 (s, 6H), 2.2-2.6 (m, 9H), 2.23 (s, 3H), 1.8-2.0 (m, 6H), 1.45 (m, 2H); MS MH⁺ 526.4; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 5%-50% acetonitrile-0.05 M ammonium acetate over 25 min, 1 ml/min) t_r 25.6 min.

Example 386: *Trans*-N1-(5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxyphenyl)acetamide acetate

10

A mixture of *trans*-5-(3-amino-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (120 mg, 0.241 mmol) in pyridine (2 mL) and dichloromethane (2 mL) was cooled to 0°C then treated with acetyl chloride (25 mg, 0.3 mmol). The mixture was warmed to ambient temperature for one hour then the solvents were removed under reduced pressure and the residue purified by preparative RP-HPLC to give *trans*-N1-(5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxyphenyl)acetamide acetate (45 mg, 35%): ¹H NMR (DMSO-*d*₆, 400 MHz) δ 9.67 (bs, 1H), 8.11 (s, 1H), 8.00 (s, 1H), 7.40 (t, 3H), 7.17 (m, 2H), 7.05 (d, 2H), 6.95 (d, 1H), 6.30 (bs, 2H), 4.55 (m, 1H), 2.2-2.6 (m, 9H), 2.14 (s, 3H), 2.04 (s, 3H), 1.8-2.0 (m, 6H), 1.89 (s, 3H), 1.44 (m, 2H); MS MH⁺ 540.5; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 5%-50% acetonitrile-0.05 M ammonium acetate over 25 min, 1 ml/min) t_r 20.37 min.

Example 387: *Trans*-5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxybenzaldehyde trismaleate

a) 4-bromo-2-phenoxybenzaldehyde

The title compound was prepared in a 46% yield from 5-bromo-2-fluorobenzaldehyde and phenol in a manner similar to that described for the preparation of

-273-

5-bromo-phenoxybenzonitrile: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 10.32 (s, 1H), 7.92 (s, 1H), 7.81 (d, 1H), 7.46 (t, 2H), 7.27 (t, 1H), 7.18 (d, 2H), 6.90 (d, 1H) RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 13.08 min.

5

b) 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde

The title compound was prepared in a 62% from 4-bromo-2-phenoxybenzaldehyde in a similar manner to that described for the preparation 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 10.43 (s, 1H), 8.14 (s, 1H), 7.89 (d, 1H), 7.48 (t, 2H), 7.27 (t, 1H), 7.20 (d, 2H), 6.88 (d, 1H), 1.30 (s, 12H); RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 14.02min.

10

15 c) *trans*-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine hydrochloride

A mixture of *trans*-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidine (750 mg, 1.63 mmol) and 1,4-dioxane (10 mL) and 30% aqueous ammonium hydroxide (10 mL) was heated at 120°C in a sealed tube for 18 hours. The mixture is cooled and lyophilized to give *trans*-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine hydrochloride (750 mg, quantitative): ¹H NMR (DMSO-*d*₆, 400 MHz) δ 10.2 (bs, 1H), 8.08 (s, 1H), 7.53 (s, 1H), 6.59 (bs, 2H), 4.50 (m, 1H), 2.5-3.2 (m, 9H), 2.51 (s, 3H), 1.8-2.0 (m, 6H), 1.46 (m, 2H); MS MH⁺ 441.2; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 10 min, 1 ml/min) t_r 3.85 min.

20

25

d) *Trans*-5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxybenzaldehyde trismaleate

30

A mixture of *trans*-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-

-274-

pyrrolo[2,3-*d*]pyrimidin-4-amine hydrochloride (750 mg, 1.63 mmol), 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (635 mg, 1.96 mmol), sodium carbonate monohydrate (490 mg, 3.92mmol) and tetrakis(triphenylphosphine)palladium(0) (115 mg, 0.1 mmol) in ethylene glycol dimethyl ether (40 mL) and water (20 mL) was heated at 85°C for 18 hours. The mixture was cooled, concentrated under reduced pressure then purified by preparative RP-HPLC then lyophilized to give *trans*-5-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-phenoxybenzaldehyde bisacetate (636 mg, 68%). A portion of this compound (75 mg, 0.132 mmol) was dissolved in ethanol (2 mL) and the treated with maleic acid (61 mg, 0.526 mmol) in ethanol (1 mL). The precipitate was collected by filtration and dried under reduced pressure: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 10.41 (s, 1H), 8.22 (s, 1H), 7.88 (s, 1H), 7.72 (d, 1H), 7.60 (s, 1H), 7.47 (t, 2H), 7.24 (m, 3H), 7.08 (d, 1H), 6.62 (bs, 2H), 6.16 (s, 6H), 4.61 (m, 1H), 2.5-3.4 (m, 9H), 2.69 (s, 3H), 1.8-2.1 (m, 6H), 1.56 (m, 2H); MS MH⁺ 511.4; RP-HPLC (Hypersil HS, 5μm, 100A, 4.6 x 250 mm; 5%-100% acetonitrile-0.05 M ammonium acetate over 25 min, 1 ml/min) t_r 14.55 min.

Example 388: *Trans* 2-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexylacetamide

A mixture of *trans* 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexylmethyl cyanide (0.300 g, 0.68 mmol) and potassium carbonate (0.377g, 2.73 mmol) in dimethylsulfoxide (3 ml) was stirred rapidly and 30% hydrogen peroxide (0.5 mL) was added dropwise, keeping the temperature at 20° C. The mixture was stirred for seven hours at ambient temperature. Water (20 mL) was added, and a precipitate formed the mixture was extracted with ethyl acetate (3 x 10 mL), dried over magnesium sulfate, and concentrated. The residue was purified by preparative RP-HPLC (Rainin C18, 8μm, 300 A, 25 cm; 30% isocratic for five minutes, then 30%-60% acetonitrile - 0.1M ammonium acetate over 30 min, 21 ml/min). The acetonitrile was removed *in vacuo*

-275-

and the aqueous mixture was lyopholyzed to give *trans* 2-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexylacetamide as a white solid (0.055 g, 0.12 mmol):

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.14 (s, 1H), 7.48 (d, 2H), 7.47 (s, 1H), 7.42 (t, 2H), 7.17 (t, 1H), 7.06-7.13 (m, 4H), 6.11 (b, 2H), 5.18 (s, 1H) 4.61-4.67 (m, 1H), 1.91-2.00 (m, 2H), 1.82-1.86 (m, 4H), 1.57-1.65 (m, 2H);

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 14.46 min.;

MS: M⁺ 458.

10

Example 389: *Trans* 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-(hydroxymethyl)-1-cyclohexanol

A *trans/cis* (4:1) mixture of 7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.300 g, 0.42 mmol) in 1,2-dimethoxyethane (15 mL) was reacted with 2.5 M aqueous potassium hydroxide (15 mL). The mixture was stirred at reflux for eighteen hours. The mixture was cooled to room temperature and water (25 mL) was added. The precipitate which formed was filtered, washing with water (20 mL). The precipitate was purified by preparative RP-HPLC (Rainin C18, 8 μ m, 300 A, 25 cm; 30% isocratic for five minutes, then 30%-60% acetonitrile - 0.1M ammonium acetate over 30 min, 21 ml/min). The acetonitrile was removed *in vacuo* and the aqueous mixture was lyopholyzed to give to give a *trans/cis* (4:1) mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-(hydroxymethyl)-1-cyclohexanol. The isomers were separated by NP-MPLC (ISCO RediSep™ (10 g), 2% isocratic for five minutes, then 2-10% methanol-dichloromethane over 25 minutes, 20 mL/min). The solvent was removed *in vacuo* to give *trans* 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-(hydroxymethyl)-1-cyclohexanol as a white solid (0.026 g, 0.60 mmol):

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.53 (s, 1H), 7.47 (d, 2H), 7.41 (t, 2H), 7.16 (t, 1H), 7.05-7.12 (m, 4H), 6.08 (b, 1H), 4.56-4.66 (m, 1H), 4.39 (t, 1H),

-276-

4.25 (s, 1H), 3.55 (d, 2H), 1.85-2.00 (m, 4H), 1.76-1.84 (m, 2H), 1.43-1.54 (m, 2H);
RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1M
ammonium acetate over 20 min, 1mL/min) R_t 14.45 min.;
MS: M⁺ 431.

5

Example 390: 7-[1-(1*H*-2-imidazolylmethyl)-4-piperidyl]-5-(4-phenoxyphenyl)-7*H*-
pyrrolo[2,3-*d*]pyrimidin-4-amine

A mixture of 5-(4-phenoxyphenyl)-7-(4-piperidyl)-7*H*-pyrrolo[2,3-
10 *d*]pyrimidin-4-amine (0.096 g, 0.249 mmol) in dichloroethane (5 mL) was treated
with 2-imidazolcarboxaldehyde (0.026 g, 0.274 mmol) and glacial acetic acid
(0.030 g, 0.498 mmol). The reaction mixture stirred for one hour at 0°C under
nitrogen atmosphere. Sodium triacetoxyborohydride (0.132 g, 0.623 mmol) was
added to the reaction mixture and stirred at 0°C for 20 minutes. The ice bath was
15 then removed, and the reaction mixture stirred for 18 hours at ambient temperature
under a nitrogen atmosphere. Additional 2-imidazolcarboxaldehyde (0.096 g, 0.996
mmol) was added to the reaction mixture, and stirred for an additional 24 hours.
Acetonitrile (2 mL) was added to the reaction mixture, and then was allowed to stir
for an additional 72 hours. Sodium bicarbonate (0.126 g, 1.49 mmol) in water (5
20 mL) was added to the reaction mixture and stirred for 2 hours. The layers were
partitioned, and the aqueous layer was extracted with dichloromethane (150 mL).
The combined organic layers were washed with water and brine (250 mL each),
dried over magnesium sulfate, filtered and evaporated under reduced pressure. The
front-running impurity (by TLC analysis) was removed by recrystallization using
25 ethyl acetate: heptane. The filtrate from the recrystallization was evaporated under
reduced pressure, and purified using a Flashtube chromatography column using 20%
methanol in dichloromethane was the eluent. Some impure product was isolated and
this was purified by preparative HPLC. 7-[1-(1*H*-2-imidazolylmethyl)-4-piperidyl]-
5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine was isolated and was
30 dried on the lyophilizer. Dichloromethane (3 mL) and 1 N sodium hydroxide (1
mL) was added to the product. The layers were separated using an Empore

-277-

extraction cartridge. The dichloromethane layer was collected and evaporated under reduced pressure to give 7-[1-(1*H*-2-imidazolylmethyl)-4-piperidyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine as a free base (0.011 g, 10%).

¹H NMR (CDCl₃, 400 MHz) δ 8.31 (s, 1H), 7.43-7.35 (m, 4H), 7.2-7.1 (m, 1H), 7.09-7.00 (m, 7H), 5.18 (s, 2H), 4.75-4.69 (m, 1H), 3.73 (s, 2H), 3.03-2.96 (m, 2H), 2.43-2.37 (m, 2H), 2.15-2.08 (m, 4H); Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5 μm, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) R_t 5.363 min.

10

Example 391: *Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-fluorophenyl)-1,3-benzoxazol-2-amine*

N2-(4-bromo-2-fluorophenyl)-1,3-benzoxazol-2-amine

15 To a solution of 4-bromo-2-fluoroaniline (1.00g, 5.26 mmol) in toluence (25 mL) was added 2-chlorobenzoxazole (0.66 mL, 5.79 mmol, 1.1 equiv). The purple solution was heated at reflux for 30 min. and then at 100°C for 17 hours. The resulting white suspension/purple solution was cooled to room temperature and the precipitate was filtered. The filter cake was washed with five 2-mL portion of
20 heptane to afford *N2-(4-bromo-2-fluorophenyl)-1,3-benzoxazol-2-amine* (1.480 g, 92%) as a light purple powder. RP-HPLC (25 to 100% CH₃CN in 0.1 N aqueous ammonium acetate over 10 minutes at 1 mL/min using a Hypersil HS C18, 250 x 4.6 mm column) tr = 12.87 min., 97%; and *m/z* 306.7 (*MH*⁺).

25 *N2-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-benzoxazol-2-amine*

To a solution of *N2-(4-bromo-2-fluorophenyl)-1,3-benzoxazol-2-amine*

-278-

(1.480 g, 4.819 mmol) in dimethylformamide (15 mL) under nitrogen was added bis(pinacolato)diboron (1.468 g, 5.781 mmol, 1.2 equiv), potassium acetate (1.419 g, 14.45 mmol, 3.0 equiv), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) complexed with dichloromethane (1:1) (0.119 g, 0.146 mmol, 0.03 equiv). The violet solution was stirred at 80 °C for 20 hours and then cooled to room temperature. The resulting dark brown mixture was concentrated *in vacuo* to give a dark brown liquid which was purified via flash chromatography on silica gel (eluting with 30% ethyl acetate/heptane) to afford 2.28 g of a yellow solid. This material was triturated with heptane and the solid was collected to afford *N*2-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-benzoxazol-2-amine (0.961 g, 56%) as a white powder. RP-HPLC (25 to 100% CH₃CN in 0.1 N aqueous ammonium acetate over 10 minutes at 1 mL/min using a Hypersil HS C18, 250 x 4.6 mm column) *tr* = 13.80 min., 88%; and *m/z* 354.9 (*MH*⁺).

15

*Cis-N*2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-fluorophenyl)-1,3-benzoxazol-2-amine

To a solution of *cis*-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.100 g, 0.227 mmol) in ethylene glycol dimethyl ether (3 mL) and water (1.5 mL) under nitrogen was added *N*2-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-benzoxazol-2-amine (0.100 g, 0.283 mmol, 1.25 equiv.), tetrakis(triphenylphosphine) palladium (0) (0.013 mg, 0.011 mmol, 0.05 equiv), and sodium carbonate monohydrate (0.070 mg, 0.568 mmol, 2.5 equiv). The solution was stirred at 80 °C for 21 hours. The resulting yellow mixture was concentrated *in vacuo* to give a yellow oil. Purification by preparative HPLC (25 to 100 % CH₃CN in 0.1 N aqueous ammonium acetate over 20 minutes at 21 mL/min. using a 8μ Hypersil HS C18, 250 x 21 mm column, *tr* = 6.4-8.5 min.) afforded *cis-N*2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl}-2-fluorophenyl)-1,3-benzoxazol-2-amine as a cream solid (34 mg, 28%). RP-HPLC (25 to 100% CH₃CN in 0.1 N aqueous

-279-

ammonium acetate over 10 min at 1 mL/min using a Hypersil HS C18, 250 x 4.6 mm column) t_r = 7.167 min., 98%; and m/z 540.8 (MH^+).

Example 392:

5 N1-4-(4-amino-7-{4-[4-(1-methylpiperidyl)piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl])-2-fluorophenyl-2,3-dichloro-1-benzenesulfonamide

Using N1-4-[4-amino-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-2,3-dichloro-1-benzenesulfonamide (0.075 mmol scale), the above methodology was followed to afford N1-4-(4-amino-7-{4-[4-(1-methylpiperidyl)piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl])-2-fluorophenyl-2,3-dichloro-1-benzenesulfonamide (32 mg), RP-HPLC RT =2.46 min and m/z 632.1.

Example 393: 7-{4-[2-(4-Methylpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

15

a) 2-{4-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyliden}acetic acid

A solution of diisopropylamine (1.40 g, 13.82 mmol) in tetrahydrofuran (60 mL) was added into a solution of 2.2 M n-BuLi (6.29 mL, 13.82 mmol) in tetrahydrofuran (20 mL) at -78°C . A solution of diethylphosphonoacetic acid (1.29 g, 6.59 mmol) in tetrahydrofuran (60 mL) was added at -78°C under the atmosphere of nitrogen. The mixture was kept at -78°C for 20 minutes and allowed to warm up to ambient temperature. The mixture was then transferred into a suspension of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanone (2.50 g, 6.28 mmol) in tetrahydrofuran (150 mL) at -78°C quickly. The resulting mixture was allowed to warm up to ambient temperature overnight and the solvent was removed under reduced pressure. The residue was taken in water and adjusted PH to be 3-4 with 1M aqueous acetic acid followed by extraction with ethyl acetate three times. The combined organic extracts were washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and evaporated under

-280-

reduced pressure to give 2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyliden}acetic acid (1.96 g, 4.44 mmol) as a white solid: ¹H NMR (DMSO-*d*₆, 400MHz) δ 11.98 (br, 1H), 7.45 (d, 2H), 7.41 (s, 1H), 7.40 (d, 2H), 7.16 (t, 1H), 7.08 (m, 4H), 6.10 (br, 2H), 5.70 (s, 1H), 4.80 (m, 1H), 2.50-1.90 (m, 8H); RP-HPLC (Hypersil C18, 5μm, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1mL/min) R_t 9.70 min. MS: MH⁺ 441.

b) 2-{4-[4-Amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}acetic acid

10 A mixture of 2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyliden}acetic acid (0.60 g, 1.36 mmol), 10% palladium on activated carbon (0.18 g), 1M aqueous sodium hydroxide (9 mL) and ethanol (60 mL) was hydrogenated under an atmosphere of hydrogen (60 psi) for 20 hours and filtered through a pad of celite. The filtrate was evaporated under reduced pressure to yield a
15 white solid which was taken into water (20 mL) followed by addition of 1M acetic acid (20 mL) to precipitate the product. The suspension was then filtered and the solid was lyophilized to yield 2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}acetic acid (0.51 g, 1.15 mmol) as a white solid: ¹H NMR (DMSO-*d*₆, 400MHz) δ 11.99 (br, 1H), 8.13 (s, 1H), 7.60 (s, 1H), 7.49 (d, 2H), 7.41 (t, 2H), 7.15 (t, 1H), 7.09 (m, 4H), 6.09 (br, 2H), 4.60 (m, 1H), 2.20-1.24 (m, 11H); RP-HPLC (Hypersil C18, 5μm, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1mL/min) R_t 9.62 min. MS: MH⁺ 443.

25 c) 2-{4-[4-Amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}-1-ethanol

A mixture of 2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}acetic acid (0.23 g, 0.51 mmol) and lithium aluminum hydride (0.30 g, 7.89 mmol) in tetrahydrofuran (25 mL) was stirred at ambient temperature
30 overnight. Water (3 mL) was added followed by 15% aqueous sodium hydroxide

-281-

(3.5 mL) and water (10.5 mL). Tetrahydrofuran (25 mL) was added and the mixture was stirred for 1 hour. The mixture was filtered through a pad of celite. The filtrate was concentrated and lyophilized to yield 2-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-1-ethanol (0.18 g, 0.42 mmol) as a white solid: ¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.51 (s, 1H), 7.48 (d, 2H), 7.42 (t, 2H), 7.16 (t, 1H), 7.09 (m, 4H), 6.10 (br, 2H), 4.57 (m, 1H), 4.36 (t, 1H), 3.47 (q, 2H), 2.70-1.65 (m, 10H); RP-HPLC (Hypersil C18, 5 μ m, 100A, 250x4.6mm; 25%-100% over 10 min then 100%-25% over 2 min acetonitrile - 0.05M ammonium acetate, 1mL/min) R_t 10.28 min. MS: MH⁺ 429.

10

d) 2-{4-[4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl} acetaldehyde

Dimethylsulfoxide (0.040 g, 0.51 mmol) was added into a solution of oxalyl chloride (0.033 g, 0.26 mmol) in dichloromethane (3 mL) at -78°C. The mixture was allowed to warm up to -40°C and stirred for 15 minutes followed by cooling down to -78°C again. 2-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl}-1-ethanol (0.10 g, 0.23 mmol) was added followed by triethylamine (0.12 mg, 1.165 mmol). The mixture was allowed to warm up to 0°C and saturated aqueous sodium bicarbonate solution (10 mL) was added to quench the reaction. The organic layer was separated from the aqueous layer and washed with 10% aqueous sodium hydrosulfate solution (4 mL), saturated aqueous sodium bicarbonate solution (4 mL) and saturated aqueous sodium chloride (4 mL). The organic layer was dried over magnesium sulfate and the solvent was removed under reduced pressure. The residue was purified by flash chromatography on silica gel using methanol / dichloromethane (5:95) as a mobile phase to yield 2-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl} acetaldehyde (0.053 g, 0.12 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 9.81 (s, 1H), 8.33 (s, 1H), 7.68 (m, 1H), 7.43 (d, 2H), 7.38 (t, 2H), 7.15 (t, 1H), 7.07 (m, 4H), 5.14 (br, 2H), 4.72 (m, 1H), 2.63-1.72 (m, 11H); TLC (methanol / dichloromethane = 5:95) R_f 0.41. MS: MH⁺ 427.

e) 7-{4-[2-(4-Methylpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

A mixture of 2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}acetaldehyde (0.025 g, 0.059 mmol), N-methylpiperazine (0.0083 g, 0.083 mmol) and acetic acid (0.0035 g, 0.059 mmol) in 1,2-dichloroethane (0.4 mL) was stirred for 10 min at ambient temperature and sodium triacetoxyborohydride (0.019 g, 0.089 mmol) was added. The mixture was stirred at ambient temperature under an atmosphere of nitrogen for 6 hours and the solvent removed under reduced to yield a yellow oil. The compound was purified by preparative RP-HPLC to yield 7-{4-[2-(4-methylpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.016 g, 0.031 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 8.27 (s, 1H), 7.45 (d, 2H), 7.37 (t, 2H), 7.16 (t, 1H), 7.09 (m, 5H), 5.57 (br, 2H), 4.73 (m, 1H), 2.33 (s, 3H), 2.49-1.65 (m, 19H); RP-HPLC (Hypersil C18, 5μm, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1mL/min) R_f 8.15 min. MS: MH⁺ 511.

Example 394: 7-[4-(2-Morpholinoethyl)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

20

A similar procedure to the preparation 7-{4-[2-(4-methylpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine yielded 7-[4-(2-Morpholinoethyl)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.015 g, 0.030 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 8.32 (br, 1H), 7.44 (d, 2H), 7.38 (t, 2H), 7.15 (t, 1H), 7.08 (m, 5H), 5.26 (br, 2H), 4.73 (m, 1H), 3.74 (m, 4H), 2.80-1.64 (m, 15H); RP-HPLC (Hypersil C18, 5μm, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1mL/min) R_f 8.50 min. MS: MH⁺ 498.

-283-

Example 395: *N*1-Methyl-2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}acetamide

A mixture of 2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}acetic acid (0.094 g, 0.21 mmol), 1-hydroxy-7-azabenzotriazole (0.044 g, 0.32 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.082 g, 0.43 mmol), 2*M* methylamine in tetrahydrofuran (2.13 mL, 4.26 mmol) and *N,N*-dimethylformamide (1.50 mL) was heated at 60°C overnight. The mixture was allowed to cool to ambient temperature and purified by preparative RP-HPLC to yield *N*1-methyl-2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}acetamide (0.025 g, 0.055 mmol) as a white solid: ¹H NMR (CDCl₃, 400 MHz) δ 8.24 (s, 1H), 7.42 (d, 2H), 7.38 (t, 2H), 7.16 (t, 1H), 7.07 (m, 5H), 5.82 (br, 2H), 5.62 (br, 1H), 4.70 (m, 1H), 2.83 (d, 3H), 2.36-1.70 (m, 11H); MS: MH⁺ 456; TLC (ethyl acetate) R_f 0.34; RP-HPLC (Hypersil C18, 5 μ m, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1 mL/min) R_t 9.32 min.

Example 396: 7-{4-[2-(Dimethylamino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

A similar procedure to the preparation 7-{4-[2-(4-methylpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine yielded 7-{4-[2-(dimethylamino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.001 g, 0.002 mmol) as a white solid: ¹H NMR (CDCl₃, 400 MHz) δ 8.19 (s, 1H), 7.63 (br, 2H), 7.44 (d, 2H), 7.38 (t, 2H), 7.17 (s, 1H), 7.15 (t, 1H), 7.07 (t, 4H), 4.72 (m, 1H), 2.76 (m, 2H), 2.58 (s, 6H), 2.03-1.75 (m, 9H); RP-HPLC (Hypersil C18, 5 μ m, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1 mL/min) R_t 8.17 min. MS: MH⁺ 456.

Example 397: *N*1-(2-{4-[4-Amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl)-*N*1,*N*2,*N*2-trimethyl-1,2-ethanediamine

A similar procedure to the preparation 7-{4-[2-(4-methylpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine yielded *N*1-(2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl)-*N*1,*N*2,*N*2-trimethyl-1,2-ethanediamine (0.0015 g, 0.003 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 8.20 (s, 1H), 8.11 (br, 2H), 7.43 (d, 2H), 7.38 (t, 2H), 7.15 (m, 2H), 7.06 (t, 4H), 4.70 (m, 1H), 2.44 (s, 3H), 2.04 (s, 6H), 2.80-1.71 (m, 17H); RP-HPLC (Hypersil C18, 5μm, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1mL/min) R_f 8.70 min. MS: MH⁺ 513.

Example 398: Ethyl 3-[(2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl)amino]propanoate

A similar procedure to the preparation 7-{4-[2-(4-methylpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine yielded ethyl 3-[(2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl)amino]propanoate (0.004 g, 0.008 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 8.18 (s, 1H), 7.58 (br, 2H), 7.39 (m, 4H), 7.08 (m, 6H), 4.72 (m, 1H), 4.17 (q, 2H), 3.13 (m, 2H), 2.83 (m, 2H), 2.74 (m, 2H), 2.03-1.76 (m, 11H), 1.25 (t, 3H); RP-HPLC (Hypersil C18, 5μm, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1mL/min) R_f 8.98 min. MS: MH⁺ 528.

Example 399: *Tert*-butyl 4-(2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl)-1-piperazinecarboxylate

A similar procedure to the preparation 7-{4-[2-(4-

methylnpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine yielded *tert*-butyl 4-(2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl)-1-piperazinecarboxylate (0.002 g, 0.003 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 8.27 (s, 1H), 7.44 (d, 2H), 7.40 (t, 2H), 7.15 (t, 1H), 7.08 (m, 5H), 5.62 (br, 2H), 4.73 (m, 1H), 3.45 (m, 4H), 2.43-1.23 (m, 17H), 1.46 (s, 9H); RP-HPLC (Hypersil C18, 5 μ m, 100A, 250x4.6mm; 25%-100% over 10 min then 100%-25% over 2 min and stayed at 25% for 3 min acetonitrile - 0.05M ammonium acetate, 1mL/min) R_t 12.22 min. MS: MH⁺ 597.

10

Example 400: 7-[4-(2-{[3-(1*H*-1-imidazolyl)propyl]amino}ethyl)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

A similar procedure to the preparation 7-{4-[2-(4-methylnpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine yielded 7-[4-(2-{[3-(1*H*-1-imidazolyl)propyl]amino}ethyl)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.003 g, 0.006 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 8.23 (s, 1H), 7.57 (s, 1H), 7.43 (d, 2H), 7.38 (t, 2H), 7.16 (t, 1H), 7.08 (m, 6H), 6.94 (br, 1H), 5.98 (br, 1H), 4.69 (m, 1H), 4.58 (br, 2H), 4.07 (t, 2H), 2.69(m, 4H), 2.06-1.71 (m, 13H); RP-HPLC (Hypersil C18, 5 μ m, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1mL/min) R_t 7.00 min. MS: MH⁺ 536.

Example 401: 1-(2-{4-[4-Amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl)-4-piperidinol

A similar procedure to the preparation 7-{4-[2-(4-methylnpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine yielded 1-(2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-

30

-286-

pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl)-4-piperidinol (0.007 g, 0.014 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 8.24 (s, 1H), 7.44 (d, 2H), 7.38 (t, 2H), 7.15 (t, 1H), 7.07 (m, 5H), 5.82 (br, 2H), 4.73 (m, 1H), 3.85 (m, 1H), 3.36 (br, 1H), 2.94 (m, 2H), 2.53 (m, 4H), 2.05-1.75 (m, 15H); RP-HPLC (Hypersil C18, 5 μ m, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1mL/min) R_t 7.75 min. MS: MH⁺ 512.

Example 402: 7-{4-[2-(4-Methyl-1,4-diazepan-1-yl)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

10

A similar procedure to the preparation 7-{4-[2-(4-methylpiperazino)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine yielded 7-{4-[2-(4-methyl-1,4-diazepan-1-yl)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.003 g, 0.006 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 8.26 (s, 1H), 7.44 (d, 2H), 7.38 (t, 2H), 7.15 (t, 1H), 7.08 (m, 5H), 5.71 (br, 2H), 4.71 (m, 1H), 2.88 (m, 8H), 2.62 (t, 2H), 2.49(s, 3H), 1.98-1.70 (m, 13H); RP-HPLC (Hypersil C18, 5 μ m, 100A, 250x4.6mm; 25%-100% acetonitrile - 0.05M ammonium acetate over 10 min, 1mL/min) R_t 7.90 min. MS: MH⁺ 525.

20

Example 403: 7-{4-[2-(1*H*-1-imidazolyl)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

a) 2-{4-[4-Amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl methanesulfonate

25

Methanesulfonyl chloride (0.036 g, 0.31 mmol) was added into a solution of 2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}-1-ethanol (0.11 g, 0.26 mmol) and triethylamine (2.5 mL) in dichloromethane (2.5 mL) at 0°C. The mixture was allowed to warm up to ambient temperature and stirred overnight. Methanesulfonyl chloride (0.036 g, 0.31 mmol) and dichloromethane (2.5

30

-287-

mL) was added. The mixture was stirred at ambient temperature for 17 hours. Methanesulfonyl chloride (0.036 g, 0.31 mmol) and dichloromethane (2.5 mL) was added. The mixture was stirred at ambient temperature for 4 hours. The solvent was removed under reduced pressure and the residue was purified by flash chromatography on silica gel using methanol / dichloromethane (5:95) as a mobile phase to yield 2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl methanesulfonate (0.10 g, 0.21 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 8.31 (s, 1H), 7.44 (d, 2H), 7.38 (t, 2H), 7.15 (t, 1H), 7.08 (m, 5H), 5.31 (br, 2H), 4.73 (m, 1H), 4.32 (t, 2H), 3.03 (s, 3H), 1.99-1.61 (m, 11H); TLC (methanol / dichloromethane = 5:95) R_f 0.37; RP-HPLC (Hypersil C18, 5μm, 100A, 250x4.6mm; 25%-100% over 10 min then 100%-25% over 2 min acetonitrile - 0.05M ammonium acetate, 1mL/min) R_t 11.45 min; MS: MH⁺ 507.

b) 7-{4-[2-(1*H*-1-imidazolyl)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

Imidazole (0.070 g, 1.03 mmol) was added into a solution of 2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}ethyl methanesulfonate (0.052 g, 0.10 mmol) in *N,N*-dimethylformamide (2 mL). The mixture was stirred at 40°C for 5 hours. 60% Sodium hydride in mineral oil (0.021 g, 0.052 mmol) was added and the mixture was stirred at ambient temperature overnight. The solvent was removed under reduced pressure and the residue was purified by preparative RP-HPLC to yield 7-{4-[2-(1*H*-1-imidazolyl)ethyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.030 g, 0.063 mmol) as a white solid: ¹H NMR (CDCl₃, 400MHz) δ 8.30 (s, 1H), 7.55 (br, 1H), 7.44 (d, 2H), 7.42 (t, 2H), 7.16 (t, 1H), 7.08 (m, 6H), 6.95 (br, 1H), 5.49 (br, 2H), 4.72 (m, 1H), 4.01 (t, 2H), 1.99-1.71 (m, 11H); RP-HPLC (Hypersil C18, 5μm, 100A, 250x4.6mm; 25%-100% over 10 min acetonitrile - 0.05M ammonium acetate, 1mL/min) R_t 9.18 min; MS: MH⁺ 479.

Examples 404 and 405: *Cis* and *trans*-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide

- 5 To 4-[4-amino-5-(4-amino-3-methoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone (0.8 g, 2.3 mmol) in pyridine/dichloromethane (1:2.5, 45 ml) was added hydrocinnamylchloride (0.57 g, 3.4 mmol) in dichloromethane (2 ml) at 0°C under a flow of nitrogen. The solution was stirred at 0°C for 2 hr. The solution was quenched with saturated aqueous citric acid solution (50 ml) and the organic layer
- 10 was washed with saturated aqueous citric acid solution (2 x 50 ml). Dry, filter and concentrate to leave a brown foam (1.0 g). This was dissolved in dichloroethane (100 ml) and N-methylpiperazine (0.63 g, 6.3 mmol) and acetic acid (0.38 g, 6.3 mmol) was added. Sodium triacetoxyborohydride (0.67 g, 3.15 mmol) was added portionwise under nitrogen and the mixture stirred overnight at room temperature.
- 15 The mixture was quenched with saturated aq. NaHCO₃ solution (50 ml) and extracted with dichloromethane (3 x 100 ml). The combined organics were dried (sodium sulphate), filtered and evaporated to leave a sludge which was purified by flash silica gel column chromatography using dichloromethane / methanol (100/0 to 50/50 in 5% increments). The fractions corresponding to the less polar material were
- 20 combined to give *cis*- N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide (0.26 g) as a glass. This was dissolved in ethylacetate (5 ml) and maleic acid (160 mg) in ethylacetate (2 ml) added. The resulting solid was filtered to give *cis*- N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-
- 25 methoxyphenyl)-3-phenylpropanamide trimaleate salt (260 mg) as a white solid. Analytical LC/MS conditions: Column: Pecosphere, C18, 3 μ m, 33x4.6 mm. Eluent: 0% B/A to 100% B/A in 4.5 min.(B: acetonitrile, A: 50 mM ammonia acetate buffer, PH 4.5) , 3.5 mL/min. (r_t = 2.86 mins, 568.4).
- 30 The fractions corresponding to the more polar material were combined to give *trans*- N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-

5-yl-2-methoxyphenyl)-3-phenylpropanamide (0.11 g) as a glass. This was dissolved in ethylacetate (5 ml) and treated with a solution of maleic acid (68 mg) in ethylacetate (2 ml). The resulting solid was filtered to give *trans*-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide tri-maleate (94 mg) as a white solid. Analytical LC/MS conditions: Column: Pecosphere, C18, 3 μ m, 33x4.6 mm. Eluent: 0% B/A to 100% B/A in 4.5 min. (B: acetonitrile, A: 50 mM ammonia acetate buffer, PH 4.5), 3.5 mL/min. (r_t = 2.68mins, 568.2).

10

Examples 406 and 407: *Cis* and *trans* -5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

4-[4-amino-5-(4-amino-3-methoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone (2.25 g, 6.5 mmol), acetic acid (1.17 g, 19.5 mmol) and N-methylpiperazine (1.95 g, 19.5 mmol) were dissolved in dichloroethane (200 ml). Sodium triacetoxymethylborohydride (2.07 g, 9.75 mmol) was added portionwise and the mixture stirred at room temperature overnight. Saturated sodium bicarbonate solution (150 ml) was added and the aqueous layer extracted with dichloromethane (3 x 100 ml). The combined organics were washed with water, dried (sodium sulphate), filtered and evaporated to leave a semi-solid which was purified by flash silica gel column chromatography using CH₂Cl₂ / methanol (0% MeOH to 50% MeOH in 5% increments). The fractions corresponding to the faster running material were combined and evaporated to give *cis*- 5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (1.2 g, 43%) as a cream solid. ¹H NMR (d₆-DMSO): δ 8.1 (1H, s), 7.11 (1H, s), 6.87 (1H, s), 6.79 (1H, d), 6.05 (2H, bs), 4.80 (2H, bs), 4.64 (1H, m), 4.08 (1H, m), 3.82 (3H, s), 3.17 (2H, m), 2.37 (6H, m), 2.21 (3H, s), 2.08 (4H, m), 1.70 (2H, m), 1.53 (2H, m). HPLC (r_t = 11.24 min, 97.6%).

The fractions corresponding to the slower running material were combined and evaporated to give *trans*- 5-(4-amino-3-methoxyphenyl)-7-[4-(4-

-290-

methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.4 g, 14%) as a white solid. ¹H NMR (d₆-DMSO): δ 8.10 (1H, s), 7.26 (1H, s), 6.87 (1H, s), 6.77 (1H, d), 6.71 (1H, d), 6.05 (2H, bs), 4.79 (2H, s), 4.52 (1H, m), 3.81 (3H, s), 3.35 (1H, m), 2.50 (5H, m), 2.31 (5H, m), 2.14 (1H, m), 1.97 (6H, m), 1.45 (2H, m).

5 HPLC (r_t = 10.13 min, 97.9%).

To a solution of *trans*- 5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (30 mg, 0.069 mmol) in pyridine (0.5 ml) was added the appropriate acid chloride (2 eq., 0.138 mmol). . The vials were capped and shaken overnight on an orbital shaker. LCMS (Micromass- Column: Pecosphere, C18, 3 μm, 33x4.6 mm. Eluents: 0% B/A to 100% B/A in 4.5 min. (B: acetonitrile, A: 50 mM ammonia acetate buffer, PH 4.5) , 3.5 mL/min.) of the resulting mixtures showed presence of product in all cases. The solutions were evaporated to dryness and the resulting residues were re- dissolved in 15 DMF (1 ml) and purified by reverse phase prep. HPLC (Hypersil BSD C18, 5 μm, 100x21mm, 0%-100% acetonitrile/0.05M ammonium acetate over 10 min, 25.0 mL/min). The resulting products were further purified by dissolving in dichloromethane (4 ml) and washed with 1.0 N sodium hydroxide (2 ml) to give the corresponding products. The compounds are detailed below alongwith the 20 appropriate ¹H NMR and LCMS data

Example 408: *trans*- N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-methoxyphenyl)-2-phenylcyclopropane-1-carboxamide

25

¹H NMR (d₆-DMSO): δ 9.54 (1H, s), 8.13 (1H, s), 8.08 (2H, d, *J* = 11.2 Hz), 7.44 (1H, s), 7.32 (2H, m), 7.20 (3H, m), 6.99 (1H, m), 6.11 (2H, bs), 4.55 (1H, s), 3.88 (3H, s), 2.50 (6H, m), 2.38 (6H, m), 2.14 (3H, s), 1.93 (6H, m), 1.47 (3H, m)

LC/MS (Pecosphere C18, 3 μm, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.69 min. MH⁺ 580.4.

30

Example 409: *trans* - *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-dimethylaminobenzamide

- 5 ¹H NMR (CDCl₃): δ 8.61 (1H, d, *J* = 8 Hz), 8.48 (1H, s), 8.33 (1H, s), 7.83 (2H, d, *J* = 8 Hz), 7.11 (1H, d, *J* = 8 Hz), 7.02 (2H, d, *J* = 8 Hz), 6.74 (2H, d, *J* = 8 Hz), 5.15 (2H, bs), 4.69 (1H, m), 3.98 (3H, s), 3.06 (6H, s), 2.43-2.65 (8H, m), 2.30 (3H, s), 2.22 (2H, m), 2.08 (2H, m), 1.85 (3H, m), 1.60 (2H, m)
LC/MS (Pecosphere C18, 3 μm, 33x4.6 mm; 0%-100% acetonitrile/0.05M
10 ammonium acetate over 5 min, 3.0 mL/min): R_t 2.59 min. MH⁺ 582.9.

Example 410: *trans*-*N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-trifluoromethoxybenzamide

- 15 ¹H NMR (d₆-DMSO): δ 9.63 (1H, s), 8.15 (1H, s), 8.09 (2H, d, *J* = 11.6 Hz), 7.85 (1H, d, *J* = 8 Hz), 7.52 (3H, m), 7.17 (1H, s), 7.06 (1H, d, *J* = 8 Hz), 6.15 (2H, bs), 4.56 (1H, m), 3.89 (3H, s), 2.50 (4, m), 2.35 (5H, m), 2.15 (3H, s), 1.92 (6H, m), 1.47 (2H, m).
LC/MS (Pecosphere C18, 3 μm, 33x4.6 mm; 0%-100% acetonitrile/0.05M
20 ammonium acetate over 5 min, 3.0 mL/min): R_t 2.86 min. MH⁺ 624.1

Example 411: *trans*-*N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-trifluoromethylbenzamide

- 25 ¹H NMR (d₆-DMSO): δ 9.76 (1H, s), 8.15 (3H, m), 7.91 (2H, d, *J* = 8.4 Hz), 7.86 (1H, d, *J* = 8.4 Hz), 7.51 (1H, s), 7.19 (1H, s), 7.08 (1H, d, *J* = 8 Hz), 6.15 (2H, bs), 4.56 (1H, m), 3.91 (3H, s), 2.50 (4H, m), 2.35 (5H, m), 2.32 (3H, s), 1.94 (6H, m), 1.46 (2, m)
LC/MS (Pecosphere C18, 3 μm, 33x4.6 mm; 0%-100% acetonitrile/0.05M
30 ammonium acetate over 5 min, 3.0 mL/min): R_t 2.69 min. MH⁺ 608.4

Example 412: *cis-N*-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-*N'*-benzylurea

5 To a solution of *cis*- 5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (50 mg, 0.116 mmol) in pyridine (1 ml) at room temperature was added benzylisocyanate (15.4 mg, 0.116 mmol). The resulting solution was shaken overnight at room temperature on an orbital shaker and then submitted directly to preparative HPLC. The resulting
10 product was further purified by dissolving in dichloromethane (4 ml) and washed with 1.0 N sodium hydroxide (2 ml) to furnish, after evaporation of the solvent, *cis-N*-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-*N'*-benzylurea as a white powder.

¹H NMR (CDCl₃): δ 8.32 (1H, s), 8.18 (1H, d), 7.34 (4H, m), 7.26 (1H, m), 7.08 (2H, m), 6.95 (2H, m), 5.25 (1H, m), 5.10 (2H, bs), 4.82 (1H, m), 4.48 (2H, m), 3.85 (3H, s), 2.47 (3H, m), 2.29 (4H, m), 2.12 (4H, m), 1.82 (3H, m), 1.62 (2H, m), 1.31 (4H, m), 0.89 (2H, m).

LC/MS (Peccosphere C18, 3 μm, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.57 min. MH⁺ 569.3

20

Example 413: *cis-N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-(E)-3-phenyl-2-propenamide

 To a solution of *cis*- 5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (50 mg, 0.116
25 mmol) in pyridine (1 ml) at room temperature was added cinnamoylchloride (39 mg, 0.232 mmol) and the solution shaken overnight at room temperature. The resulting solution was submitted directly to prep HPLC. The resulting product was further purified by dissolving in dichloromethane (4 ml) and washed with 1.0 N sodium hydroxide (2 ml) to furnish, after evaporation of the solvent, *cis-N*1-(4-4-amino-7-
30 [4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-

-293-

methoxyphenyl)-(E)-3-phenyl-2-propenamide as an off-white powder (42 mg).

¹H NMR (CDCl₃): δ 8.62 (1H, d, *J* = 8.4 Hz), 8.34 (1H, s), 7.99 (1H, s), 7.77 (1H, d, *J* = 8 Hz), 7.57 (2H, m), 7.40 (3H, m), 7.15 (2H, m), 7.04 (1H, s), 6.63 (1H, d, *J* = 15.2 Hz), 5.16 (2H, bs), 4.83 (1H, m), 3.99 (3H, s), 2.61 (6H, m), 2.29 (4H, m), 2.12 (4H, m), 1.86 (4H, m), 1.65 (2H, m)

LC/MS (Pecosphere C18, 3 μm, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.82 min. MH⁺ 566.3

10 Example 414: *Cis*-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2-phenylacetamide

To a solution of *cis*- 5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (50 mg, 0.116 mmol) in pyridine (1 ml) at room temperature was added phenacetyl chloride (36 mg, 0.232 mmol). The resulting solution was shaken overnight and then submitted directly for prep. HPLC. The resulting product was further purified by dissolving in dichloromethane (4 ml) and washed with 1.0 N sodium hydroxide (2 ml) to furnish, after evaporation of the solvent, *cis*-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2-phenylacetamide as a white powder (15 mg).

¹H NMR (CDCl₃): δ 8.44 (1H, d, *J* = 8.4 Hz), 8.42 (1H, s), 7.83 (1H, s), 7.37 (4H, m), 7.06 (2H, m), 6.93 (1H, s), 5.12 (2H, s), 4.80 (1H, m), 3.80 (3H, s), 2.61 (6H, m), 2.29 (4H, m), 2.13 (4H, m), 1.98 (2H, m), 1.83 (2H, m), 1.62 (2H, m).

25 LC/MS (Pecosphere C18, 3 μm, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.58 min. MH⁺ 554.3

All the following compounds were made by parallel synthesis according to the following procedure:

30 To *cis* - 5-(4-amino-3-methoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (30 mg, 0.069 mmol) in pyridine (0.5 mL) was

added the appropriated acid chloride (0.138 mmol) slowly while vortexing. The reaction mixtures were shaken for 5-20 hr. The reactions were monitored by analytical HPLC. For the reactions that still had starting material left after 5 hours, another two equivalents of acid chloride were added while vortexing. The crude
5 reaction mixtures were purified by reverse phase preparative LC/MS (Hypersil BSD C18, 5 μ m, 100x21mm, 0%-100% acetonitrile/0.05M ammonium acetate over 10 min, 25.0 mL/min). The resulting products were further purified by dissolving in dichloromethane (4 ml) and washed with 1.0 N sodium hydroxide (2 ml) to give the corresponding products. Product yields are from 38% to 88% and purities are from
10 94% to 100%.

Example 415: Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2-methoxyacetamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium
15 acetate over 5 min, 3.0 mL/min): Rt 2.32 min. MH⁺ 508.3.

Example 416: Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2,6-difluorobenzamide,
20 LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.61 min. MH⁺ 576.3.

Example 417: Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2-methoxybenzamide,
25 LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 3.02 min. MH⁺ 570.3.

Example 418: Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2,6-dimethoxybenzamide,
30 LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M

-295-

ammonium acetate over 5 min, 3.0 mL/min): R_t 2.61 min. MH^+ 600.3.

Example 419: Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3,4-dichlorobenzamide,

5

LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 3.26 min. MH^+ 608.3.

Example 420: Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-methoxybenzamide

10

LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.74 min. MH^+ 570.3.

Example 421: Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-fluorobenzamide,

15

LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.78 min. MH^+ 558.34.

20

Example 422: Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-chlorobenzamide,

LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 3.00 min. MH^+ 574.3.

25

Example 423

Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-methoxybenzamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.76 min. MH^+ 570.3.

30

Example 424

- Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-(trifluoromethyl)benzamide, LC/MS
5 (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 3.26 min. MH^+ 608.3.

Example 425

- Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2-phenoxyacetamide, LC/MS (Pecosphere C18,
10 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.94 min. MH^+ 570.3.

Example 426

- Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2-(4-chlorophenoxy)acetamide, LC/MS
15 (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 3.13 min. MH^+ 604.3.

Example 427

- Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-cis-2-phenylcyclopropane-1-carboxamide,
20 LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 3.16 min. MH^+ 580.3.

25 Example 428

- Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-nitrobenzamide, LC/MS (Pecosphere C18, 3
um, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0
mL/min): R_t 2.90 min. MH^+ 585.3.

30

Example 429

Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2,5-difluorobenzamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.90 min. MH^+ 576.3.

5

Example 430

Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2-(benzyloxy)acetamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.90 min. MH^+ 584.3.

10

Example 431

Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-cyanobenzamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.74 min. MH^+ 565.6.

15

Example 432

Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2,3-difluorobenzamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 3.06 min. MH^+ 576.3.

20

Example 433

Cis *N*3-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-6-chloronicotinamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.53 min. MH^+ 575.3.

25

Example 434

*N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-(*tert*-butoxy)benzamide, LC/MS (Pecosphere C18, 3 μ m,

30

-298-

33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 3.32 min. MH^+ 624.3.

Example 435

- 5 Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2,4,6-trifluorobenzamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.85 min. MH^+ 594.4.

Example 436

- 10 Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2-chloro-6-fluorobenzamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.76 min. MH^+ 592.3.

15 Example 437

Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-(dimethylamino)benzamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.86 min. MH^+ 583.3.

20

Example 438

- Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-cyanobenzamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.68 min. MH^+ 565.3.

25

Example 439

- Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-nitrobenzamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.84 min. MH^+ 585.3.

30

Example 440

Cis N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-
d]pyrimidin-5-yl-2-methoxyphenyl)-3-fluorobenzamide, LC/MS (Pecosphere C18, 3
um, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0
5 mL/min): R_t 2.73 min. MH⁺ 558.1.

Example 441

Cis N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-
d]pyrimidin-5-yl-2-methoxyphenyl)-2,5-dimethoxybenzamide, LC/MS (Pecosphere
10 C18, 3 um, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5
min, 3.0 mL/min): R_t 2.93 min. MH⁺ 600.2.

Example 442

Cis N5-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-
15 d]pyrimidin-5-yl-2-methoxyphenyl)-1,3-benzodioxole-5-carboxamide, LC/MS
(Pecosphere C18, 3 um, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium
acetate over 5 min, 3.0 mL/min): R_t 2.73 min. MH⁺ 584.3.

Example 443

Cis N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-
20 d]pyrimidin-5-yl-2-methoxyphenyl)-2,6-dimethylbenzamide, LC/MS (Pecosphere
C18, 3 um, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5
min, 3.0 mL/min): R_t 2.84 min. MH⁺ 568.2.

Example 444

Cis N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-
d]pyrimidin-5-yl-2-methoxyphenyl)-2-chloro-4-fluorobenzamide, LC/MS
(Pecosphere C18, 3 um, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium
25 acetate over 5 min, 3.0 mL/min): R_t 2.86 min. MH⁺ 592.1

30

Example 445

Cis N5-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

d]pyrimidin-5-yl-2-methoxyphenyl)-2,1,3-benzoxadiazole-5-carboxamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_f 2.74 min. MH^+ 582.1.

5 Example 446

Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-4-phenylbutanamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_f 2.92 min. MH^+ 582.1.

10

Example 447

Cis *N*4-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-1-methyl-5-propyl-1*H*-4-pyrazolecarboxamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_f 2.57 min. MH^+ 586.4.

15

Example 448

Cis *N*1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-2-methoxybenzamide, LC/MS (Pecosphere C18, 3 μ m, 33x4.6 mm; 0%-100% acetonitrile/0.05M ammonium acetate over 5 min, 3.0 mL/min): R_t 2.32 min. MH^+ 508.3.

20

Example 449

Cis-5-(4-phenoxyphenyl)-7-{4-[(3*R*)tetrahydro-1*H*-3-pyrrolylamino]cyclohexyl}-pyrrolo[2,3-*d*]pyrimidin-4-amine

25

A mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexanone (1.00g, 2.51 mmol), (3*R*)-(+)-3-aminopyrrolidine (0.65 g, 7.5 mmol), and acetic acid (0.43 mL, 7.5 mmol) in 1,2-dichloroethane (50 mL) was stirred at ambient temperature under an atmosphere of nitrogen for 45 minutes.

30

Sodium triacetoxyborohydride (0.691 g, 3.26 mmol) was added and the mixture stirred at ambient temperature for 15 hours. Water (50 mL) and sodium bicarbonate (1.35 g, 16.1 mmol) were added and the mixture was stirred for 45 minutes. The

reaction mixture was transferred to a separatory funnel and the organic layer was separated. The organic portion was dried over magnesium sulfate, filtered, and the solvent removed under reduced pressure to yield an oily brown solid. The compound was purified by flash chromatography on silica gel (1 L 10% MeOH in CH₂Cl₂, then 1 L 20% MeOH in CH₂Cl₂, followed by 500 mL 30% MeOH in CH₂Cl₂) to yield cis-5-(4-phenoxyphenyl)-7-{4-[(3*R*)tetrahydro-1*H*-3-pyrrolylamino]cyclohexyl}-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine as a beige solid (0.285 g, 0.608 mmol): ¹H NMR (d₆ DMSO, 400 MHz): δH 8.13 (1H, s), 7.39-7.49 (5H, m), 7.07-7.17 (5H, m), 6.09 (2H, bs), 4.65 (1H, m), 3.29-3.35 (3H, m), 2.63-2.67 (2H, m), 1.94-2.51 (8H, m), 1.46-1.80 (4H, m); RP-HPLC (Delta Pak C18, 5μm, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 12.59 min.

The following compound was made in a similar manner to cis-5-(4-phenoxyphenyl)-7-{4-[(3*R*)tetrahydro-1*H*-3-pyrrolylamino]cyclohexyl}-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine.

Example 450

Cis-5-(4-phenoxyphenyl)-7-{4-[(3*S*)tetrahydro-1*H*-3-pyrrolylamino]cyclohexyl}-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine: ¹H NMR (d₆ DMSO, 400 MHz): δH 8.13 (1H, s), 7.37-7.49 (5H, m), 7.07-7.17 (5H, m), 6.11 (2H, bs), 4.64 (1H, m), 3.17-3.33 (3H, m), 2.49-2.56 (2H, m), 1.90-2.36 (8H, m), 1.58-1.89 (4H, m); RP-HPLC (Delta Pak C18, 5μm, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 12.75 min.

25

Examples 451 and 452

Cis-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}-4-piperidinol dimaleate salt and trans-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}-4-piperidinol dimaleate salt

30

A mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-

7-yl]cyclohexanone (0.997 g, 2.50 mmol), 4-hydroxypiperidine (0.760 g, 7.5 mmol), sodium triacetoxyborohydride (0.689 g, 3.25 mmol), and acetic acid (0.43 mL, 7.5 mmol) in 1,2-dichloroethane (50 mL) was stirred at 80 °C under an atmosphere of nitrogen for 58 hours. The reaction mixture was cooled and water (50 mL) and sodium bicarbonate (1.35 g, 16.1 mmol) were added and the mixture was stirred for 2 hours. The organic layer was separated, dried over magnesium sulfate, filtered, and the solvent removed under reduced pressure to yield a brown solid. The cis and trans isomers were purified by flash chromatography on silica gel (1 L 5% MeOH in CH₂Cl₂, then 500 mL 10% MeOH in CH₂Cl₂, 500 mL 50:45:5 CH₂Cl₂:MeOH:Et₃N, and 500 mL 45:45:10 CH₂Cl₂:MeOH:Et₃N). In order to remove residual Et₃N, each of the products was taken up in CH₂Cl₂, washed with 40 mL water, the organic portion separated, dried over magnesium sulfate, filtered, and concentrated to yield cis-1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}-4-piperidinol as a brown solid (0.185 g, 0.382 mmol) and trans-1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}-4-piperidinol as a brown solid (0.115 g, 0.237 mmol). The cis-1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}-4-piperidinol (0.185 g, 0.383 mmol) was dissolved in warm ethyl acetate (5 mL) then added to a solution of maleic acid (0.089 g, 0.765 mmol) in ethanol (5 mL). The mixture was cooled to ambient temperature and the solid was collected by filtration and dried to give cis-1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}-4-piperidinol dimaleate salt (0.202 g) as a yellow solid: ¹H NMR (d₆ DMSO, 400 MHz): δH 8.61 (1H, bs), 8.25 (1H, s), 7.40-7.56 (5H, m), 7.08-7.19 (5H, m), 6.40 (2H, bs), 6.13 (4H, s), 5.00-5.20 (1H, m), 4.80 (1H, m), 3.03-3.95 (9H, m), 2.30-2.32 (2H, m), 1.63-1.99 (6H, m); RP-HPLC (Delta Pak C18, 5μm, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 13.33 min. MS: MH⁺ 484.

Trans-1-{4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}-4-piperidinol dimaleate salt was prepared from the free base in the

same manner: ¹H NMR (d₆ DMSO, 400 MHz): δH 8.90 (1H, bs), 8.20 (1H, s), 7.40-7.48 (5H, m), 7.08-7.19 (5H, m), 6.45 (2H, bs), 6.14 (4H, s), 5.00-5.15 (1H, m), 4.75 (1H, m), 4.00 (1H, m), 3.05-3.90 (8H, m), 1.50-2.17 (8H, m); RP-HPLC (Delta Pak C18, 5μm, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 13.49 min. MS: MH⁺ 484.

Examples 453 and 454

Cis-7-{4-[(3*R*)-3-(dimethylamino)tetrahydro-1*H*-1-pyrrolyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt and trans-7-{4-[(3*R*)-3-(dimethylamino)tetrahydro-1*H*-1-pyrrolyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt

A mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexanone (1.00g, 2.51 mmol), (3*R*)-(+)-3-(dimethylamino)pyrrolidine (0.86 g, 7.5 mmol), and acetic acid (0.43 mL, 7.5 mmol) in 1,2-dichloroethane (45 mL) was stirred at ambient temperature under an atmosphere of nitrogen for 30 minutes. Sodium triacetoxyborohydride (0.689 g, 3.26 mmol) was added and the mixture stirred at ambient temperature for 22 hours. Water (50 mL) and sodium bicarbonate (1.35 g, 16.1 mmol) were added and the mixture was stirred for 3 hours. The reaction mixture was transferred to a separatory funnel and the organic layer was separated. The aqueous layer was extracted with CH₂Cl₂ (20 mL), and the combined organic extracts were dried over magnesium sulfate, filtered, and the solvent removed under reduced pressure to yield a red oil. The cis and trans isomers were purified by flash chromatography on silica gel (1 L 5% MeOH in CH₂Cl₂, then 1 L 10% MeOH in CH₂Cl₂, 1 L 20% MeOH in CH₂Cl₂, 1 L 30% MeOH in CH₂Cl₂, 1 L 40% MeOH in CH₂Cl₂, and 1 L 50% MeOH in CH₂Cl₂) to yield cis-7-{4-[(3*R*)-3-(dimethylamino)tetrahydro-1*H*-1-pyrrolyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine as a pink solid (0.558 g, 1.12 mmol) and trans-7-{4-[(3*R*)-3-(dimethylamino)tetrahydro-1*H*-1-pyrrolyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine as a pink solid (0.210 g, 0.422 mmol). The cis-7-{4-[(3*R*)-3-(dimethylamino)tetrahydro-1*H*-1-pyrrolyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

(0.330 g, 0.670 mmol) was dissolved in warm ethanol (5 mL) then maleic acid (0.233 g, 2.01 mmol) in ethanol (5 mL) was added. The mixture was cooled to ambient temperature and the solid was collected by filtration and dried to give cis-7-{4-[(3*R*)-3-(dimethylamino)tetrahydro-1*H*-1-pyrrolyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt (0.622 g) as a beige solid: ¹H NMR (d₆ DMSO, 400 MHz): δH 8.20 (1H, s), 7.41-7.48 (4H, m), 7.35 (1H,s), 7.08-7.19 (5H, m), 6.45 (2H, bs), 6.16 (6H, s), 4.70 (1H, m), 4.30 (2H, bs), 3.80 (1H, bs), 3.08 (3H, m), 2.76 (6H, s), 2.00-2.21 (6H, m), 1.74-1.72 (4H, m); RP-HPLC (Delta Pak C18, 5μm, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_f 13.94 min. MS: MH⁺ 497.

Trans-7-{4-[(3*R*)-3-(dimethylamino)tetrahydro-1*H*-1-pyrrolyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt was prepared from the free base in the same manner: ¹H NMR (d₆ DMSO, 400 MHz): δH 8.18 (1H, s), 7.40-7.47 (5H, m), 7.08-7.19 (5H, m), 6.33 (2H, bs), 6.12 (6H, s), 4.61 (1H, m), 3.07-3.60 (6H, m), 2.64 (6H, s), 2.18-2.20 (3H, m), 1.98-2.03 (5H, m), 1.55-1.58 (2H, m); RP-HPLC (Delta Pak C18, 5μm, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_f 14.08 min. MS: MH⁺ 497.

The following compounds were made in a similar manner to cis- and trans-7-{4-[(3*R*)-3-(dimethylamino)tetrahydro-1*H*-1-pyrrolyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt.

Examples 455 and 456

Cis-7-{4-[(3*S*)-3-(dimethylamino)tetrahydro-1*H*-1-pyrrolyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt: ¹H NMR (d₆ DMSO, 400 MHz): δH 8.20 (1H, s), 7.42-7.48 (4H, m), 7.41 (1H,s), 7.08-7.17 (5H, m), 6.45 (2H, bs), 6.15 (6H, s), 4.67 (1H, m), 3.08-3.79 (6H, m), 2.76 (6H, s), 1.91-2.23 (6H, m), 1.74-1.77 (4H, m); RP-HPLC (Delta Pak C18, 5μm, 300A, 15 cm; 5%-85%

acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 13.89 min. MS: MH^+ 497.

- 5 **Trans-7-{4-[(3*S*)-3-(dimethylamino)tetrahydro-1*H*-1-pyrrolyl]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt:** 1H NMR (d_6 DMSO, 400 MHz): δ H 8.18 (1H, s), 7.40-7.48 (5H, m), 7.08-7.19 (5H, m), 6.34 (2H, bs), 6.12 (6H, s), 4.62 (1H, m), 3.24-3.91 (6H, m), 2.66 (6H, s), 2.18-2.21 (3H, m), 1.94-2.03 (5H, m), 1.55-1.58 (2H, m); RP-HPLC (Delta Pak C18, 5 μ m, 300A, 10 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 14.07 min. MS: MH^+ 497.

Example 457

- 15 **Cis-(3*R*)-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}tetrahydro-1*H*-3-pyrrolol dimaleate salt**

A mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexanone (1.00 g, 2.51 mmol) and (*R*)-(+)-3-pyrrolidinol (0.62 mL, 7.5 mmol) in 1,2-dichloroethane (50 mL) was stirred at ambient temperature under an atmosphere of nitrogen for 1.5 hours. Sodium triacetoxymethylborohydride (0.691 g, 3.26 20 mmol) was added and the mixture stirred at ambient temperature for 22 hours. Water (50 mL) and sodium bicarbonate (1.34 g, 16.1 mmol) were added and the mixture was stirred for 2 hours. The reaction mixture was transferred to a separatory funnel and the organic layer was separated, dried over magnesium sulfate, filtered, and the solvent removed under reduced pressure to yield a yellow-brown solid. The 25 cis isomer was purified by flash chromatography on silica gel (1 L 5% MeOH in CH_2Cl_2 , then 2 L 10% MeOH in CH_2Cl_2 , 1 L 20% MeOH in CH_2Cl_2 , and 1 L 40% MeOH in CH_2Cl_2) to yield cis-(3*R*)-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}tetrahydro-1*H*-3-pyrrolol as a pale yellow oil (0.529 g, 1.12 mmol). The cis-(3*R*)-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}tetrahydro-1*H*-3-pyrrolol (0.464 g, 0.988 30 mmol) was dissolved in warm ethanol (5 mL) and added to a solution of maleic acid

(0.344 g, 2.96 mmol) in ethanol (5 mL). The mixture was cooled to ambient temperature then the solid was collected by filtration and dried to give cis-(3*R*)-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}tetrahydro-1*H*-3-pyrrolol dimaleate salt (0.549 g) as a pale yellow solid: ¹H NMR (d₆ DMSO, 400 MHz): δH 8.22 (1H, s), 7.41-7.50 (5H, m), 7.08-7.19 (5H, m), 6.49 (2H, bs), 6.13 (4H, s), 4.85 (1H, bs), 4.49 (1H, bs), 3.37-3.68 (5H, m), 1.92-2.18 (11H, m); HPLC: (Hypersil HS C18, 5 μm, 254 nm, 250 x 4.6 mm; 25-100% acetonitrile-0.1N ammonium acetate over 10 min, 1 ml/min) t_r=7.167 min.

Examples 458

Trans-((2*S*)-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}tetrahydro-1*H*-2-pyrrolyl)methanol dimaleate salt

A mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexanone (0.200 g, 0.502 mmol) and (*S*)-(+)-2-pyrrolidinemethanol (0.152 g, 1.51 mmol) in ethanol (2 mL) was stirred at ambient temperature under an atmosphere of nitrogen for 20 hours. The reaction mixture was filtered and concentrated to afford a yellow oil. The crude product was combined with sodium borohydride (0.019 g, 0.502 mmol) in methanol (10 mL) and stirred at ambient temperature under an atmosphere of nitrogen for 2 hours. Water (10 mL) was added, the organic portion was separated, and the aqueous portion was extracted with ethyl acetate (25 mL). The organic portions were combined, dried over magnesium sulfate, filtered, and concentrated to afford an oily yellow solid. Purification by flash chromatography on silica gel afforded trans-((2*S*)-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}tetrahydro-1*H*-2-pyrrolyl)methanol (0.064 g, 0.132 mmol) as a white solid. The trans-((2*S*)-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}tetrahydro-1*H*-2-pyrrolyl)methanol (0.064 g, 0.132 mmol) was dissolved in warm ethyl acetate (2 mL) and a solution of maleic acid (0.031 g, 0.265 mmol) in ethanol (2 mL) was added. The mixture was cooled to ambient

temperature and the solid was collected by filtration and dried to give trans-((2*S*)-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}tetrahydro-1*H*-2-pyrrolyl)methanol dimaleate salt (0.062 g) as a pale yellow solid: ¹H NMR (d₆ DMSO, 400 MHz): δH 8.18 (1H, s), 7.40-7.47 (5H, m), 7.08-7.19 (5H, m), 6.32 (2H, bs), 6.13 (4H, s), 5.50 (1H, s), 4.65 (1H, m), 3.34-3.81 (6H, m), 1.77-2.09 (12H, m); RP-HPLC (Delta Pak C18, 5μm, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 13.78 min. MS: MH⁺ 484.

10 The following compound was made in a similar manner to trans-((2*S*)-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}tetrahydro-1*H*-2-pyrrolyl)methanol dimaleate salt:

Examples 459

15 **Trans-((2*R*)-1-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]cyclohexyl}tetrahydro-1*H*-2-pyrrolyl)methanol dimaleate salt:** ¹H NMR (d₆ DMSO, 400 MHz): δH 8.18 (1H, s), 7.40-7.47 (5H, m), 7.08-7.19 (5H, m), 6.31 (2H, bs), 6.13 (4H, s), 5.50 (1H, s), 4.65 (1H, m), 3.33-3.81 (6H, m), 1.78-2.06 (12H, m); RP-HPLC (Delta Pak C18, 5μm, 300A, 15 cm; 5%-85% acetonitrile – 20 0.1M ammonium acetate over 20 min, 1mL/min) R_t 13.83 min. MS: MH⁺ 484.

***Cis*-7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (Intermediate 1)**

In a heat dried flask, trimethylsulfoxonium iodide (1.33 g, 6 mmol) in dimethylsulfoxide (10 mL) was reacted with 60% sodium hydride dispersion in mineral oil (0.22 g, 5.5 mmol). The mixture was stirred at room temperature for 30 minutes and then cooled to 10°C. A solution of 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone (2 g, 5 mmol) in dimethylsulfoxide (10 mL) was added, and the mixture was stirred at ambient temperature for 2 hours. Water (10 30 mL) was added and the mixture was extracted with ethyl acetate (2 x 20 mL). The

organic phase was separated and dried over magnesium sulfate. The solvent was removed *in vacuo* to give *cis*-7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine as a white solid (1.98 g, 4.8 mmol).

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.15 (s, 1H), 7.49 (d, 2H), 7.48 (s, 1H), 7.42 (t, 2H), 7.16 (t, 1H), 7.09 (d, 2H), 6.11 (bs, 2H), 4.72-4.78 (m, 1H), 2.70 (s, 2H), 2.47-2.52 (m, 2H), 2.03-2.26 (m, 4H), 1.26-1.35 (m, 2H);

MS: M⁺ 413

***Trans*-7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (Intermediate 2)**

To a mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone (2 g, 5 mmol) in tetrahydrofuran (17.5 mL) were added trimethylsulfonium iodide (1.53 g, 7.5 mmol) in dimethyl sulfoxide (25 mL) and potassium-*t*-butoxide (7.5 mL, 7.5 mmol, 1 M in tetrahydrofuran) under an atmosphere of nitrogen at -5 °C. The mixture was stirred at -5 °C for 1 hour. The mixture was poured into ice water (50 mL). The water phase was extracted with ethyl acetate (3 x 30 mL). The combined organic extracts were washed with saturated ammonium chloride solution (2 x 30 mL), water (1 x 30 mL), and brine (2 x 30 mL) and dried over sodium sulfate. The solvent was removed under reduced pressure to yield 7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (1.9 g, 4.6 mmol, 2:1-mixture of *trans* and *cis*). The mixture was suspended in dichloromethane (3 mL). The solid was filtered and was washed with dichloromethane (1mL) to yield 7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.994 g, 2.4 mmol, 4:1- mixture of *trans* and *cis*).

¹H NMR for *trans* isomer (DMSO-*d*₆, 400 MHz) δ 8.15 (s, 1H), 7.45 (m, 5H), 7.16 (t, 1H), 7.09(m, 4H), 6.11(br, 2H), 4.73 (br, 1H), 2.65 (s, 2H), 2.16 (br, 6H), 1.38 (br, 2H)

RP-HPLC (Hypersil C18, 5 μ m, 250 x 4.6 mm; 25% - 100% over 23 min with 0.1 M

ammonium acetate, 1mL/min) R_t 10.53 min.

MS: MH^+ 413

Example 460

5 ***Cis*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexylmethyl cyanide**

A mixture of *cis*-7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.750 g, 1.8 mmol), lithium perchlorate (0.290 g, 2.7 mmol) and potassium cyanide (0.177 g, 2.7 mmol) in acetonitrile (100 mL) was heated at
10 80°C for three days. Cooled to ambient temperature, diluted with water (50 mL) and extracted with diethyl ether (3x 50 mL). The combined organic phases were dried over magnesium sulfate. The solvent was removed *in vacuo* and the crude product was purified by flash column chromatography on silica using dichloromethane/methanol (95:5). The solvent was removed *in vacuo* to give *cis*-4-
15 [4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexylmethyl cyanide as a white solid (0.380 g, 0.9 mmol, 50% yield):
 1H NMR (DMSO- d_6 , 400MHz) δ 8.14 (s, 1H), 7.49 (d, 2H), 7.42 (t, 2H), 7.37 (s, 1H), 7.16 (t, 1H), 7.09 (d, 2H), 6.11 (bs, 2H), 4.51-4.62 (m, 1H), 2.66 (s, 2H), 2.10-2.29 (m, 2H), 1.72-1.87 (m, 4H), 1.60-1.72 (m, 2H);
20 RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 15.90 min.;
MS: M^+ 440

Example 461

25 ***Trans*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexylmethyl cyanide**

Ring opening of *trans*-7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (1 g, 2.4 mmol) with cyanide as described above led to *trans*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-
30 hydroxycyclohexyl-methyl cyanide as a white solid (0.435 g, 1.03 mmol, 43% yield):

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.14 (s, 1H), 7.63 (s, 1H), 7.47 (d, 2H), 7.43 (t, 2H), 7.15-7.07 (m, 5H), 6.20 (br, 2H), 4.65 (m, 1H), 2.98 (s, 2H), 1.92-1.86 (m, 6H), 1.80-1.65 (m, 2H),

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1M

5 ammonium acetate over 20 min, 1mL/min) R_t 15.88.

MS: M⁺ 440

Example 462

Cis-1-(2-aminoethyl)-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-
10 *d*]pyrimidin-7-yl]-1-cyclohexanol

To *cis*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxy-cyclohexylmethyl cyanide (0.340 g, 0.77 mmol) in methanol (30 ml) and ammonium hydroxide (2 mL) was added Raney nickel (0.5 mL). The mixture was stirred 18 hours under hydrogen (1 atm). The reaction mixture was filtered through
15 celite and the solvent was removed *in vacuo* to give *cis*-1-(2-aminoethyl)-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanol as a white solid (0.230 g, 0.52 mmol):

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.48 (d, 2H), 7.42 (t, 2H), 7.36 (s, 1H), 7.16 (t, 1H), 7.09 (d, 2H), 6.09 (bs, 2H), 4.50-4.63 (m, 1H), 2.77-2.87 (m, 2H),
20 2.09-2.24(m, 2H), 1.66-1.78 (m, 4H), 1.42-1.62 (m, 2H);

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1 M ammonium acetate over 20 min, 1mL/min) R_t 13.07 min.;

MS: M⁺ 444

25 Example 463

Trans-1-(2-aminoethyl)-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-
d]pyrimidin-7-yl]-1-cyclohexanol

Reduction of *trans*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxy-cyclohexylmethyl cyanide (0.448 g, 1.0 mmol) as described above
30 for the *cis*-isomer yielded *trans*-1-(2-aminoethyl)-4-[4-amino-5-(4-phenoxyphenyl)-

7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanol (0.015 g, 0.034 mmol)

¹H NMR (Chloroform-*d*, 400 MHz) δ 8.32 (s, 1H), 7.44 (m, 4H), 7.15 (t, 1H), 7.09 (m, 4H), 6.99 (s, 1H), 5.13 (br, 2H), 4.77 (br, 1H), 3.09 (br, 2H), 2.10 (br, 2H), 2.00 (br, 2H), 1.84 (br, 6H).

- 5 RP-HPLC (Hypersil C18, 5 μ m, 250 x 4.6 mm; 25% - 100% over 10 min with 0.1 M ammonium acetate, 1 mL/min) *R*_t 6.75 min.

MS: MH⁺ 444

Example 464

- 10 ***Cis*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-2-[(1*H*-2-imidazolylmethyl)amino]ethyl-1-cyclohexanol diacetate**

A mixture of *cis*-1-(2-aminoethyl)-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanol (0.192 g, 0.43 mmol), 1*H*-2-imidazolecarbaldehyde

- 15 (0.042 g, 0.43 mmol), sodium triacetoxyborohydride (0.119 g, 0.56 mmol) and acetic acid (0.052 g, 0.87 mmol) in 1,2-dichloroethane (25 mL) was heated at 40°C for one hour, after which time additional sodium triacetoxyborohydride (0.119 g, 0.56 mmol) was added. The mixture was stirred at 40°C for two days. The solvent was removed *in vacuo* and the residue was partitioned between saturated aqueous
20 sodium bicarbonate (50 mL) and dichloromethane (25 mL). The layers were separated, and the aqueous layer was extracted with dichloromethane (3x 25 mL). The combined organic layers were dried over magnesium sulfate and the solvent was removed *in vacuo*. The residue was purified by preparative RP-HPLC (Rainin C18, 8 μ m, 300 A, 25 cm; 30% isocratic for five minutes, then 30%-60% acetonitrile - 0.1
25 M ammonium acetate over 30 min, 21 mL/min). The solvent was removed and the residue was subjected to a second purification by preparative RP-HPLC using identical conditions. The organics were removed and the aqueous mixture was lyophilized to give *cis*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-2-[(1*H*-2-imidazolylmethyl)amino]ethyl-1-cyclohexanol
30 diacetate as a white solid (0.020 g, 0.03 mmol):

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.12 (s, 1H), 7.48 (d, 2H), 7.42 (t, 2H), 7.34 (s,

1H), 7.16 (t, 1H), 7.08-1.10 (m, 4H), 6.90 (bs, 2H), 6.09 (bs, 1H), 4.52-4.58 (m, 1H), 3.69 (s, 2H), 2.67-2.70 (m, 2H), 2.11-2.17 (m, 2H), 1.90 (s, 6H), 1.69-1.71 (m, 4H), 1.53-1.62 (m, 2H), 1.42-1.51 (m, 2H);

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1 M

5 ammonium acetate over 20 min, 1mL/min) R_t 13.55 min.;

MS: M⁺ 524.

Example 465

10 ***Cis*-2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexyl}-acetic acid**

A mixture of *cis*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexylmethyl cyanide (0.172 g, 0.39 mmol) in dioxane (2 ml) was reacted with 2 M aqueous sodium hydroxide (2 mL) and 30% hydrogen peroxide (3 drops) at reflux for ten days. The mixture was cooled to ambient
15 temperature and adjusted to pH7 with 5% aqueous citric acid. The solvent was removed *in vacuo* and the residue was purified by preparative RP-LC/MS (Gilson- Micromass C18, 5 μ m, 130A, 21 cm, 0%-100% acetonitrile-0.1 M ammonium acetate over 9 min, 25 mL/min). The solvent was removed and the residue was subjected to a second purification by preparative RP-HPLC (Rainin C18, 8 μ m, 300
20 A, 25 cm; 35%-80% acetonitrile - 0.1 M ammonium acetate over 20 min, 21 mL/min). The acetonitrile was removed *in vacuo* and the aqueous mixture was lyophilized to give to give *cis*-{2-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexyl}acetic acid as a white solid (0.008 g, 0.02 mmol):

25 ¹H NMR (DMSO-*d*₆, 400MHz) δ 11.94 (b, 1H), 8.13 (s, 1H), 7.48 (d, 2H), 7.41 (t, 2H), 7.35 (s, 1H), 7.16 (t, 1H), 7.08-7.10 (m, 4H), 6.09 (b, 2H), 4.51-4.57 (m, 2H), 2.39 (s, 2H), 2.10-2.28 (m, 2H), 1.79-1.90 (m, 2H), 1.62-1.78 (m, 4H);

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1 M ammonium acetate over 20 min, 1mL/min) R_t 14.25 min.;

30 MS: M⁺ 459.

Example 466***Cis*-2-{4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexyl}-acetamide**

- 5 A mixture of *cis*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxycyclohexylmethyl cyanide (0.150 g, 0.34 mmol) and potassium carbonate (0.200g, 1.45 mmol) in dimethylsulfoxide (3 ml) was stirred rapidly and 30% hydrogen peroxide (0.5 mL) was added dropwise, keeping the temperature at 20° C. The mixture was stirred for seven hours at ambient temperature. Water (9
- 10 mL) was added, and the precipitate which formed was filtered, washing with water. The precipitate was purified by preparative RP-HPLC (Rainin C18, 8 μ m, 300 A, 25 cm; 30% isocratic for five minutes, then 30%-60% acetonitrile - 0.1M ammonium acetate over 30 min, 21 ml/min). The acetonitrile was removed *in vacuo* and the aqueous mixture was lyopholyzed to give *cis*-2-{4-[4-amino-5-(4-phenoxyphenyl)-
- 15 7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-hydroxy-cyclohexyl}-acetamide as a white solid (0.040 g, 0.09 mmol):
- ¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.48 (d, 2H), 7.42 (t, 2H), 7.36 (s, 1H), 7.16 (t, 1H), 7.05-7.12 (m, 4H), 6.09 (b, 2H), 4.98 (s, 1H) 4.51-4.59 (m, 1H), 2.24 (s, 2H), 2.13-2.23 (m, 2H), 1.91 (s, 1H), 1.72-1.77 (m, 4H), 1.57-1.65 (m, 2H);
- 20 RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile - 0.1M ammonium acetate over 20 min, 1mL/min) R_t 14.34 min.;
- MS: M⁺ 458.

25 Example 467***Cis*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-(hydroxy-methyl)-1-cyclohexanol**

- A mixture of *cis*-7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.100 g, 0.24 mol) in 1,2-dimethoxyethane (3 mL) was
- 30 reacted with 2.5 M aqueous potassium hydroxide (3 mL). The mixture was stirred at

reflux for eighteen hours. The mixture was cooled to room temperature and water (10 mL) was added. The precipitate which formed was filtered, washing with water (20 mL). The precipitate was purified by preparative RP-HPLC (Rainin C18, 8 μ m, 300 A, 25 cm; 30% isocratic for five minutes, then 30%-60% acetonitrile - 0.1M ammonium acetate over 30 min, 21 ml/min). The acetonitrile was removed *in vacuo* and the aqueous mixture was lyophilized to give to give *cis*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-(hydroxymethyl)-1-cyclohexanol as a white solid (0.012 g, 0.03 mol):

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.49 (d, 2H), 7.42 (t, 2H), 7.36 (s, 1H), 7.16 (t, 1H), 7.05-7.12 (m, 4H), 6.08 (b, 1H), 4.48-4.61 (m, 2H), 4.12 (s, 1H), 3.22 (d, 2H), 2.10-2.25 (m, 2H), 1.72-1.76 (m, 2H), 1.55-1.70 (m, 4H);
RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile - 0.1 M ammonium acetate over 20 min, 1mL/min) R_t 14.31 min.;
MS: M⁺ 431.

15

General Procedure for Epoxide Opening by Amines

A mixture of 7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (0.075 g, 0.18 mmol) and amine (0.54 mmol) in 25% dimethylformamide/iso-propanol (2.5 mL) was heated at 80 °C for 8 hours. The mixture was allowed to cool to ambient temperature and the solvent was removed under reduced pressure. The residue was purified by preparative HPLC-MS (Hypersil 100 x 21.2 mm; 5 μ BDS C₁₈, 25 mL/min; 0 - 70 % over 8 min; 0.05 M ammonium acetate / acetonitrile; Micromass Mass spec). The solvent of the collected fractions was removed under the reduced pressure. The residue was dissolved in H₂O and lyophilized for 24 hours.

25

Compounds prepared from *cis*-7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine and the corresponding amine:

Example 468

***Cis*-1-(aminomethyl)-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanol**

¹H NMR (Chloroform-*d*, 400 MHz) δ 8.19 (s, 1H), 7.34 (m, 4H), 7.10 (t, 1H), 7.03 (m, 5H), 5.74 (br, 2H), 4.65 (br, 1H), 2.85 (s, 2H), 2.17 (br, 2H), 1.93 (br, 4H), 1.56 (br, 2H).

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1 M ammonium acetate over 20 min, 1mL/min) R_t 13.0 min.

MS: MH⁺ 430

10

Example 469

***Cis*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[(dimethylamino)methyl]-1-cyclohexanol**

¹H NMR (Chloroform-*d*, 400 MHz) δ 8.32 (s, 1H), 7.40 (m, 4H), 7.16 (t, 1H), 7.10 (m, 4H), 7.00 (s, 1H), 5.30 (br, 2H), 4.77 (br, 1H), 2.58 (s, 2H), 2.41 (s, 6H), 2.09 (br, 2H), 1.93 (br, 4H), 1.83 (br, 2H).

15

RP-HPLC (Hypersil C18, 5 μ m, 250 x 4.6 mm; 25% - 100% over 10 min with 0.1 M ammonium acetate, 1mL/min) R_t 7.28 min.

MS: MH⁺ 458

Example 470

Cis-2-[(4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-hydroxycyclohexylmethyl)amino]-1,3-propanediol

¹H NMR (Chloroform-*d*, 400 MHz) δ 8.27 (s, 1H), 7.40 (m, 4H), 7.15 (t, 1H), 7.10 (m, 5H), 5.24 (br, 2H), 4.65 (br, 1H), 3.70 (m, 4H), 2.75 (m, 1H), 2.65 (s, 2H), 2.20 (m, 2H), 2.12 (m, 4H), 1.55 (m, 2H).

RP-HPLC (Hypersil C18, 5 μ m, 250 x 4.6 mm; 25% - 100% over 10 min with 0.1 M ammonium acetate, 1mL/min) R_t 6.87 min.

MS: MH⁺ 504

10

Example 471

Cis-4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-[(2-morpholinoethyl)amino]methyl-1-cyclohexanol

¹H NMR (Chloroform-*d*, 400 MHz) δ 8.31 (s, 1H), 7.42 (m, 4H), 7.10 (m, 6H), 5.11 (br, 2H), 4.70 (br, 1H), 3.73 (br, 4H), 2.85 (m, 2H), 2.65 (s, 2H), 2.54 (m, 2H), 2.49 (br, 4H), 2.21 (br, 2H), 1.96 (br, 2H), 1.85 (br, 2H), 1.58 (br, 2H).

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile - 0.1 M ammonium acetate over 20 min, 1mL/min) R_t 13.6 min.

MS: MH⁺ 543

20

Compounds prepared from *trans*-7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine

Example 472

***Trans*-1-(aminomethyl)-4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanol diacetate**

¹H NMR (Chloroform-*d*, 400 MHz) δ 8.19 (s, 1H), 7.40 (m, 4H), 7.14 (t, 1H), 7.07 (m, 5H), 5.91 (br, 2H), 4.70 (br, 1H), 3.14 (s, 2H), 2.00 (br, 6H), 1.92 (br, 2H).

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile - 0.1 M ammonium acetate over 20 min, 1mL/min) R_t 12.7 min.

30

MS: MH⁺ 430

Example 473

**Trans- 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-
5 [(dimethylamino)methyl]-1-cyclohexanol**

¹H NMR (Chloroform-*d*, 400 MHz) δ 8.26 (s, 1H), 7.40 (m, 4H), 7.15 (t, 1H), 7.10 (m, 5H), 5.31 (br, 2H), 4.70 (br, 1H), 3.11 (s, 2H), 2.76 (s, 6H), 2.10 (br, 6H), 1.87 (br, 2H).

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1 M
10 ammonium acetate over 20 min, 1mL/min) R_t 13.3 min.

MS: MH⁺ 458

Example 474

**Trans-2-[(4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-
15 hydroxycyclohexylmethyl)amino]-1,3-propanediol**

¹H NMR (Chloroform-*d*, 400 MHz) δ 8.17 (s, 1H), 7.35 (m, 4H), 7.15 (t, 1H), 7.06 (m, 5H), 6.20 (br, 2H), 4.70 (br, 1H), 3.89 (m, 4H), 3.34 (s, 2H), 3.27 (br, 1H), 2.10 (br, 6H), 1.90 (br, 2H).

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1 M
20 ammonium acetate over 20 min, 1mL/min) R_t 12.8 min.

MS: MH⁺ 504

Example 475

**Trans-4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[(2-
25 morpholinoethyl)amino]methyl-1-cyclohexanol**

¹H NMR (Chloroform-*d*, 400 MHz) δ 8.30 (s, 1H), 7.42 (m, 4H), 7.10 (m, 5H), 6.99 (s, 1H), 5.46 (br, 2H), 4.70 (br, 1H), 3.71 (br, 4H), 2.91 (s, 2H), 2.86 (m, 2H), 2.55 (m, 2H), 2.44 (br, 4H), 2.10 (br, 2H), 1.90 (br, 4H), 1.80 (br, 2H).

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1 M
30 ammonium acetate over 20 min, 1mL/min) R_t 13.6 min.

MS: MH^+ 543

Compounds prepared from a mixture of *cis*- and *trans*-7-(1-oxaspiro[2.5]oct-6-yl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (ratio *cis/trans* 2:1) and the
5 corresponding amine (RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1 M ammonium acetate over 20 min, 1mL/min))

Example 476

10 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[(2-hydroxyethyl)amino]methyl-1-cyclohexanol
HPLC: Rt 12.9 min, 13.1 min
MS: M^+ =474

Example 477

15 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[(3-hydroxypropyl)amino]methyl-1-cyclohexanol
HPLC: Rt 13.1 min
MS: M^+ =488

20 **Example 478**

4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[(3-(1*H*-1-imidazolyl)propyl)aminomethyl]-1-cyclohexanol
HPLC: Rt 12.4 min, 12.8 min
MS: M^+ =538

25

Example 479

4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-(1*H*-1-imidazolylmethyl)-1-cyclohexanol

-319-

HPLC: Rt 13.9**MS: M^+ =481****Example 480**

- 5 **4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-([2-(2-hydroxyethoxy)ethyl]aminomethyl)-1-cyclohexanol**

HPLC: Rt 13.1 min**MS: M^+ =518**

- 10 **Example 481**

4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[di(2-hydroxyethyl)amino]methyl-1-cyclohexanol

HPLC: Rt 13.1 min, 13.3 min**MS: M^+ =518**

15

Example 482

4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-([2-(dimethylamino)ethyl]aminomethyl)-1-cyclohexanol

HPLC: Rt 12.9 min, 13. min

- 20 **MS: M^+ =501**

Example 483

4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[(4-methylpiperazino)methyl]-1-cyclohexanol

- 25 **HPLC: Rt 13.7 min, 14.0 min**

MS: M^+ =513**Example 484**

4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-(morpholinomethyl)-1-cyclohexanol

- 30

HPLC: Rt 13.9 min, 14.0 min

MS: $M^+=500$

Example 485

1-(4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-
5 hydroxycyclohexylmethyl)-4-piperidinol

HPLC: Rt 13.2 min, 13.4 min

MS: $M^+=514$

Example 486

10 4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[methyl(1-
methyl-4-piperidyl)amino]methyl-1-cyclohexanol

HPLC: Rt 12.5 min, 13.0 min

MS: $M^+=541$

15 **Example 487**

4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[(3-
morpholinopropyl)amino]methyl-1-cyclohexanol

HPLC: Rt 12.8 min, 13.1 min

MS: $M^+=557$

20

Example 488

4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[(2-
piperidinoethyl)amino]methyl-1-cyclohexanol

HPLC: Rt 13.4 min, 13.6 min

25 MS: $M^+=541$

Example 489

4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-[(3-
(diethylamino)propyl)aminomethyl]-1-cyclohexanol

30 HPLC: Rt 12.5 min, 13.0 min

MS: $M^+=543$

Example 490

**4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-
[(tetrahydro-2-furanylmethyl)amino]methyl-1-cyclohexanol**

5 HPLC: Rt 14.2 min

MS: M^+ =514

Example 491

***Cis*-8-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1,3-
10 diazaspiro[4.5]decane-2,4-dione.**

A mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanone (0.500 g, 0.00125 mol), ammonium carbonate (0.602 g, 6.27 mmol), and potassium cyanide (0.163 g, 2.51 mmol) in ethyl alcohol (5 mL) and water (5 mL) was stirred 18 hours at 60°C, after which time all material had gone into
15 solution. The solvents were removed *in vacuo* and the residue was partitioned between ethyl acetate (80 mL) and water (20 mL). The phases were separated and the organic phase was washed with brine (20 mL). The organic phase was dried over magnesium sulfate, and the solvent was removed *in vacuo*. The crude material had a *cis:trans* ratio of 7:1. The product was purified by flash column
20 chromatography on silica using dichloromethane /methanol (90:10). The solvent was removed *in vacuo* to give *cis*-8-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1,3-diazaspiro[4.5]decane-2,4-dione as a white solid (0.183 g, 0.39 mmol):

^1H NMR (DMSO-*d*₆, 400MHz) δ 10.71 (s, 1H), 8.64 (s, 1H), 8.15 (s, 1H), 7.48 (d, 2H), 7.42 (t, 2H), 7.16 (t, 1H), 7.12 (d, 2H), 7.09 (d, 2H), 6.13 (b, 2H), 4.73-4.79 (m, 1H), 2.00-2.10 (m, 2H), 1.88-1.94 (m, 4H), 1.71-1.74 (m, 2H);

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 15.04 min.

MS: M^+ 469.

Example 492***Cis*-8-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1,3-diazaspiro[4.5]decan-2-one**

5 A mixture of *cis*-8-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1,3-diazaspiro[4.5]decan-2,4-dione (0.350 g, 0.75 mmol) in tetrahydrofuran (20 mL) was stirred at room temperature and lithium aluminum hydride (0.057 g, 1.49 mmol) was added over a 10 minute time period at ambient temperature. Gas evolution was observed, and the mixture was stirred for 18 hours at 50° C.

10 Additional lithium aluminum hydride (0.057 g, 1.49 mmol) was added and the mixture was heated at reflux for 24 hours. Water (10 mL) was added, followed by 15% aqueous sodium hydroxide (10 mL). The mixture was stirred 30 minutes and additional water (15 mL) was added. The mixture was filtered through a pad of Celite ® 521. The filtrate was extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over magnesium sulfate and the solvent was removed *in vacuo*. The residue was purified by flash column chromatography on silica using dichloromethane/methanol (95:5) as an eluent. The solvent was removed *in vacuo* to give *cis*-8-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1,3-diazaspiro[4.5]decan-2-one as a white solid (0.045 g, 0.10 mmol):

20 ¹H NMR (DMSO-*d*₆, 400MHz) δ 8.12 (s, 1H), 7.64 (s, 1H), 7.47 (d, 2H), 7.42 (t, 2H), 7.14 (t, 1H), 7.11 (d, 2H), 7.09 (d, 2H), 6.18 (s, 1H), 6.08 (b, 2H), 4.66-4.71 (m, 1H), 3.09 (s, 2H), 2.06-2.11 (m, 2H), 1.76-1.81 (m, 4H), 1.63-1.69 (m, 2H);

RP-HPLC (Delta Pak C18, 5µm, 300A, 15 cm; 5%-85% acetonitrile – 0.1

M ammonium acetate over 20 min, 1mL/min) R_t 15.11 min.;

MS: M⁺ 455.

25

Example 493***Cis*-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-ammoniocyclohexylmethanol acetate**

30 *a.*) 1-amino-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-

1-cyclohexanecarboxylic acid

A mixture of *cis*- and *trans*-8-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1,3-diazaspiro[4.5]decane-2,4-dione (0.600 g, 1.3 mmol, ratio *cis/trans* 7:1) in 2 M aqueous sodium hydroxide (25 mL) was heated at reflux for seven days. The mixture was cooled to room temperature and brought to pH 8 by drop-wise addition of concentrated hydrochloric acid. The precipitate which formed was collected by filtration and washed with water. The precipitate was triturated with methanol (50 mL) for 18 hours. The mixture was filtered, and the solvent was removed from the filtrate *in vacuo* to give 1-amino-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanecarboxylic acid (0.194 g, 0.43 mol) which was used without further purification.:

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.12-8.14 (m, 1H), 7.37-7.55 (m, 5H), 7.05-7.11 (m, 5H), 6.08 (b, 2H), 4.47-4.53 (m, 1H), 4.10 (b, 3H), 1.35-1.22 (m, 8H); RP-HPLC (Hypercil C18, 5 μ m, 100 Å, 15 cm; 5%-100% acetonitrile – 0.1M ammonium acetate over 15 min, 1mL/min) R_t 10.12 min.; MS: M⁺ 444.

b.) Methyl 1-amino-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanecarboxylate

A mixture of *cis*- and *trans*-1-amino-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanecarboxylic acid (0.696 g, 1.6 mmol, ratio *cis/trans* 7:1) was suspended in methanol (50 mL). The mixture was cooled to 0° C and thionyl chloride (0.211 g, 0.1.77 mmol) was added dropwise. After the addition was complete, the mixture was heated at reflux for three days, with addition of an additional equivalent of thionyl chloride each day. The solvent was removed *in vacuo* to give crude methyl 1-amino-4-[4-amino-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanecarboxylate (1.171 g) which was carried forward without further purification.:

¹H NMR (DMSO-*d*₆, 400MHz) δ 9.08 (b, 2H), 8.53 (s, 1H), 8.30 (s, 1H), 7.51 (d, 2H), 7.43 (t, 2H), 7.18 (t, 1H), 7.10-7.15 (m, 4H), 4.82-4.98 (m, 1H), 3.17 (s, 3H), 2.05-2.28 (m, 4H), 1.86-1.98 (m, 2H);

RP-HPLC (Perkin-Elmer Pecosphere C18, 3 μ m, 100 A, 33x4.6 mm; 0%-100% acetonitrile – 0.1 M ammonium acetate; 3-3.5 mL/min over 4.5 min, then 100% acetonitrile at 3 mL/min over 0.5 min) R_t 2.81 min.;

MS: M⁺ 458.

5

c.) *Cis*-4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-ammoniocyclohexylmethanol acetate

- A crude mixture of *cis*- and *trans*-ethyl 1-amino-4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-cyclohexanecarboxylate (1.17 g) in
- 10 tetrahydrofuran (75 mL) was stirred at room temperature and lithium aluminum hydride (0.18 g, 4.7 mmol) was added over a 10 minute time period at ambient temperature. Gas evolution was observed, and the mixture was stirred for 18 hours at 40° C. Water (5 mL) was added, followed by 15% aqueous sodium hydroxide (15 mL) and additional water (15 mL). The mixture was filtered through a pad of Celite
- 15 © 521. The filtrate was extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over magnesium sulfate and the solvent was removed *in vacuo*. The residue was purified by preparative RP-HPLC (Rainin C18, 8 μ m, 300 A, 25 cm; 35%-80% acetonitrile - 0.1 M ammonium acetate over 10 min, 21 ml/min). The acetonitrile was removed *in vacuo* and the aqueous mixture was lyophilized to
- 20 give *cis*-4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-7-yl]-1-ammoniocyclohexylmethanol acetate as a white solid (0.577 g, 1.16 mmol):
- ¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.55 (s, 1H), 7.48 (d, 2H), 7.42 (t, 2H), 7.14 (t, 1H), 7.11 (d, 2H), 7.09 (d, 2H), 6.08 (b, 1H), 4.56-4.65 (m, 1H), 3.29 (s, 2H), 2.13-2.26 (m, 2H), 1.80 (s, 3H), 1.50-1.79 (m, 8H);
- 25 RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1 M ammonium acetate over 20 min, 1mL/min) R_t 12.92 min.;
- MS: M⁺ 430.

Example 494 and 495

- 30 ***Cis*- and *trans*-7-[4-amino-4-(ammoniomethyl)cyclohexyl]-5-(4-phenoxyphenyl)-**

7H-pyrrolo[2,3-d]pyrimidin-4-amine acetate**a.) *Cis-* and *trans*-1-amino-4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanecarbonitrile.**

- 5 A mixture of 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanone (3.24 g, 8.1 mmol), potassium cyanide (1.06 g, 0.0162 mol), and ammonium chloride (0.869 g, 16.2 mmol) in ammonium hydroxide (32 mL) and ethyl alcohol (26 mL) was heated at 50°C for eighteen hours. Water (150 mL) was added and the mixture was extracted with dichloromethane (3 x 60 mL). The
10 combined organic layers were dried over magnesium sulfate and the solvent was removed *in vacuo* to give a mixture of *cis* and *trans*-1-amino-4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanecarbonitrile as an amorphous white solid (3.17 g, 7.5 mmol):

- ¹H NMR (DMSO-*d*₆, 400MHz) δ 8.14 (s, 0.7 H), 8.13 (s, 0.3 H), 7.45-7.51 (m, 2H),
15 7.38-7.44 (m, 3H), 7.13-7.18 (m, 1H), 7.06-7.12 (m, 4H), 6.11 (b, 1H), 4.60-4.68 (m, 1H), 2.19-2.28 (m, 2H), 1.97-2.10 (m, 4H), 1.72-1.76 (m, 2H);

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile – 0.1M ammonium acetate over 20 min, 1mL/min) R_t 15.98, 16.38 min.;

MS: M⁺ 425.

20

b.) *Cis*-7-[4-amino-4-(ammoniomethyl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine acetate

- A mixture of *cis* and *trans*-1-amino-4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanecarbonitrile (1.00 g, 2.4 mmol) in
25 tetrahydrofuran (75 mL) was stirred at room temperature and lithium aluminum hydride (0.16 g, 4.2 mmol) was added over a 10 minute time period at ambient temperature. Gas evolution was observed, and the mixture was stirred for 18 hours. Water (5 mL) was added, followed by 15% aqueous sodium hydroxide (15 mL) and additional water (15 mL). The mixture was filtered through a pad of Celite ® 521.
30 The filtrate was extracted with ethyl acetate (3 x 15 mL). The combined organic

layers were dried over magnesium sulfate and the solvent was removed *in vacuo*.

The isomers were separated by preparative RP-HPLC (Rainin C18, 8 μ m, 300 A, 25 cm; 30% isocratic for five minutes, then 30%-60% acetonitrile - 0.1 M ammonium acetate over 30 min, 21 ml/min). The acetonitrile was removed from the less polar fraction and this fraction was lyopholyzed to give *cis*-7-[4-amino-4-(ammoniomethyl)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate as a white solid (0.137 g, 0.28 mmol):

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.48 (d, 2H), 7.41 (t, 2H), 7.41 (s, 1H), 7.16 (t, 1H), 7.10 (d, 2H), 7.08 (d, 2H), 6.08 (b, 1H), 4.52-4.58 (m, 1H), 2.71-2.79 (m, 1H), 1.80-1.95 (m, 6H), 1.30-1.36 (m, 2H);

RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile - 0.1 M ammonium acetate over 20 min, 1mL/min) R_f 13.31 min.;

MS: M⁺ 429.

c.) *Trans*-7-[4-amino-4-(ammoniomethyl)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate

The solvents were removed *in vacuo* from the more polar fraction from the above procedure. The residue was subjected to a second purification by preparative RP-HPLC (Rainin C18, 8 μ m, 300 A, 25 cm; 20%-60% acetonitrile - 0.1M ammonium acetate over 30 min, 21 ml/min). Acetonitrile was removed *in vacuo* and the aqueous solution was lyopholyzed to give *trans*-7-[4-amino-4-(ammoniomethyl)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine acetate as a white solid (0.037 g, 0.00008 mol):

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.45-7.54 (m, 3H), 7.42 (t, 2H), 7.16 (t, 1H), 7.06-7.13 (m, 4H), 6.09 (b, 1H), 4.52-4.60 (m, 1H), 1.91-2.07 (m, 2H), 1.86 (s, 3H), 1.71-1.84 (m, 4H), 1.40-1.53 (m, 2H); RP-HPLC (Delta Pak C18, 5 μ m, 300A, 15 cm; 5%-85% acetonitrile - 0.1 M ammonium acetate over 20 min, 1mL/min) R_f 12.18 min.; MS: M⁺ 429.

Example 496**5-[4-(benzyloxy)phenyl]-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine****5 1,4-dioxaspiro[4.5]decan-8-ol**

A solution of 1,4-dioxaspiro[4.5]decan-8-one (150 g, 962 mmol) in methanol (1 L) was treated with sodium borohydride (36.38 g, 962 mmol) portion-wise over 2 hours at 0°C under a nitrogen atmosphere. The ice bath was removed after 2 hours, and the reaction mixture stirred over night at room temperature. After 24 hours, the solvent was removed under reduced pressure, dichloromethane:iso-propanol (3:1, 1 L) solution and 2 N sodium hydroxide aqueous solution (400 mL) were added. The aqueous layer was extracted with the dichloromethane:iso-propanol solution (1 L). The organic layers were combined, washed water (500 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure. Residual solvent was removed under high vacuum pressure to give 144.18 g (94 %) of the product 1,4-dioxaspiro[4.5]decan-8-ol. ¹H NMR (DMSO-*d*₆, 400 MHz) δ 4.46-4.45 (d, 1H, *J* = 4 Hz), 3.83 (s, 4H), 3.55 (br s, 1H), 1.69-1.64 (m, 4H), 1.49-1.40 (m, 4H). TLC (ethyl acetate / heptane = 1:3, stain potassium permanganate) R_f = 0.2

20 4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-5-iodo-7H-pyrrolo[2,3-*d*]pyrimidine

A solution of 4-chloro-5-iodo-7H-pyrrolo[2,3-*d*]pyrimidine (25 g, 89.46 mmol) in tetrahydrofuran (600 mL) was treated with 1,4-dioxaspiro[4.5]decan-8-ol (42.45 g, 268.5 mmol), triphenylphosphine (46.95 g, 179 mmol), and diethylazodicarboxylate (31.17 g, 179 mmol). The reaction mixture stirred for 24 hours at room temperature under a nitrogen atmosphere. The solid, which precipitated, was filtered and washed with ethyl acetate. The reaction solution was partially evaporated under reduced pressure. A solid precipitated and was filtered. The product contained reduced DEAD. Ethyl acetate (50- 100 mL) was added to the solid. The product is not soluble in ethyl acetate, and was filtered. The trituration yielded 23.69 g (63 %) of 4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-5-

iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine. ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.64 (s, 1H), 8.10 (s, 1H), 4.77-4.71 (m, 1H), 3.95-3.88 (m, 4H), 2.17-2.08 (m, 2H), 1.93-1.90 (d, 2H, *J* = 12 Hz), 1.79-1.70 (m, 4H); Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5 μm, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) R_t 6.99 min.

5-[4-(benzyloxy)phenyl]-4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidine

A mixture of 4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-5-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine (3.0 g, 7.15 mmol) in ethylene glycol dimethyl ether (100 mL) was treated with 4-(benzyloxy)phenylboronic acid (1.79 g, 7.87 mmol), tetrakis(triphenylphosphine)palladium (0.496 g, 0.429 mmol), and a solution of sodium carbonate (1.83 g, 17.16 mmol) in water (50 mL). A precipitate formed after 20 minutes. Reaction was stirred for 5 hours at 80°C under a nitrogen atmosphere. The mixture was allowed to cool to room temperature and the organic solvent was removed under reduced pressure. The product was partitioned between the aqueous sodium carbonate layer and ethyl acetate. The aqueous layer was further extracted with ethyl acetate three times. The organic layers were combined, washed with water and brine, dried over magnesium sulfate, and partially concentrated until a precipitate formed. The solid was filtered, washed with ethyl acetate, and dried under a high vacuum. Yielded 2.06 g (61%) of 5-[4-(benzyloxy)phenyl]-4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidine. ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.64 (s, 1H), 7.88 (s, 1H), 7.52-7.33 (m, 7H), 7.08-7.05 (d, 2H, *J* = 12 Hz), 5.15 (s, 2H), 4.82-4.78 (m, 1H), 3.95-3.89 (m, 4H), 2.21-2.13 (m, 2H), 1.98-1.96 (m, 2H), 1.85-1.75 (m, 4H); Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5 μm, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) R_t 8.356 min.

5-[4-(benzyloxy)phenyl]-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

A mixture of 5-[4-(benzyloxy)phenyl]-4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidine (1.925 g, 4.01 mmol) and concentrated ammonium hydroxide (50 ml) in dioxane (50 mL) was heated at 120°C in a pressure vessel for 20 hours. The reaction mixture was allowed to cool to room temperature. Ethyl acetate (300 mL) and saturated sodium chloride aqueous solution (300 mL) were added. The layers were partitioned and the aqueous layer was extracted with ethyl acetate (700 mL). The organic layers were combined, washed with water, dried over magnesium sulfate, and the solvent removed under reduced pressure. The compound was purified by flash chromatography on silica using 5% methanol in dichloromethane to give 1.457 g (81%) of 5-[4-(benzyloxy)phenyl]-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine. ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.13 (s, 1H), 7.49-7.31 (m, 8H), 7.121-7.100 (d, 2H, *J* = 8Hz), 6.02 (br s, 2H), 5.149 (s, 2H), 4.681-4.620 (m, 1H), 3.94-3.88 (m, 4H), 2.12-2.03 (m, 2H), 1.93-1.90 (m, 2H), 1.82-1.71 (m, 4H); Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5 μm, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) R_t 6.924 min.

Examples 497 and 498

***Cis*-5-[4-(benzyloxy)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine and *Trans*-5-[4-(benzyloxy)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine**

4-{4-amino-5-[4-(benzyloxy)phenyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl}-1-cyclohexanone

A suspension of 5-[4-(benzyloxy)phenyl]-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (1.447 g, 3.06 mmol) in acetone (100 mL) was treated with 5 N hydrochloric acid aqueous solution (25 mL) drop-wise over 10 min at 0°C under a nitrogen atmosphere. The reaction mixture was stirred at 0°C for 30 minutes and ice bath was removed. The reaction mixture was stirred for 72 hours then the organic layer was removed under reduced pressure. The aqueous layer was

-330-

basified to approximately pH 8 with 50 % sodium hydroxide aqueous solution. The aqueous layer was extracted with dichloromethane (600 mL). The organic layer was dried with magnesium sulfate, filtered, concentrated under reduced pressure, and dried under high vacuum for 3 hours to give 1.221 g (94 %) of 4-4-amino-5-[4-(benzyloxy)phenyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl-1-cyclohexanone. ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.15 (s, 1H), 7.48-7.34 (m, 8H), 7.13-7.11 (d, 2H, *J* = 8H), 6.13-6.04 (br s, 2H), 5.19-5.15 (s, 3H), 2.79-2.67 (m, 2H), 2.33-2.30 (m, 4H), 2.30-2.20 (m, 2H); Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5 μm, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) R_t 6.51 min.

a. A suspension of the 4-{4-amino-5-[4-(benzyloxy)phenyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl}-1-cyclohexanone (1.22g, 2.96 mmol) in dichloroethane (40 ml) was treated with *N*-methylpiperazine (0.889g, 8.88 mmol) and glacial acetic acid (0.534 g, 8.88 mmol) at 0°C for 1 hour. Subsequently, sodium triacetoxymethylborohydride (0.816g, 3.85 mmol) was added and the reaction mixture was stirred overnight. Additional *N*-methylpiperazine (0.445 g, 4.44 mmol), sodium triacetoxymethylborohydride (0.407 g, 1.92 mmol), and glacial acetic acid (0.267 g, 4.44 mmol) were added and the reaction mixture was stirred for an additional 1.5 hour. To the reaction solution, a solution of sodium bicarbonate (1.49 g, 17.76 mmol) in 25 mL water was added and stirred for 1 hour. The aqueous layer was extracted with ethyl acetate (4 x 125 mL). The organic layers were combined, washed with water and brine (each 4x 125 ml), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 1.6 g of crude material. The compound was purified by flash chromatography on silica gel using 10% methanol in dichloromethane, 20% methanol in dichloromethane, and then 30% methanol in dichloromethane. The column yielded 0.83 g (56%) of *Cis*-5-[4-(benzyloxy)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine, and 0.305g (21%) of *trans*-5-[4-(benzyloxy)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine.

-331-

***Cis*-5-[4-(benzyloxy)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine:**

¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.12 (s, 1H), 7.49-4.47 (m, 2H), 7.43-7.34 (m, 5H), 7.20 (s, 1H), 7.13-7.11 (d, 2H, *J* = 8 Hz), 6.1-5.9 (br s, 2H), 5.15 (s, 2H), 4.70-4.64 (m, 1H), 2.5-2.3 (br s, 8H), 2.18 (s, 4H), 2.11-2.05 (m, 4H), 1.70-1.67 (m, 2H), 1.59-1.52 (m, 2H); Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5 μm, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) R_t 5.161 min.

***Trans*-5-[4-(benzyloxy)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine** ¹H NMR (DMSO-*d*₆, 400 MHz) 8.11 (s, 1H), 7.48-7.46 (d, 2H, *J* = 7.6 Hz), 7.42-7.33 (m, 6H), 7.12-7.10 (d, 2H, *J* = 8.8 Hz), 6.1-5.9 (br s, 2H), 5.14 (s, 2H), 4.55-4.50 (m, 1H), 2.6-2.4 (br s, 4H), 2.40-2.25 (m, 5H), 2.14 (s, 3H), 2.0-1.8 (m, 6H), 1.5-1.3 (m, 2H). Waters 2690 Alliance HPLC

(Symmetry Shield RP₁₈ 3.5 m, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) R_t 5.129 min.

Example 499

4-amino-5-(4-phenoxyphenyl)-7-[1-(1-methyl-4-piperidiny)-4-piperidiny]-7*H*-pyrrolo[2,3-*d*]pyrimidine

***tert*-butyl 4-hydroxy-1-piperidinecarboxylate**

A solution of *tert*-butyl 4-oxo-1-piperidinecarboxylate (179.24 g, 899.62 mmol) in anhydrous methanol (1.5 L) at 0°C under a nitrogen atmosphere was treated with sodium borohydride (34.03 g, 899.62 mmol). Sodium borohydride was added portion-wise (5 g every 10 minutes). The ice bath was removed 20 minutes after the last addition of sodium borohydride, and the reaction mixture stirred for 72 hours. To the reaction solution, 1 N sodium hydroxide aqueous solution (1L) was added, and allowed to stir for 2 hours. The organic layer was removed under

reduced pressure, and anhydrous diethyl ether (200 mL) was added. The aqueous layer was extracted with anhydrous diethyl ether (1.5 L). The organic layers were combined, washed with brine, dried over magnesium sulfate, filtered and evaporated under reduced pressure to give a yellow oil. The product was further dried under high vacuum to remove residual solvent to give 177.04 g (97%) of *tert*-butyl 4-hydroxy-1-piperidinecarboxylate as a white solid. ¹H NMR (DMSO-d₆, 400 MHz) δ 4.688 (s, 1H), 3.678-3.589 (m, 3H), 2.940 (m, 2H), 1.689-1.646 (m, 2H), 1.385 (s, 9H), 1.252-1.212 (m, 2H).

10 ***tert*-butyl 4-(4-chloro-5-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl)-1-piperidinecarboxylate**

A solution of 4-chloro-5-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine (6.48 g, 21.78 mmol) in tetrahydrofuran (200 mL) at 0°C under a nitrogen atmosphere was treated with *tert*-butyl 4-hydroxy-1-piperidinecarboxylate (13.147g, 65.33 mmol) and triphenylphosphine (11.43 g, 43.56 mmol) and stirred for 30 minutes. Diethylazodicarboxylate (7.61 g, 43.56 mmol) was added drop-wise over 15 minutes to the reaction solution. The ice bath was removed after 15 minutes, and the reaction mixture was allowed to stir over night. The solvent was evaporated under reduced pressure, and then the yellow gummy solid dissolved in dichloromethane. The solid precipitated was filtered and discarded. The filtrate was evaporated under reduced pressure. Recrystallization from ethyl acetate / heptane yielded 4.82 g (47%) of *tert*-butyl 4-(4-chloro-5-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl)-1-piperidinecarboxylate. ¹H NMR (DMSO-d₆, 400 MHz) 8.64 (s, 1H), 8.20 (s, 1H), 4.89-4.84 (m, 1H), 4.13-4.10 (m, 2H), 3.00-2.80 (br s, 2H), 2.01-1.88 (m, 4H), 1.43 (s, 9H). Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5 m, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) R_t 7.825 minutes.

4-chloro-5-iodo-7-(4-piperidyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine

A mixture of *tert*-butyl 4-(4-chloro-5-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-

yl)-1-piperidinecarboxylate (1.0 g, 2.16 mmol) in dichloromethane (10 mL) at 0°C was treated with a cold solution of trifluoroacetic acid (20%) in dichloromethane (total volume 56 mL). Reaction stirred at 0°C under a nitrogen atmosphere for 3 hours. The solvent was evaporated under reduced pressure at ambient temperature.

5 Ethyl acetate (50 mL) and 5 N hydrochloric acid (50 mL) were added to the solid. The layers were partitioned, and the organic layer was extracted with 5 N hydrochloric acid (150 mL). The aqueous layers were combined, cooled to 0°C, and basified using 50% sodium hydroxide aqueous solution at 0°C. The aqueous layer was extracted with dichloromethane (300 mL). The organic layers were combined,

10 dried over magnesium sulfate, filtered, and evaporated under reduced pressure. The resulting product, 4-chloro-5-iodo-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidine (0.520 g, 99%) was dried under high vacuum. ¹H NMR (DMSO-d₆, 400 MHz) 8.63 (s, 1H), 8.12 (s, 1H), 4.75-4.68 (m, 1H), 3.09-3.06 (d, 2H, J = 12 Hz), 2.70-2.60 (m, 2H), 1.99-1.83 (m, 4H); Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5

15 m, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) R_t 4.022 min.

4-chloro-5-iodo-7-[1-(1-methyl-4-piperidinyl)-4-piperidinyl]-7H-pyrrolo[2,3-d]pyrimidine

20 A mixture of 4-chloro-5-iodo-7-(4-piperidinyl)-7H-pyrrolo[2,3-d]pyrimidine (0.52 g, 1.43 mmol), 1-methyl-4-piperidone (0.178 g, 1.57 mmol), and glacial acetic acid (0.094 g, 1.57 mmol) in dichloroethane was stirred at 0°C for 20 minutes. Sodium triacetoxy borohydride (0.455 g, 2.15 mmol) was added and stirred for 15 minutes at 0°C, after which the ice bath was removed, allowed to warm to room

25 temperature and stirred over night. Additional 1-methyl-4-piperidone (0.178 g, 1.57 mmol), glacial acetic acid (0.094 g, 1.57 mmol), and sodium triacetoxy borohydride (0.455 g, 2.15 mmol) were added and stirred at room temperature. To the reaction solution was added sodium bicarbonate (0.721 g, 8.58 mmol) in water (10 mL) and stirred for 1 hour. The organic layer was evaporated under reduced pressure. Ethyl

30 acetate was added, the layers were partitioned, and the aqueous layer was extracted

with ethyl acetate. The organic layers were combined, washed with water and brine, dried over magnesium sulfate, filtered and evaporated under reduced pressure. The compound was purified by flash chromatography on silica using dichloromethane / ethyl acetate (1:1), 10% methanol in dichloromethane, and then 20% methanol in
5 dichloromethane to give 400 mg (61%) of 4-chloro-5-iodo-7-[1-(1-methyl-4-piperidiny)-4-piperidiny]-7*H*-pyrrolo[2,3-*d*]pyrimidine

¹H NMR (DMSO-*d*₆, 400 MHz) 8.62 (s, 1H), 8.16 (s, 1H), 4.66-4.58 (m, 1H), 3.17 (s, 1H), 3.02-3.00 (d, 2H, *J* = 8 Hz), 2.84-2.82 (d, 2H, *J* = 8 Hz), 2.33-2.26 (m, 2 H), 2.17 (s, 3H), 2.08-2.04 (m, 2H), 1.95-1.85 (m, 4H), 1.91-1.88 (d, 2H, *J* = 12 Hz),
10 1.49-1.45 (m, 2H); Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5 m, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) *R*_f 3.505 min.

4-chloro-5-(4-phenoxyphenyl)-7-[1-(1-methyl-4-piperidiny)-4-piperidiny]-7*H*-pyrrolo[2,3-*d*]pyrimidine
15

A mixture of 4-chloro-5-iodo-7-[1-(1-methyl-4-piperidiny)-4-piperidiny]-7*H*-pyrrolo[2,3-*d*]pyrimidine (0.390 g, 0.845 mmol), 4-phenoxyphenyl boronic acid (0.199 g, 0.93 mmol), tetrakis(triphenylphosphine)palladium (0.058 g, 0.051 mmol), and sodium carbonate (0.215 g, 2.03 mmol) were heated in a mixture of ethylene
20 glycol dimethyl ether (20 mL) and water (10 mL) at 80°C for 7 hours under a nitrogen atmosphere. Reaction solution was allowed to cool to room temperature, and the organic layer was removed under reduced pressure. Ethyl acetate was added, the layers were partitioned and the aqueous layer was extracted with ethyl acetate (250 mL). The organic layers were combined, washed with water and brine,
25 dried over magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by flash chromatography on silica using 10 % methanol in dichloromethane, then 20 % methanol in dichloromethane as eluent to give 0.241 g (51%) of 4-chloro-5-(4-phenoxyphenyl)-7-[1-(1-methyl-4-piperidiny)-4-piperidiny]-7*H*-pyrrolo[2,3-*d*]pyrimidine

30 ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.99 (s, 1H), 7.94 (s, 1H), 7.55-7.53 (d, 2H, *J* = 8

Hz), 7.45-7.41 (m, 2H), 7.20-7.05 (m, 5H), 4.69 (m, 1H), 3.06-3.03 (m, 2H), 2.95-2.85 (m, 2H), 2.45-2.25 (m, 4H), 2.16 (s, 3H), 2.00-1.80 (m, 5H), 1.75-1.70 (m, 2H), 1.55-1.45 (m, 2H); Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5 μ m, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min)
5 R_t 5.583 min.

4-amino-5-(4-phenoxyphenyl)-7-[1-(1-methyl-4-piperidiny)-4-piperidiny]-7H-pyrrolo[2,3-*d*]pyrimidine

10 A mixture of 4-chloro-5-(4-phenoxyphenyl)-7-[1-(1-methyl-4-piperidiny)-4-piperidiny]-7H-pyrrolo[2,3-*d*]pyrimidine (0.241 g, 0.48 mmol) and concentrated ammonium hydroxide (20 mL) in dioxane (20 mL) was heated at 120°C in a pressure vessel under a nitrogen atmosphere for 20 hours. The reaction mixture was allowed to cool to room temperature, and dioxane was removed under reduced pressure. The
15 residue was partitioned between ethyl acetate and saturated sodium chloride aqueous solution. The aqueous layer was extracted with ethyl acetate (500 mL). The combined organic layers were washed with water, dried over magnesium sulfate, filtered and evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel using 20% methanol in dichloromethane to 35%
20 methanol in dichloromethane in 5% increments, yielding 0.119 g of product which was subsequently dissolved in ethylacetate. To this solution, maleic acid (0.087 g, 0.75 mmol) in ethyl acetate was added. The solid, which precipitated, was filtered under a nitrogen atmosphere, and dried under high vacuum. The product contained some impurity. Approximately 5 mL of saturated sodium bicarbonate aqueous
25 solution and 10 mL of dichloromethane was added. The layers were separated using an Empore extraction cartridge. The remaining material was sent for preparative HPLC, 38 mg was received. The product (0.038g, 0.079 mmol) was dissolved in ethyl acetate. To this solution, (0.027 g, 0.23 mmol) of maleic acid in ethyl acetate was added. The product (0.063 g) formed was a trimaleate salt. ¹H NMR (DMSO-
30 d₆, 400 MHz) δ 8.18 (s, 1H), 7.48-7.40 (m, 5H), 7.19-7.08 (m, 5H), 6.29 (s, 6H),

-336-

4.80 (m, 1H), 3.70-2.90 (m, 9H), 2.67 (s, 3H), 2.40-2.20 (m, 6 H), 1.90-1.75 (m, 2H); Waters 2690 Alliance HPLC (Symmetry Shield RP₁₈ 3.5 μ m, 2.1 x 50 mm; 5%-95% acetonitrile-0.1 M ammonium acetate over 15 min, 0.5 mL/min) R_t 4.629 min.

5

Examples 500 and 501

Trans-5-[4-(aminomethyl)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine tetramaleate salt

- 10 Cis-5-[4-(aminomethyl)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine tetramaleate salt

a)

- A mixture of 4-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-cyclohexanone (20.0 g, 53.3 mmol), 1-methylpiperazine (6.42 g, 128 mmol) and acetic acid (7.7 g, 128 mmol) in 1,2-dichloromethane (1 L) was stirred for 15 minutes at ambient temperature. Sodium triacetoxyborohydride (14.7 g, 69.3 mmol) was added and stirring was continued for 20 hours. Water (400 mL) was added followed by sodium bicarbonate (26.0 g, 310 mmol). The mixture was transferred to a separatory funnel and the layers separated. The aqueous layer was extracted with dichloromethane (300 mL). The combined organic extracts were dried over magnesium sulfate, filtered and the filtrate concentrated under reduced pressure. The resulting oil was purified by flash chromatography on silica gel (275 g) using dichloromethane/methanol (9:1) as an eluent to give cis-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine (10.2 g, 42%) and trans-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine (5.8 g) which contained 10% of the cis isomer. This mixture was stirred in diethyl ether (100 mL) for 1.5 hours then the solid was collected by filtration to provide pure trans-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine (5.0 g, 20.2%).

-337-

Cis-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidine: ¹H NMR (DMSO-*d*₆, 400MHz) δ 8.60 (s, 1H), 7.52 (s, 1H), 4.84 (m, 1H), 2.06-2.53 (m, 16H), 1.79 (m, 2H), 1.62 (m, 2H); RP-HPLC (Hypersil HS C18 Hypersil HS C18, 5 μm, 100A, 250 X 4.6 mm; 25%-100% acetonitrile over 10 min, 1 mL/min) t_r 7.3 min; MS:MH⁺ 460.2.

Trans-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidine: ¹H NMR (DMSO-*d*₆, 400MHz) δ 8.60 (s, 1H), 7.43 (s, 1H), 4.70 (m, 1H), 2.42-2.67 (m, 9H), 2.32 (s, 3H), 2.09-2.18 (m, 4H), 1.76-1.86 (m, 2H), 1.53-1.61 (m, 2H); RP-HPLC (Hypersil HS C18, 5 μm, 100A, 250 X 4.6 mm; 25%-100% acetonitrile over 10 min, 1 mL/min) t_r 6.7 min; MS:MH⁺ 460.2.

b) Tert-butyl N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]carbamate

A mixture of 4-bromobenzylamine hydrochloride (10.0 g, 45.0 mmol), di-tert-butyl dicarbonate (11.8 g, 54.0 mmol) and diisopropylethyl amine (8.7 g, 68 mmol) in tetrahydrofuran (100 mL) was heated at reflux for 1 hour. The mixture was cooled and the solvent evaporated under reduced pressure. The material was dissolved in dichloromethane (200 mL) and then washed with water, dried over magnesium sulfate, filtered and the filtrate concentrated under reduced pressure to provide an oil (14.0 g). The oil was dissolved in *N,N*-dimethylformamide (250 mL) then treated with diboron pinacol ester (11.4 g, 45 mmol), potassium acetate (13.2 g, 135 mmol) and [1.1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) complex with dichloromethane (1:1) (1.1 g, 1.35 mmol). The mixture was heated at 85°C for 18 hours then cooled and the solvent removed under reduced pressure. The residue was stirred with dichloromethane (250 mL) then filtered through a pad of celite. The filtrate was concentrated under reduced pressure and the residue purified by flash chromatography on silica gel using heptane/ethyl acetate (8:2) as an eluent to provide tert-butyl N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]carbamate (11.8 g, 78%): ¹H NMR (DMSO-*d*₆, 400MHz) δ 7.63 (d, 2H), 7.40 (t, 1H), 7.23 (d, 2H), 4.14 (d, 2H), 1.39 (s, 9H), 1.28 (s, 12H); RP-HPLC

(Hypersil HS C18, 5 μ m, 100A, 250 X 4.6 mm; 25%-100% acetonitrile over 10 min, 1 mL/min) t_r 12.65 min.

5

c) Trans-5-[4-(aminomethyl)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine tetramaleate salt PH 4011342C

A mixture of trans-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidine (1.0 g, 2.18 mmol), tert-butyl *N*-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]carbamate (0.8 g, 2.40 mmol), sodium carbonate (0.56 g, 5.24 mmol) and tetrakis(triphenyl-phosphine)palladium (70 mg, 0.131 mmol) in ethylene glycol dimethyl ether (16 mL) and water (8 mL) was heated at 85°C under an atmosphere of nitrogen for 18 hours. The mixture was cooled to ambient temperature and the solvent evaporated under reduced pressure. Water (25 mL) was added and the mixture was extracted with ethyl acetate (2 X 25 mL) and dichloromethane (25 mL). The combined organic extracts were washed with brine (25 mL), dried over magnesium sulfate then filtered and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography on silica using dichloromethane/methanol (85:15) as an eluent to yield an oil (1.0 g) which was dissolved in 1,4-dioxane (75 mL) and 30% aqueous ammonium hydroxide (75 mL). The mixture was heated at 120°C in a sealed vessel for 18 hours then cooled to ambient temperature and concentrated under reduced pressure. The residue was dissolved in acetone (50 mL) and 6N aqueous hydrochloric acid (25 mL). The solution was stirred at ambient temperature for 20 hours then concentrated and purified by preparative reverse-phase chromatography. Lyophilization provided a hygroscopic solid (750 mg). The solid (75 mg, 0.179 mmol) was dissolved in ethanol (1 mL) then treated with a solution of maleic acid (104 mg, 0.894 mmol) in ethanol (2 mL). The suspension which resulted was heated at 85°C with stirring for 30 minutes then cooled to ambient temperature and the solid collected by filtration to provide trans-5-[4-(aminomethyl)phenyl]-7-[4-(4-

methyloperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tetramaleate salt as a white solid: ¹H NMR (DMSO-*d*₆, 400MHz) δ 8.19 (s, 1H), 8.15 (bs, 2H), 7.54 (m, 4H), 7.49 (s, 1H), 6.30 (bs, 2H), 6.14 (s, 8H), 4.60 (m, 1H), 4.09 (s, 2H), 2.5-3.5 (m, 8H), 2.69 (s, 3H), 1.91-2.00 (m, 7H), 1.54-1.59 (m, 2H); RP-HPLC (Hypersil
5 HS C18, 5 μm, 100A, 250 X 4.6 mm; 2%-25% acetonitrile over 25 min, 1 mL/min) *t*_r 6.7 min.; MS:MH⁺ 420.2.

A similar procedure using cis-4-chloro-5-iodo-7-[4-(4-methyloperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidine was used to prepare cis-5-[4-(aminomethyl)phenyl]-7-[4-(4-methyloperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
10 *d*]pyrimidin-4-amine tetramaleate salt: ¹H NMR (DMSO-*d*₆, 400MHz) δ 8.19 (s, 1H), 8.14 (bs, 2H), 7.53 (m, 4H), 7.38 (s, 1H), 6.13 (s, 8H), 4.72 (m, 1H), 4.10 (s, 2H), 3.1-3.6 (m, 8H), 2.77 (s, 3H), 1.65-2.50 (m, 9H); RP-HPLC (Hypersil HS C18, 5 μm, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) *t*_r 10.18 min.; MS:MH⁺ 420.2.

15

Examples 502 and 503

**Trans-*N*1-(4-{4-amino-7-[4-(4-methyloperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
d]pyrimidin-5-yl}benzyl)benzamide**
**and Cis-*N*1-(4-{4-amino-7-[4-(4-methyloperazino)cyclohexyl]-7*H*-pyrrolo[2,3-
20 *d*]pyrimidin-5-yl}benzyl)benzamide**

A mixture of trans-5-[4-(aminomethyl)phenyl]-7-[4-(4-methyloperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine (50 mg, 0.119 mmol) in pyridine (2 mL) and dichloromethane (2 mL) was cooled to 0°C then treated with benzoyl chloride (19 mg, 0.13 mmol). The mixture was allowed to
25 warm to ambient temperature and stirred for 1 hour. The solvents were removed under reduced pressure then the residue was purified by preparative reverse phase chromatography to give trans-*N*1-(4-{4-amino-7-[4-(4-methyloperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}benzyl)benzamide (50 mg) as a white solid: ¹H NMR (DMSO-*d*₆, 400MHz) δ 9.08 (t, 1H), 8.13 (s,
30 1H), 7.91 (m, 2H), 7.4-7.54 (m, 8H), 6.0 (bs, 2H), 4.53 (m, 3H), 2.30-2.40 (m, 5H),

2.15 (s, 3H), 1.85-1.89 (m, 10H), 1.43-1.46 (m, 2H); RP-HPLC (Hypersil HS C18, 5 μ m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) t_r 18.20 min.; MS:MH⁺ 524.3.

The cis isomer was prepared in a similar manner as described above: ¹H NMR

5 (DMSO-*d*₆, 400MHz) δ 9.08 (t, 1H), 8.14 (s, 1H), 7.91 (d, 2H), 7.41-7.56 (m, 7H), 7.26 (s, 1H), 4.67 (m, 1H), 4.54 (d, 2H), 1.5-2.5 (m, 20 H); RP-HPLC (Hypersil HS C18, 5 μ m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) t_r 18.40 min.; MS:MH⁺ 524.3.

10 Example 504

Cis-N1-(4-{4-amino-7-[4-(4-ethylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-yl}benzyl)acetamide

The title compound was prepared in a similar manner cis-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-5-

15 yl}benzyl)benzamide :

¹H NMR (DMSO-*d*₆, 400MHz) δ 8.37 (t, 1H), 8.14 (s, 1H), 7.44 (d, 2H), 7.35 (d, 2H), 7.25 (s, 1H), 6.0 (bs, 2H), 4.68 (m, 1H), 4.30 (d, 2H), 1.5-2.45 (m, 23 H); RP-HPLC (Hypersil HS C18, 5 μ m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) t_r 13.38 min.; MS:MH⁺ 462.3.

20

Example 505

Cis-5-{4-[(benzylamino)methyl]phenyl}-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine

A mixture of cis-5-[4-(aminomethyl)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (100 mg, 0.238 mmol), benzaldehyde (28 mg, 0.262 mmol) and acetic acid (43 mg, 0.714 mmol) in 1,2 dichloroethane (4 mL) was stirred at ambient temperature for 1 hour. Sodium triacetoxyborohydride (100 mg, 2.6 mmol) was added and the mixture was stirring continued for 2 hours. Sodium borohydride (100 mg, 2.60 mmol) was added and
30 stirring was continued for an additional 30 minutes, the solvents were removed

under reduced pressure and the residue purified by preparative reverse phase chromatography to yield cis-5-{4-[(benzylamino)methyl]phenyl}-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine: ¹H NMR (DMSO-*d*₆, 400MHz) δ 8.13 (s, 1H), 7.2-7.50 (m, 10H), 6.03 (bs, 2H), 4.67 (m, 1H), 3.71 (d, 2H), 1.52-2.50 (m, 20H); RP-HPLC (Hypersil HS C18, 5 μ m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) *t*_r 14.42 min.; MS:MH⁺ 510.3.

Examples 506 and 507

10 **Trans-benzyl N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)carbamate and Cis-benzyl N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)carbamate**

A mixture of trans-5-[4-(aminomethyl)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (50 mg, 0.119 mol) in pyridine (2 mL) and dichloromethane (2 mL) was cooled to 0°C then treated with benzyl chloroformate (22 mg, 0.131 mmol). The mixture was warmed to ambient temperature and stirred an additional 2 hours, evaporated and the residue purified by preparative reverse-phase chromatography to give trans-benzyl N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)carbamate: ¹H NMR (DMSO-*d*₆, 400MHz) 8.13 (s, 1H), 7.85 (t, 1H), 7.3-7.42 (m, 10 H), 6.02 (bs, 2H), 5.06 (s, 2H), 4.54 (m, 1H), 4.26 (d, 2H), 1.44-2.37 (m, 20H); RP-HPLC (Hypersil HS C18, 5 m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) *t*_r 22.15min.; MS:MH⁺ 554.3.

25 **Cis-benzyl N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)carbamate:** ¹H NMR (DMSO-*d*₆, 400MHz) 8.14 (s, 1H), 7.86 (t, 1H), 7.26-7.48 (m, 10 H), 6.04 (bs, 2H), 5.10 (s, 2H), 4.67 (m, 1H), 4.26 (d, 2H), 1.44-1.56-2.5 (m, 20H); RP-HPLC (Hypersil HS C18, 5 m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) *t*_r 22.72min.; MS:MH⁺ 554.3.

Examples 508 and 509

Trans-N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)-1-benzenesulfonamide and Cis-N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)-1-benzenesulfonamide

The compound was prepared from trans-5-[4-(aminomethyl)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine and benzene sulfonyl chloride in a manner similar as that described for the synthesis of Trans-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)benzamide: ¹H NMR (DMSO-d₆, 400MHz) 8.13 (s, 1H), 7.79 (d, 2H), 7.54-7.64 (m, 3H), 7.38 (s, 1H), 7.28-7.35 (m, 4H), 6.0 (bs, 2H), 4.54 (m, 1H), 4.06 (s, 2H), 2.3-2.5 (m, 6H), 2.14 (s, 3H), 1.86-1.94 (m, 9H); RP-HPLC (Hypersil HS C18, 5 m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) t_r 19.9 min.; MS:MH⁺ 560.3.

Cis-N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)-1-benzenesulfonamide: ¹H NMR (DMSO-d₆, 400MHz) 8.22 (s, 1H), 8.14 (s, 1H), 7.78 (d, 2H), 7.54-7.62 (m, 3H), 7.23-7.37 (m, 5H), 5.98 (bs, 2H), 4.67 (m, 1H), 4.07 (d, 2H), 2.05-2.55 (m, 16H), 1.53-1.77 (m, 4H); RP-HPLC (Hypersil HS C18, 5 m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) t_r 20.45 min.; MS:MH⁺ 560.3.

Examples 510 and 511

Trans-N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)-N-phenylurea and Cis-N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)-N-phenylurea

The trans-5-[4-(aminomethyl)phenyl]-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (50 mg, 0.119 mmol) was dissolved in dichloromethane (2 mL) then treated with phenyl isocyanate (16 mg, 0.131 mmol) and stirred for 1 hour at ambient temperature. The solvent was removed under reduced pressure and the residue purified by preparative reverse phase

chromatography to give trans-N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)-N-phenylurea: ¹H NMR (DMSO-d₆, 400MHz) 8.67 (s, 1H), 8.13 (s, 1H), 7.38-7.44 (m, 7H), 7.22 (t, 2H), 6.91 (t, 1H), 6.76 (t, 1H), 6.02 (bs, 2H), 4.54 (m, 1H), 4.35 (d, 2H), 2.37-2.50 (m, 5H), 2.14 (s, 3H), 1.86-1.95 (m, 10H), 1.40-1.49 (m, 2H); RP-HPLC (Hypersil HS C18, 5 m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) t_r 18.8 min.; MS:MH⁺ 539.3.

Cis-N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzyl)-N-phenylurea: ¹H NMR (DMSO-d₆, 400MHz) 8.67 (s, 1H), 8.14 (s, 1H), 7.40-7.47 (m, 6H), 7.20-7.24 (m, 3H), 6.89 (t, 1H), 6.71 (t, 1H), 6.0 (bs, 2H), 4.67 (m, 1H), 4.35 (d, 2H), 2.05-2.5 (m, 16H), 1.53-1.71 (m, 4H); RP-HPLC (Hypersil HS C18, 5 m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) t_r 19.3min.; MS:MH⁺ 539.3.

15 Examples 512 and 513

Cis-N1-phenyl-2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2.3-d]pyrimidin-5-yl}phenyl)acetamide trismaleate and Trans-N1-phenyl-2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2.3-d]pyrimidin-5-yl}phenyl)acetamide trismaleate

20 a) N1-phenyl -2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

A mixture of 4-bromophenyl acetic acid (5.0 g, 23.3 mmol), and oxalyl chloride (3.25 g, 25.6 mmol) in dichloromethane (100 mL), was stirred at ambient temperature, treated with 3 drops of N,N-dimethylformamide, then stirred for 2.5 hours. The solvents were removed under reduced pressure then the residue was dissolved in dichloromethane (100 mL) and triethylamine (5.9 g, 58.3 mmol). Aniline (2.4 g, 25.6 mmol) was added and the mixture was stirred an additional 1 hour. The solution was washed with 1N aqueous hydrochloric acid (2 X 50 mL), saturated sodium bicarbonate (100 mL), brine (50 mL), then dried over magnesium sulfate, filtered and the filtrate evaporated under reduced pressure to give N1-phenyl-2-(4-bromophenyl)acetamide (4.62g, 68%) [RP-HPLC (Hypersil HS C18, 5

m, 100A, 250 X 4.6 mm; 25%-00% acetonitrile over 10 min, 1 mL/min) t_r 10.85 min.] which was used without further purification. A mixture of N1-phenyl-2-(4-bromophenyl)acetamide (4.62g, 15.9 mmol), diboron pinacol ester (4.45g, 17.5 mmol), potassium acetate (4.68 g, 47.8 mmol) and [1.1'-

- 5 bis(diphenylphosphino)ferrocene]dichloropalladium (II) complex with dichloromethane (1:1) (0.39 g, 0.5 mmol) in N,N-dimethylformamide (90 mL) was heated at 100°C under an atmosphere of nitrogen for 18 hours then cooled to ambient temperature. The solvent was removed under reduced pressure and the residue was triturated with dichloromethane (100 mL). The insoluble material was removed by
10 filtration through a pad of celite and then the filtrate was concentrated under reduced pressure and purified by flash chromatography on silica gel using dichloromethane/ethyl acetate (95:5) as an eluent to provide N1-phenyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide (4.82 g, 89%): ^1H NMR (DMSO- d_6 , 400MHz) 10.15 (s, 1H), 7.64 (d, 2H), 2.59 (d, 2H), 7.36 (d, 2H),
15 7.29 (t, 2H), 7.03 (t, 1H), 3.67 (s, 2H), 1.29 (s, 12H); RP-HPLC (Hypersil HS C18, 5 m, 100A, 250 X 4.6 mm; 5%-50% acetonitrile over 25 min, 1 mL/min) t_r 11.7 min.

b) N1-phenyl-2-(4-{4-chloro-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine-5-yl}phenyl)acetamide

- 20 A mixture of cis-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine (1.0 g, 2.18 mmol), N1-phenyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide (0.81 g, 2.40 mmol), tetrakis(triphenylphosphine)palladium (70 mg, 0.131 mmol) and sodium carbonate monohydrate (0.65g, 2.40 mmol) in ethylene glycol dimethyl ether (16 mL) and water (8 mL) was
25 heated at 85°C under an atmosphere of nitrogen for 18 hours. The mixture was cooled to ambient temperature and the solvent was removed under reduced pressure. The residue was purified by flash chromatography on silica using dichloromethane/methanol (9:1) as an eluent to give N1-phenyl-2-(4-{4-chloro-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine-5-
30 yl}phenyl)acetamide (0.74g, 62%): ^1H NMR (DMSO- d_6 , 400MHz) 10.20 (s, 1H), 8.66 (s, 1H), 7.81 (s, 1H), 7.62 (d, 2H), 7.52 (d, 2H), 7.41 (d, 2H), 7.31 (t, 2H), 7.04

-345-

(t, 1H), 4.83 (m, 1H), 3.70 (s, 2H) < 2.05-2.5 (m, 13H), 2.17 (s, 3H), 1.59-1.77 (m, 4H); RP-HPLC (Hypersil HS C18, 5 m, 100A, 250 X 4.6 mm; 25%-100% acetonitrile over 10 min, 1 mL/min) t_r 8.23 min.; MS:MH⁺ 543.2.

5 c) N-phenyl-2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)acetamide trismaleate

The N1-phenyl-2-(4-{4-chloro-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine-5-yl}phenyl)acetamide (0.74 g, 1.41 mmol) in 1,4-dioxane (50 mL) and concentrated ammonium hydroxide (50 mL) was heated in a pressure
10 vessel at 120°C for 18 hours. The mixture was cooled to ambient temperature and the solvents evaporated under reduced pressure. The residue was purified by reverse-phase preparative chromatography then lyophilized to give a light yellow solid (485 mg, 68%). The material was dissolved in ethyl acetate (25 mL) and ethanol (5 mL) then treated with a hot solution of maleic acid (325 mg, 2.79 mmol)
15 in ethyl acetate (20 mL). The slurry was cooled and the solid collected by filtration to give the cis-N-phenyl-2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)acetamide trismaleate as a white solid (630 mg, 80%): ¹H NMR (DMSO-d₆, 400MHz) 10.18 (s, 1H), 8.21 (s, 1H), 7.61 (d, 2H), 7.28-7.47 (m, 7H), 7.05 (dd, 1H), 6.34 (bs, 2H), 6.16 (s, 6H), 4.74 (m, 1H), 3.70 (s, 2H), 1.6-3.6 (20H); RP-HPLC (Hypersil HS C18, 5 m, 100A, 250 X 4.6 mm; 25%-
20 100% acetonitrile over 10 min, 1 mL/min) t_r 6.33 min.; MS:MH⁺ 524.2.
trans-N-phenyl-2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)acetamide trismaleate was prepared from trans-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine
25 (1.0 g, 2.18 mmol) and N1-phenyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide in a similar method to that described for the cis-isomer: ¹H NMR (DMSO-d₆, 400MHz) 10.18 (s, 1H), 8.18 (s, 1H), 7.61 (d, 2H), 7.51 (m, 5H), 7.31 (t, 2H), 7.04 (t, 1H), 6.3 (bs, 2H), 6.11 (s, 6H), 4.58 (m, 1H), 3.69 (s, 2H), 2.6-3.6 (bm, 9H), 2.68 (s, 3H), 1.91-2.04 (m, 6H), 1.51-1.59 (m, 2H);); RP-HPLC
30 (Hypersil HS C18, 5 m, 100A, 250 X 4.6 mm; 25%-100% acetonitrile over 10 min, 1 mL/min) t_r 6.07min.; MS:MH⁺ 524.3.

General procedure of the preparation of urea variants.

The appropriately substituted isocyanate (1.2 equiv., 0.142 mmol) was added to a solution of the corresponding trans- or cis- 5-(4-amino-3-fluorophenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (50 mg, 0.118mmol) in DMF (2.5 ml) at room temperature and the solution was shaken for 2.5 days. Water (1 ml) was added to each reaction and then concentrated *in vacuo*. The residues were then purified by mass actuated preparative RP-HPLC (Micromass/Gilson, Hypersil BDS C18, 5 μ m, 100x 21.2mm; 100-100% ammonium acetate (0.05 M, pH 4.5)-acetonitrile over 12.5 min, 25 mL/min) to afford products including those detailed in Table 1..

Each sample was analysed by LCMS and in each case the target ion was observed. The retention time is given in Table 1. The LCMS conditions used for the analysis of examples 1 –20, 22, 25 and 26 are:

LC Column : Hypersil BDS C18, 5 μ m, (100x 2.1mm)

Mobile Phase: 0.1M NH₄OAc (pH 4.55) : MeCN

10% to 100% MeCN gradient over 8 min.

100% MeCN for 1 min.

100% to 10% MeCN over 2 min. at 1 ml/min throughout.

MS method : APCI observing both +ve and –ve ions.

Table 1. Urea variants

Example	RP-HPLC RT (min)	m/z (MH ⁺)
Example 514. <i>cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(2,4-difluorophenyl)urea</i>	3.09	579.3
Example 515. <i>cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(4-dimethylaminophenyl)urea</i>	2.82	586.3
Example 516. <i>cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-benzyl)urea</i>	2.84	557.3
Example 517. <i>cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'(3-methylbenzyl)urea</i>	3.01	571.4

<i>Example 518. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(4-phenoxyphenyl)urea</i>	3.49	635.1
<i>Example 519. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(4-methylbenzyl)urea</i>	2.97	571.1
<i>Example 520. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(3-methylphenyl)urea</i>	3.14	556.9
<i>Example 521. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(3,5-dimethoxyphenyl)urea</i>	3.08	603.1
<i>Example 522. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-[2-(2-thienyl)ethyl]urea</i>	2.94	577.0
<i>Example 523. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(2-methylphenyl)urea</i>	3.08	557.0
<i>Example 524. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(3,5-dichlorophenyl)urea</i>	3.61	611.0
<i>Example 525. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(2,6-dichlorophenyl)urea</i>	3.02	610.9
<i>Example 526. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(3,5-bis-trifluoromethylphenyl)urea</i>	3.72	679.1
<i>Example 527. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(3-methoxyphenyl)urea</i>	3.00	572.9
<i>Example 528. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(2,4,6-trichlorophenyl)urea</i>	3.33	645.0
<i>Example 529. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(1-biphen-2-yl)urea</i>	5.20	619.2
<i>Example 530. cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(4-methylphenyl)urea</i>	3.38	557.3
<i>Example 531. trans-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(3-methylphenyl)urea</i>	2.66	557.3

Example 532. <i>cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(2-phenoxyphenyl)urea</i>	5.41	635.3
Example 533. <i>cis-N-(4-{4-Amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-N'-(2,5-dimethoxyphenyl)urea</i>	3.50	603.4

Example 534

N1-4-[4-amino-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-2,3-dichloro-1-benzenesulfonamide

- 5 A solution containing N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-2,3-dichloro-1-benzenesulfonamide (0.156 g, 0.25 mmol) and α -chloroethylchloroformate (4 equiv., 1.0 mmol, 0.108 ml) and 1,2-dichloroethane (20 ml) was heated at reflux for a total of 24 h. The solvent was removed, methanol (10 ml) added and the reaction was heated at reflux for a further
- 10 24 h. The methanol was removed *in vacuo* and the residue was purified by column chromatography using neat ethyl acetate (100 ml) followed by 79:19:2 ethyl acetate: methanol: aq NH_4OH as the eluent to afford N1-4-[4-amino-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-2,3-dichloro-1-benzenesulfonamide (0.105 g, 82 %), RP-HPLC RT=2.64 min and *m/z* 534.9.

15

Example 535

N1-(4-{4-amino-7-(4-oxo-cyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide

- 20 ***tert*-Butyl N-4-[4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-chlorophenylcarbamate**
- A suspension of the 4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (6.8 g, 16.2 mmol), *tert*-butyl N-[2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate (1.5 equiv, 8.59 g, 24.3
- 25 mmol), sodium carbonate (2.5 equiv, 4.30 g, 40.5 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (4 mol%, 0.76 g, 0.65 mmol) in DME (280 ml) and degassed H_2O (50 mL) was heated at 80°C under nitrogen for 16 h. The reaction was concentrated under reduced pressure and

the residue dissolved in CH_2Cl_2 (500 mL) and washed with water (300 mL). The aqueous layer was re-extracted with CH_2Cl_2 (3 x 300 mL) and the combined organic extracts were combined, dried (MgSO_4) and concentrated *in vacuo*. Column chromatography purification over silica gel using 1:1 EtOAc:heptane afforded *tert*-butyl N-4-[4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-chlorophenylcarbamate as yellow oil (5.38 g), RP-HPLC RT=4.51 min and m/z 519.2 (MH^+).

10 **5-(4-Amino-3-chlorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine**

A cloudy mixture of *tert*-butyl N-4-[4-chloro-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-chlorophenylcarbamate (5.38 g, 10.35 mmol), aq. ammonium hydroxide (28 - 30 %, 100 mL) and dioxane (100 mL) was placed in a sealed vessel at ambient temperature then heated to 120°C with stirring for 24 h.

15 The reaction was concentrated *in vacuo*, diluted with EtOAc (300 mL), washed with brine (2 x 150 mL), dried (MgSO_4) and concentrated under reduced pressure and scrupulously dried to afford 5-(4-amino-3-chlorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a brown solid (4.0 g), RP-HPLC (5 to 85 % CH_3CN in 0.1 N aqueous ammonium acetate over 30 min at 1 mL/min using a

20 Waters Deltapak C18, 300Å, 150 x 3.9 mm column) RT= 14.049 min., 72%.

4-[4-amino-5-(4-amino-3-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanone

5M HCl (700 mL) was added slowly to a solution of 5-(4-amino-3-chlorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (4.0g, 10.0 mmol) in acetone (300 mL) at 0°C then allowed to warm to ambient temperature for 24 h. The acetone was removed under reduced pressure and the acidic layer was basified to approx. pH 8 using sat. aq. Na_2CO_3 . After extraction with CH_2Cl_2 (4 x 300 mL), the combined organic layers were dried (MgSO_4) and concentrated to

30 afford 4-[4-amino-5-(4-amino-3-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanone as a beige solid (1.71 g), RP-HPLC (5 to 85 % CH_3CN in 0.1 N

aqueous ammonium acetate over 30 min at 1 mL/min using a Waters Deltapak C18, 300Å, 150 x 3.9 mm column) RT= 12.392 min., 75%.

N1-(4-{4-amino-7-(4-oxo-cyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide

2,3-Dichlorobenzenesulfonyl chloride (1.1 equiv., 1.04 g, 4.26 mmol) was added to a solution of 4-[4-amino-5-(4-amino-3-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-1-cyclohexanone (1.38 g, 3.87 mmol) in pyridine (25 mL) at 40°C. After 3 h. at 40°C and 14 h at ambient temperature, additional 2,3-dichlorobenzenesulfonyl chloride (1.2 g) was added and the reaction stirred at 40°C for a further 24 h. The reaction was concentrated in vacuo, dissolved in CH₂Cl₂ (500 ml) and washed with sat. aq. Na₂CO₃ (2 x 100 ml). The organic layer was dried (MgSO₄) and concentrated in vacuo to afford a brown solid. Purification by column chromatography over silica gel using 1% MeOH in dichloromethane as the eluent afforded as a white solid (60% pure). Trituration with hot ethyl acetate gave N1-(4-{4-amino-7-(4-oxo-cyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide as a white solid (70 mg), RP-HPLC RT=3.14 min and m/z 564.2 (MH⁺).

20

Example 536

trans-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide

To a solution of N1-(4-{4-amino-7-(4-oxo-cyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide (0.2 g, 0.35 mmol), N-methylpiperazine (3 equiv, 1.05 mmol, 0.116 mL) and glacial acetic acid (3 equiv., 0.061 mL, 1.05 mmol) in 1,2-dichloroethane (20 mL) under nitrogen was added

30

sodium triacetoxyborohydride (1.3 equiv., 0.096 g, 0.455 mmol). The solution was stirred for 18 hr then additional sodium triacetoxyborohydride (0.10 g) was added and the reaction continued for a further 48 h. The reaction was concentrated in vacuo, partitioned between dichloromethane (100 mL) and sat. aq. NaHCO₃ (100 mL). The aqueous layer was re-extracted with dichloromethane (4 x 100 mL) and the combined organic layers were dried over magnesium sulfate and evaporated to dryness. Purification by column chromatography over silica gel using dichloromethane:methanol (19 : 1) as the eluent afforded trans-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide as a white solid (10 mg), RP-HPLC (5 to 85 % CH₃CN in 0.1 N aqueous ammonium acetate over 30 min at 1 mL/min using a Waters Deltapak C18, 300Å, 150 x 3.9 mm column) RT= 14.475 min., 100% and *m/z* 648.1 (*MH*⁺)

15 Example 537

1. 4-chloro-5-iodo-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7H-pyrrolo[2,3-d]pyrimidine

4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (9.78 g, 0.035mol) was dissolved in tetrahydrofuran (400 ml) at room temperature under a nitrogen atmosphere. Tropine (10 g, 0.071 mol) and triphenylphosphine (18.6 g, 0.071 mol) were added to this solution. The reaction mixture was cooled to 0° C and diethyl azodicarboxylate (12.35 g, 0.071 mol) was added slowly. Stirring was continued at 0° C for one hour then the reaction mixture was warmed to room temperature and stirred for 20 hours. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (250-300 ml) and concentrated again under reduced pressure. A precipitate formed which was collected by filtration and washed with ethyl acetate to give 4-chloro-5-iodo-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7H-pyrrolo[2,3-d]pyrimidine as a light yellow solid (43%, 6.09 g, 0.015 mol): ¹H NMR (DMSO-d₆, 400 MHz) δ 8.64 (s, 1H), 8.13 (s, 1H), 4.98 (m, 1H), 3.23 (m,

2H), 2.29 (s, 3H), 2.22 (m, 2H), 2.04 (m, 2H), 1.70 (m, 4H). TLC (dichloromethane/methanol = 9:1) R_f 0.68; LC/MS: MH^+ = 402.9.

5 2. *tert*-butyl *N*-[4-(4-chloro-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-fluorophenyl]carbamate

A suspension of 4-chloro-5-iodo-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidine (6.09 g, 0.015 mol), *tert*-butyl *N*-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate (7.64 g, 0.023 mol),
10 tetrakis(triphenylphosphine)palladium(0) (699 mg, 0.605 mmol) and sodium carbonate (4.01 g, 0.039 mol) in degassed water (45 mL) and dimethoxyethane (240 mL) was heated at 80 °C for 36 h. The reaction mixture was concentrated under reduced pressure, then diluted with dichloromethane and washed with 10% aqueous
15 sodium carbonate, followed by brine. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The filtrate was purified by column chromatography on silica gel eluting with 5% methanol / dichloromethane/2% ammonium hydroxide to afford *tert*-butyl *N*-[4-(4-chloro-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-
20 fluorophenyl]carbamate as a white foam (6.62 g, 0.014 mol): 1H NMR (DMSO- d_6 , 400MHz) 9.02 (brs, 1H), 8.66 (m, 1H), 8.03 (s, 1H), 7.65 (m, 1H), 7.39 (m, 1H), 7.30 (m, 1H), 5.76 (s, 1H), 5.05 (m, 2H), 3.26 (brs, 3H), 2.26 (m, 6H), 2.06 (m, 2H), 1.73 (m, 5H), 1.47 (s, 9H). LC/MS: MH^+ = 486.2.

25 3. 5-(4-amino-3-fluorophenyl)-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine

A solution of *tert*-butyl *N*-[4-(4-chloro-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)-2-
30 fluorophenyl]carbamate (6.62 g, 0.014 mol) in dioxane (100 mL) and ammonium

hydroxide (100 mL) was heated at 120 °C in a stainless steel bomb for 18 hours. The reaction mixture was concentrated under reduced pressure, then diluted with ethyl acetate and washed with water. The aqueous layer was concentrated under reduced pressure at 60 °C and the remaining solid was dried on the lyophilizer.

- 5 Isolated 5-(4-amino-3-fluorophenyl)-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a brown solid (5.73 g, 0.016 mol):); TLC (dichloromethane/methanol = 9:1) R_f 0.147. LC/MS: MH^+ = 367.1.

- 10 4. N1-[4-(4-amino-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 2,3-dichlorobenzenesulfonic acid salt

- A mixture of 5-(4-amino-3-fluorophenyl)-7-(8-methyl-8-
15 aza[3.2.1]bicyclooctan-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (4.0 g, 0.011 mol) and 2,3-dichlorobenzenesulfonyl chloride (2.95 g, 0.012 mol) in pyridine (55 mL) was heated at 40 °C for 18 hours. Additional 2,3-dichlorobenzenesulfonyl chloride (429 mg, 1.75 mmol and 671 mg, 2.73 mmol) was added over approximately 3
20 days. The reaction mixture was concentrated under reduced pressure to give an orange oil/foam (10 g, 0.017 mol). The crude material was purified twice by column chromatography on silica gel. The first column was eluted with 10% methanol / dichloromethane, followed by 10% methanol / dichloromethane/2% ammonium
hydroxide to afford N1-[4-(4-amino-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide
25 as an orange oil (7.2 g, 80% purity by HPLC). The second column was eluted with a 0% to 10% methanol/dichloromethane/2% ammonium hydroxide gradient to afford N1-[4-(4-amino-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide as a light
yellow foam (1.77 g, 3.08 mmol, 99% purity by HPLC): 1H NMR (DMSO- d_6 ,
30 400MHz) 8.15 (s, 1H), 7.95 (d, 1H), 7.86 (m, 2H), 7.58 (m, 1H), 7.50 (m, 1H), 7.30

(m, 3H), 7.13 (m, 2H), 6.18 (br s, 2H), 5.05 (m, 1H), 3.91 (m, 2H), 3.21 (s, 1H), 2.75 (s, 3H), 2.26 (m, 2H), 2.04 (m, 4H). LC/MS: MH+= 575.0.

5 **5. N1-[4-(4-amino-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide**

A solution of N1-[4-(4-amino-7-(8-methyl-8-aza[3.2.1]bicyclooctan-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide
10 2,3-dichlorobenzenesulfonic acid salt (106 mg, 0.133 mmol) in dichloromethane (30mL) and a minimal amount of methanol was washed with saturated aqueous sodium bicarbonate. The organic layer was dried over sodium sulfate then concentrated under reduced pressure to afford N1-[4-(4-amino-7-(8-methyl-8-
15 aza[3.2.1]bicyclooctan-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide as an off-white solid (74 mg, 0.129 mmol): 1H NMR (DMSO-d₆, 400MHz) δ 8.13 (s, 1H), 7.99 (d, 1H), 7.77 (d, 1H), 7.44 (t, 1H), 7.28 (t, 1H), 7.06 (m, 3H), 6.12 (br s, 2H), 5.01 (m, 1H), 3.69 (br s, 2H), 2.62 (s, 3H), 2.35 (m, 2H), 2.21 (m, 2H), 1.94 (m, 4H). LC/MS: MH+= 575.1..

20

Example 538

N1-4-(4-amino-7-{4-[4-(1-methylpiperidyl)piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl})-2-fluorophenyl-4-fluoro-1-benzenesulfonamide









25 To a solution containing N1-4-[4-amino-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide (50 mg, 0.103 mmol), 1-methylpiperid-4-one (1.5 equiv., 17.5 mg, 0.019 ml) and glacial acetic acid (0.025 ml) in N-methyl-2-pyrrolidinone (3 ml) was added sodium triacetoxyborohydride (1.3 equiv., 28.1 mg). The reaction was stirred for 24 h at
30 room temperature prior to the addition of extra sodium triacetoxyborohydride (1.3

equiv., 28.1 mg) was added and the reaction continued for a further 48 h. The reaction was concentrated in vacuo, partitioned between dichloromethane (100 mL) and sat. aq. NaHCO₃ (100 mL). The aqueous layer was re-extracted with dichloromethane (4 x 100 mL) and the combined organic layers were dried over
5 magnesium sulfate and evaporated to dryness. Purification by column chromatography over silica gel using dichloromethane:methanol: aqueous ammonium hydroxide (78:19:3) as the eluent afforded a biege solid (45 mg, 75 %), RP-HPLC RT=2.28 min and *m/z* 582.1.

10 **General Procedure for Substituted Pyrrolopyrimidine Aryl sulfonamides**

A 0.19 M solution of 5-(4-amino-3-fluorophenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine in pyridine was added one equivalent of substituted aryl sulfonyl chloride. The mixture was heated to 45o C while being shaken in an Incubator Shaker for 24h. The reaction
15 mixture was purified by using mass actuated preparative RP-HPLC (Micromass/Gilson, Hypersil BDS C18, 5u, 100x21.2mm; 100-100% ammonium acetate (0.05 M, pH 4.5)-acetonitrile over 12.5 min, 25 mL/min).

-356-

Structure	RT/min		Example
	LC, rt = 3.08	MH+ = 618.3	539
	LC, rt = 3.29	MH+ = 758.1	540
	LC, rt = 2.41	MH+ = 582.2	541
	LC, rt = 2.76	MH+ = 632.2	542
	LC, rt = 2.57	MH+ = 632.1	543
	LC, rt = 2.49	MH+ = 623.2	544
	LC, rt =	MH+ =	545
	LC, rt = 2.38	MH+ = 606.3	546

5 The following compounds are prepared using the general methods described above.

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-benzoxazol-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-methylbenzoxazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-methylbenzoxazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-methylbenzoxazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-methylbenzoxazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-dimethylbenzoxazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-dimethylbenzoxazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-dimethylbenzoxazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-dimethylbenzoxazol)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,7-dimethylbenzoxazol)-2-amine
- 50 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-dimethylbenzoxazol)-2-amine
- 55 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluorobenzoxazol)-2-amine
- 60 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluorobenzoxazol)-2-amine
- 65 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluorobenzoxazol)-2-amine
- 70 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluorobenzoxazol)-2-amine

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-difluorobenzoxazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-difluorobenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-difluorobenzoxazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-difluorobenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,7-difluorobenzoxazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-difluorobenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chlorobenzoxazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chlorobenzoxazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chlorobenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chlorobenzoxazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-dichlorobenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-dichlorobenzoxazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-dichlorobenzoxazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-dichlorobenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,7-dichlorobenzoxazol)-2-amine
- 45

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-dichlorobenzoxazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-4-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-4-methylbenzoxazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-4-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-4-methylbenzoxazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-4-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-4-methylbenzoxazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-5-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-5-methylbenzoxazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-5-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-5-methylbenzoxazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-5-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-5-methylbenzoxazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-6-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-6-methylbenzoxazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-6-methylbenzoxazol)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-6-methylbenzoxazol)-2-amine

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-6-methylbenzoxazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-6-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-6-methylbenzoxazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-6-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-7-methylbenzoxazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-7-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-7-methylbenzoxazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-7-methylbenzoxazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-7-methylbenzoxazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-7-methylbenzoxazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-benzothiazol-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-methylbenzothiazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-methylbenzothiazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-methylbenzothiazol)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-methylbenzothiazol)-2-amine

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-dimethylbenzothiazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-dimethylbenzothiazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-dimethylbenzothiazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-dimethylbenzothiazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,7-dimethylbenzothiazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-dimethylbenzothiazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluorobenzothiazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluorobenzothiazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluorobenzothiazol)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluorobenzothiazol)-2-amine
- 50 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-difluorobenzothiazol)-2-amine
- 55 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-difluorobenzothiazol)-2-amine
- 60 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-difluorobenzothiazol)-2-amine
- 65 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-difluorobenzothiazol)-2-amine
- 70 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,7-difluorobenzothiazol)-2-amine

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-difluorobenzothiazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chlorobenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chlorobenzothiazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chlorobenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chlorobenzothiazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-dichlorobenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-dichlorobenzothiazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-dichlorobenzothiazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-dichlorobenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,7-dichlorobenzothiazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-dichlorobenzothiazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-4-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-4-methylbenzothiazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-4-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-4-methylbenzothiazol)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-4-methylbenzothiazol)-2-amine

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-4-methylbenzothiazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-4-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-5-methylbenzothiazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-5-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-5-methylbenzothiazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-5-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-5-methylbenzothiazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-5-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-6-methylbenzothiazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-6-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-6-methylbenzothiazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-6-methylbenzothiazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-6-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-6-methylbenzothiazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-7-methylbenzothiazol)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-7-methylbenzothiazol)-2-amine

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-7-methylbenzothiazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-7-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-7-methylbenzothiazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-7-methylbenzothiazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-7-methylbenzothiazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-benzimidazol-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-methylbenzimidazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-methylbenzimidazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-methylbenzimidazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-dimethylbenzimidazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-dimethylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-dimethylbenzimidazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-dimethylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-dimethylbenzimidazol)-2-amine
- 45

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-dimethylbenzimidazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluorobenzimidazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluorobenzimidazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluorobenzimidazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-difluorobenzimidazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-difluorobenzimidazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-difluorobenzimidazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-difluorobenzimidazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-difluorobenzimidazol)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-difluorobenzimidazol)-2-amine
- 50 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chlorobenzimidazol)-2-amine
- 55 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chlorobenzimidazol)-2-amine
- 60 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chlorobenzimidazol)-2-amine
- 65 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chlorobenzimidazol)-2-amine

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-dichlorobenzimidazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-dichlorobenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-dichlorobenzimidazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-dichlorobenzimidazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-dichlorobenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-dichlorobenzimidazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-4-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-4-methylbenzimidazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-4-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-4-methylbenzimidazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-4-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-4-methylbenzimidazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-5-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-5-methylbenzimidazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-5-methylbenzimidazol)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-5-methylbenzimidazol)-2-amine

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-5-methylbenzimidazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-5-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-5-methylbenzimidazol)-2-amine
- 10
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-6-methylbenzimidazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-6-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-6-methylbenzimidazol)-2-amine
- 20
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-6-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-6-methylbenzimidazol)-2-amine
- 25
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-6-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-7-methylbenzimidazol)-2-amine
- 30
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-7-methylbenzimidazol)-2-amine
- 35
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-7-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-7-methylbenzimidazol)-2-amine
- 40
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-7-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-7-methylbenzimidazol)-2-amine
- 45

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1-methylbenzimidazol-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4-dimethylbenzimidazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5-dimethylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,6-dimethylbenzimidazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,7-dimethylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4,5-trimethylbenzimidazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4,6-trimethylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4,7-trimethylbenzimidazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5,6-trimethylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5,7-trimethylbenzimidazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,6,7-trimethylbenzimidazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-1-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-1-methylbenzimidazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-1-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-1-methylbenzimidazol)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-1-methylbenzimidazol)-2-amine

- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-difluoro-1-methylbenzimidazol)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-difluoro-1-methylbenzimidazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-difluoro-1-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-difluoro-1-methylbenzimidazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-difluoro-1-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-difluoro-1-methylbenzimidazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-1-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-1-methylbenzimidazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-1-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-1-methylbenzimidazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-dichloro-1-methylbenzimidazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-dichloro-1-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-dichlorobenzimidazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-dichloro-1-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-dichloro-1-methylbenzimidazol)-2-amine
- 45

- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-dichloro-1-methylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-1,4-dimethylbenzimidazol)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4-dimethyl-5-fluorobenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-1,4-dimethylbenzimidazol)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4-dimethyl-6-fluorobenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-1,4-dimethylbenzimidazol)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4-dimethyl-7-fluorobenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-1,5-dimethylbenzimidazol)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5-dimethyl-4-fluorobenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-1,5-dimethylbenzimidazol)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5-dimethyl-6-fluorobenzimidazol)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-1,5-dimethylbenzimidazol)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5-dimethyl-7-fluorobenzimidazol)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-1,6-dimethylbenzimidazol)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

d]pyrimidin-5-yl}phenyl)-(1,6-dimethyl-4-fluorobenzimidazol)-2-amine

Trans-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-1,6-dimethylbenzimidazol)-2-amine

5

Trans-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,6-dimethyl-5-fluorobenzimidazol)-2-amine

10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-1,6-dimethylbenzimidazol)-2-amine

Trans-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,6-dimethyl-7-fluorobenzimidazol)-2-amine

15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-1,7-dimethylbenzimidazol)-2-amine

Trans-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,7-dimethyl-4-fluorobenzimidazol)-2-amine

20

Trans-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-1,7-dimethylbenzimidazol)-2-amine

25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,7-dimethyl-5-fluorobenzimidazol)-2-amine

Trans-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-1,7-dimethylbenzimidazol)-2-amine

30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,7-dimethyl-6-fluorobenzimidazol)-2-amine

Trans-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-quinazolino-2-amine

35

Trans-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-methylquinazolino)-2-amine

40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-methylquinazolino)-2-amine

Trans-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-methylquinazolino)-2-amine

45

Trans-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-(7-methylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-dimethylquinazolino)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-dimethylquinazolino)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-dimethylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-dimethylquinazolino)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-dimethylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-dimethylquinazolino)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoroquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoroquinazolino)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoroquinazolino)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoroquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-difluoroquinazolino)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-difluoroquinazolino)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-difluoroquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-difluoroquinazolino)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-(5,7-difluoroquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-difluoroquinazolino)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloroquinazolino)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloroquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloroquinazolino)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloroquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-dichloroquinazolino)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-dichloroquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-dichloroquinazolino)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-dichloroquinazolino)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-dichloroquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-dichloroquinazolino)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-4-methylquinazolino)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-4-methylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-4-methylquinazolino)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-(6-fluoro-4-methylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-4-methylquinazolino)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-4-methylquinazolino)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-5-methylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-5-methylquinazolino)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-5-methylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-5-methylquinazolino)-2-amine
- 20 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-5-methylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-5-methylquinazolino)-2-amine
- 25 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-6-methylquinazolino)-2-amine
- 30 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-6-methylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-6-methylquinazolino)-2-amine
- 35 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-6-methylquinazolino)-2-amine
- 40 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-6-methylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-6-methylquinazolino)-2-amine
- 45 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-(4-chloro-7-methylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-7-methylquinazolino)-2-amine
- 5 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-7-methylquinazolino)-2-amine
- 10 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-7-methylquinazolino)-2-amine
- Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-7-methylquinazolino)-2-amine
- 15 *Trans*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-7-methylquinazolino)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-benzoxazol-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-methylbenzoxazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-methylbenzoxazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-methylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-methylbenzoxazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-dimethylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-dimethylbenzoxazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-dimethylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-dimethylbenzoxazol)-2-amine
- 45 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-1,3-(5,7-dimethylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-dimethylbenzoxazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluorobenzoxazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluorobenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluorobenzoxazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluorobenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-difluorobenzoxazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-difluorobenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-difluorobenzoxazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-difluorobenzoxazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,7-difluorobenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-difluorobenzoxazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chlorobenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chlorobenzoxazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chlorobenzoxazol)-2-amine
- 45 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-1,3-(7-chlorobenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-dichlorobenzoxazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-dichlorobenzoxazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-dichlorobenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-dichlorobenzoxazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,7-dichlorobenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-dichlorobenzoxazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-4-methylbenzoxazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-4-methylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-4-methylbenzoxazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-4-methylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-4-methylbenzoxazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-4-methylbenzoxazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-5-methylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-5-methylbenzoxazol)-2-amine
- 45 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-5-methylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-5-methylbenzoxazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-5-methylbenzoxazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-5-methylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-6-methylbenzoxazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-6-methylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-6-methylbenzoxazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-6-methylbenzoxazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-6-methylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-6-methylbenzoxazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-7-methylbenzoxazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-7-methylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-7-methylbenzoxazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-7-methylbenzoxazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-7-methylbenzoxazol)-2-amine
- 45 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-7-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-benzothiazol-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-methylbenzothiazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-methylbenzothiazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-dimethylbenzothiazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-dimethylbenzothiazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-dimethylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-dimethylbenzothiazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,7-dimethylbenzothiazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-dimethylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluorobenzothiazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluorobenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluorobenzothiazol)-2-amine
- 45 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-1,3-(7-fluorobenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-difluorobenzothiazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-difluorobenzothiazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-difluorobenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-difluorobenzothiazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,7-difluorobenzothiazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-difluorobenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chlorobenzothiazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chlorobenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chlorobenzothiazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chlorobenzothiazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,5-dichlorobenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,6-dichlorobenzothiazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4,7-dichlorobenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5,6-dichlorobenzothiazol)-2-amine
- 45 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-1,3-(5,7-dichlorobenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6,7-dichlorobenzothiazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-4-methylbenzothiazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-4-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-4-methylbenzothiazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-4-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-4-methylbenzothiazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-4-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-5-methylbenzothiazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-5-methylbenzothiazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-5-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-5-methylbenzothiazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-5-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-5-methylbenzothiazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-6-methylbenzothiazol)-2-amine
- 45 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

- d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-6-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-6-methylbenzothiazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-6-methylbenzothiazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-chloro-6-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(7-fluoro-6-methylbenzothiazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-chloro-7-methylbenzothiazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(4-fluoro-7-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-chloro-7-methylbenzothiazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(5-fluoro-7-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-chloro-7-methylbenzothiazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1,3-(6-fluoro-7-methylbenzothiazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-benzimidazol-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-methylbenzimidazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-methylbenzimidazol)-2-amine
- 45 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

d]pyrimidin-5-yl}phenyl)-(7-methylbenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-dimethylbenzimidazol)-2-amine

5

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-dimethylbenzimidazol)-2-amine

10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-dimethylbenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-dimethylbenzimidazol)-2-amine

15

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-dimethylbenzimidazol)-2-amine

20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-dimethylbenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluorobenzimidazol)-2-amine

25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluorobenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluorobenzimidazol)-2-amine

30

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluorobenzimidazol)-2-amine

35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-difluorobenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-difluorobenzimidazol)-2-amine

40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-difluorobenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-difluorobenzimidazol)-2-amine

45

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-

d]pyrimidin-5-yl}phenyl)-(5,7-difluorobenzimidazol)-2-amine

5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-difluorobenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chlorobenzimidazol)-2-amine

10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chlorobenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chlorobenzimidazol)-2-amine

15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chlorobenzimidazol)-2-amine

20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-dichlorobenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-dichlorobenzimidazol)-2-amine

25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-dichlorobenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-dichlorobenzimidazol)-2-amine

30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-dichlorobenzimidazol)-2-amine

35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-dichlorobenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-4-methylbenzimidazol)-2-amine

40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-4-methylbenzimidazol)-2-amine

Cis-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-4-methylbenzimidazol)-2-amine

45

- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-4-methylbenzimidazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-4-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-4-methylbenzimidazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-5-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-5-methylbenzimidazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-5-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-5-methylbenzimidazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-5-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-5-methylbenzimidazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-6-methylbenzimidazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-6-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-6-methylbenzimidazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-6-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-6-methylbenzimidazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-6-methylbenzimidazol)-2-amine
- 45 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-6-methylbenzimidazol)-2-amine

- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-7-methylbenzimidazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-7-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-7-methylbenzimidazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-7-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-7-methylbenzimidazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-7-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-1-methylbenzimidazol-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4-dimethylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5-dimethylbenzimidazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,6-dimethylbenzimidazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,7-dimethylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4,5-trimethylbenzimidazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4,6-trimethylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4,7-trimethylbenzimidazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5,6-trimethylbenzimidazol)-2-amine
- 45

- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5,7-trimethylbenzimidazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,6,7-trimethylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-1-methylbenzimidazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-1-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-1-methylbenzimidazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-1-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-difluoro-1-methylbenzimidazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-difluoro-1-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-difluoro-1-methylbenzimidazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-difluoro-1-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-difluoro-1-methylbenzimidazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-difluoro-1-methylbenzimidazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-1-methylbenzimidazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-1-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-1-methylbenzimidazol)-2-amine
- 45

- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-1-methylbenzimidazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-dichloro-1-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-dichloro-1-methylbenzimidazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-dichlorobenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-dichloro-1-methylbenzimidazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-dichloro-1-methylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-dichloro-1-methylbenzimidazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-1,4-dimethylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4-dimethyl-5-fluorobenzimidazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-1,4-dimethylbenzimidazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4-dimethyl-6-fluorobenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-1,4-dimethylbenzimidazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,4-dimethyl-7-fluorobenzimidazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-1,5-dimethylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5-dimethyl-4-fluorobenzimidazol)-2-amine
- 45

- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-1,5-dimethylbenzimidazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5-dimethyl-6-fluorobenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-1,5-dimethylbenzimidazol)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,5-dimethyl-7-fluorobenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-1,6-dimethylbenzimidazol)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,6-dimethyl-4-fluorobenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-1,6-dimethylbenzimidazol)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,6-dimethyl-5-fluorobenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-1,6-dimethylbenzimidazol)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,6-dimethyl-7-fluorobenzimidazol)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-1,7-dimethylbenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,7-dimethyl-4-fluorobenzimidazol)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-1,7-dimethylbenzimidazol)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,7-dimethyl-5-fluorobenzimidazol)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-1,7-dimethylbenzimidazol)-2-amine
- 45

- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(1,7-dimethyl-6-fluorobenzimidazol)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-quinazolino-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-methylquinazolino)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-methylquinazolino)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-dimethylquinazolino)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-dimethylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-dimethylquinazolino)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-dimethylquinazolino)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-dimethylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-dimethylquinazolino)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoroquinazolino)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoroquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoroquinazolino)-2-amine
- 45

- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoroquinazolino)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-difluoroquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-difluoroquinazolino)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-difluoroquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-difluoroquinazolino)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-difluoroquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-difluoroquinazolino)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloroquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloroquinazolino)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloroquinazolino)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloroquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,5-dichloroquinazolino)-2-amine
- 35 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,6-dichloroquinazolino)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4,7-dichloroquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,6-dichloroquinazolino)-2-amine
- 45

- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5,7-dichloroquinazolino)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6,7-dichloroquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-4-methylquinazolino)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-4-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-4-methylquinazolino)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-4-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-4-methylquinazolino)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-4-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-5-methylquinazolino)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-5-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-5-methylquinazolino)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-5-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-5-methylquinazolino)-2-amine
- 40 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-5-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-6-methylquinazolino)-2-amine
- 45


- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-6-methylquinazolino)-2-amine
- 5 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-6-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-6-methylquinazolino)-2-amine
- 10 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-chloro-6-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(7-fluoro-6-methylquinazolino)-2-amine
- 15 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-chloro-7-methylquinazolino)-2-amine
- 20 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(4-fluoro-7-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-chloro-7-methylquinazolino)-2-amine
- 25 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(5-fluoro-7-methylquinazolino)-2-amine
- Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-chloro-7-methylquinazolino)-2-amine
- 30 *Cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-(6-fluoro-7-methylquinazolino)-2-amine
- 35 In addition to the foregoing compounds, the corresponding 2-fluorophenyl analogs of the above list of compounds are also preferred, e.g., *cis*-N2-(4-{4-amino-7-[4-(4-methylpiperazino)-cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-3-fluorophenyl)-(6-fluoro-7-methylquinazolino)-2-amine.

CLAIMS

We Claim:

5

1. A compound represented by the following structural formula:



10

and pharmaceutically acceptable salts thereof, wherein:

Ring A is a six membered aromatic ring or a five or six membered heteroaromatic ring which is optionally substituted with one or more substituents selected from the group consisting of a substituted or unsubstituted aliphatic group, a halogen, a substituted or unsubstituted aromatic group, substituted or unsubstituted heteroaromatic group, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaralkyl, cyano, nitro, $-NR_4R_5$, $-C(O)_2H$, $-OH$, a substituted or unsubstituted alkoxycarbonyl, $-C(O)_2$ -haloalkyl, a substituted or unsubstituted alkylthio ether, a substituted or unsubstituted alkylsulfoxide, a substituted or unsubstituted alkylsulfone, a substituted or unsubstituted arylthio ether, a substituted or unsubstituted arylsulfoxide, a substituted or unsubstituted arylsulfone, a substituted or unsubstituted alkyl carbonyl, -


C(O)-haloalkyl, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, carboxamido, tetrazolyl, trifluoromethylsulphonamido, trifluoromethylcarbonylamino, a substituted or unsubstituted alkynyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkyl amido, a substituted or unsubstituted aryl amido, -NR₉₅C(O)R₉₅, a substituted or unsubstituted styryl and a substituted or unsubstituted aralkyl amido, wherein R₉₅ is an aliphatic group or an aromatic group;

L is -O-; -S-; -S(O)-; -S(O)₂-; -N(R)-; -N(C(O)OR)-; -N(C(O)R)-; -N(SO₂R)-; -CH₂O-; -CH₂S-; -CH₂N(R)-; -C(NR)-; -CH₂N(C(O)R)-; -CH₂N(C(O)OR)-; -CH₂N(SO₂R)-; -CH(NHR)-; -CH(NHC(O)R)-; -CH(NHSO₂R)-; -CH(NHC(O)OR)-; -CH(OC(O)R)-; -CH(OC(O)NHR)-; -CH=CH-; -C(=NOR)-; -C(O)-; -CH(OR)-; -C(O)N(R)-; -N(R)C(O)-; -N(R)S(O)-; -N(R)S(O)₂-; -OC(O)N(R)-; -N(R)C(O)N(R)-; -NRC(O)O-; -S(O)N(R)-; -S(O)₂N(R)-; -N(C(O)R)S(O)-; -N(C(O)R)S(O)₂-; -N(R)S(O)N(R)-; -N(R)S(O)₂N(R)-; -C(O)N(R)C(O)-; -S(O)N(R)C(O)-; -S(O)₂N(R)C(O)-; -OS(O)N(R)-; -OS(O)₂N(R)-; -N(R)S(O)O-; -N(R)S(O)₂O-; -N(R)S(O)C(O)-; -N(R)S(O)₂C(O)-; -SON(C(O)R)-; -SO₂N(C(O)R)-; -N(R)SON(R)-; -N(R)SO₂N(R)-; -C(O)O-; -N(R)P(OR')O-; -N(R)P(OR')-; -N(R)P(O)(OR')O-; -N(R)P(O)(OR')-; -N(C(O)R)P(OR')O-; -N(C(O)R)P(OR')-; -N(C(O)R)P(O)(OR')O-; -N(C(O)R)P(OR')-; -CH(R)S(O)-; -CH(R)S(O)₂-; -CH(R)N(C(O)OR)-; -CH(R)N(C(O)R)-; -CH(R)N(SO₂R)-; -CH(R)O-; -CH(R)S-; -CH(R)N(R)-; -CH(R)N(C(O)R)-; -CH(R)N(C(O)OR)-; -CH(R)N(SO₂R)-; -CH(R)C(=NOR)-; -CH(R)C(O)-; -CH(R)CH(OR)-; -CH(R)C(O)N(R)-; -CH(R)N(R)C(O)-; -CH(R)N(R)S(O)-; -CH(R)N(R)S(O)₂-; -CH(R)OC(O)N(R)-; -CH(R)N(R)C(O)N(R)-; -CH(R)N(R)C(O)O-; -CH(R)S(O)N(R)-; -CH(R)S(O)₂N(R)-; -CH(R)N(C(O)R)S(O)-; -CH(R)N(C(O)R)S(O)₂-; -CH(R)N(R)S(O)N(R)-; -CH(R)N(R)S(O)₂N(R)-; -CH(R)C(O)N(R)C(O)-; -CH(R)S(O)N(R)C(O)-; -CH(R)S(O)₂N(R)C(O)-; -CH(R)OS(O)N(R)-; -CH(R)OS(O)₂N(R)-; -CH(R)N(R)S(O)O-; -CH(R)N(R)S(O)₂O-; -CH(R)N(R)S(O)C(O)-; -

$\text{CH(R)N(R)S(O)}_2\text{C(O)-}$; - CH(R)SON(C(O)R)- ; - $\text{CH(R)S(O)}_2\text{N(C(O)R)-}$; -
 CH(R)N(R)SON(R)- ; - $\text{CH(R)N(R)S(O)}_2\text{N(R)-}$; - CH(R)C(O)O- ; -
 CH(R)N(R)P(OR')O- ; - CH(R)N(R)P(OR')- ; - $\text{CH(R)N(R)P(O)(OR')O-}$; -
 $\text{CH(R)N(R)P(O)(OR')-}$; - $\text{CH(R)N(C(O)R)P(OR')O-}$; -
5 $\text{CH(R)N(C(O)R)P(OR')-}$; - $\text{CH(R)N(C(O)R)P(O)(OR')O-}$ or -
 $\text{CH(R)N(C(O)R)P(OR')-}$, wherein each R and R' is, independently, -H, an
acyl group, a substituted or unsubstituted aliphatic group, a substituted or
unsubstituted aromatic group, a substituted or unsubstituted arylalkyl group,
a substituted or unsubstituted heteroaromatic group, or a substituted or
10 unsubstituted cycloalkyl group or a substituted or unsubstituted arylalkyl
group; or

L is $-\text{R}_b\text{N(R)S(O)}_2-$, $-\text{R}_b\text{N(R)P(O)-}$, or $-\text{R}_b\text{N(R)P(O)O-}$, wherein R_b is
an alkylene group which when taken together with the sulphonamide,
phosphinamide, or phosphonamide group to which it is bound forms a five or
15 six membered ring fused to ring A; or

L is represented by one of the following structural formulas:



20 wherein R_{85} taken together with the phosphinamide, or phosphonamide is a 5-, 6-, or 7-membered, aromatic, heteroaromatic or heterocycloalkyl ring system;

G is a direct bond; $-(CH_2)_j-$, wherein j is 1 to 6; a C_2-C_6 - alkenylene group, a C_3-C_8 -cycloalkylene group or a C_1-C_6 -oxaalkylene group;

25 R_1 is a substituted aliphatic group, a substituted cycloalkyl, a substituted bicycloalkyl, a substituted cycloalkenyl, an optionally substituted aromatic group, an optionally substituted heteroaromatic group, an optionally substituted heteroaralkyl, an optionally substituted heterocycloalkyl, an optionally substituted heterobicycloalkyl, an optionally substituted

30 alkylamido, and optionally substituted arylamido, an optionally substituted - $S(O)_2$ -alkyl or optionally substituted - $S(O)_2$ -cycloalkyl, a - $C(O)$ -alkyl or an

optionally substituted $-C(O)-$ alkyl, provided that when R_1 is an aliphatic group or cycloalkyl group, R_1 is not exclusively substituted with one or more substituents selected from the group consisting of hydroxyl and lower alkyl ethers, provided that the heterocycloalkyl is not 2-phenyl-1,3-dioxan-5-yl and provided that an aliphatic group is not substituted exclusively with one or more aliphatic groups;

wherein one or more substituents are selected from the group consisting of a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aromatic ether, a substituted or unsubstituted aliphatic ether, a substituted or unsubstituted alkoxy carbonyl, a substituted or unsubstituted alkyl carbonyl, a substituted or unsubstituted aryl carbonyl, a substituted or unsubstituted heteroaryl carbonyl, substituted or unsubstituted aryloxy carbonyl, $-OH$, a substituted or unsubstituted aminocarbonyl, an oxime, a substituted or unsubstituted azabicycloalkyl, heterocycloalkyl, oxo, aldehyde, a substituted or unsubstituted alkyl sulfonamido group, a substituted or unsubstituted aryl sulfonamido group, a substituted or unsubstituted bicycloalkyl, a substituted or unsubstituted heterobicycloalkyl, cyano, $-NH_2$, an alkylamino, ureido, thioureido; or

R_1 is $-B-E$, wherein

B is a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aromatic, a substituted or unsubstituted heteroaromatic, an alkylene, an aminoalkyl, an alkylenecarbonyl, or an aminoalkylcarbonyl; and

E is a substituted or unsubstituted azacycloalkyl, a substituted or unsubstituted azacycloalkylcarbonyl, a substituted or unsubstituted azacycloalkylsulfonyl, a substituted or unsubstituted azacycloalkylalkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted

heteroarylcarbonyl, a substituted or unsubstituted heteroarylsulfonyl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted alkyl sulfonamido, a substituted or unsubstituted aryl sulfonamido, a substituted or unsubstituted bicycloalkyl, a substituted or unsubstituted ureido, a substituted or unsubstituted thioureido or a substituted or unsubstituted aryl;

R_2 is -H, a substituted or unsubstituted aliphatic group, a substituted or unsubstituted cycloalkyl, a halogen, -OH, cyano, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaralkyl, $-(CH_2)_{0-3}NR_4R_5$, or $-(CH_2)_{0-3}C(O)NR_4R_5$;

R_3 is a substituted or unsubstituted aliphatic group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocycloalkyl;

provided that L is -SN(R)-, -S(O)N(R)-, -S(O)₂N(R)-, -N(R)S-, -N(R)S(O)-, -N(R)S(O)₂-, -N(R)SN(R')-, -N(R)S(O)N(R')-, or -N(R)S(O)₂N(R')-when R_3 is a substituted or unsubstituted aliphatic group, a substituted or unsubstituted alkenyl group;

provided that when L is -O-, -CH₂NR-, -C(O)NR- or -NRC(O)- and R_3 is azacycloalkyl or azaheteroaryl, G is a direct bond; a C₂-C₆- alkenylene group, a C₃-C₈-cycloalkylene group or a C₁-C₆-oxaalkylene; and

provided that when L is -O- and R_3 is phenyl, G is a direct bond; a C₂-C₆-alkenylene group, a C₃-C₈-cycloalkylene group or a C₁-C₆-oxaalkylene;

R_4 , R_5 and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterobicycloalkyl or a substituted or unsubstituted heteroaromatic; or

R_4 and R_5 are each, independently, -H, azabicycloalkyl, heterocycloalkyl, a substituted or unsubstituted alkyl group or Y-Z;

-400-

Y is selected from the group consisting of -C(O)-, -(CH₂)_p-, -S(O)₂-, -C(O)O-, -SO₂NH-, -CONH-, -(CH₂)_pO-, -(CH₂)_pNH-, -(CH₂)_pS-, -(CH₂)_pS(O)-, and -(CH₂)_pS(O)₂-;

p is an integer from 0 to 6; and

5 Z is -H, a substituted or unsubstituted alkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl group.

- 10 2. The compound of Claim 1, wherein R₃ is selected from the group consisting of a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted pyridyl, a substituted or unsubstituted thienyl, a substituted or unsubstituted benzotriazole, a substituted or unsubstituted tetrahydropyran-
15 yl, a substituted or unsubstituted tetrahydrofuran-yl, a substituted or unsubstituted dioxane, a substituted or unsubstituted dioxolane, a substituted or unsubstituted quinoline, a substituted or unsubstituted thiazole, substituted or unsubstituted isoxazole, substituted or unsubstituted cyclopentyl, a substituted or unsubstituted benzofuran, substituted or unsubstituted benzothiophene, substituted or
20 unsubstituted benzisoxazole, substituted or unsubstituted benzisothiazole, substituted or unsubstituted benzothiazole, substituted or unsubstituted benzoxazole, substituted or unsubstituted benzoxazole, substituted or unsubstituted benzimidazole, substituted or unsubstituted benzoxadiazole, substituted or unsubstituted benzothiadiazole, substituted or unsubstituted
25 isoquinoline, substituted or unsubstituted quinoxaline, substituted or unsubstituted indole and substituted or unsubstituted pyrazole.

3. The compound of Claim 2 wherein R_3 is substituted with one or more substituent selected from the group consisting of F, Cl, Br, I, CH_3 , NO_2 , OCF_3 , OCH_3 , CN, CO_2CH_3 , CF_3 , t-butyl, pyridyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted benzyl, substituted or unsubstituted benzenesulfonyl, substituted or unsubstituted phenoxy, substituted or unsubstituted phenyl, substituted or unsubstituted amino, carboxyl, substituted or unsubstituted tetrazolyl, styryl, -S-(substituted or unsubstituted aryl), -S-(substituted or unsubstituted heteroaryl), substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, - NR_fR_g , alkynyl, -C(O) NR_fR_g , R_c and CH_2OR_c ,

R_f , R_g and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterobicycloalkyl or a substituted or unsubstituted heteroaromatic; or

R_f and R_g are each, independently, -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aromatic group; and

R_c is hydrogen, or substituted or unsubstituted alkyl or substituted or unsubstituted aryl, -W-(CH_2)_t- NR_dR_e , -W-(CH_2)_t-O-alkyl, , -W-(CH_2)_t-S-alkyl, -W-(CH_2)_t-OH; or -W-(CH_2)_t-OR_f;

t is an integer from 0 to 6;

W is a bond or -O-, -S-, -S(O)-, -S(O)₂-, or -NR_k-;

R_k is -H or alkyl; and

R_d , R_e and the nitrogen atom to which they are attached together form a 3, 4, 5, 6 or 7-membered substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterobicyclic group; or

R_d and R_e are each, independently, -H, alkyl, alkanoyl or -K-D;

K is -S(O)₂-, -C(O)-, -C(O)NH-, -C(O)₂-, or a direct bond;

D is a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted

-402-

heteroaralkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aminoalkyl, a substituted or unsubstituted aminocycloalkyl, COOR_i, or substituted or unsubstituted alkyl; and


5 R_i is a substituted or unsubstituted aliphatic group or a substituted or unsubstituted aromatic group.

4. The compound of Claim 3, wherein R₃ is a substituted or unsubstituted phenyl or phenyl fused to a five- or six-membered heterocyclic group.

10

5. The compound of Claim 4 wherein R₃ is selected from the group consisting of

15



20

wherein R is hydrogen or alkyl.

6. The compound of Claim 5 wherein ring A is a 1,4-phenylene group substituted with methoxy or fluoro.
7. The compound of Claim 1, wherein ring A is selected from the group
 - 5 consisting of a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted pyridyl, and a substituted or unsubstituted indole.
8. The compound of Claim 7 wherein ring A is substituted with one or more
 - 10 substituent selected from the group consisting of -F, -Cl, -Br, -I, -OH, -CH₃, -NO₂, -OCF₃, -OCH₃, -CN, -CO₂CH₃, -CF₃, -CH₂OH, -CH₂NMe₂, -CH₂NHMe, CH₂NH₂, t-butyl, pyridyl, methylenedioxy; substituted or unsubstituted oxazolyl, substituted or unsubstituted benzyl, substituted or unsubstituted benzenesulfonyl, substituted or unsubstituted phenoxy, substituted or unsubstituted phenyl, substituted or
 - 15 unsubstituted amino, carboxyl, substituted or unsubstituted tetrazolyl, styryl, -S-(substituted or unsubstituted aryl), -S-(substituted or unsubstituted heteroaryl), substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -NR_fR_g, alkynyl, -C(O)NR_fR_g, R_c and CH₂OR_c;
 R_f, R_g and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered,
 - 20 substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterobicycloalkyl or a substituted or unsubstituted heteroaromatic; or
 R_f and R_g are each, independently, -H, a substituted or unsubstituted aliphatic group or a substituted or unsubstituted aromatic group; and
- R_c is hydrogen, substituted or unsubstituted alkyl, substituted or
 - 25 unsubstituted aryl, -W-(CH₂)_t-NR_dR_e, -W-(CH₂)_t-O-alkyl, -W-(CH₂)_t-S-alkyl, -W-(CH₂)_t-OH; or -W-(CH₂)_t-OR_f;
- t is an integer from 0 to 6;
- W is a bond or -O-, -S-, -S(O)-, -S(O)₂-, or -NR_k-;
- R_k is -H or alkyl; and
- 30 R_d, R_e and the nitrogen atom to which they are attached together form a 3, 4, 5, 6 or 7-membered substituted or unsubstituted heterocycloalkyl, substituted or

-404-

unsubstituted heterobicycloalkyl or a substituted or unsubstituted heteroaromatic; or

R_d and R_e are each, independently, -H, alkyl, alkanoyl or -K-D;

K is -S(O)₂-, -C(O)-, -C(O)NH-, -C(O)₂-, or a direct bond;

- 5 D is a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aminoalkyl, a substituted or unsubstituted aminocycloalkyl, COOR_i, or a substituted or unsubstituted alkyl; and

10 R_i is a substituted or unsubstituted aliphatic group or a substituted or unsubstituted aromatic group.


- 15 9. The compound of Claim 8, wherein ring A is a substituted or unsubstituted phenyl.

10. The compound of Claim 9 wherein ring A is a substituted or unsubstituted 1,4-phenylene group.

20

11. The compound of Claim 1 wherein R_i is of the formula

25



- 30 wherein m is an integer from 0 to 3.

-405-

12. The compound of Claim 1 wherein R_1 is of the formula



wherein:

m is an integer from 0 to 3;

15 t is an integer from 1 to 6; and

R_8 , R_9 and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted heteroaromatic or substituted or unsubstituted heterobicyclicalkyl group; or

20 R_8 and R_9 are each, independently, -H, azabicycloalkyl, heterocycloalkyl or Y_2 - Z_2 ;


Y_2 is selected from the group consisting of -C(O)-, $-(\text{CH}_2)_q$ -, $-\text{S}(\text{O})_2$ -, $-\text{C}(\text{O})\text{O}$ -, $-\text{SO}_2\text{NH}$ -, $-\text{CONH}$ -, $(\text{CH}_2)_q\text{O}$ -, $-(\text{CH}_2)_q\text{NH}$ -, $-(\text{CH}_2)_q\text{S}$ -, $-(\text{CH}_2)_q\text{S}(\text{O})$ -, and $-(\text{CH}_2)_q\text{S}(\text{O})_2$;

25 q is an integer from 0 to 6; and

Z_2 is -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl group.

-406-

13. The compound of Claim 1 wherein R_1 is of the formula



10 wherein:

m is an integer from 1 to 3;

s and t are each, independently, an integer from 0 to 6; and

15 R_8 , R_9 and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl group, substituted or unsubstituted heteroaryl group, or a substituted heterobicyclicalkyl group; or R_8 and R_9 are each, independently, -H, azabicycloalkyl, heterocycloalkyl; alkyl; hydroxyalkyl; dihydroxyalkyl; or $-Y_2-Z_2$;

20 Y_2 is selected from the group consisting of $-C(O)-$, $-(CH_2)_q-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$ and $(CH_2)_qS(O)_2-$;

q is an integer from 0 to 6;

Z_2 is -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl;

25 R_{77} is -H, $-OR_{78}$, or $-NR_{79}R_{80}$;

R_{78} is -H or a substituted or unsubstituted aliphatic group;

R_{79} , R_{80} and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl group, substituted or unsubstituted heteroaryl group, or a substituted heterobicyclicalkyl group; or

30 R_{79} and R_{80} are each, independently, -H, azabicycloalkyl, heterocycloalkyl or $-Y_3-Z_3$;


-407-

Y_3 is selected from the group consisting of $-C(O)-$, $-(CH_2)_q-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$, $-(CH_2)_qN(C_1-C_6\text{-alkyl})-$, $-(CH_2)_qC(O)O-(CH_2)_q-$ and $-(CH_2)_qS(O)_2-$; q is an integer from 0 to 6;

- 5 Z_3 is $-H$, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl.


14. The compound of Claim 13 wherein m is 2; s is 0; and R_{77} is $-OH$.

15. The compound of Claim 14 wherein R_1 is selected from the group consisting of:



15


-408-



-409-

16. The compound of Claim 1 wherein R_1 is of the formula

5



wherein:

10

v is an integer from 1 to 3

R_{10} is -H, azabicycloalkyl, heterocycloalkyl or Y_2-Z_2 ;

Y_2 is selected from the group consisting of -C(O)-, $-(CH_2)_q-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $-(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$, and $-(CH_2)_qS(O)_2-$;


15

q is an integer from 0 to 6; and

Z_2 is -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl.

- 20 17. The compound of Claim 1 wherein R_1 is of the formula

25



wherein:

30

m is an integer from 0 to 3;

R_{10} is -H, azabicycloalkyl, heterocycloalkyl or Y_2-Z_2 ;

-410-

Y_2 is selected from the group consisting of $-C(O)-$, $-(CH_2)_p-$, $-S(O)_2-$, $C(O)O-$, $-SO_2NH-$, $-CONH-$, $-(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$, and $-(CH_2)_qS(O)_2-$;

q is an integer from 0 to 6; and


5 Z_2 is $-H$, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl; and

R_{11} represents one or more substituents independently selected from the group consisting of hydrogen, hydroxy, oxo, a substituted or unsubstituted aliphatic
 10 group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted alkoxy carbonyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted aminocarbonyl, a substituted or unsubstituted alkylcarbonyl, a substituted or unsubstituted arylcarbonyl, a substituted or unsubstituted
 15 heteroarylcarbonyl, a substituted or unsubstituted aminoalkyl and a substituted or unsubstituted aralkyl groups, provided that the carbon atoms adjacent to the nitrogen atom are not substituted by a hydroxy group.

18. The compound of Claim 17 wherein Z_2 is of the formula $N(R_{35})R_{36}$, wherein
 20 R_{35} and R_{36} are each, independently, hydrogen, alkyl, alkoxy carbonyl, alkoxyalkyl, hydroxyalkyl, aminocarbonyl, cyano, alkylcarbonyl or aralkyl.

19. The compound of Claim 17 wherein Z_2 is of the formula

25



30


-411-

wherein:

each X_1 is, independently, CH or N; and

R_{37} is hydrogen, cyano or a substituted or unsubstituted alkyl, a substituted or unsubstituted alkoxycarbonyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted aminocarbonyl, a substituted or unsubstituted alkylcarbonyl or a substituted or unsubstituted aralkyl group.

20. The compound of Claim 17 wherein Z_2 is of the formula



wherein

g is an integer from 0 to 3;


T is $-O-$, $-C(O)-$, $-S-$, $-SO-$, $-SO_2-$, $-CH_2-$, $-CH(OR_{34})-$ or $-N(R_{34})-$;

R_{34} is hydrogen, substituted or unsubstituted alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl; and

R_{37} is hydrogen, cyano or a substituted or unsubstituted alkyl, a substituted or unsubstituted alkoxycarbonyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted aminocarbonyl, a substituted or unsubstituted alkylcarbonyl or a substituted or unsubstituted aralkyl group.

-412-

21. The compound of Claim 17 wherein Z_2 is of the formula




wherein:

g is an integer from 0 to 3; and

R_{37} is hydrogen, cyano or a substituted or unsubstituted alkyl, a substituted or unsubstituted alkoxycarbonyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted aminocarbonyl, a substituted or unsubstituted alkylcarbonyl or a substituted or unsubstituted aralkyl group.

22. The compound of Claim 17 wherein Z_2 is of the formula



wherein:

T is $-O-$, $-C(O)-$, $-S-$, $-SO-$, $-SO_2-$, $-CH_2-$, $-CH(OR_{34})-$ or $-N(R_{34})-$;


R_{34} is hydrogen, substituted or unsubstituted alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl; and

g is an integer from 0 to 3; and

R_{37} is hydrogen, cyano or a substituted or unsubstituted alkyl, a substituted or unsubstituted alkoxycarbonyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted

aminocarbonyl, a substituted or unsubstituted alkylcarbonyl or a substituted or unsubstituted aralkyl.

23. The compound of Claim 17 wherein Z_2 is of the formula




wherein:

R₃₇ is hydrogen, cyano, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkoxycarbonyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted aminocarbonyl, a substituted or unsubstituted alkylcarbonyl, a substituted or unsubstituted thioalkoxy or a substituted or unsubstituted aralkyl; and

R₃₈ is hydrogen, substituted or unsubstituted alkyl, a substituted or unsubstituted alkoxycarbonyl, a substituted or unsubstituted alkoxyalkyl, a substituted or unsubstituted aminocarbonyl, perhaloalkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkylcarbonyl or a substituted or unsubstituted aralkyl.

-414-

24. The compound of Claim 1 wherein R_1 is of the formula



wherein:

R_{10} is H, azabicycloalkyl, heterocycloalkyl or Y_2-Z_2 ;


20 Y_2 is selected from the group consisting of $-C(O)-$, $-(CH_2)_q-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$, and $-(CH_2)_qS(O)_2-$;

q is an integer from 0 to 6; and

25 Z_2 is $-H$, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl.


-415-

25. A compound of claim 24 wherein R_{10} is methyl; ring A is



L is $-N(R)C(O)-$, where R is H;


- 5 G is a direct bond, $-CH_2-O-$, $-O-CH_2-$, cyclopropylene, $-CH_2-O-CH_2-$ or $-(CH_2)_3-$;
 R_3 is phenyl, 2,6-difluorophenyl, 2-methoxyphenyl, 2,6-dimethoxyphenyl, 3,4-dichlorophenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 3-nitrophenyl, 2,5-difluorophenyl, 3-cyanophenyl, 2,3-difluorophenyl, 2-chloropyridin-5-yl, 4-trifluoromethoxyphenyl, 2,4,6-trifluorophenyl, 2-fluoro-6-chlorophenyl, 4-dimethylaminophenyl, 4-cyanophenyl, 3-fluorophenyl, 2,5-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 2,6-dimethylphenyl, 2-chloro-4-fluorophenyl, 4-nitrophenyl,
- 10



15

26. The compound of Claim 1 wherein R_1 is of the formula

20



25

wherein:

r is an integer from 1 to 6; and

-416-

R_8 , R_9 and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl group, substituted or unsubstituted heteroaryl group, or a substituted heterobicyclicalkyl group; or


R_8 and R_9 are each, independently, -H, azabicycloalkyl, heterocycloalkyl or Y_2 - Z_2 ;

Y_2 is selected from the group consisting of -C(O)-, $-(CH_2)_q-$, $-S(O)_2-$, -C(O)O-, -SO₂NH-, -CONH-, $(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$, and $(CH_2)_qS(O)_2-$;

q is an integer from 0 to 6; and

Z_2 is -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl group.

27. The compound of Claim 26 wherein R_8 , R_9 and the nitrogen atom together form a heterocycloalkyl group; of the formula



wherein:

R_{13} , R_{14} , R_{15} , R_{16} , R_{17} , R_{18} , R_{19} and R_{20} are each, independently, lower alkyl or hydrogen; or

at least one pair of substituents R_{13} and R_{14} ; R_{15} and R_{16} ; R_{17} and R_{18} ; or R_{19} and R_{20} together are an oxygen atom; or

at least one of R_{13} and R_{15} is cyano, CONHR₂₁, COOR₂₁, CH₂OR₂₁ or

CH₂NR₂₁(R₂₂);

-417-

R_{21} , R_{22} and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl group, substituted or unsubstituted heteroaryl group, or a substituted heterobicyclicalkyl group; or

R_{21} and R_{22} are each, independently, -H, azabicycloalkyl, heterocycloalkyl or Y_3 - Z_3 ;

Y_3 is selected from the group consisting of -C(O)-, $-(CH_2)_q-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$; and $-(CH_2)_qS(O)_2-$;

q is an integer from 0 to 6; and

Z_3 is -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl;


X is -O-, -S-, -SO-, $-SO_2-$, $-CH_2-$, $-CH(OR_{23})-$ or NR_{23} ;

R_{23} is -H, substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, $-C(NH)NH_2$, $-C(O)R_{24}$, or $-C(O)OR_{24}$;

R_{24} is hydrogen, substituted or unsubstituted alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl; and

u is 0 or 1.

28. The compound of Claim 26 wherein R_8 , R_9 and the nitrogen atom together form a heterocycloalkyl of the formula



wherein:

R_{25} and R_{26} are each, independently, hydrogen or lower alkyl; or

-418-

R_{25} and R_{26} together are an oxygen atom; and

R_{21} , R_{22} and the nitrogen atom together form a 3, 4, 5 or 6-membered, substituted or unsubstituted heterocycloalkyl group; or

R_{21} and R_{22} are each, independently, -H, azabicycloalkyl, heterocycloalkyl or Y_3 -
 5 Z_3 ;

Y_3 is -H, selected from the group consisting of -C(O)-, $-(CH_2)_s-$, $-S(O)_2-$, $-C(O)O-$,
 , $-SO_2NH-$, $-CONH-$, $(CH_2)_sO-$, $-(CH_2)_sNH-$, $-(CH_2)_sS-$, $-(CH_2)_sS(O)-$, and -
 $(CH_2)_sS(O)_2-$;

s is an integer from 0 to 6; and

10 Z_3 is a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a
 substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a
 substituted or unsubstituted heterocycloalkyl;


i is an integer from 1 to 6; and

t is an integer from 0 to 6.

15

29. The compound of Claim 26 wherein R_8 , R_9 and the nitrogen atom together
 form a heterocycloalkyl group; of the formula

20



25

wherein:


i is an integer from 1 to 6; and

R_{27} is OH, CH_2OH , $C(O)NR_{24}R_{28}$ or $COOR_{24}$;

R_{24} and R_{28} are each, independently, hydrogen or a substituted or unsubstituted
 alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl
 30 group.


-419-

30. The compound of Claim 26 wherein R_8 , R_9 and the nitrogen atom together form a heteroaromatic group of the formula



- 5
- 10 wherein:
- R_{29} is a $-Cl$, substituted or unsubstituted alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl group, carboxylic acid, cyano, $C(O)OR_{30}$, CH_2OR_{30} , $CH_2NR_{21}R_{22}$ or $C(O)NR_{21}R_{22}$;
- R_{30} is $-H$, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl,
- 15 a substituted or unsubstituted aralkyl, a substituted or unsubstituted heterocycloalkyl or heterocycloaryl group; and
- R_{21} , R_{22} and the nitrogen atom together form a 3, 4, 5 or 6-membered, substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted heteroaromatic or a substituted or unsubstituted heterobicycloalkyl; or
- 20 R_{21} and R_{22} are each, independently, H , azabicycloalkyl, heterocycloalkyl or Y_3-Z_3 ;
- Y_3 is selected from the group consisting of $-C(O)-$, $-(CH_2)_t-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_tO-$, $-(CH_2)_tNH-$, $-(CH_2)_tS-$, $-(CH_2)_tS(O)-$, and $-(CH_2)_tS(O)_2-$;
- 25 t is an integer from 0 to 6; and
- Z_3 is $-H$, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl.
- 30 31. The compound of Claim 26 wherein at least one of R_8 and R_9 is of the formula Y_3-D , wherein D is of the formula

-420-



5

wherein:

10 Y_3 is selected from the group consisting of $-C(O)-$, $-(CH_2)_t-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_tO-$, $-(CH_2)_tNH-$, $-(CH_2)_tS-$, $-(CH_2)_tS(O)-$, and $-(CH_2)_tS(O)_2-$;

t is an integer from 0 to 6;

T is $-O-$, $-C(O)-$, $-S-$, $-SO-$, $-SO_2-$, $-CH_2-$, $-CH(OR_{24})-$ or $-N(R_{24})-$;

R_{24} is hydrogen or a substituted or unsubstituted alkyl, aryl or aralkyl group;

15 and

x is 0, 1 or 2.

32. The compound of Claim 26 wherein at least one of R_8 and R_9 is of the formula $Y_3-N(R_{31})R_{32}$, wherein:


20 Y_3 is selected from the group consisting of $-C(O)-$, $-(CH_2)_t-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_tO-$, $-(CH_2)_tNH-$, $-(CH_2)_tS-$, $-(CH_2)_tS(O)-$, and $-(CH_2)_tS(O)_2-$;

t is an interger from 0 to 6;

25 R_{31} and R_{32} are each, independently, substituted or unsubstituted carboxyalkyl, a substituted or unsubstituted alkoxycarbonylalkyl, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted alkylsulfonyl, a substituted or unsubstituted alkylcarbonyl or a substituted or unsubstituted cyanoalkyl; or R_{31} and R_{32} , together with the nitrogen atom, form a five- or six-membered heterocycloalkyl group, a substituted or unsubstituted heteroaromatic or a
30 substituted or unsubstituted heterobicycloalkyl.

-421-

33. The compound of Claim 1 wherein R_1 is of the formula



5

wherein:

10 w is an integer from 0 to 4;

t is an integer from 0 to 6;

u is 0 or 1;

R_{12} is hydrogen, hydroxy or a substituted or unsubstituted alkoxy group;

15 R_8 , R_9 and the nitrogen atom together form a 3, 4, 5 or 6-membered, substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted heteroaromatic, or a substituted or unsubstituted heterobicycloalkyl; or

R_8 and R_9 are each, independently, -H, azabicycloalkyl, heterocycloalkyl or Y_2 - Z_2 ;


20 Y_2 is selected from the group consisting of -C(O)-, $-(CH_2)_q$ -, $-S(O)_2$ -, $-C(O)O$ -, $-SO_2NH$ -, $-CONH$ -, $(CH_2)_qO$ -, $-(CH_2)_qNH$ -, $-(CH_2)_qS$ -, $-(CH_2)_qS(O)$ -, and $-(CH_2)_qS(O)_2$ -;

q is an integer from 0 to 6; and

-422-

Z_2 is -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl.

- 5 34. The compound of Claim 33 wherein R_8 , R_9 and the nitrogen atom together form a heterocycloalkyl of the formula



wherein

R_{13} , R_{14} , R_{15} , R_{16} , R_{17} , R_{18} , R_{19} and R_{20} are each, independently, lower alkyl or hydrogen; or

at least one pair of substituents R_{13} and R_{14} ; R_{15} and R_{16} ; R_{17} and R_{18} ; or R_{19} and R_{20} together are an oxygen atom; or

at least one of R_{13} and R_{15} is cyano, CONHR_{21} , COOR_{21} , $\text{CH}_2\text{OR}_{21}$ or $\text{CH}_2\text{NR}_{21}(\text{R}_{22})$;

R_{21} , R_{22} and the nitrogen atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl group, substituted or unsubstituted heteroaryl group, or a substituted heterobicyclicalkyl group; or

R_{21} and R_{22} are each, independently, -H, azabicycloalkyl, heterocycloalkyl or Y_3 - Z_3 ;

Y_3 is selected from the group consisting of -C(O)-, $-(\text{CH}_2)_s$ -, $-\text{S}(\text{O})_2$ -, $-\text{C}(\text{O})\text{O}$ -, $-\text{SO}_2\text{NH}$ -, $-\text{CONH}$ -, $(\text{CH}_2)_s\text{O}$ -, $-(\text{CH}_2)_s\text{NH}$ -, $-(\text{CH}_2)_s\text{S}$ -, $-(\text{CH}_2)_s\text{S}(\text{O})$ - and $-(\text{CH}_2)_s\text{S}(\text{O})_2$;

s is an integer from 0 to 6; and

-423-

Z_3 is $-H$, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl;


X is $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-CH_2-$, $-CH(OR_{23})-$ or NR_{23} ;

- 5 R_{23} is hydrogen, substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, $-C(NH)NH_2$, $-C(O)R_{24}$, or $-C(O)OR_{24}$;
 R_{24} is hydrogen, substituted or unsubstituted alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl; and
 y is 0 or 1.

10

35. The compound of Claim 33 wherein R_8 , R_9 and the nitrogen atom together form a heterocycloalkyl of the formula

15



20

wherein

R_{25} and R_{26} are each, independently, hydrogen or lower alkyl; or

R_{25} and R_{26} together are an oxygen atom;

- 25 R_{21} , R_{22} and the nitrogen atom together form a 3, 4, 5 or 6-membered, substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted heteroaromatic or a substituted or unsubstituted heterobicycloalkyl; or
 R_{21} and R_{22} are each, independently, $-H$, azabicycloalkyl, heterocycloalkyl or Y_3 -
 Z_3 ;

-424-

Y_3 is selected from the group consisting of $-C(O)-$, $-(CH_2)_s-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_sO-$, $-(CH_2)_sNH-$, $-(CH_2)_sS-$, $-(CH_2)_sS(O)-$, and $-(CH_2)_sS(O)_2-$;


s is an integer from 0 to 6; and

- 5 Z_3 is $-H$, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl group; or
 r is an integer from 1 to 6; and
 z is an integer from 0 to 6.

10

36. The compound of Claim 33 wherein R_8 , R_9 and the nitrogen atom together form a heterocycloalkyl group of the formula

15



20

wherein

i is an integer from 1 to 6; and

R_{27} is CH_2OH , $C(O)NR_{24}R_{28}$ or $COOR_{24}$;


25

R_{24} and R_{28} are each, independently, hydrogen or a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl group.

-425-

37. The compound of Claim 33 wherein R_8 , R_9 and the nitrogen atom together form a heteroaromatic group of the formula

5



wherein:

10

R_{29} is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl group, carboxyl, cyano, $C(O)OR_{30}$, CH_2OR_{30} , $CH_2NR_{21}R_{22}$ or $C(O)NR_{21}R_{22}$;

15

R_{30} is a $-H$, substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heterocycloalkyl or a substituted or unsubstituted heterocycloaryl group;

R_{21} , R_{22} and the nitrogen atom together form a 3, 4, 5 or 6-membered, substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted heteroaromatic or a substituted or unsubstituted heterobicycloalkyl; or

20

R_{21} and R_{22} are each, independently, $-H$, azabicycloalkyl, heterocycloalkyl or Y_3-Z_3 ;

Y_3 is selected from the group consisting of $-C(O)-$, $-(CH_2)_s-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_sO-$, $-(CH_2)_sNH-$, $-(CH_2)_sS-$, $-(CH_2)_sS(O)-$, and $-(CH_2)_sS(O)_2-$;


s is an integer from 0 to 6; and

25

Z_3 is $-H$, a substituted or unsubstituted alkyl group, a substituted or unsubstituted amino, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group or a substituted or unsubstituted heterocycloalkyl group.

-426-

38. The compound of Claim 33 wherein at least one of R_8 and R_9 is of the formula Y_3 -D, wherein D is of the formula



wherein:

Y_3 is selected from the group consisting of $-C(O)-$, $-(CH_2)_s-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_sO-$, $-(CH_2)_sNH-$, $-(CH_2)_sS-$, $-(CH_2)_sS(O)-$, and $-(CH_2)_sS(O)_2-$;

s is an integer from 0 to 6;

T is $-O-$, $-C(O)-$, $-S-$, $-SO-$, $-SO_2-$, $-CH_2-$, $-CH(OR_{33})-$ or $-NR_{33}-$;

R_{33} is hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, $-C(NH)NH_2$, $-C(O)R_{34}$, or $-C(O)OR_{34}$;

R_{34} is hydrogen, substituted or unsubstituted alkyl, aryl or aralkyl; and

x is 0, 1 or 2.

39. The compound of Claim 33 wherein at least one of R_8 and R_9 is of the formula Y_3 - $N(R_{31})R_{32}$, wherein:

Y_3 is selected from the group consisting of $-C(O)-$, $-(CH_2)_s-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_sO-$, $-(CH_2)_sNH-$, $-(CH_2)_sS-$, $-(CH_2)_sS(O)-$, and $-(CH_2)_sS(O)_2-$;

s is an integer from 0 to 6;


R_{31} and R_{32} are each, independently, substituted or unsubstituted carboxyalkyl, a substituted or unsubstituted alkoxycarbonylalkyl, a substituted or unsubstituted hydroxyalkyl, a substituted or unsubstituted alkylsulfonyl, a substituted or unsubstituted alkylcarbonyl or a substituted or unsubstituted cyanoalkyl; or

-427-

R_{31} and R_{32} , together with the nitrogen atom, form a five- or six-membered heterocycloalkyl group, a substituted or unsubstituted heteroaromatic or a substituted or unsubstituted heterobicycloalkyl.

- 5 40. The compound of Claim 1 wherein R_1 is of the formula

10



wherein:

15

w is an integer from 0 to 4;

t is an integer from 0 to 6;

R_{10} is hydrogen or a substituted or unsubstituted alkyl group;

R_{12} is -H, azabicycloalkyl, heterocycloalkyl or Y_2-Z_2 ;

20

Y_2 is selected from the group consisting of -C(O)-, $-(CH_2)_q-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$, and $-(CH_2)_qS(O)_2-$;

q is an integer from 0 to 6; and


Z_2 is -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted

25

heteroaryl or a substituted or unsubstituted heterocycloalkyl.

-428-

41. The compound of Claim 1 wherein R_1 is of the formula



wherein:

u is 0 or 1;

R_{39} , R_{40} , R_{41} , R_{42} , R_{43} , R_{44} , R_{45} and R_{46} are each, independently, methyl or hydrogen; or


15 at least one pair of substituents R_{39} and R_{40} ; R_{41} and R_{42} ; R_{43} and R_{44} ; or R_{45} and R_{46} together are an oxygen atom; and R_{47} is H, azabicycloalkyl, heterocycloalkyl or Y_2-Z_2 ;

Y_2 is selected from the group consisting of $-C(O)-$, $-(CH_2)_q-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$, and $-(CH_2)_qS(O)_2-$;

20 q is an integer from 0 to 6; and

Z_2 is $-H$, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl group; or

25 R_{47} is of the formula



-429-

wherein:

y is 0 or 1;

5 R_{48} , R_{49} , R_{50} , R_{51} , R_{52} , R_{53} , R_{54} and R_{55} are each, independently, methyl or hydrogen; or

at least one pair of substituents R_{48} and R_{49} ; R_{50} and R_{51} ; R_{52} and R_{53} ; or R_{54} and R_{55} together are an oxygen atom; and

R_{56} is -H, azabicycloalkyl, heterocycloalkyl or Y_3 - Z_3 ,

10 Y_3 is selected from the group consisting of -C(O)-, $-(CH_2)_t$ -, $-S(O)_2$ -, -C(O)O-, - SO_2NH -, -CONH-, $(CH_2)_tO$ -, $-(CH_2)_tNH$ -, $-(CH_2)_tS$ -, $-(CH_2)_tS(O)$ -, and $-(CH_2)_tS(O)_2$;


t is an integer from 0 to 6; and

15 Z_3 is -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl.

42. The compound of Claim 1 wherein R_1 is of the formula

20

25



30

wherein:

e, f, h, u and y are independently 0 or 1;

-430-

R_{57} , R_{58} , R_{59} , R_{60} , R_{61} , R_{62} , R_{63} , R_{64} , R_{65} and R_{66} are each, independently, methyl or hydrogen; or

at least one pair of substituents R_{57} and R_{58} ; R_{59} and R_{60} ; R_{61} and R_{62} ; or R_{63} and R_{64} together are an oxygen atom; and


5 R_{67} is H, azabicycloalkyl, heterocycloalkyl or Y_2-Z_2 ;

Y_2 is selected from the group consisting of $-C(O)-$, $-(CH_2)_q-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_qO-$, $-(CH_2)_qNH-$, $-(CH_2)_qS-$, $-(CH_2)_qS(O)-$, and $-(CH_2)_qS(O)_2-$;

p is an integer from 0 to 6; and

10 Z_2 is $-H$, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl; or

R_{67} is of the formula



15

wherein:

d is 0 or 1;

R_{68} , R_{69} , R_{70} , R_{71} , R_{72} , R_{73} , R_{74} and R_{75} are each, independently, lower alkyl or hydrogen; or

25 at least one pair of substituents R_{68} and R_{69} ; R_{70} and R_{71} ; R_{72} and R_{73} ;

and R_{74} and R_{75} together are an oxygen atom; and

R_{76} is $-H$, azabicycloalkyl, heterocycloalkyl or Y_3-Z_3 ;

Y_3 is selected from the group consisting of $-C(O)-$, $-(CH_2)_t-$, $-S(O)_2-$, $-C(O)O-$, $-SO_2NH-$, $-CONH-$, $(CH_2)_tO-$, $-(CH_2)_tNH-$, $-(CH_2)_tS-$, $-(CH_2)_tS(O)-$, and $-(CH_2)_tS(O)_2-$;

30

-431-

p is an integer from 0 to 6;


Z₃ is -H, a substituted or unsubstituted alkyl, a substituted or unsubstituted amino, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl group.

5

43. The compound of Claim 1, wherein R₂ is -H.
44. The compound of Claim 1, wherein L is -O-, -NHSO₂R-, -NC(O)O-, or NHC(O)-.

-432-

45. The compound of Claim 1 wherein R_1 is of the formula




wherein m is 0, 1 or 2;

- R_{81} and R_{82} are each, independently, selected from the group consisting of
 5 hydrogen, hydroxyl, cyanomethyl, carboxymethyl, aminocarbonylmethyl,
 aminocarbonyl, aminomethyl, hydroxymethyl and amino, provided that no more
 than one of R_{81} and R_{82} is hydrogen; or

R_{81} and R_{82} together are oxo; $-O-(CH_2)_i-O-$, wherein i is 2 or 3;


- $-NH-C(O)-NH-C(O)-$; or $-NH-C(O)-NH-CH_2-$ provided that m is not 1 when
 10 R_{82} is hydroxy.

46. The compound of Claim 45 wherein R_1 is selected from the group consisting
 of




15

-433-



47. The compound of Claim 1 wherein G is selected from the group consisting of
 5 a direct bond; $-(CH_2)_j-$, wherein j is 1 or 2; trans $-CH=CH-$; $-cycloC_3H_4-$; and CH_2O-
48. The compound of Claim 13 wherein m is 2.
49. The compound of Claim 48 wherein S is 0 and R_{77} is hydrogen.

50. The compound of Claim 49 wherein the $-(CH_2)_i-NR_8R_9$ group is



51. The compound of Claim 49 wherein L is $-O-$, j is 0 or 1 and R_3 is phenyl.

52. The compound of Claim 48 wherein

L is $-CH_2NHC(O)-$; $-CH_2NHC(O)NH-$; $-CH_2NHC(O)O-$; $-CH_2C(O)NH-$; $-CH_2NHS(O)_2-$; $-NHC(O)-$; $-NHC(O)NH-$; $-NHC(O)O-$; $-C(O)NH-$; or $-NS(O)_2-$;

A is 1,4-phenylene or 1,4-phenylene substituted with one or more methoxy groups or fluorine atoms;

R_3 is phenyl or phenyl substituted with one or more substituents selected from the group consisting of chloro, cyano, bromo, fluoro, trifluoromethoxy, methoxy, methylenedioxy, methyl, amino, dimethylamino and nitro;


R_2 is hydrogen; and

G is a direct bond or $-(CH_2)_j-$, wherein j is 0 to 4.

53. The compound of Claim 24 wherein R_{10} is methyl, isopropyl or methoxyethyl.

-435-

54. A compound of claim 24, 26, 27, 28, 29, 30, 31, 45 or 47 wherein ring A is



5 L is -O-;

G is a direct bond; and

R₃ is phenyl.

55. A compound selected from the group consisting of:

10

Cis-5-(4-phenoxyphenyl)-7-(4-pyrrolidinocyclohex-1-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-ylamine,

Trans-5-(4-phenoxyphenyl)-7-(4-pyrrolidinocyclohex-1-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-ylamine,

15

Cis-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohex-1-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-ylamine hydrochloride,

Trans-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohex-1-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-ylamine,

20

Trans-7-(4-dimethylaminocyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-ylamine,

Cis-7-(4-dimethylaminocyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-ylamine,

5-(4-phenoxyphenyl)-7-(4-piperidyl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-ylamine dihydrochloride,

25

5-(4-phenoxyphenyl)-7-(3-pyrrolidinyl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-ylamine dihydrochloride,

Cis-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine,

30

Trans-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine,

Cis-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine,

Trans-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine,

- Cis*-7-[4-(4-ethylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine,
trans-7-[4-(4-ethylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine,
- 5 *Cis*-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tris maleate,
Trans-7-[4-(4-isopropylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tris maleate,
- 10 *Cis*-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tris maleate,
Trans-7-{4-[4-(2-methoxyethyl)piperazino]cyclohexyl}-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tris maleate,
- 15 *Cis*-7-(4-{[3-(1*H*-1-imidazolyl)propyl]amino}cyclohexyl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt,
Trans-7-(4-{[3-(1*H*-1-imidazolyl)propyl]amino}cyclohexyl)-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine dimaleate salt,
- 20 *Cis*-7-[4-(dimethylamino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine dimaleate salt,
Trans-5-(4-phenoxyphenyl)-7-(4-piperidinocyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine dimaleate salt,
- Trans*-5-(4-phenoxyphenyl)-7-(4-tetrahydro-1*H*-1-pyrrolylcyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine dimaleate salt,
- Cis*-5-(4-phenoxyphenyl)-7-(4-piperazinocyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt,
- 25 *Trans*-5-(4-phenoxyphenyl)-7-(4-piperazinocyclohexyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate salt,
- 7-[3-(4-methylpiperazino)cyclopentyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-maleate,
- Trans*-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine,
- 30 *Trans*-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-maleate,
- trans*-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-hydrochloride,
- 35 *cis*-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-maleate salt,
cis-7-[3-(4-methylpiperazino)cyclohexyl]-5-(4-phenoxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-hydrochloride,

- Trans*-5-(2-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine trimaleate,
- Cis*- benzyl N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl} 2-methoxyphenyl)carbamate tri-maleate,
- 5 *Trans*- benzyl N-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl} 2-methoxyphenyl)carbamate tri-maleate,
- Trans*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl} 2-methoxyphenyl)benzamide,
- 10 *Trans*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl} 2-methoxyphenyl)benzamide tri-maleate,
- Cis*-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl} 2-methoxyphenyl)-3-phenylpropanamide,
- Trans*- N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl} 2-methoxyphenyl)-3-phenylpropanamide,
- 15 *cis*- N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide trimaleate salt,
- trans*-N1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl-2-methoxyphenyl)-3-phenylpropanamide tri-maleate,
- 20 *cis*-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-ylphenoxy)-6-[(3-methoxypropyl)amino]benzonitrile tri-maleate,
- trans*-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-ylphenoxy)-6-[(3-methoxypropyl)amino]benzonitrile tri-maleate,
- is*-2-amino-6-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-ylphenoxy)benzonitrile tri-maleate,
- 25 *trans*-2-amino-6-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-ylphenoxy)benzonitrile tri-maleate,
- cis*-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-ylphenoxy)-6-[(4-methylphenyl)sulfanyl]benzonitrile tri-maleate,
- trans*-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-ylphenoxy)-6-[(4-methylphenyl)sulfanyl]benzonitrile tri-maleate,
- 30 *cis*-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-ylphenoxy)-6-(2-pyridylsulfanyl)benzonitrile tri-maleate,
- trans*-2-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-ylphenoxy)-6-(2-pyridylsulfanyl)benzonitrile tri-maleate,
- 35 *cis*-5-(2-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-maleate,
- trans*-5-(2-methyl-4-phenoxyphenyl)-7-[4-(4-methylpiperazino)cyclohexyl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amine tri-maleate,

- cis-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide tri-maleate,
trans-N1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide tri-maleate,
- 5 N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide,
N1-4-[4-amino-7-(1-benzyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-2,3-dichloro-1-benzenesulfonamide,
- 10 N1-4-[4-amino-7-(4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide,
N1-4-[4-amino-7-(1-formyl-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl-4-fluoro-1-benzenesulfonamide,
- 15 N1-[4-(4-amino-7-1-[(1-methyl-1H-4-imidazolyl)sulfonyl]-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide dimaleate,
N1-[4-(4-amino-7-1-[(1,2-dimethyl-1H-4-imidazolyl)sulfonyl]-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide,
N1-[4-(4-amino-7-1-[(1,3-dimethyl-1H-5-pyrazolyl)carbonyl]-4-piperidyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide,
- 20 N1-(4-{4-amino-7-[1-(2-pyridylcarbonyl)-4-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide,
N1-4-(4-amino-7-{4-[1-(1-methylpiperid-4-yl)piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl})-2-fluorophenyl)-4-fluoro-1-benzenesulfonamide tri-maleate,
Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-(trifluoromethoxy)-1-benzenesulfonamide trimaleate,
- Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-5-chloro-2-thiophenesulfonamide benzenesulfonamide trimaleate,
- Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-4-fluoro-1-benzenesulfonamide benzenesulfonamide trimaleate,
- Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-4-fluoro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl-2-fluorophenyl)-2,5-difluoro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,6-difluoro-1-benzenesulfonamide trimaleate,

Trans-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzothiadiazole-4-sulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trifluoro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-nitro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-fluoro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,4,6-trichloro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,6-dichloro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-fluoro-1-benzenesulfonamide dimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-

5-yl}-2-fluorophenyl)-5-chloro-2-thiophenesulfonamide dimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-bromo-2,6-difluoro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-chloro-4-fluoro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-iodo-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-(trifluoromethoxy)-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-6-methyl-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-4-cyano-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trifluoro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3,4-difluoro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-bromo-2-fluoro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-5-bromo-2-thiophenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,4-dichloro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trichloro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-bromo-5-chloro-2-thiophenesulfonamide trimaleate,

cis-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzothiadiazole-4-sulfonamide trimaleate,

cis-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzoxadiazole-4-sulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,5-dichloro-1-thiophenesulfonamide trimaleate,

cis-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(7-chloro-2,1,3-benzoxadiazole)-4-sulfonamide trimaleate,

cis-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(7-methyl-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate,

cis-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(5-methyl-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate,

cis-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(5-chloro-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-chloro-2-methyl-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-bromo-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-

-442-

5-yl}-2-fluorophenyl)-2,5-dibromo-3,6-difluoro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate,

cis-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(2-nitrophenyl)methanesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-nitro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-fluoro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,4,6-trichloro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,6-dichloro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-fluoro-1-benzenesulfonamide dimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-bromo-2,5-difluoro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-chloro-4-fluoro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-iodo-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3-dichloro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-6-methyl-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-chloro-4-cyano-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3,4-difluoro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-4-bromo-2-fluoro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-5-bromo-2-thiophenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,4-dichloro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,3,4-trichloro-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-bromo-5-chloro-2-thiophenesulfonamide trimaleate,

Trans-N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,1,3-benzoxadiazole-4-sulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,5-dichloro-1-thiophenesulfonamide trimaleate,

-444-

Trans- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(7-chloro-2,1,3-benzoxadiazole)-4-sulfonamide trimaleate,

Trans- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(7-methyl-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate,

Trans- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(5-methyl-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate,

Trans- N-4-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-(5-chloro-2,1,3-benzothiadiazole)-4-sulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-3-chloro-2-methyl-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2-bromo-1-benzenesulfonamide trimaleate,

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)-2,5-dibromo-3,6-difluoro-1-benzenesulfonamide trimaleate, or

Trans-N-1-(4-{4-amino-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-fluorophenyl)- (2-nitrophenyl)methanesulfonamide trimaleate.

- 56 .A method of inhibiting protein kinase activity comprising administering a
5 compound of Claim 1 or a physiologically acceptable salt, prodrug or biologically
active metabolites thereof.

-445-

57. The method of Claim 56 wherein said protein kinase is selected from the group consisting of KDR, FGFR-1, PDGFR β , PDGFR α , IGF-1R, c-Met, Flt-1, TIE-2, Lck, Src, fyn, Lyn, Blk, and yes.
- 5 58. The method of Claim 56 wherein the activity of said protein kinase affects hyperproliferative disorders.
59. The method of Claim 56 wherein the activity of said protein kinase affects angiogenesis, vascular permeability, immune response or inflammation.
- 10 60. A method of treating a patient having a condition which is mediated by protein kinase activity, said method comprising the step of administering to the patient a therapeutically effective amount of a compound of Formula I as defined in Claim 1 or a physiologically acceptable salt, prodrug or biologically active
- 15 metabolite thereof.
61. The method of Claim 60 wherein said protein kinase is selected from the group consisting of KDR, Flt-1, PDGFR β , PDGFR α , IGF-1R, c-Met, TIE-2, Lck, Src, fyn, Lyn, Blk, and yes.
- 20 62. The method of Claim 60 wherein the condition mediated by protein kinase activity is a hyperproliferative disorder.
63. The method of Claim 60 wherein the activity of said protein kinase affects
- 25 angiogenesis, vascular permeability, an immulogic response or an inflammatory response.
64. The method of Claim 60 wherein the protein kinase is a protein serine/threonine kinase or a protein tyrosine kinase.
- 30

-446-

65. The method of Claim 60 wherein the condition mediated by protein kinase activity is one or more ulcers.

66. The method of Claim 65 wherein the ulcer or ulcers are caused by a bacterial or fungal infection; or the ulcer or ulcers are Mooren ulcers; or the ulcer or ulcers are a symptom of ulcerative colitis.

67. The method of Claim 60 wherein the condition mediated by protein kinase activity is Lyme disease, sepsis or infection by Herpes simplex, Herpes Zoster, human immunodeficiency virus, parapoxvirus, protozoa or toxoplasmosis.

68. The method of Claim 60 wherein the condition mediated by protein kinase activity is von Hippel Lindau disease, pemphigoid, psoriasis, Paget's disease or polycystic kidney disease.

69. The method of Claim 60 wherein the condition mediated by protein kinase activity is fibrosis, sarcoidosis, cirrhosis, thyroiditis, hyperviscosity syndrome, Osler-Weber-Rendu disease, chronic occlusive pulmonary disease, asthma, exudates, ascites, pleural effusions, pulmonary edema, cerebral edema or edema following burns, trauma, radiation, stroke, hypoxia or ischemia.

70. The method of Claim 60 wherein the condition mediated by protein kinase activity is ovarian hyperstimulation syndrome, preeclampsia, menometrorrhagia, or endometriosis.

71. The method of Claim 60 wherein the condition mediated by protein kinase activity is chronic inflammation, systemic lupus, glomerulonephritis, synovitis, inflammatory bowel disease, Crohn's disease, glomerulonephritis, rheumatoid arthritis and osteoarthritis, multiple sclerosis or graft rejection.

72. The method of Claim 60 wherein the condition mediated by protein kinase

-447-

activity is sickle cell anaemia.

73. The method of Claim 60 wherein the condition mediated by protein kinase activity is an ocular condition.

5

74. The method of Claim 73 wherein the ocular condition is ocular or macular edema, ocular neovascular disease, scleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser treatment complications, conjunctivitis, Stargardt's disease, Eales disease, retinopathy or macular
10 degeneration.

75. The method of Claim 60 wherein the condition mediated by protein kinase activity is a cardiovascular condition.

15 76. The method of Claim 75 wherein the condition mediated by protein kinase activity is atherosclerosis, restenosis, ischemia/reperfusion injury, vascular occlusion, venous malformation or carotid obstructive disease.

20 77. The method of Claim 60 wherein the condition mediated by protein kinase activity is cancer.

78. The method of Claim 77 wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy and
25 malignant ascites.

79. The method of Claim 78 wherein the cancer is Kaposi's sarcoma, Hodgkin's disease, lymphoma, myeloma or leukemia.

30 80. The method of Claim 60 wherein the condition mediated by protein kinase activity is Crow-Fukase (POEMS) syndrome or a diabetic condition.

81. The method of Claim 80 wherein the diabetic condition is insulin-dependent diabetes mellitus glaucoma, diabetic retinopathy or microangiopathy.
- 5 82. The method of Claim 60 wherein the compound of Formula I or a physiologically acceptable salt, prodrug or biologically active metabolite thereof is administered in an amount effective to promote angiogenesis or vasculogenesis.
83. The method of Claim 82 wherein the protein kinase is Tie-2.
- 10 84. The method of Claim 82 wherein the compound of Formula I, or physiologically acceptable salt, prodrug or biologically active metabolite thereof, is administered in combination with a pro-angiogenic growth factor.
- 15 85. The method of Claim 84 wherein the pro-angiogenic growth factor is selected from the group consisting of VEGF, VEGF-B, VEGF-C, VEGF-D, VEGF-E, HGF, FGF-1, FGF-2, derivatives thereof and antiidotypic antibodies.
- 20 86. The method of Claim 82 wherein the protein kinase-mediated condition is anemia, ischemia, infarct, transplant rejection, a wound, gangrene or necrosis.
- 25 87. The method of Claim 60 wherein the protein kinase activity is involved in T cell activation, B cell activation, mast cell degranulation, monocyte activation, the potentiation of an inflammatory response or a combination thereof.
88. A method of decreasing fertility in a patient, said method comprising the step of administering to the patient an effective amount of a compound of Formula I as defined in Claim 1 or a physiologically acceptable salt, prodrug or biologically active metabolite thereof.

INTERNATIONAL SEARCH REPORT

Inter	Application No
PC1/US	00/08593

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D487/04 A61K31/505 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 32879 A (NOVARTIS AG) 12 September 1997 (1997-09-12) claims 1-13 ---	1-88
X	WO 97 28161 A (NOVARTIS AG) 7 August 1997 (1997-08-07) claims 1-11 ---	1-88
X	WO 97 49706 A (NOVARTIS AG) 31 December 1997 (1997-12-31) claims 1-12 ---	1-88
X	WO 96 10028 A (CIBA-GEIGY AG) 4 April 1996 (1996-04-04) claims 1-14 ---	1-88
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 October 2000

Date of mailing of the international search report

23/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

Intern

Application No

PCT/US 00/08593

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 34895 A (NOVARTIS AG) 25 September 1997 (1997-09-25) claims 1-11 ---	1-88
E	WO 00 17202 A (BASF AG) 30 March 2000 (2000-03-30) claims 1-45 ---	1-88
E	WO 00 17203 A (BASF AG) 30 March 2000 (2000-03-30) claims 1-72 ---	1-88
X	WO 98 41525 A (KNOLL AG) 24 September 1998 (1998-09-24) claims 1-30 ---	1-88
X	WO 96 40686 A (ABBOTT LABORATORIES) 19 December 1996 (1996-12-19) claims 1-21 ---	1-88
X	EP 0 496 617 A (GENSIA PHARMACEUTICALS, INC.) 29 July 1992 (1992-07-29) claims 1-25 ---	1-88
X	DE 30 36 390 A (TROPONWERKE GMBH & CO KG) 13 May 1982 (1982-05-13) claims 1-8 ---	1-88
X	WO 94 17803 A (GENSIA, INC.) 18 August 1994 (1994-08-18) claims 1-20 ---	1-88
X	US 5 665 721 A (S. S. BHAGWAT, M. D. COWART) 9 September 1997 (1997-09-09) claims 1-32 ---	1-88
X	US 5 639 757 A (R. L. DOW, K. KOCH) 17 June 1997 (1997-06-17) claims 1-7 -----	1-88

INTERNATIONAL SEARCH REPORT

 Intern Application No
 PCT/US 00/08593

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9732879 A	12-09-1997	AU 1794697 A	22-09-1997
WO 9728161 A	07-08-1997	AU 1595197 A	22-08-1997
WO 9749706 A	31-12-1997	AU 3176297 A	14-01-1998
WO 9610028 A	04-04-1996	AU 694801 B	30-07-1998
		AU 3564395 A	19-04-1996
		BR 9509048 A	06-01-1998
		CA 2200210 A	04-04-1996
		CN 1164234 A,B	05-11-1997
		EP 0783505 A	16-07-1997
		FI 971225 A	14-05-1997
		HU 76785 A	28-11-1997
		JP 10506624 T	30-06-1998
		NO 971342 A	21-03-1997
		NZ 293249 A	29-04-1999
		US 5869485 A	09-02-1999
WO 9734895 A	25-09-1997	AU 716383 B	24-02-2000
		AU 2153497 A	10-10-1997
		BR 9709443 A	10-08-1999
		CA 2249739 A	25-09-1997
		CN 1216544 A	12-05-1999
		EP 0888353 A	07-01-1999
		JP 2000506537 T	30-05-2000
		NO 984199 A	05-11-1998
		US 6051577 A	18-04-2000
WO 0017202 A	30-03-2000	AU 6047599 A	10-04-2000
WO 0017203 A	30-03-2000	AU 6048499 A	10-04-2000
WO 9841525 A	24-09-1998	AU 6829398 A	12-10-1998
		BG 103785 A	30-06-2000
		BR 9808281 A	16-05-2000
		CN 1259950 T	12-07-2000
		EP 0970084 A	12-01-2000
		NO 994509 A	17-09-1999
		PL 335685 A	08-05-2000
		US 6001839 A	14-12-1999
WO 9640686 A	19-12-1996	CA 2220006 A	19-12-1996
		EP 0873340 A	28-10-1998
		JP 2000501694 T	15-02-2000
EP 496617 A	29-07-1992	AT 187175 T	15-12-1999
		AU 665184 B	21-12-1995
		AU 1359992 A	27-08-1992
		CA 2100863 A	24-07-1992
		DE 69230347 D	05-01-2000
		DE 69230347 T	06-07-2000
		FI 933303 A	31-08-1993
		IL 100742 A	18-06-1996
		JP 5112595 A	07-05-1993
		MX 9200294 A	01-01-1993
		NO 180418 B	06-01-1997
		NZ 241381 A	28-05-1996

INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/US 00/08593

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 496617 A		WO 9212718 A	06-08-1992
		US 5646128 A	08-07-1997
		US 5864033 A	26-01-1999
		US 5721356 A	24-02-1998
		US 5726302 A	10-03-1998
		US 5674998 A	07-10-1997
		US 5763596 A	09-06-1998
		US 5763597 A	09-06-1998
		US 5795977 A	18-08-1998
DE 3036390 A	13-05-1982	NONE	
WO 9417803 A	18-08-1994	AU 6236594 A	29-08-1994
		EP 0682519 A	22-11-1995
		US 5646128 A	08-07-1997
US 5665721 A	09-09-1997	NONE	
US 5639757 A	17-06-1997	NONE	

THIS PAGE BLANK (USPTO)